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 Introduction 
This study starts off with a puzzle about how to understand human 
embryonic stem cells (hESCs). By using actor-network theory (ANT), this puzzle 
becomes a topic for a theory of science study. ANT is put to work on 
largely textual materials, often directly from US political settings, such as 
Congressional debates and national panels. Beginning in the time period 
November 1998 – August 2001, this study then goes backwards to un-
derstand processes in the 1980’s and 90’s that can be related to the later 
situation in hESC research and politics in the USA.  
 However, unlike most ANT studies, a meta-theoretical interest in so-
me notions that have been central to ANT and related approaches, con-
tinually guides the empirical inquiries in this work. Such notions include 
the circulatory system of science, obligatory point of passage, and boundary objects. As 
the empirical case unfolds, the concepts in use are continually tested, 
elaborated and expanded, and hESCs and ANT both become topics for 
analysis. A more detailed aim of the study therefore runs: To explore ANT 
in order to understand the sociotechnical reality of hESCs in the USA prior to 
August 2001 – in particular with regard to the public and political dynamics. All 
the elaborations serve a more general aim, viz. an exercise in seeing differently.  
 Making sense of the specific aim requires a first theoretical chapter. In 
this Introduction I will be happy if I can resolve the possibly (and 
probably) lingering confusion about the study’s main title. I will attempt 
this resolution by presenting my initial puzzles about stem cell research. 
Then I introduce Theory of Science – the home discipline of the author and 
this publication. Theory of science is a way of seeing deliberately, and delibe-
rating on how to see science and politics. Other scholars have approached 
the subject of stem cell research from a variety of perspectives. The 
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chapter will clarify why one more study is needed. Finally, I offer an out-
line of the main arguments and chapters.  
 Starting off by describing my first experiences with stem cells and my 
struggle with how to turn this into a topic is not only pedagogically sane 
when introducing complicated matters such as stem cells and theory of 
science; it also reflects the process of research and will permeate the con-
sequent use of methods, theory, and progress of investigation. Instead of 
reconstructing the empirical, theoretical and methodological boundaries 
– as if they were there from the start – the reader is invited to follow my 
own perplexity when approaching an empirical situation and some theo-
retical tools.1 In this respect you are invited to a work in progress to-
gether with me: A doctoral student in theory of science who discovers 
stem cell realities by acquiring, using, and modifying theoretical tools. 
Taking the first steps with stem cells 
The title is itself confusing. In order to sort out the first half of Pluripotent 
Circulations I consult an on-line dictionary (Oxfordreference.com). There 
are two entries for the term “pluripotent”. One states that “pluripotent” 
is an adjective “(of an immature or stem cell) capable of giving rise to 
several different cell types” (The Concise Oxford English Dictionary 
2004a). A pluripotent cell can produce many different cell types. For this 
to make sense something has to be said about cell types (“immature or 
stem cells”), and how cells develop from other cells. The other entry on 
“pluripotent” in the same dictionary is a hyperlink to an explanation of 
the term “stem cell”: 
A cell that is not differentiated itself but can undergo unlimited division to 
form other cells, which either remain as stem cells or differentiate to form 
specialized cells. For example, stem cells in the bone marrow divide to produ-
ce daughter cells that differentiate into various types of immune cells (e.g. mo-
nocytes, lymphocytes, mast cells). Also, stem cells in the intestine continually 
divide to replace cells sloughed off the gut lining. Embryonic stem cells, such as 
those taken from an early human embryo, are capable of differentiating into 
many or all of the various tissue cells found in a fully developed individual – 
they are described as pluripotent. (The Concise Oxford English Dictionary 
2004b) 
                                     
1   My view of the research process and mode of presentation thus in many ways 
resembles Law’s Method Assemblage in his After Method, 2004. 
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“Differentiated”, “specialized”, or “mature” cells are the cells that make 
up most of what we usually see of our bodies, such as skin, hair, or eye 
cells, or various type of blood cells. Undifferentiated and immature cells 
are the mother and father cells of the specialized cells. One of the daily 
occasions when we can “see” the work of stem cells is when a wound is 
healing. The new cells that seal up the wounded tissue are produced by 
stem cells. However, new cells are continually being produced all over 
the body by various stem cells. All cells have come from stem cells.  
 “Pluripotent” was not mentioned in the above lines until the later 
third. It is only after the introduction of a specific type of stem cell that 
pluripotent is mentioned: “Embryonic stem cells”. Unlike the first-men-
tioned stem cells, the embryonic stem cells are said to have the capacity 
to become “many or all of the various tissue cells found in a fully develo-
ped individual”. According to the dictionary, pluripotent is used to sig-
nify this capacity in contrast to the capacity of other stem cells. Due to 
their “pluripotency” (the noun-form of the adjective “pluripotent”) the 
cells can become many more cell types than other stem cells. On the 
University of Wisconsin website this is graphically presented as a flow 
from an in-vitro fertilized egg (i.e. an embryo resulting from the combi-
nation of an egg and a sperm outside of the body), to a Petri-dish, and 
then to specialized tissue cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Stem Cell Cultivation. (Reprinted by permission of the 
University of Wisconsin. Copyright held by the University  
of Wisconsin Board of Regents). 
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While a full explanation of Pluripotent Circulations will not be available un-
til the final chapter, a first, preliminary meaning can be derived from my 
initial experiences with stem cells. Those experiences are quite recent. It 
may be a comfort for the reader who happens to know little or nothing 
about pluripotency to learn that roughly five years ago (in late 2000, give 
or take six months) the author of this study had never heard of this 
property of stem cells (or of stem cells in general).2 In retrospect, pluri-
potency and human embryonic stem cells became a part of my 
imagination – and soon more than that – mainly due to President Bush’s 
decision in August 2001:  
Based on preliminary work that has been privately funded, scientists believe 
further research using stem cells offers great promise that could help improve 
the lives of those who suffer from many terrible diseases – from juvenile 
diabetes to Alzheimer’s, from Parkinson’s to spinal cord injuries. And while 
scientists admit they are not yet certain, they believe stem cells derived from 
embryos have unique potential. (Bush 2001)3 
Bush used prime television time to inform the country about stem cells 
and a long awaited decision on federal funding for research on hESCs. 
In practice, no Federal funding had been possible. After two and a half 
years of debates, policy statements, panel deliberations, drafts, and guide-
lines, Bush announced his policy. Hearing this on the news in Göteborg, 
Sweden, carried a special meaning. When Bush declared his decision he 
referred to a number of stem cell “lines”: 
As a result of private research, more than 60 genetically diverse stem cell lines 
already exist. They were created from embryos that have already been destroy-
ed, and they have the ability to regenerate themselves indefinitely, creating on-
going opportunities for research. I have concluded that we should allow fede-
ral funds to be used for research on these existing stem cell lines, where the 
life and death decision has already been made. (Bush 2001)  
Stem cells seldom come alone.4 After being “derived from human em-
bryos” (in the terms of the practising scientists) they are cultured in little 
                                     
2   It is difficult to recall ignorance, but five years is an honest guess. 
3   When no pages are mentioned in references following upon quotations, it im-
plies that full information is available in the bibliography. In this case there are 
no page numbers in the source. 
4   Some would say it is necessary that the cells come alone. The need for purified 
populations has been crucial in the last few years’ debates about the 
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plastic “batches”. If the researchers are lucky and/or skilled the cells 
multiply, and new batches are filled with the solution in which the – for 
the bare eye – invisible cells are floating. These multiply and result in 
new batches of cells-in-solution that all stem from the same original cells 
and the same embryo. Each such pedigree of cells is called a line. Of the 
60 stem cell lines mentioned by Bush, the largest joint number of lines 
existed in Göteborg, where I was living and doing graduate studies.  
 In the decision, these already existing lines were very important, since 
they “could lead to breakthrough therapies and cures” without having to 
destroy more of the human embryos that served as sources for the stem 
cells. Bush described his decision as a balancing act between the concern 
for these embryos and the possibilities to alleviate suffering. By not fun-
ding any new production of hESC lines no more embryos would be 
destroyed. By funding the already existing cell lines from laboratories 
(some thus situated also outside of the USA) the researchers would have 
sufficient numbers of cells to explore the therapeutic promises.  
 However, I would not stay beside the 24 important stem cell lines in 
Göteborg the coming year, but leave for the USA for a one-year stay at a 
center for philosophy of science. My advisors were sure to let me know 
that I could still redirect my dissertation work in theory of science to 
another subject – for instance the subject of stem cell research.  
 Upon my arrival I soon realized that such research was being done on 
the same campus half a mile away from my temporary office. Six months 
after hearing Bush’s decision, I connected with the main researchers and 
was allowed to observe their work and listen in to their conversations. 
These cells were not stem cells from human embryos, but from adult 
bone marrow. However, the laboratory claimed that their stem cells had 
very similar capacities to the pluripotent embryonic stem cells. Another 
term for such capacities in adult stem cells is “plasticity”. High plasticity 
means more potency, maybe even pluripotency. The alleged high plastici-
ty of these cells attracted interest from other laboratories at the univer-
sity, nationally, and internationally. 
 I interviewed people from these other laboratories, but mostly I fol-
lowed one scientist in his daily business of doing research. I looked at his 
interaction with colleagues and his boss. I looked at the mundane tasks 
and often boring routines he had to perform in order to secure the life of 
                                                                                                                 
appropriate criteria for assessing claims about adult stem cell plasticity, 
Weissman et al. 2001. 
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his cells. After a week there was “the journal club”, a weekly event where 
the members of several groups of the stem cell lab gathered to discuss a 
current paper. People were a little upset. Two papers had challenged the 
results of the lab. 
Y: It doesn’t happen in vitro. Can we rule out that it happens in vivo? 
X: Co-culture of adult and embryo cells in this paper […] that’s my biggest 
concern. 
[---] 
X: It is a contrived system. No one has ever used such a system to prove 
plasticity. It’s speculation! Reporters called me 2 weeks ago about this [before 
the publication]. 
Z: Can they do that? 
X: They can’t, but Nature can. 
Y: Burden of proof is on them. But, they put a question mark on a lot. 
A: Show the karyotype and you ward off such doubts? 
[---] 
X: They didn’t do it in vivo. 
Y: So, it’s a long step to that question mark. Dr. X, Do we have to change our 
routines? 
X: GFP + cells and put it in blastocyst. Stain both and get independent 
staining, not from both. That would do it. 
[---] 
B: FISH-analysis? 
X: The problem is you cut through tissue so some things could be on the 
other side. 
C: Tissue sections are hard. 
(Laboratory notes 2002) 
The atmosphere was tense. Afterwards I went back to see what the pa-
pers said. 
the altered phenotype does not arise by direct conversion of brain to em-
bryonic stem cell but rather through spontaneous generation of hybrid cells. 
The tetraploid hybrids exhibit full pluripotent character, including multilineage 
contribution to chimaeras. We propose that transdetermination consequent to 
cell fusion could underlie many observations otherwise attributed to an intrin-
sic plasticity of tissue stem cells. (Ying et al. 2002: 545) 
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If the first part of the quotation is too complicated, then focus on the 
latter. The laboratory I was visiting was just about to publish a paper 
about remarkable “plasticity of tissue stem cells”. Ying et al. suggested 
that such observations could be due to a fusion of embryonic cells and 
adult cells. If so, the plasticity observations – and the adult cells – would 
basically be less valuable. In the other paper the speculative nature of the 
“fusion experiments” was admitted:  
Contribution of cell fusion to apparently transdifferentiated cells in vivo is cur-
rently pure speculation; however, our data raise a warning to the overzealous 
trend in stem cell research to conclude transdifferentiation or dedifferentiation 
of cells without careful examination of genotypes. (Terada et al. 2002: 544) 
Usually, scientific papers are written and published to suggest something 
new, or at least combine some things already known in a new way. 
Studies aiming to falsify other results are quite uncommon (pace Pop-
per). Here were two papers that, based on preliminary experiments, specu-
lated on the inadequacy of other findings. At a conference a few days later 
in Colorado the main author of the first paper (Ying et al.), Austin Smith 
from Edinburgh, appeared and presented a paper. The room was full of 
excitement and people grabbed the microphones afterwards to ask que-
stions. Jonas Frisén, neuro stem cell researcher, from Karolinska, Swe-
den, who had reported on plasticity himself asked: 
Frisén: Have you checked other plasticity work? If they show hyperploidity? 
Smith: No we haven’t done that. As you know our interest is in embryonic 
stem cells…  
(Laboratory notes 2002) 
Smith presented his results to challenge research, beyond an actual inte-
rest in plasticity and the adult stem cells. Furthermore it was not himself 
involved with the research.5 What was this about?  
 As soon as I attempted to understand my observations in and around 
the laboratory, I realized that stem cell research in America needed more 
than a laboratory study. The laboratory was immersed in references and 
“context”. Therefore I turned to politics.  
                                     
5   Though, he was to be involved in it. On the same occasion he announced that 
his center in Edinburgh advertised a lectureship in adult stem cells, Laborato-
ry notes 2002. 
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 Returning to the political stage, which had awoken my interest from 
the beginning, merely looking at the social groups was not enough. The 
standard categories of American politics – pro-life vs. pro-choice – did 
not suffice.6 The questions massed above my head: Why did the Republi-
can pro-life President partly endorse research on embryos (although with 
strong restrictions), in spite of his election promises and pro-life opin-
ion? The ethical and political disputes could not overshadow the achieve-
ments of the hESCs, possibly even “success”. What was the big 
attraction of the hESCs and what was the role of plasticity in the lab I 
was visiting?  
 In the strictly biological sense pluripotent is an adjective: “(of an im-
mature or stem cell) capable of giving rise to several different cell types” 
(The Concise Oxford English Dictionary 2004a). It is illustrated above 
(Figure 1) by the flow from embryos, to Petri-dishes, and to multiple tis-
sue types. What attracted me about stem cells was, however, not only 
their biological pluripotent capacities. Equally interesting was that the pluri-
potency seemed to influence people and make them important. The cells 
had a political pluripotency (metaphorically speaking):  
The issue of research involving stem cells derived from human embryos is 
increasingly the subject of a national debate and dinner table discussions. The 
issue is confronted every day in laboratories as scientists ponder the ethical 
ramifications of their work. It is agonized over by parents and many couples 
as they try to have children, or to save children already born. (Bush 2001) 
When approaching the issues of stem cell research a number of people 
played important roles, most visibly President Bush, but also ethicists, 
parents, and patients. Bush’s decision was televised and watched by mil-
lions. I learned about it thousands of miles away. It even caught my ad-
visors’ imagination and made them suggest that I could still redirect my 
dissertation. In my contacts with the laboratory, I saw how pluripotency 
and plasticity were bringing researchers at the university and from out-
side laboratories together. Sometimes these meetings were more critical 
than approving. In any case, people’s lives were redefined. The “political 
pluripotency” I had noticed, pointed toward other flows than those 
illustrated on the University of Wisconsin website. The stem cells I wan-
ted to understand did not only flow from embryos to multiple tissue 
                                     
6   Pro-life is a position and movement against abortion. Pro-choice is the oppo-
site. See Chapter 2. 
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types of the human body, but also circulated between political bodies and 
multiple other actors in the wider society. There it is, the title: Pluripotent 
Circulations in one phrase sums up my initial perplexity, and interest in 
stem cell research in the USA as being both biological and political.  
 My first steps into stem cell research were prompted by seeing Bush 
on the news, which led me to the laboratory. Leaving the lab, my empi-
rical concerns were to understand the struggles and reality that it was 
involved in. So much was already in place prior to Bush’s decision. My 
curiosity soon homed in on the circulations that preceded it. This curio-
sity ultimately led me to the developments of assisted reproduction and 
fetal tissue research in the 1980’s and 90’s – although they may seem to 
be far from the 2001 situation. The historical inquiries of this study stop 
just before “my” laboratory became involved in the political and 
scientific dynamics subsequent to August 2001.7 This study thus does 
not draw on the data from the participant observations (and it does not 
further analyze Swedish stem cell research and its importance for Bush’s 
decision).  
Turning stem cells into a topic 
After these elementary observations on stem cells my question was how 
to turn them into a topic. This is an important question, since there are 
many possible ways to turn stem cell research in the USA into a topic. I 
am not a biologist, not even a natural scientist. I cannot approach stem 
cells by e.g. making a “southern blot” and then writing a paper based on 
the result.8 My training is in theory of science. 
 There are several ways to define theory of science. In a first basic 
respect, theory of science is everywhere people see and do science. Ety-
mologically, theory comes from the Greek theoreia whose meaning is, to 
see or comprehend. Seeing is thus in a derived sense theoretical. In line 
with, for instance, hermeneutics and paradigm theory, I believe that see-
ing always presupposes or works together with perspectives. This rough-
ly amounts to what hermeneutics calls pre-understanding or pre-judg-
ment or what the historian of science, Thomas Kuhn has called para-
digm. In Karl Popper’s words, observations are not neutral, but theory-
                                     
7   For the temporal limitations of the study, see more in the next chapter. 
8   Southern blotting is the detection of  DNA fragments by gel-transfer hybridiza-
tion. It is a common method in stem cell laboratories. 
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laden, theory-impregnated. In this sense, theory of science is pursued by 
every human being looking at science, whether or not s/he is aware of it.  
 There are also professionals trained in seeing or studying science who 
have therefore elaborated specific theories of science for this use. A number 
of disciplines have studied the (natural, human or social) sciences, for 
instance philosophy, sociology, history, and anthropology. Within studies 
of science there are two versions of theory of science, often side by side. 
First, analysts draw on and expand perspectives on science.9 The integral 
elements of a specific perspective are related to each other explicitly. 
Usually there has been some fundamental idea about knowledge produc-
tion, about the relationship between knowledge and reality, criteria for 
truth or truth-likeness, and methods for studying science. Second, when 
analysts juxtapose, contrast, and/or compare various perspectives and 
analyze the implications and effects of theories of science they pursue 
theory of science in another respect: as meta-theory, theorizing theories of 
science, seeing their seeing of science, as it were. A meta-theoretical inquiry 
is thus not only to analyze science – by applying various theories of 
science – but also to analyze the theories of science thereby applied.  
 Before turning my observations into a topic for a study in theory of 
science, I surveyed several already existing analyses. I distinguish between 
three groups of analyses: commentaries (on science, ethics, and politics), 
popular science writing, and academic work. The first group was found 
in collections of commentaries. Thus they presented a multitude of 
voices, rather than a coherent account. The commentaries include books 
and special issues of bioethics journals (e.g. American Journal of Bioethics 
2001, Yale Journal of Health, Law, and Ethics 2001, Holland et al. 2001, 
Kiessling and Anderson 2003, Ruse and Pynes 2003, Snow 2003, Waters 
and Cole-Turner 2003). To me these commentaries were a probably 
necessary entrance to stem cell research and politics in the USA. 
However, as a theorist of science I could not avoid seeing their implicit 
theory of science. Although including diverse contributions from various 
commentators (such as ethicists, politicians, and scientists) they usually 
share one common way of seeing stem cell research. In spite of the 
                                     
9   A thoroughly incomplete list of theories of science could contain logical posi-
tivism, hermeneutics and Critical Theory, and individual theorists such as 
Ludwick Fleck, Karl Popper, Paul Feyerabend, Imre Lakatos, or Thomas 
Kuhn. 
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diversity of views they usually divide the world into two realms: the clo-
sed realm of science and a more open-ended one of politics and ethics.  
 One example of this is James Thomson’s chapter in a collection, The 
Human Embryonic Stem Cell Debate: Science, Ethics, and Public Policy (Holland 
et al. 2001).  
Human embryonic stem (hES) cells capture the imagination because they are 
immortal and have an almost unlimited developmental potential. After many 
months growing in culture dishes, these rather nondescript cells maintain the 
ability to form cells ranging from muscle to nerve to blood, and potentially 
any cell type that makes up the body. Their proliferative and developmental 
potential promises an essentially unlimited supply of specific cell types for 
transplantation in disorders ranging from heart disease to Parkinson’s disease 
to leukemia. (Thomson 2001: 15)  
Thomson, at the University of Wisconsin, is considered one of the main 
experts on hESCs. He headed one of the two groups that first announ-
ced the successful cultures of such cells. Here he starts in the public 
imagination, the effect of which is explained with reference to the im-
mortal and developmental properties of the cells. These are harbored in 
the culture dishes, and from there Thomson takes the reader to the 
therapeutic promises for certain diseases. The powers and promises of 
these “nondescript cells” do not come from nowhere. Thomson anchors 
the powers of hESCs somewhere outside the laboratory and outside the 
scientist. The powers arrive at the scientists’ culture dishes because of 
the early embryo.  
To understand hES cells, it is necessary to understand something about the 
basic properties of early human embryos. (Thomson 2001: 15)  
It is the developmental plasticity of early mammalian embryos that allows the 
derivation of embryonic stem (ES) cells. (Thomson 2001: 17)  
The early embryo “allows” the scientist to get at the stem cells. If the 
early embryo were not so flexible in its developmental program, the 
scientist would kill the cells when removing them from the inner room 
of the developing embryo, the inner cell mass (ICM; see stage 3 in the 
above Figure 1). Fortunately, the flexibility (or the plasticity) allows an 
arrest of the cells’ march toward maturity, in the scientist’s culture dish.  
because of the developmental plasticity of mammalian embryos, if the ICM is 
taken out of its normal embryonic environment and cultured under approp-
riate conditions, ICM-derived cells can proliferate and replace themselves in-
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definitely, yet maintain the developmental potential to form any cell type. 
These pluripotent, ICM-derived cells are ES cells. (Thomson 2001: 17)  
Thomson ties together the public imagination, the promises, and the thera-
peutic potential, with the scientists’ culture dish and ultimately the em-
bryo. Although he started with the former aspects, the direction is clear: 
All the promises and applications come from the cells. The latter are, in 
turn, the “pluripotent ICM-derived cells” from the early embryo. The 
movement is unidirectional and unilateral. The origin of properties and 
promises is the embryo that (or who) has allowed, and let go, of the cells 
into the hands and dishes of the scientists.  
 Most of the commentaries assume that the therapeutic promises are 
harbored in scientists’ culture dishes because of the developmental featu-
res of the early embryo. The ethical appropriateness, or the comparative 
strength of hESCs may be challenged, but the nature and capacities of 
hESCs, as presented by Thomson above, are not denied or questioned. 
This is an indisputable reality of hESCs, based on cell lines in culture 
dishes, embryo development, and a unanimous community of scientists. 
 Another reality is more diverse and heterogeneous, at least on the 
surface. Thus, it is not enough to let one representative speak, as in the 
case of Thomson. There is not one voice here. The ethics usually 
contains questions about the status of embryos, when life begins, and 
how to balance the life of embryos and the lives of future patients. Erik 
Parens, associate at the Hastings Center in New York (a leading bioethics 
center) presents the arguments: 
The major argument for doing embryo research is that it promises to reduce 
human suffering and promote well-being. The major argument against using 
embryos for research is that they have the moral status of persons and thus 
should not be destroyed, no matter how great the human benefit. (Parens 
2001: 40) 
Parens bases the conflict over hESC research on two major arguments 
about how to use the hESCs that – in accordance with the scientific 
reality – are already there. David A Prentice, Professor of Life Sciences 
and Medical and Molecular Genetics, Indiana, who has advocated to 
slow down hESC research, claims: 
The real root of the debate is this: What does it mean to be human? As we 
look at different forms or stages of human life, to whom will we choose to 
assign value? Who will decide, and who will benefit, from these value choices? 
(Snow 2003: 20)  
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Parens and Prentice are in one sense saying the same thing. It comes 
down to people’s views and stance on what it is to be human, and who is 
to benefit from the research. Representatives of religious communities 
suggest guidance for people based on religious faith and on philosophical 
thinking. Although much of this guidance relates to “how God is”, 
“what humans are” or “what good actions are” many acknowledge they 
are explicitly oriented toward people and their decision-making 
capacities. Even when representatives have a firm position they do not 
deny that there are other disagreeing views. Frank E Young, an ordained 
evangelical minister who has served at the US Department of Health and 
Human Services (DHHS), participates in a third volume of papers and 
explains how political decisions should follow from some people’s 
views:10  
Many people consider this research immoral, illegal, and unnecessary. There-
fore, it is imperative to proceed cautiously. Federal funding of research using 
human embryos or pluripotent cells derived from them would be inappropri-
ate until further resolution of the ethical issues has been achieved. (Young 
2003: 213)  
Young opposes the federal funding of hESC research. This had been a 
crucial political question for many years, linked to people’s views. Bio-
ethics Professor Arthur Caplan, also chairman of the advisory committee 
to the DHHS and the FDA, supported federal funding based on a trade-
off between the harm to embryos and the benefits and the good to 
patients.  
I do not think we are in the realm of absolutes. I think we need judgment. I 
think we need virtues. That is why we need public funding, public accounta-
bility, to make the right tradeoffs. (US Senate 1999b: 37)  
Caplan explicates another reality of hESCs beyond the scientific: a realm 
of arguments, values, virtues, faith, judgment and people’s decisions. 
Many actors would oppose calling the ethical disputes and the political 
controversies the reality of hESCs, but they maybe recognize them as the 
realities in which hESCs are. Those realities are sometimes related to the 
abortion wars, and the history of embryo research in general. Following 
the many accounts of the science, ethics and politics of hESCs the stem 
                                     
10   Young is also a former commissioner of the federal supervisory authority, the 
Food and Drug Administration (FDA), and at the World Health Organization 
(WHO). 
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cells appear in at least two realms. While the ethics and politics are kept 
open-ended in the commentaries, the realm of science is closed. In the 
scientific realm hESCs are matters of fact, that via culture dishes in the 
scientists’ laboratories, because of their particular properties, are finally 
conceived as getting to patients through transplantation therapies. In the 
ethical and political realm (or realms) hESCs are matters of opinion: peo-
ple can express their opinions whether to use or fund the hESCs or not, 
and how.  
 The seeing implied in these commentaries thus divides the world. Mo-
re than pluripotent circulations, pluripotency stays in the scientific realm 
separated from the political and ethical uncertainties. The commentaries 
usually separate stem cells that can be explained and represented (by 
scientists), from their application and reception (by ethicists, politicians, 
and patients).  
 This way of seeing stem cell science and politics is common, perhaps 
even a common sense one. At least it seems so, judging from a second 
group of accounts, viz. popular science writing. In contrast to the com-
mentaries, the popular science texts, however, attend to the history of 
stem cells. Just as in the above commentaries, science is closed off from 
the uncertainties and disputes in the outside world. There may be dis-
putes, but they are misunderstandings and deviances from the rational 
pursuit of science.  
 For natural reasons there was initially very little popular literature on 
the issue: The stem cells lived quite hidden from public interest until 1998. 
One of the first to give an easy-to-read introduction to general stem cell 
biology was Ricki A. Lewis’s Windows On the Life Sciences (2001), of which 
stem cells were one of eight windows. Another popular-science writer, 
Ann B. Parson, goes as far back as the 1700’s to understand what stem 
cells are in her historical account The Proteus Effect (2004). This is an in-
teresting work, not least because of Parson’s empirical material, which to 
some extent consists of interviews with (what are often considered to be) 
key stem cell researchers. Robin Marantz Henig’s Pandora’s Baby (Henig 
2004) is a history of in vitro fertilization (IVF) about the “test tube ba-
bies” that “sparked the reproductive revolution” (following the book’s 
subtitle). Thus it does not concern stem cells specifically until its final 
chapter, where a connection between IVF and stem cells is mentioned. 
Parson and Henig are two examples of popular science history relating to 
hESC research. To the extent that these authors uncritically take up and 
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convey definitions of stem cells they are part of the empirical material I 
draw on.11  
 These two groups of literature thus represent a similar way of seeing 
stem cell research and politics by dividing the realms of biological pluri-
potency and political/ethical uncertainties. In addition, stem cell research 
is analyzed without a theoretical awareness. The noted “division of realms” 
is my explication of their implicit theories of science. Within the discipline 
of theory of science there are other perspectives that would result in 
another topic of study. Furthermore, these perspectives are explicitly and 
deliberately applied to the analysis of scientific activity. One such “play-
ing-ground for perspectives” is the field of Science and Technology Stu-
dies (sometimes Science, Technology and Society) or just STS. Accor-
ding to work done within STS, research can be as heterogeneous and 
open-ended as the ethics and politics above were. Since the 1970’s this 
emerging inter-disciplinary field has gathered an increasing number of 
scholars and researchers studying science and technology. They have 
done so as if science were not a closed box, but one possible to open up. 
Approaches used in STS have, for instance, been the Sociology of Scien-
tific Knowledge (SSK), the Social Construction of Technology (SCOT), 
Social worlds theory, and Actor-Network Theory (ANT).12 This field has 
inspired meta-theoretical work at the home department of this study.13 
My work is congruent with these reflections on the theories of science 
used within STS. 
 Of the many approaches available, I will (in the next chapter) select to 
draw mainly on the theory of science presented by ANT, and more 
specifically Bruno Latour’s version of this. This should be obvious from 
the subtitle of the book and it will add a second more theoretical dimen-
sion to the title. According to Latour, the capacities or powers of entities 
(whether cells or Presidents) are not within that entity, but happen as a 
                                     
11   However, they usually fall outside of the empirical territory by not being prior 
to 2001. To the extent that these authors convey empirical material about the 
situation prior to 2001, I will use it as I use other materials. See more below, 
Materials and Methods in Chapter 2. 
12   For more full-length accounts of the many perspectives and tools used within 
STS, see Jasanoff, et al. 1995. For collections of seminal papers see Biagioli 
1999, and for introductory works where SSK and SCOT also are outlined see 
Hess 1997, Sismondo 2004, Yearley 2005.  
13   For examples of this, see Bohlin 1995, Bragesjö 2004, Hallberg 2001, Kaspe-
rowski 2001, Landström 1998, Larsson 2003. 
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continuous movement between a number of things and people. Latour 
has spoken of these movements as circulations (1999b: Chapter 2). He 
has also spoken of the interplay between science and society as a 
circulatory system (1999b: Chapter 3). Seeing science in this way goes 
explicitly against any partition of science, ethics and politics.  
 The commentaries above are examples of what Bruno Latour calls 
“purification” and are part of a “modern” view of science and society. 
Purification, in short, is the analysis of knowledge and things in terms of 
either (1) the external reality of nature, (2) the social bonds, the “forces 
that structure society” (Latour 1993: 88), (3) signification and meaning 
“that make up the stories that we tell ourselves”, ”the great narratives 
that dominate us infinitely” (p. 88), or (4) the Existence (or Being) as 
opposed to all the existences. In relation to the phenomena at hand 
Latour seems to ask us to stop debating about the status of embryos or 
stem cells in terms of what they “really are” in the Bible or in the Petri-
dish, or merely with reference to their social role, or as an issue of 
discourses shaping the meaning of “embryo”, or in comparison with Be-
ing itself (God?) as opposed to the cold, disenchanted technoscience. 
Seeing science and politics as involved in circulations across those realms 
is one alternative to the “modernist purification”. Circulations are thus 
not only a general metaphor, but can be part of a theoretically informed 
attempt to look differently on stem cells and their pluripotency – as a 
movement between a number of entities.  
 Putting ANT to work on stem cells in the USA thus amounts to seeing 
circulations. It is an attempt to avoid the separation of e.g. discourse and 
social bonds from “external reality”. My fascination with stem cells was 
tied up with my observation that these cells seemed to make a difference 
among so many people. I called this the stem cells’ “biological and 
political pluripotency”. However, it is no surprise that many of the 
people that go out of their way to oppose or support such research have 
never encountered a stem cell in a petri-dish, in a laboratory or in a 
clinic. This suggests that I was wrong to assume that stem cells were 
making a difference among e.g. politician or ethicists – or I was merely 
using an imprecise figure of speech. The “political pluripotency” was not 
due to stem cells, but to the representations, or receptions of stem cells. 
However, when spending time in the laboratory it became clear to me 
that even laboratory personnel, who could be said to handle the stem 
cells in their daily business, were not dealing with them as you handle a 
spoon, a dog, or a friend. On a daily basis they claimed to pour stem cells 
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from one batch to the other, put them through machines, and even 
“see” the stem cells in a microscope. But, all of these meetings were 
highly mediated by other things. These machines and techniques were trusted 
means to handle cells – just as Bush and the ethicists trusted that what 
they learned about stem cells was correct when commenting and making 
decisions.  
 I am making a philosophical suggestion here, about reality. Batches are 
not necessarily closer to reality than political documents. They are all part 
of what will later be called sociotechnical reality – as opposed to biology 
separate from politics, or natural reality separate from social reality. 
Instead of drawing a line between what intermediaries are, and are not, 
giving access to the real stem cells, ANT talks of articulations. Articula-
tions are the combinations performed of e.g. stem cells with other things 
or people, such as microscopic light or Federal funds. Bush is articulating 
stem cells with his televised speech, just as well as Thomson is articula-
ting stem cells in his lab together with microscopes. Thus, in order to 
access the sociotechnical reality of stem cells and the pluripotent circula-
tions I will be analyzing the articulations of stem cells. Much of the next chap-
ter will be spent on explaining Latour’s version of ANT, including the 
notion of sociotechnical reality, the role of articulations, and the con-
cepts of obligatory point of passage and boundary objects.  
 In this study, I am not only fascinated by stem cells, but also with the 
view of science provided by ANT. In relation to many of the existing po-
pular science texts and the collections (about science, politics and ethics) 
ANT provides another way of seeing hESC research and politics. An 
underlying aim of the whole study stems from being meta-theoretically 
aware and encountering stem cells via the lab and the literature: A drive 
to see stem cells differently. This aim is summarized in the title as a 
matter of pluripotent circulations. 
 Putting ANT to work on stem cell research and politics is an attempt 
to exercise a different seeing than the (perhaps commonsensical) seeing 
exemplified in the commentaries and popular science writing. The task is 
however not a straightforward one. My choice of empirical material and 
ongoing critique of ANT call for meta-theoretical elaboration of ANT.
 Had I stayed in the lab, an ANT approach would have been natural. 
Latour has urged students of science and technology to follow the scien-
tists. I did not do this. I went back to Bush’s decision and tried to un-
derstand the situation prior to August 2001. More specifically, I attended 
to the role of stem cell research within a public and political dynamics 
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(and not as, e.g., within a laboratory dynamics). There are at least four 
reasons for this choice. The first reason came from my puzzles about the 
preceding dynamics. There seemed to be more to the struggles around 
plasticity and pluripotency than I could find in the lab. Second, the poli-
tical ramifications of hESC research were tangible upfront – as in Bush’s 
speech – and they attracted my interest. As I did come from Sweden, the 
heated public debates about the life sciences were something new. Third, 
because of the lack of Federal policies the stem cells existed in the US 
public and political debates just as much as (or more than) they existed in 
US laboratories during this period: hESCs were still quite modestly re-
searched in the USA. There were only a dozen hESC lines out there. A 
final reason has to do with the underlying aim of seeing differently. To 
display the effects of another way of seeing, the most appropriate topic is 
a well-known one. When observing something never seen before, the 
very act of seeing, or the differences in seeing, are much harder to detect. 
It is when ex-patriots return to home ground after a time abroad that a 
change in seeing suddenly can be noticed. If ANT were to be applied to 
a completely new material the result would be a completely different pheno-
menon. The politics and public debates are therefore especially interesting 
to analyze from an ANT perspective. However, ANT has not been ex-
tensively used to cover a predominantly public and political dynamics. 
The empirical case thus requires an elaboration of ANT. This meta-theo-
retical task converges with another one.  
 ANT has been criticized within STS. One criticism has been that ANT 
studies have given a human-centered view of how research takes place.14 
Critics have argued that though such a view of science is sometimes 
called for, it is not always useful. They have suggested more distributed 
models for understanding the flows between the various participants in 
the production of knowledge. This critique thus also uses a flowing, 
circulatory metaphor. Taking this critique seriously will add to the notion 
of circulations already introduced. Furthermore, it constitutes a second 
meta-theoretical task that puts ANT on the operating-table.  
The relevance and contribution of this study in relation to previous 
research 
In relation to the existing popular science and commentaries on stem cell 
science, ethics, and politics, a first area of relevance for this study can now 
                                     
14   For the critique raised by proponents of SSK, see the next chapter. 
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be stated: The relevance consists in approaching stem cell research and 
politics in terms of a different seeing which does not divide the biologi-
cal and political reality of stem cells. Furthermore, the ANT perspective 
is applied with a meta-theoretical awareness. The title indicates this by 
drawing on Latour’s notion of circulations.  
 ANT is, however, not the only way to see stem cells differently. The 
discipline of Theory of Science as well as STS provide plenty of other per-
spectives. In addition, there are other approaches in academia. Stem cell 
research has triggered a number of academic studies. I will focus here on 
studies done in (or in the proximity of) STS. Thereby I am leaving a 
survey of, e.g., the bioethical literature to professional bioethicists. There 
have so far been relatively few STS-related publications on stem cell re-
search, although the number is increasing. Some of these include sciento-
metric studies of how words occur in media and scientific reports 
(Leydesdorff and Hellsten 2006), various “framings” of embryonic stem 
cells (Hviid Nielsen 2005, Nisbet et al. 2003), how the boundaries of 
human life and between politics, science, and ethics are managed 
(Leinhos 2005, Waldby and Squier 2003) and cross-disciplinary analyses 
on stem cells in global and/or national contexts (Salter et al. forthco-
ming, Koch and Høyer in press). 
 On-going projects that have not yet resulted in publications have been 
presented at conferences. There have been several sessions of papers 
devoted exclusively to stem cell research at conferences held by the 
Society for Social Studies of Science (4S), and the European Associations 
for the Study of Science and Technology (EASST). At the 2004 4S/EASST 
conference in Paris, there were three sessions of papers (4S/EASST 
Conference 2004: Sessions 19 and 114).15 Few of these papers concerned 
American politics and hESC research (Gottweis 2004, Hogle 2004), and 
even fewer included a historical dimension. There is at least one UK-
based project on the historical emergence of hematopoietic (i.e. blood-
forming) stem cells (Brown et al. 2005). In her Whose View of Life?, histo-
rian of biology Jane Maienschein has traced the present-day “hopes and 
hypes” of stem cell research back to early cloning experiments and ge-
netic research (Maienschein 2003). This is not strictly STS and not popu-
lar science, but a historical study written also for a non-academic reader.  
 There is to my knowledge no book-length study done within STS on 
the public and political dynamics of hESC research in the USA drawing 
                                     
15   Three since session 19 was a double session. 
 
 
 
20 
consistently on ANT. In popular science writing, authors have traced the 
historical emergence of stem cell research. This has not been done from 
an STS- and/or ANT-inspired perspective. In the present study I do not 
stop at the events immediately preceding 2001, but go backwards to 
events in the 1980’s and 90’s within assisted reproduction (in vitro ferti-
lization) and fetal tissue debates. These processes were not directly tied 
up with stem cell research at the time. I have not seen any STS studies 
tying together those processes and the negotiations over stem cell re-
search at the turn of the century. A second area of relevance for this study 
can thereby be stated: Within STS, it is one of the (so far) few book-
length studies drawing on ANT to understand the historical emergence 
of the public and political dynamics of stem cell research at the turn of 
the 20th century.  
 A third area of relevance concerns the meta-theoretical contribution and 
elaboration of ANT-according-to-Latour. The empirical case challenges 
ANT’s analysis of public and political processes. This study also makes 
ANT into a topic by considering the critique from more distributed 
approaches. It will thereby put the metaphors of circulations into more 
explicit use than earlier.  
 By now the title and subtitle should be a little less opaque. The detailed 
aim presented when starting this chapter (in the second paragraph) will 
need the next chapter to be fully understandable. (To explore ANT in 
order to understand the sociotechnical reality of hESCs in the USA prior 
to August 2001 – in particular with regard to the public and political 
dynamics.) However, by now it is clear that the aim is the result of my 
meta-theoretical interests oriented towards both actor-network theory as 
well as stem cell research and politics in the USA. 
Outline 
The four first chapters form Part One. More than being all-encompassing 
analyses, these chapters are exercises in how to understand the socio-
technical reality of hESCs 1998–2001.  
 The first part of Chapter 1, A Meta-Theory Assemblage: Methods, Materials 
and Theories of Science continues this Introduction, by assuming that hESC 
research and politics as a topic is not something given. It may be many 
things, depending on the perspective. By juxtaposing possible analysts, 
and adjacent constructions of topics, the added value of selecting ANT is 
suggested. After making this selection the second half of the chapter pre-
sents my modifications of ANT. Instead of being left alone, ANT beco-
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mes a topic for meta-theoretical explorations. It is tossed, tried and tur-
ned by means of the existing critique. Lastly I present and justify my 
choice of empirical materials, i.e. political and public texts, and how to 
approach them.  
 In Chapter 2, Attempting an Obligatory Point Of Passage: Federal Funding of 
Human Embryonic Stem Cells, I approach probably the most striking phe-
nomenon for a foreigner beginning to look at articulations of hESCs in 
the USA, viz. the issue of federal funding. Instead of seeing this merely 
as a struggle between the pro-life movement and liberals together with a 
biomedical lobby, the articulations of hESCs were of a specific kind, re-
sembling the classic studies of Latour and Callon on obligatory points of 
passage (OPP). The references to the cells’ capacities and therapeutic 
uses were closely linked to the Federal administration. To exercise seeing 
differently, I stress both useful similarities, as well as the discrepancies 
between this case and the classic ones.  
 Susan Leigh Star and James Griesemer presented an alternative ap-
proach to the OPP, to capture a less dominating coordination of actors. 
Chapter 3, Outlining a Boundary Object Coordination: Diverse Actors and Mul-
tiple Uses, draws on their approach. By looking for a distributed coordina-
tion of boundary objects, instead of the centralized OPP, other things 
are seen. Articulations of hESCs are thus not only dominant and exclu-
ding, but also enabling, and address many actors’ needs without total 
transformation. Again, the analysis is drawing out what it would mean to 
see the hESCs from a specific perspective, viz. as boundary objects.  
 Chapter 4, Theoretical Tensions and Innovations: A Boundary Package in Mul-
tiple Loops, reflects a struggle to make place for the reality of hESCs as 
seen in the previous two chapters. While those chapters started from two 
specific and contrasting approaches fully applied as precise and sharp 
tools, this chapter searches for theoretical convergence – with due re-
spect to the tensions. Whether seen with one or the other theoretical 
tool, three elements of hESCs are central: pluripotency, transplantation 
therapies and “spare embryos” are all aspects of the hESCs’ flows among 
diverse actors. Thus combining the empirical findings in one theoretical 
space gives a preliminary answer to what the reality of hESCs was in the 
USA, 1998–2001, and ends the first part of the book. 
 In Part Two, this reality is unpacked in order to understand how the 
sociotechnical reality of hESCs came to be. A first step is to go back-
wards and look at the hESCs before they became laboratory objects, but 
were nevertheless entities in official reports and debates. Chapter 5, A 
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Project, its Problems and Prescriptions: The 1994 Human Embryo Research Panel, 
finds actors engaged in, but disappointed with, the negotiations of fede-
rally funded human embryo research. Their references to two of the three 
hESC elements suggest that the multiple flows of 1998–2001 were set in 
motion even before 1994. The observations also suggest a specific role 
for the hESCs, as a solution to the problems of federally funded human 
embryo research.  
 In Chapter 6, Multiple and Partial Stabilizations: The Necessity of ”spare em-
bryos”, and the Urgency of (Possible) Transplantation Therapies, two of the ele-
ments in the reality of hESCs in 1998–2001 are unpacked. Instead of 
taking their stability in 1998–2001 (and already in 1994) for granted, I use 
the debates about in vitro fertilization and fetal tissue research to exa-
mine the flows of actors that enabled the stable references. These histo-
ries also challenge the traditional notion of stabilization as a gradual in-
crease of linkages.  
 Drawing on the elements’ stabilization the hypothesis from Chapter 5 
about the role of hESCs is tested in Chapter 7, Pluripotent Articulation: Re-
lating hESCs to Embryos and Transplantation Therapies. The study returns to 
the period of 1998–2001. Now the focus is not on patterns in circula-
tions, but rather on how hESCs are configured by relating to embryos 
and transplantation therapies. A central locus for such configuration is 
the terminological definitions of pluripotency.  
 In Chapter 8, Conclusion, I briefly summarize and pull out some of the 
key contributions of the study. 
1.   A Meta-Theory Assemblage: Methods, Materials and 
Theories of Science 
The Introduction laid out the need to see differently as a matter of 
turning the initial puzzles into a topic. This chapter will enact this on a 
larger scale by introducing the selected theory of science (ANT), the 
meta-theoretical interests, and the empirical materials. Together these 
three components constitute an assemblage. My use of this notion – assem-
blage – signals that the theories and questions will have to unfold and 
change during the confrontation with the empirical material.16 It is im-
portant to redefine what methods can be. Methods are not used here to 
draw up roads with already prepared lanes for the investigation or for a 
reader. Obviously, an outline was already presented in the Introduction. 
But my methods, the meta-theory, and the initial material define each 
other as the study proceeds. They come in a “bundle-in-progress” that 
continues to bundle and re-bundle (in Law’s words, 2004). This is not a 
methodological failure, but reflects the research process. Again, the rea-
der is invited to follow the work in progress, as I approach the hESCs 
and the theoretical tools.  
Among theories of science  
In the Introduction I asked how the elementary puzzles of hESC re-
search could become a topic for a study in theory of science. The answer 
is that I use ANT. The first part of this chapter further develops this 
answer by envisioning two other contrasting theories of science, and how 
they would turn the initial puzzles about stem cells into a topic. This is 
also a way to outline the added value of ANT in relation to other app-
roaches. However, it must be made clear: The two contrasts are not gi-
                                     
16   To this extent I am inspired by Law’s Method Assemblage in his After Method, 
2004. He in turn credits Deleuze and Guattari 1988 for the notion assemblage.  
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ven the same space or elaboration as ANT is. It will not be a symmetric 
account, but a pedagogical and heuristic juxtaposition of various appr-
oaches. A full comparison between ANT and other approaches will need 
a study of its own. This first part of the chapter mainly serves the 
purpose of outlining the characteristics of ANT.  
A social realist analyst and topic 
I have already announced what interests me, viz. the “biological and 
political pluripotency” of hESCs. Depending on what theory of science 
is used, those initial and quite common observations can be studied in 
different ways by an analyst. To see what happens with the object of 
study when a perspective is applied, I will draw on SSK and in particular 
Harry Collins’s social realism (Collins 1985, Collins and Kusch 1998, 
Collins and Yearley 1992a). 
 The strong program in the sociology of scientific knowledge was laun-
ched in the 1970’s by David Bloor (Bloor 1973, 1976). He introduced the 
symmetry principle as one of four main methodological principles: 
Apparently successful scientific beliefs as well as the “mistakes” can be 
explained with reference to the same factors. The content – not only the 
institutional environment – of scientific knowledge was thus opened for 
sociological analysis. One contribution of this symmetry principle was the 
introduction of an impartiality to the analysis of science. Some things are 
also left out of the analysis. By explaining beliefs, proponents have made 
clear that they explain scientists’ representations or beliefs of natural reality, 
but they do not claim to thereby explain natural reality. The analyst’s 
topic is thus representations of nature, not nature itself (Bloor 1999a: 
92).17  
 SSK, as an acronym for the sociology of scientific knowledge, later 
came to include also the Bath school and the related Empirical Program 
of Relativism (EPOR) (Collins 1983), the program of discourse analysis 
(Mulkay et al. 1983), and the reflexivists (Ashmore 1989, Woolgar 1988).18 
                                     
17   Barnes, Bloor and Henry 1996 is a contemporary textbook written by some of 
the original proponents of the “Strong Program”, covering many of the cen-
tral theses. 
18   See Yearley 2005 for the internal development of SSK, including the Bath 
School and the Strong Program. 
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Collins has proposed that social realism is central for SSK.19 For instan-
ce, in a paper co-authored with Steven Yearley he stated:  
Natural scientists, working at the bench, should be naive realists – that is what 
will get the work done. Sociologists, historians, scientists away from the 
bench, and the rest of the general public should be social realists. Social rea-
lists must experience the social world in a naive way, as the day-to-day foun-
dation of reality (as natural scientists naively experience the natural world). 
(Collins and Yearley 1992a: 308) 
To explain scientific beliefs about nature, the analyst can draw on resour-
ces from social reality, such as professional or economic interests. Fin-
ding such factors is the sociologist’s contribution to the study of science 
and technology.  
 By drawing on Collins’s social realist version of SSK there are now a 
few important and decisive notions for turning hESC research into a to-
pic: scientific beliefs, natural reality, and social reality. The first is the to-
pic and the latter is the resource. Natural reality is left for the scientists 
(at their benches). Based on Collins’s theory of science it is possible to 
envision a social realist analyst and the way s/he would turn hESC research 
into a topic. Such an analyst approaching hESC research would not be 
identical to Collins, but borrow traits from him. The social realist is thus 
my simplification, my temporary construction. It is more elaborate than 
the common strawman, but hardly doing full justice to how Collins or 
SSK would have approached hESC research.  
 One study that displays how the social realist would approach a topic 
related to hESC research is offered by Michael Mulkay. He pursues a 
sociological analysis in The Embryo Research Debates (1997) that fits the 
symmetry principle. In this book Mulkay analyzed the British parliamen-
tary and related debates on human embryo research, between 1984 and 
1990. Scientific results and expectations were brought in, by scientists 
and others, to argue for a specific regulation of embryo research. Ultima-
tely the UK did get a liberal, and simultaneously very detailed, regulation 
of embryo research. Mulkay’s study was in accordance with SSK by not 
taking sides. An asymmetric study would have referred to truths versus 
misconceptions of science. When Mulkay discusses the science of em-
bryo research he lets the scientists speak for themselves without taking 
sides (Mulkay 1997: especially Chapter 7). Embryo research is not inclu-
                                     
19   This is Collins’s position and not SSK’s in general. 
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ded in his story in order to find out how truth or natural reality was 
unfolded to scientists or how falsity was ultimately seen through. Scien-
tists’ and others’ representations of embryo research, whether regarded 
as true or false, were treated in the same way by Mulkay.  
 Mulkay exemplifies some aspects of a social realist analysis. However, 
he does not treat the construction of scientific beliefs. Mulkay did not 
chiefly study science, but debates about science. Within Mulkay’s study the 
social realist could ask about the scentific beliefs. One such instance is the 
consensus among scientists about the benefits of embryo research (p. 
106–112). Among the benefits most significant in the debates were the 
scientists’ references to the control of genetic diseases through the selec-
tive screening of IVF embryos. Members of Parliament could refer to 
“the overwhelming weight of scientific and medical opinion”.20 A scien-
tific consensus is a possible topic for the social realist, especially if there are 
cracks in the consensus. According to Mulkay the “major sources of autho-
ritative scientific opinion” (p. 110) were the Royal Society, the Medical 
Research Council, the British Medical Association, and the Royal Society 
of Obstetricians and Gynaecologists. These all supported embryo research 
and the scientific testimonies in the Parliament were unanimous. How-
ever, Mulkay tentatively concludes from his conversations with scientists 
that they probably “were less unified in private than in their public testi-
mony” (p. 198, note 61). The social realist would pick up on this and start 
interviewing people, learning about which results warranted the promises 
of genetic screening, and then see how professional or other interests 
affected scientists’ beliefs. Typical questions would be: How were the 
societies and councils assembled? What people were assessing the future 
benefits and what relations did they have with embryo research? What 
were their interests?  
 From an overwhelming scientific consensus allegedly based on scienti-
fic facts the social realist would find cracks and social interests. This would 
be the contribution: To not a priori accept scientists’ beliefs but to start 
looking for underlying social processes. While the scientists’ subject and 
explanatory resources are natural reality, the social scientists’ subject is 
made up of beliefs about natural reality analyzed by recourse to the social 
reality of groups and interests. 
                                     
20   Lord McGregor in the parliamentary debates in 1989 quoted in Mulkay 1997: 
111. 
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A natural realist analyst and topic 
By using notions introduced in relation to SSK above, it is possible to 
analyze the implicit theory of science in Bush’s and Thomson’s accounts 
of hESCs (see Introduction). Bush refers to the problems and decisions 
that stem cell research actualizes. Because of the medical promise and 
the unique potential there is a need to federally fund the research. When 
Thomson comments on the popular imagination, he refers to the pluri-
potency of hESCs and the “the basic properties of early human em-
bryos” (Thomson 2001: 15). Politics and ethics are affected by scientific 
research. In the terms introduced above social reality is affected by natu-
ral reality. The role of humans is to discover natural reality and to make 
ethical choices and political decisions, such as the one made by Bush. 
This distribution of work between humans and the natural reality of cells 
is tangible in a recently published history of stem cells. Science writer 
Ann Parson’s The Proteus Effect (2004) goes as far back as the 1700’s to 
understand stem cells. She describes how  
humans have gradually awakened to these distinctive, often camouflaged, cells 
in our midst and slowly come to recognize their worth [---] Stem cells are 
basic to the regeneration of every multicellular plant and animal, and as scien-
tists discover more about them, these flexible worlds-unto-themselves should 
open our eyes to the presence of forces in Nature that are far greater than 
anything humans could imagine or invent. As neuroscientist Evan Snyder has 
aptly put it, “Even the dumbest stem cell is smarter than the smartest scien-
tist.” (Parson 2004: 8f) 
In her thorough and fascinating history of stem cells, Parson is practicing 
a theoreia of science in which hESCs were there all the time in our midst, 
although camouflaged, as instances of natural forces. hESCs are defined 
as part of natural reality beyond social reality and human invention. It is 
an asymmetric analysis. There is no space for professional or economic 
interests in Parson’s account of the unfolding of natural reality before 
the eyes of scientists, except for the cases where scientists were obstruc-
ted from finding the truth about stem cells.  
 It is unfair to let the contrast with the SSK-inspired social realist be 
borne by non-professional theorists of science. Many philosophers of 
science have developed more sophisticated versions of natural realism. 
 
 
 
28 
Common to these is usually that humans can attain knowledge about natu-
ral reality in various ways.21  
 One example is Ronald Giere’s constructive realism. In his Explaining 
Science (1988) scientific knowledge is not a direct reflection of reality, but 
comes in models, which correspond to particular aspects of real systems. 
Giere admits that SSK and other constructivist approaches have contri-
buted to the understanding of laboratories and the process of ongoing 
research. However, by denying the causal interaction between scientists 
and the natural world, SSK is missing out on something important. Giere 
also sees science as constructed, but not socially constructed. Giere’s ver-
sion of realism has lately come to focus on how cognition interacts with 
a complex reality by the distribution of discrete tasks to material, techno-
logical, and societal aids (Giere 2002, Giere and Moffatt 2003). Such di-
stribution draws on cognitive rather than social constructs. Although 
highly involved, the cognitive capacities of humans result in true knowl-
edge due to their interaction with the natural world. For Giere, the suc-
cess of cognitive systems hinges on the interaction with real systems in 
nature, e.g. the real stem cells and the truth about them. This is the 
similarity between Parson’s implicit theory of science and Giere’s con-
structive realism: Both theories of science ultimately judge the success of 
science by reference to natural reality. In this sense natural reality is the 
ultimate resource, although mediated by many smaller ones, such as scien-
tists’ experiments and cognitive systems.22  
 Based on these similarities and Giere’s attention to distributed cogni-
tion, I envision a second analyst. This natural realist is not any specific 
natural realist. It is an analyst envisioned in order to see how hESC re-
search could be approached by means of a second theory of science. For 
the natural realist there is a stem cell that can be interacted with, or unco-
vered, by humans through experimental, conceptual, and cognitive de-
signs with subsequent political and ethical decisions to be made. The 
object of study is science, uncovering and interacting with natural reality, 
with effects on a social reality. Pluripotency is a feature of nature captu-
red by the scientists and affecting politics. Empirically the study amounts 
to talking to people who were there when “it” happened, or reading 
                                     
21   For collections on natural realist philosophers of science see Boyd et al. 1991, 
Sklar 2000. 
22   Except for the already quoted papers, this paragraph’s reproduction of Giere’s 
position is based on his book (1988), mainly chapters 1 and 4. 
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scientific and news articles reporting on the events. A study could also 
involve experimental designs in detail, visits to the labs, and observations 
of the researchers. Nevertheless, the truth/falsity of claims about stem cells 
would ultimately refer to a natural reality “out there”. In this respect 
natural reality is the ultimate resource for the natural realist. 
 For the social realist the main topic could be the parliamentary debates 
about hESC research, and the beliefs among scientists. Those beliefs 
would not be explained by recourse to natural reality, but by finding out 
what professional and other interests determined this consensus. Society 
is no longer merely affected by the research, but is a resource for un-
derstanding how representations have come about. The pluripotency of 
hESC research would reside in politics or social factors, rather than in 
any biological objects. Empirically, both analysts start in the same reality. 
Both of them could start in Bush’s decision and Thomson’s explana-
tions, but then move in different directions. The natural realist would go 
from the research claims to the stem cells, and then assume asymmetry, 
i.e. humans would be right when contributing to cognitive systems or to 
the uncovering of natural reality, but wrong otherwise. The social realist’s 
analysis of hESC research would not move to the cells from the scien-
tific claims, but to the social factors that influenced both (allegedly) true 
and false representations of the cells. With regard to the interests announ-
ced in the Introduction, the natural realist does not include Bush’s decision 
in his construction of the topic, and the social realist explains biological 
pluripotency in terms of social causes. The purpose of the natural realist 
would be to explain science in terms of cognitive science, e.g. as a distri-
buted cognitive system. The social realist would formulate the topic of this 
study as explaining beliefs about hESCs in terms of social reality. 
An ANT analyst and topic 
The third theory of science is actor-network theory (ANT).23 It started 
out in the works by Bruno Latour, Michel Callon, and Madeleine Akrich 
                                     
23   Bruno Latour has explicitly rejected the T of ANT. 
  Far from being a theory of the social or even worse an explanation of what 
makes society exert pressure on actors, it always was, […] a very crude me-
thod to learn from the actors without imposing on them an a priori defini-
tion of their world-building capacities. (Latour 1999a: 20) 
  Also see Latour 2005: 141–156. As will be evident below, this study is not a 
typical ANT study.  
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in the 1980’s.24 Early on, it is possible to see common traits, but the later 
directions of research have multiplied. ANT has come to denote an 
open-ended cluster of ideas, methods, books, scholars, and more.25 It is 
therefore difficult to claim any main streams or clear boundaries in ANT.26 
Steven Yearley has stated this eloquently in his guide to science studies, 
Making Sense of Science: 
In important ways Actor-Network Theory (ANT) resists summary. It did not 
set out from a fundamental and unchanging programmatic statement in the 
way that the Strong Programme or EPOR did. Moreover, Latour’s leading 
methodological injunction is to “follow scientists around”, which sounds 
attractively simple but is also beguilingly vague. Worse still, ANT is a conspi-
cuously moving target. The two authors principally responsible for this ap-
proach, Latour and Callon, have followed by no means identical intellectual 
trajectories […]. (Yearley 2005: 55) 
From this “conspicuously moving target” I choose to focus on Latour’s 
production in this chapter.27 In the rest of the study my ANT inspiration 
will also come from a few works by Callon.  
 I take two recurrent motifs to be central in Latour’s version(s) of ANT. 
One concerns the notion of reality, and the other concerns agency. The 
first redefines the topic of investigation, and the second continues this 
motion, by emphasizing the wide range of roles played by all sorts of 
entities. 
                                     
24   Some central works from this period are Laboratory Life 1979, by Latour and 
Steve Woolgar; The Pasteurization of France [1984] 1988, and Science in Action 
1987, both by Latour; Callon’s “Some Elements of a Sociology of 
Translation” 1986b; and Akrich’s “Beyond Social Construction of Techno-
logy” 1992. 
25   For some signs of this diversity, see Lancaster University 2005, Callon 1992, 
Callon et al. 1986, Law 1986, Law and Hassard 1999, Mol 2002, Mol and Berg 
1998.  
26   For one story about the intellectual evolution of ANT set in an STS neigh-
bourhood – including “Classic ANT”, its close kinship relations, and deter-
mined dissenters – see Landström 1998. 
27   For more about the debates relating to ANT see below on social worlds 
theory. 
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Sociotechnical reality 
The natural and the social realist both pursue epistemological projects in a 
relationship to ontological sources or potencies. “Epistemological pro-
jects” since the natural realist examines the cognitive systems that interact 
with a natural reality that is knowable. His/her topic is the epistemic pro-
cesses. The social realist’s topic is beliefs, not natural reality. “In a relation-
ship to ontological sources” since the natural realist’s reality is the ultimate 
arbiter of the knowledge attained through cognitive systems. For the social 
realist there are two arbiters depending on whether you are a natural scien-
tists or a sociologist, historian, or in the general public: The latter groups 
relate to social reality as the resource just as the natural scientists relate to 
natural reality as the resource.  
 In contrast to these epistemological projects, ANT assumes that the 
topic of study is reality, not knowledge; not social reality as opposed to a 
natural reality; not beliefs about natural reality in contrast to actual rea-
lity; and not cognitive systems that interact with a natural world out the-
re. In order to understand how ANT can approach hESC research, a first 
step is to understand what ANT reality is. This will have implications for 
the ANT resources.  
 There is no other fundamental reality, or ontological source, except 
the one that is there to be studied in a number of elements and entities 
that make up science and society. In contrast to the social and natural 
reality of the social and natural realists this seems counterfactual, counter-
intuitive, or bizarre: Should there not be a reality out there to know? Ac-
cording to ANT, reality is out there all the time. It is just a matter of 
grabbing a hold. The reality that is not there, is an alleged reality beyond 
the reality we find when we are grabbing. It is not something we believe 
in or not. What is thereby rejected is the notion of a “reality being some-
where else” – but always available to be referred to by philosophers or 
sociologists (Latour 1999b: Chapter 1).  
 According to my view, ANT’s notion of reality builds on three di-
stinct, but intertwined themes: the entanglement of texts and materiality, the 
reality-construction of knowledge-production, and sociotechnical transformation. I will 
exemplify these three themes by drawing on three of Latour’s case stu-
dies. 
 The first theme, entanglement of texts and materiality, is visible in La-
boratory Life, by Latour and Woolgar (1979), and in “Circulating Refe-
rence” in Pandora’s Hope (1999). In the former case study the authors ob-
served that most of the laboratory work was centered on texts. These 
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texts were, however, based on inscriptions coming from (usually) machi-
nes, or inscription devices, that combined material substances and turned 
them into some sort of textual trace, such as a diagram or a graph.28 By 
comparing inscriptions and using other inscription devices producing addi-
tional inscriptions, and by relating to other texts relating to other traces, 
the scientists may ultimately be allowed to produce statements about “a 
substance”. The beliefs of scientific articles are the results of step-by-step 
transformations of mice, forests, and more.  
 Also “Circulating Reference” exemplifies this fundamental entangle-
ment of signs and materials. According to Latour there was a referential 
chain leading from the forest of Boa Vista in the Amazon to the claims 
about ”the forest of Boa Vista” in a scientific article:  
Notice that, at every stage, each element belongs to matter by its origin and to 
form by its destination; it is abstracted from a too-concrete domain before it 
becomes, at the new stage, too concrete again. We never detect the rupture 
between things and signs, and we never face the imposition of arbitrary and 
discrete series of well-nested elements, each of which plays the role of sign for 
the previous one and of thing for the succeeding one. (Latour 1999b: 56) 
By pointing out how the signs are nested in matter, Latour and others 
have claimed that there are no essential differences between words and 
the world. Texts are entangled in materiality, and vice versa.  
 Another, and second theme, was also tangible in Laboratory Life. Natu-
ral or material reality is not the underlying cause of knowledge, but a 
consequence of the inscription devices:  
The central importance of this material arrangement is that none of the 
phenomena “about which” participants talk could exist without it. Without a 
bioassay, for example, a substance could not be said to exist. The bioassay is 
not merely a means of obtaining some independently given entity; the bio-
                                     
28   John Law has discussed the ramifications of Latour and Woolgar’s study for 
the issue of realism in his After Method, 2004. Law neatly summarized and 
exemplified the workings of an inscription device like this:  
  For instance, an inscription device might start out with rats. These would 
be sacrificed to produce extracts which would be placed in small test tubes. 
Then those test tubes would be placed in a machine, for instance a radia-
tion detector, which would convert them into an array of figures or inscrip-
tions on a sheet of paper. These inscriptions would be said – or assumed – 
to have a direct relation to the “original substance”. (Law 2004: 20) 
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assay constitutes the construction of the substance. (Latour and Woolgar 
1979: 64) 
Another way to phrase it, is that the scientific process of making know-
ledge is making reality. “Nothing is known – only realized” (Latour [1984] 
1988: 159). When Latour asserts that there is only realization, not a reali-
ty to know, this is thus not to say that there is no reality out there. To 
know something, assumes a binary relation between a knower and some-
thing known. If knowledge-production is what Laboratory Life claims it is, 
then the things known are the things produced in the process. The 
“phenomena [say, a substance] are thoroughly constituted by the material set-
ting of the laboratory” (Latour and Woolgar 1979: 64, their italics). Rea-
lity is not known, but comes to be.29  
 A third and final theme that helps understanding how reality is not 
somewhere else is Latour’s study of Louis Pasteur (Latour [1984] 1988). I 
will use this study to make a third point that captures the two earlier 
ones on a larger scale. Not only are signs entangled in materiality, or ma-
terial phenomena constructed by means of inscription devices, but scien-
tific claims are also turned into a societal, natural and technological rea-
lity – or sociotechnical reality – of farming, veterinary, medical and everyday 
practices.30  
 Pasteur’s finding on anthrax microbes became a finding about a socio-
technical reality, since the laboratory reality was spread “all over France” 
                                     
29   There are centuries of debate about the relationship between reality and 
knowledge. Some accept these case studies as important and relevant and 
some don’t. Some accept some of the claims but not the whole package. Ro-
nald Giere, for instance, has picked up on the case study about Boa Vista, 
accepting every step of the analysis, Giere and Moffatt 2003: 307f. However, 
this does not make him accept the metaphysical interpretations: Reality is not 
the consequence but an independent determinant for cognitive interaction, 
Giere 1988: 110. 
30   I use this notion – sociotechnical reality and transformation – to characterize the 
process described in The Pasteurization of France, although (to my knowledge) 
never used by Latour himself in that text. However, Latour devotes a large 
part of Chapter 6 in Pandora’s Hope, 1999, to the explanation of sociotechnical. 
He does so to make a point about the intertwinement of society, nature, tech-
nology (and more). This is precisely what I mean when using sociotechnical reality 
and The Pasteurization is my example of it. Another reason to use the notion is 
that it indicates the kinship between Latour’s study and Thomas Hughes’s 
work, 1983 (see section about the obligatory point of passage below).  
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transforming, or “Pasteurizing” the nation (Latour [1983] 1999: 264). There 
was reality in every step of the process. First, Pasteur and his co-workers 
picked up on the interests that were there among farmers and hygienists, 
and then went to the field to gather bits and pieces from the realities of 
cattle farming (Latour [1983] 1999: 260). Second, the laboratory condi-
tions and methods enabled Pasteur and his disciples to see more of the 
microbes than out in the dirty and unordered farm situation. Third, by a 
series of operations Pasteur extended his lab to the outside world. In 
field trials, in the later transfer of vaccines, in new practices, such as dis-
infection and inoculation, the instruments and the phenomena in the lab 
were transferred to the farms. The “nature” of microorganisms and the 
“society around” the laboratory were constructed in the same process. 
Pasteur ensured his “scientific” reference to microbes by enabling the 
circulation of instruments, colleagues, veterinaries, political allies, 
farmers, sanitation (such as the pasteurization of milk) and public 
support.31  
 With each new flow of such things, the truth of his theories and the 
reality of the anthrax microbes increased. More than a discovery of micro-
organisms in nature, it was a sociotechnical transformation, or in Latour’s 
term, a Pasteurization of France. Latour compares the transformative 
effects of the Pastuerization with socialist politicians:  
it is clear that in political terms the influence of Pasteurian laboratories 
reached further, deeper, and more irreversibly since they could intervene in 
the daily details of life – spitting, boiling milk, washing hands – and at the 
macroscale – rebuilding sewage systems, colonizing countries, rebuilding hos-
pitals – without ever being clearly seen as a stated political power. (Latour [1983] 
1999: 268) 
Pasteur’s research did not take place in a social and natural reality, but 
itself resulted in a societal and natural reality. According to Latour, re-
search can perform a sociotechnical transformation that extends beyond 
changes attempted by means of political action. 
 As was mentioned above, the natural and the social realists have specific 
resources to approach the topic of hESC research. In the first case, the 
analyst accesses cognitive systems of the scientists. These systems have 
explanatory power because of their interaction with the ontological sour-
ce of natural reality. In contrast, the social realist would access social reali-
                                     
31   This particular metaphor of the reference and the flows is not from The Pasteu-
rization, but from Latour 1999b. 
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ties that have explanatory power because of their influence on scientific 
beliefs. According to the ANT view, a sociotechnical reality is in the ma-
king, and cannot be used straightforwardly as a resource to explain hESC 
research; the latter is involved in a transformation of social and natural 
reality. In Chapter 3 of Pandora’s Hope, “Science’s Blood Flow”, Latour 
presented two figures to explain this difference (Figures 2 and 3). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Latour has used this picture to describe “externalist” versus “internalist” 
histories of science. 32 It fits the two first analysts exactly. The social realist 
explains the inside by using resources from the outside context or socie-
ty. The natural realist observes how science may affect society on the one 
hand, and on the other hand be hindered or furthered by society. The 
territory of the social realist is the corona and the natural realist would keep 
inside the core, maybe with reference to a natural reality inside the core, 
as a kernel.  
                                     
32   The labels externalism and internalism have long histories, Shapin 1992. There 
is no reason to attach those labels to my natural and social realists. Nevertheless, 
I do keep close to Latour’s argument in Pandora’s Hope, chapter 3, 1999, in the 
following pages of my explanation. Below I will question and extend ANT’s 
approach according to my meta-theoretical interests. 
Figure 2: The common model for externalist and 
internalist explanations (Latour 1999b: 92). (With 
permission from Bruno Latour. Copyright by the 
President and Fellows of Harvard College.) 
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 For the ANT analyst there is no way of saying a priori whether hESCs 
were the results of social or natural factors. Scientists move all around 
and manage a number of resources. They modify and draw on social and 
economic interests that feed back into their laboratories, or their concep-
tual work. For the social realist such interests would be highly interesting 
factors that explain the ultimate experimental design. But, it also seems 
reasonable when explaining the experimental design, to focus on specific 
laboratory materials, such as the use of growth media and laboratory 
techniques. These factors would typically be the natural realist’s first prio-
rity. Which is primary? The pre-existing interests, the social expectations, 
or the cognitive aids in the laboratory? According to ANT they mutually 
define and enforce each other. Neither social reality nor natural reality can 
be used as a privileged analytic resource. The analyst has to follow the 
scientists’ trails wherever they lead, whether to allegedly social or natural 
places. What needs to be analyzed are the multiple flows or loops that 
scientists have to get going between labs and other parties (Figure 3). 
 This figure specifies the sociotechnical processes mentioned above. 
Flows of instruments and things, other scientists, allies (such as corpora-
tions and politicians), and the public all feed into the laboratory and the 
conceptual work. The latter is inextricable from the four other loops. 
According to Latour, the conceptual heart of scientific references is ma-
de up of the “links and knots” that tie the outer loops together. Together 
all these flows make up a circulatory system – “blood vessel after blood 
vessel”. The system works better the more connected the blood vessels 
are. Science is dependent on these flows as the heart is dependent on its 
circulatory system of veins and arteries.   
 Seeing hESC research as sociotechnical reality thus in a sense robs the 
analyst of resources but leaves flows, trails.33 The analyst is redefined, from 
having resources to having trails to follow which suggests that the acro-
nym of ANT should be read as an animistic redescription of the analyst: 
He is an ant (Latour 2005: 9).34  
                                     
33   I am using “trails” in Latour’s commonsense use – not according to either 
Adrian or Charis Cussins’s elaboration of the metaphor, Cussins 1996. 
34   On the use of gendered pronouns: For political reasons I have tried to envi-
sion a female ant, but failed, probably because of Latour. 
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From having a predetermined view of science and already defined 
resources at hand, the ANT analyst, according to Latour, becomes a 
much more myopic follower of trails, an ant. 35 If the ant wants to under-
stand hESC research, the only resource consists in the traces out there of 
reality being articulated, in various settings: materials turning into signs, 
the reality-production of knowledge-production, and the transformation 
of society and nature. 
 However, the difference between the ant and the two other analysts is 
not about following trails or not. The natural and the social realist can follow 
scientists closely, too. They are also ants in this sense. But, whereas the 
natural realist stays within the cognitive systems, and the social realist exa-
                                     
35   Henceforth I will italicize the an(t)imalized ANT analyst to distinguish him 
from the more mundane counterparts.  
Figure 3: The five loops of the circulatory system of science 
(Latour 1999b: 100). (With permission from Bruno Latour. 
Copyright by the President and Fellows of Harvard College.) 
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mines the social realities of the laboratories, the ANT analyst continues 
to follow the scientists as they cross those realms. Resources are thus not 
only about which factors to refer to, but say something about where to go, 
and where not to go. Resources thus have to do with realms and territo-
ries. Social and natural reality are not only a matter of resources but can 
be a matter of territories. What separates the ANT analyst from the natural 
and the social realists is not that the former follows trails and the others 
don’t, but that the former follows the trails also when they start criss-crossing 
between natural reality, cognitive systems and social realities. 
 This has been a pedagogical account to explain what scientists are doing, 
according to ANT, and where the analysts could go. It has implications 
for my initial observations of the stem cells’ “biological and political plu-
ripotency”. The social realist would explain biological pluripotency as a 
matter of social reality and human agency. The natural realist would ana-
lyze the political events as a consequence of (cognitive) laboratory systems 
capturing the biological and naturally real pluripotency. The ant would 
follow scientists moving in their laboratories, and from laboratories to 
the Congress, to the public, to colleagues. But, this raises the question: 
Which of these sites would account for the stem cells’ pluripotency as 
biological and political phenomena? Critics have (in other words) asked: 
If everything is flowing, then where can the analyst place her/himself to 
get a perspective on the flows?36  
Agency 
As a response to natural and social realist approaches, respectively, ANT 
has talked about human and nonhuman agency. Sometimes this is called gene-
ralized symmetry – in contrast to the first symmetry principle that was in-
troduced by Bloor (1976). There are many aspects of generalized sym-
metry and it has been opposed fiercely by critics.37 This opposition will 
not be treated here. Instead the purpose is to understand the effects for 
the ant. Assuming human and nonhuman agency widens the analyst’s 
attention.  
 A first thing has to be noted before anyone’s mind runs off with the 
idea of nonhuman agency: It is not a principle saying anything positive 
about the world, such as for instance claiming that stones or nuclear par-
                                     
36   This was basically what was asked in Collins and Yearley 1992a: 303. 
37   For such critics see e.g. Bloor 1999a, 1999b, Collins and Kusch 1998, Collins 
and Yearley 1992a, 1992b.  
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ticles have intentions or reflexive capacities (Latour 2005: 70ff). How-
ever, baskets and hammers make a difference for humans fetching provi-
sions or hitting nails. Baskets and hammers are thus  
participants in the course of action […] This, of course, does not mean that 
these participants “determine” the action, that baskets “cause” the fetching of 
provisions or that hammers “impose” the hitting of the nail. [---] Rather, it 
means that there might exist many metaphysical shades between full causality 
and sheer inexistence. In addition to “determining” and serving as a “back-
drop for human action”, things might authorize, allow, afford, encourage, 
permit, suggest, influence, block, render possible, forbid, and so on. (Latour 
2005: 71f) 
Generalized symmetry is useful since it tells the analyst not to turn 
around when the trails of research are leading to an object instead of 
people or social groups. In the hands of the analyst, generalized sym-
metry helps by paying attention to agency wherever it appears.  
 In some respects agency plays the same role as natural and social 
reality does for the two first analysts. Reality for these, signifies what 
makes a difference in the world, or “ontological potency”. Seeing agency 
in humans and nonhumans is to accept the ontological force of – in 
principle – any entity of the circulatory system of science-and-society.  
 In the sense of being effective and active, agency is also tied up with 
ANT’s reality. Seeing agency is seeing what really makes a difference. In 
Swedish or German this would be clear from the words that could be 
used for agency and reality: the Swedish verkan and verklighet, and the Ger-
man Wirkung and Wirklichkeit. What is ontologically active, what really 
makes a difference to others, is real – whether it be humans, nonhumans 
or anything in between, below, and above. For reasons of simplicity: In-
stead of referring to all these kinds of entities (humans, nonhumans, etc) 
in the rest of the text, I will usually just call them heterogeneous elements or 
entities. 
 Agency is the ontological activity of something or someone affecting 
other entities. In spite of this similarity between ANT’s use of agency 
and the other analysts’ uses of social and natural reality their attitude to-
ward this activity is radically different. Since agency in ANT is the result 
of scientific (or other) processes – such as the Pasteurization of France – 
it is a starting-point for the ant. The social and the natural realists study 
knowledge-production, and various sorts of reality come in to explain or 
account for this. Ontological activity is thus the end-point for the two 
latter theories of science, and the starting-point for ANT studies. ANT 
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starts in reality and agency and then finds out how something has become real 
and active. The social realist starts in knowledge and finds out how this has 
become perceived as true by finding out the social reality of those knowledge 
claims. The natural realist starts in knowledge claims and assumes that 
their references to a natural reality are there.  
 Imagine analysts following the trails of scientific work: Whenever the 
natural realist runs into social factors they motivate him to go and find 
cognitive factors. Whenever the social realist analyst runs into cognitive fac-
tors or nonhumans the attention is turned toward social factors. When 
the ANT analyst comes to an agency the first reflex, according to the 
generalized symmetry, should not be to turn away, but to stay curious 
and respectful. It thus becomes a matter of attitude. Latour claims that 
this attitude should extend to the explanations of pilgrims too:  
“I came to this monastery because I was called by the Virgin Mary.” How 
long should we resist smiling smugly, replacing at once the agency of the 
Virgin by the “obvious” delusion of an actor “finding pretext” in a religious 
icon to “hide” one’s own decision? [---] “As long as possible in order to seize 
the chance offered by the pilgrim to fathom the diversity of agencies acting at 
once in the world.” (Latour 2005: 48) 
The ant’s attempt to fathom the agency starts by examining the variety of 
factors that occur in relation to the acting entity, whether the Virgin 
Mary, anthrax microbes, or hESCs. In the latter case, pluripotency is not 
assumed to be something else – such as social or cognitive factors – but 
indeed something related to other elements playing a role in a net of 
relations. This role of Virgins, microbes or cells amid relations to hetero-
geneous elements is so important for ANT that it is part of its name. 
Actor-network is a term to signify how action happens in relation to other 
elements where neither the point of agency nor the surrounding relation-
ships are reducible from the equation (Latour 1999a). Drawing on the 
metaphor of networks is obviously not the exclusive property of ANT.38 
What makes ANT unique is the heterogeneity of these networks’ asso-
ciations.39 Actor-network is not an actor without a network, not an actor 
reducible to a network, and it is not a network without distribution of 
                                     
38   Networks have been used to describe scientific theories at least since Pierre 
Duhem [1906] 1954, and others have been Willard V. O. Quine 1964, Mary 
Hesse 1974, and Collins 1985 (just to mention a few). 
39   Association is a theoretical term within ANT. For more about its connotations, 
see below.  
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agency to certain elements. ANT focuses on how things or people make 
a real difference in co-dependence with a network of heterogeneous ele-
ments. The term used to capture the investment of agency in an element 
is delegation.  
 Seeing agency in this manner is not to ask for explanations. Finding the 
relationships does not explain pluripotency but contributes to an under-
standing of its role.40 Generalized symmetry about human and nonhu-
man agency helps the analyst to remain respectful of the phenomenon. 
In relation to my initial interests, in the “biological and political pluripo-
tency” of hESCs, both of these issues can be studied as the reality and 
agency of stem cells, without reducing one to the other. Biological agen-
cy and political agency do not have to be reduced to another repertoire, 
at least not immediately. I raised the question above: Which of the many 
sites where hESC research takes place should account for the stem cells’ 
pluripotency as biological and political objects? This question asked for 
something like an explanation. According to ANT’s view of agency no 
single site is responsible for pluripotency. Viewing pluripotency through 
the ANT theory of science means “seizing the chance to fathom the di-
versity of agencies acting in the world at once”. 
 I find the claim that science is involved in – and even the main vehicle 
for – sociotechnical reality an extremely interesting way of seeing hESC 
research and politics. It is interesting since it implies another way of topi-
calizing the two initial observations of hESCs, as biologically and politi-
cally pluripotent. The observations do not necessarily concern two di-
stinct phenomena but interlocking flows of the same circulatory system. 
If so, then there is not a biology distinct from politics. Plainly put: In-
stead of a social and/or natural reality of hESC research this study draws 
on ANT and therefore the hESCs and their “biological and political 
pluripotency” is understood as the sociotechnical reality of hESCs. The initial 
puzzle has thus been turned into a first ANT-inspired research question: 
(ANT-Question No 1) What is the sociotechnical reality of hESCs? 
                                     
40   I am fully aware that ANT in general does not refer to understanding, probably 
because of this notion’s hermeneutic connotations. ANT has preferred to 
speak of description in contrast to explanation, Latour 1988. However, I find 
the notion appropriate below Latour’s lines about “fathoming the diversity of 
agencies”, which to me implies precisely understanding.  
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 This chapter has outlined the added value of viewing hESC research as 
sociotechnical reality in relation to natural and social realist approaches. ANT is 
merely one among several approaches – not least within STS – that account 
for the heterogeneity and intertwinement of science and society.41 In this 
study however, ANT provides the main analytic assumptions. These 
assumptions are a first step in exercising how to see differently.  
 Whether the assumptions are defendable or not, there is a direct metho-
dological consequence for the analyst. Since reality is all there is – every-
where – the analyst shifts, from studying knowledge to studying reality 
(wherever it is), from being an epistemologist to being an “ontologist”, 
from being a sociologist of the social, or a philosopher of the cognitive, 
to becoming a sociologist of heterogeneous associations (Latour 2005: 9). 
Some ANT concepts in use42 
ANT scholars have coined specific words to capture sociotechnical rea-
lity in becoming. Articulation is one term which brings in linguistic and ma-
terial connotations: linguistic in the sense of expressing something clear-
ly; material in the sense of articulating a joint or a lorry. Turning mate-
rials into sign is articulation. The reality-production of knowledge-pro-
duction whether in the laboratory or on a larger scale is also articulation.  
 Earlier terms used by Latour for the same basic phenomenon are e.g. 
construction, translation, and coordination. There is little need to start 
laying out the differences between the various notions. They are all meta-
phors for capturing various aspects of the process of discovery-inven-
tion-construction (Latour [1984] 1988, 1999b: Chapter 5, Latour and Wool-
gar 1979). According to Latour, articulations are the fundamental entity 
of the universe. I make no such fundamental claims when referring to 
articulations. My use is a little more modest. I look for articulations to 
capture the making of actor-networks, bits of sociotechnical reality, or 
associations.  
 Association is the term for an articulated connection – whether it is 
between matter and sign or between a laboratory and people’s daily prac-
tices. To signify that in principle anything/anyone can connect with any-
thing/anyone these associations are heterogeneous. By way of associations 
                                     
41   For more about alternative approaches and the added value of choosing ANT, 
see below. 
42   Also see the Glossary (at the back) for definitions of the most frequently used 
terms. 
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the analyst attends to the connections made in articulations. The chain 
going from the Amazon to the scientific article could be said to consist 
of associations. Likewise the process going from inscription devices to 
diagrams, to comparisons, to statements and texts could be said to con-
sist of associations. The Pasteurization of France was also accomplished 
by way of associations. Above, there was another metaphor, the one of 
loops in a circulatory system. Associations between heterogeneous ele-
ments enable the multiple flows.  
 The temporal connection of articulation, associations in actor-net-
works and the resulting sociotechnical reality may be tracked as a process 
of stabilization. As e.g. laboratory claims are more and more articulated, 
and more and more associated, they become stabilized. Sociotechnical 
transformation is the stabilization of facts and people, places and prac-
tices. This process and its results have many names in ANT. Elements 
can, for instance, be packaged in black boxes or immutable mobiles, in order 
to be moved to new places and used off the shelf. These are examples of 
“frozen articulations”, or “congealed labor”. An articulation is a unique 
event, and only contributes to a tiny bit of reality (Latour [1984] 1988: 
162). To make it last, work has to be done. Black-boxing is one way of 
making articulations endure from one space or one time to the other 
(Latour 1987).  
 Such processes are reversible, although often at a high price. If the black-
boxing is a congealment of labor, it requires energy and effort to “flui-
dize”. In practice, this can often be impossible. It would by now be diffi-
cult, but not impossible, to reverse e.g. the use of electricity in Western 
societies. It may be the case that too many applications and practices are 
tied up with the use of electricity to make a reversal possible. Stabiliza-
tion enables the extension of actor-networks, but also constrains future 
articulations. Anything can, in principle, be done, but many (if not most) 
things are too cost-demanding. 
 Although it is hard for actors to open and, even harder to reverse, an 
achieved stabilization, the ant can do something similar but on an ana-
lytic level. If an analyst follows the associations implied in a stabilization 
backwards he is unpacking the stabilized object. When Latour analyzed 
the impact of Pasteur and the microbes on France in the 19th century, 
he was thus unpacking sociotechnical reality. This is not the same as ac-
tors’ attempts to reverse a stabilization, but it may speak to the same 
intuitions. The opening of today’s black boxes may show that “it could 
have been otherwise” (Bijker 1995, Fujimura 1996, Law 2004). hESCs 
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could be effects of stabilization processes, examples of stable elements, 
entities that are repeatedly articulated together with certain other entities. 
This notion of unpacking and stabilization thus results in a second ANT-
inspired question akin to the previous one: 
(ANT-Question No 2) How has the sociotechnical reality of hESCs come to 
be? 
It should by now be clear that the implied “how” of such a question is 
not a strictly explanatory one (as if asked by the social realist), but neither 
is it merely descriptive. It is an unpacking “how” that searches descrip-
tion; not just any but a specific description to understand the stabiliza-
tion processes and the emergence of agencies.  
 The first part of this chapter has transformed the preliminary observa-
tions in the Introduction into a preliminary topic by drawing on several 
theories of science. By juxtaposing three envisioned analysts I have 
suggested the added value of a sociotechnical approach. Unlike the social 
realism inspired by Collins, and the natural realism inspired by Giere, the 
ANT analyst’s topic is the heterogeneous associations and the multiple 
flows of hESC research. My interpretation of ANT suggests that the do-
cumented biological and political pluripotencies of hESCs are not di-
stinct phenomena, but involved in one circulatory system. The pheno-
mena indicate a strong agency that, according to ANT, is the result of 
delegation in a network. It should be possible to unpack the stabilization 
of hESCs and find out when and how agencies have been delegated. 
Since the hESCs are the result of sociotechnical transformation, then the 
emergence of this reality can be tracked down – association by associa-
tion, element by element. Starting with the “biological and political pluri-
potency” of hESCs, the analyst can assume that a stabilization of reality 
has occured. As new relations have been added, as other people, animals, 
objects, or arguments have participated, the sociotechnical reality of hESCs 
has increased and resulted in the “biological and political pluripotency”. 
The analyst therefore goes backwards to track the addition of elements. 
This is unpacking. It should preferably not result in an explanation or a 
reduction of hESC research and politics to other processes (see Virgin 
Mary quotation above). Unpacking the sociotechnical reality of hESCs 
should instead outline the role of hESCs in a heterogeneous network. 
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Meta-theoretical modification of the ant 
The above sections were enacting a zooming-in movement. It went from 
many theories of science to the construction of an ANT analyst. The 
next third of the chapter will zoom out again, but not to end up in the 
same place. The agnostic ant will not be the analyst of this study. He will 
be burdened with conceptual glasses and limitations before he is put to 
work on a specific material with specific questions.  
 After having focused on the ant, he will now become one component 
in a larger assemblage of methods and theories. The analyst can start out 
with puzzles and aims, but they will be specified and modified as it runs 
into empirical or theoretical issues. Research questions can be asked to 
get the ant going, but not too far in advance. Materials can be limited at 
the outset, as initial values, but not indefinitely. Since the study will move 
in an unpacking manner the methodological package has also to be 
flexible, like an assemblage. Who knows what is inside the next black 
box, and what then to ask?  
 Above, the ant was accessing sites, traveling from one flow to the 
other. Below, I will turn ANT into a theory, a perspective that can be 
applied and elaborated. This goes against the ANT as presented by La-
tour. According to him, it is not a perspective that can be used to under-
stand a particular material. It is more like a tool that can be used to re-
cord and describe – not a theory to filter out, or discipline (Latour 2005: 
55). The ant is thus not alone in this study. He will be guided by meta-
theoretical interests and research questions on an ANT non-typic textual 
and public/political material. The purpose of the rest of this chapter is to 
explain in what way this is not a characteristic ANT study (if there is 
such a thing). Outlining this, will add to the analyst’s theoretical, metho-
dological and empirical presuppositions.  
 Most probably I am treating ANT in my own way (as a perspective) 
because of my training and assimilation of it. Whereas one of Latour’s 
slogans for how to learn ANT is “sur le terrain” – get into the field, into 
the laboratories, follow the actors – I have learnt about ANT from a 
book and in a context where meta-theory is emphasized (Latour 1987). 
Theories of science at this department (of History of Ideas and Theory 
of Science at Göteborg University) are not merely introduced for stu-
dents in order to be used, but to be juxtaposed, contrasted, and compa-
red. More than any privileged resource the physical department of theory 
of science offers an intellectual space in which to theorize theories.  
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 I have thus started by reading ANT, not by doing it. Many doing ANT 
may have started that way (probably most) and then assimilated the 
method. Instead of turning native as ANTer and becoming the ant sniffing 
on trails, I keep a conceptual, meta-theoretical distance to ANT in this 
study, treating it as one theory of science among others. When I ap-
proach ANT there are similarities with Manuel in the series Fawlty Towers 
claiming to know English since he “learnt it from a book”. Another way 
to see it – more flattering, I think – is that I am a linguist approaching 
English, or a religious philosopher approaching religious practices, i.e. 
with a meta-awareness. This may disturb some believers, and may pollute 
or contribute to the actual practice. At least, I have now admitted my 
starting-point: “I learnt it from a book”.  
 Some basic ANT concepts in use have already been mentioned above. 
Critics have pointed out that the alleged agnosticism of the generalized 
symmetry has often resulted in human-centered accounts with strategic 
actors (Fujimura 1995: 304, Star and Griesemer 1989). Finding associa-
tions is not innocent. In her The Body Multiple (2002), Annemarie Mol 
recognizes a necessary shift from the logical coherence of Foucault’s 
structures to the material coherence of actor-networks achieved through 
associations. However, she also criticized the equality, or even “homoge-
neity”, of actor-network associations. Coordination is “bivalent” – either 
on or off: 
Each new and successful association makes a network larger. But however 
great the difference between the coherence in a network and logical coherence, 
to talk of ”associations” does have a homogenizing effect. Either an associa-
tion is made or it isn’t. An element is either inside or outside a network. 
Coordination is established or not. There are no distinctive forms of coordina-
tion. (Mol 2002: 65f) 
Mol is putting her finger on what could be one of the most salient 
developments within ANT since the 80’s and early 90’s. Many scholars 
who accepted the basic tenets of “Classic ANT”, have turned to multi-
plying their understandings of sociotechnical reality, heterogeneity, etc 
(Bijker 1995, Landström 1998, Law and Hassard 1999). I take Mol’s ques-
tion about forms of coordination seriously, as an interesting meta-theoretical 
challenge for this study.  
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Alternative forms of coordinations: OPP and boundary objects 
One form of coordination that has been heavily criticized is the obliga-
tory point of passage (OPP). In several case studies Latour, Callon, and 
Law have shown how OPP is one means to coordinate heterogeneous 
elements. One of these cases was The Pasteurization of France. The OPP 
was Pasteur’s laboratory and his institute. In Callon’s study about three 
scallops researchers, the OPP is the attempt and failure to achieve the 
same absolute degree of domination. Three researchers return from Ja-
pan with a new way to understand the scallops’ reproductive processes. 
By formulating a new research problem for other researchers, by sugges-
ting to fishermen a more lucrative method for scallops fishing, and lastly, 
inviting the scallops to reproduce themselves in new places the three 
researchers become the centre of an actor-network. They re-position the 
actors through their new understanding of the situation and themselves 
become an OPP for all actors – ultimately, however, without success. 
Callon and Law mapped a military aircraft project – the TSR 2 – in the 
UK. In this case the OPP was set up to protect a local sociotechnical net-
work of production and a global one supplying funds. The OPP and the 
TSR 2 project eventually failed.  
 There are two features in the OPP stories that single them out in the 
ANT literature. One is the dominating degree of stabilization, and ano-
ther is the mode of alignment through entrepreneurial activity and funne-
ling of other actors.  
 Firstly, the OPP is an either-or. The attempt at a dominating stabiliza-
tion can succeed or it can fail. There are no in-betweens. In this sense 
the Pasteurization of France draws on the socio-technical system presen-
ted in Thomas Hughes’s work on the “Electrification of America”. One 
of his articles is subtitled The System Builders:  
Not one of them [the system builders] was satisfied to solve a part of the 
problem, simply to invent, manage, or finance, for each believed that the 
invention would not become an innovation, the managerial structure would 
not evolve, and the financial means would not bring growth unless electric 
light and power were viewed as a coherent system. (Hughes 1979: 125) 
The system story about the Electrification, just like the OPP story about 
the Pasteurization, suggests how a whole cloth comes into being without 
seams. One example of the systematic character of this growth was the 
mutual adjustment of the generators, the lamps and the system voltage 
(Hughes 1979: 139). The objects had to be stabilized together with the 
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infrastructures in which they could move. One could not be put in place 
without the others.  
 The system story and the OPP stories are examples of the simulta-
neous and total stabilization of objects and their networks. Both stories 
present similar models of what a network is and how it is built. They 
both concern huge transformations. To achieve any success, you have to 
achieve total success. Although impressive, not all innovations end up 
becoming the total transformation achieved through the electrification of 
America and the pasteurization of France, or the total failures in the ca-
ses of the scallops and TSR 2. Everything is either drawn in and con-
nected through the network, or the network is not established.  
 Secondly, on agency, the OPP story seems to side with human actors 
rather than the nonhumans. The driving force in the OPP networks is 
the agency of human entrepreneurs. Latour describes a series of articula-
tions in which new objects were shaped and spread to other actors, 
whether cows, farmers, or veterinaries. In spite of the symmetry between 
humans and nonhumans a central feature in Latour’s story is the agency 
of Pasteur. The OPPs of Callon, Latour, and Law are dependent on en-
trepreneurial humans.  
 Some approaches have related explicitly to ANT, such as social worlds 
theory. This is a development within the Chicago School of symbolic in-
teractionist sociology (Clarke 1990). Social worlds have been combined 
with ANT notions by virtue of their heterogeneity, fluidity, and inclina-
tion for mixing, intersecting, and segmenting. Similar to ANT, the social 
worlds perspective emphasizes “antideterminism”, is interested in prac-
tices and does not stop at a specific scale of the objects of study (micro 
vs. macro) (Strauss 1978: 121). Such common orientations have been 
points of contact when scholars – such as Adele Clarke, Joan Fujimura, 
and Elihu Gerson – have productively drawn on the two perspectives 
(see also e.g. Fujimura and Clarke 1992, Star 1995a).  
 Susan Leigh Star and James Griesemer start from social worlds theory 
in their criticism of the OPP approach. The latter attributes too much of 
the network formation to entrepreneurial humans, they claim (Star and 
Griesemer 1989). They also observed that the OPP assumed a funneling 
of all actors through a specific interdefinition and problematization. For 
the network to be established, actors had to accept the OPP formulation 
of the situation, or be left on the shrinking outside of the actor-network. 
In a conference paper, Star pointed toward the crucial issue: 
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How can two entities (or objects or nodes) with two different and irrecon-
cilable epistemologies cooperate? If understanding is necessary for coopera-
tion, […] what is the nature of an understanding that can cooperate across 
viewpoints? (Star 1989: 42) 
Star suggested an alternative to the actor-network OPP that would account 
for the coordination of actors of different viewpoints and from diverse 
social worlds (1989). Together with James Grisemer, she elaborated the 
notion in a paper about the establishment of the Museum for Vertebrate 
Zoology (MVZ) in Berkeley, California. Actors were coordinated through 
the circulation of certain objects. These boundary objects retain their iden-
tity across various social worlds and actors, but are sufficiently plastic for 
specific usage in individual sites. In common use they are weakly struc-
tured, enabling communication between different actors. In individual 
use they are strongly structured contributing to the actors in question 
(Star and Griesemer [1989] 1999: 509).  
 Although the OPP and the boundary objects are both examples of how 
disparate elements can come together, the means, the agency, and the 
actor-networks and socio-technical reality resulting from the two models 
differ greatly. Boundary objects are positioned and travel between coope-
rating institutions and actors that are conjoined through the boundary 
objects. The resulting network does not depend on the common accep-
tance of one situation, one problem or the identities of the actors. Star 
and Griesemer talk about the loose coordination of actors as an ecological 
system (or in other places an ecology of knowledge). Around the boundary ob-
ject(s) an ecology of social worlds, institutions, things and actors emer-
ges, where no actor necessarily is more important than others.  
The ecological analysis does not presuppose an epistemological primacy for 
any one viewpoint; the viewpoint of the amateurs is not inherently better or 
worse than that of the professionals. The important questions concern the flow 
of objects and concepts through the network of participating allies and social 
worlds. (Star and Griesemer [1989] 1999: 507, their italics)  
The ecology is not dominated through one site, in this case, but multiple 
sites define the situation through the boundary objects. Actors are not 
funneled through the definition of one or a few actors. The multitude of 
connected actors is in a sense explained through the role of the boundary 
objects. Actors, their interests, and material objects together make up a 
“boundary object”. Instead of watching a few actors move other actors, 
the vantage point is the objects that enable cooperation between diffe-
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rent actors. This has implications for the agency issues. Boundary objects 
are gateways to other worlds. Whatever the intentions of the original en-
trepreneurs, the objects and their flows are in focus. There are entre-
preneurs in the boundary object story too, but they are not the driving 
force – the objects are. They are not primarily facts, artifacts, or black 
boxes, but coordinators.  
 As an alternative to the translations of human entrepreneurs of the 
OPP, Star and Griesemer point toward the coordinating effects of ob-
jects. Such an alternative is in full accordance with the eclectic nature of 
ANT. Latour has in any case not locked himself into any specific way to 
understand scientific work. Different metaphors have their own benefits 
and weaknesses. Articulation, for instance, “stresses the independence of 
the thing” brought forward and maintains the historical and material 
character of such events (Latour 1999b: 140). Translation, seizes on the 
gap between actors and their understanding of a situation, including their 
perceived interests, but risks becoming too linguistic and non-material. 
Coordination, similarly, is one figure of speech among many, with benefits 
and weaknesses. One benefit is that coordinated actors presumably have 
to be and remain relatively independent to be coordinated. Actors are 
not linked by having all of their interests, respectively, translated into 
terms of one institution or group. Rather, actors maintain their interests 
and their social worlds, but meet through and in the objects. One pos-
sible weakness could be that coordination has too little to do with an 
ontological event, is too far removed from the innovative aspect of scien-
tific work. Henceforth articulation and coordination will be used when they 
are appropriate respectively, often interchangeably without assuming any 
fundamental differences between them. They both concern the combina-
tion of elements. 
 The ecology of knowledge also addresses the question about different 
kinds of networks and network building by leaving a space for partial 
stabilization in contrast to the total domination of the OPP stories. Wiebe 
Bijker refers to boundary objects in relation to his own notion of artifacts’ 
obduracy. This latter notion is a direct answer to the ANT stabilization. 
When objects (or in Bijker’s term: artifacts) are stabilized and less malle-
able, less fluid, they are more obdurate. Their obduracy is the result of 
the linkage of “different social groups to form a (new) semiotic power 
structure” (Bijker 1995: 285). To assess their obduracy is to assess the 
strength of the actor-network. To ascertain that objects are boundary 
objects is to say that the actor-network is not all encompassing and to-
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tally dominant. Instead of Bijker’s obduracy I will stick to stabilization or 
stability, but adopt the correspondence between the strengths of boun-
dary objects and their actor-networks. In my usage the stability of boun-
dary objects does not transform all actors, but continues to be modi-
fiable, unlike the stabilization of a successful OPP.43 The OPP is esta-
blished – or not. When it is there, it has transformed everything. The 
black boxes also have this black-and-white character (Fujimura 1992). 
Star and Grisemer present a form of stabilization in shades. Various ac-
tors buy into the boundary objects while remaining in their social world. 
The social worlds are not totally dependent on the stability of the boun-
dary objects, as in the case of Callon’s scallop researchers. When they 
failed to become an OPP the particular actor-network failed too. Al-
though Star and Griesemer’s story has mostly omitted the dissenters, the 
mode of coordination does not require total acceptance or nothing. The 
boundary object is stabilized in proportion to the number of actors using 
it, and is, in these terms, a grey, nuanced or, preferably, a multi-colored box. 
The “composition of colors” is determined by the actors connecting to 
each other through the object. 
Combining OPP and boundary objects 
OPP and boundary objects have been presented as two alternative forms 
of coordination (Star and Griesemer 1989). From a meta-theoretical van-
tage point ANT could be challenged and complemented. The first third 
of this chapter introduced ANT on its own terms, and formulated the 
issue of stem cell research and politics as sociotechnical reality. This part 
has provided two ways in which to capture sociotechnical reality. Through 
the confrontation with the actual practices of ANT, and the critique, a 
meta-theoretically informed research question can be posed:  
(Meta-theoretical Question No 1) How can the notions of obligatory point of 
passage and boundary objects be put to use in order to understand the socio-
technical reality of hESCs? 
This is most probably a far more “deductive” question than the 
approach that originally produced the notions. The OPP and the 
boundary objects were suggested in order to capture the phenomena of 
                                     
43   Bijker equates obligatory point of passage and boundary objects, 1995: 285, 
which is contradictory to my own and Star and Griesemer’s use of the con-
cepts. 
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coordination. ANTish analysts have followed associations and the 
patterns have suggested the OPP and the boundary objects. According 
to Latour, what is needed is not more terms, but fewer. ANT notions 
should only be used to let “new actors define the world in their own 
terms using their own dimensions and touchstones” (Latour 1999a: 20). I 
start from the other end of the stick. Beginning with the notions, what 
phenomena will we see? That is the issue in part one of this study. 
 Obviously this question is not posed innocently beforehand. When wri-
ting this, I know the story.44 But the above account is also true. I started 
by learning ANT from a book – including the OPP and the boundary ob-
jects. When approaching the stem cell situation in the US, those con-
cepts functioned as paradigms, as glasses. It is a grave difference in ap-
proach, compared to the ant (-ideal). My fascination with the two notions 
in a sense equaled my fascination with stem cell research and politics. By 
approaching the latter by means of the former, new metaphors may result. 
 This is a second way that is opened up. It will only be hinted here to 
indicate a future possible rebundling waiting among the reeds, as it were. 
Combining the two notions is an opportunity to shift the central meta-
phor from networks to something else. Many have suggested other spa-
tial metaphors than that of network: topical contextures (Lynch 1991), 
rhizome (Latour 1999a), choreography (Cussins 1996), and fluids (Mol 
and Law 1994). Concepts such as regions, networks, or fluids, are all possible 
topological presuppositions in analyses of science and society.45  
 A less sophisticated (but not necessarily less deep) way to formulate 
the role of metaphors is that they enable another way of seeing. The boun-
dary objects come with another topology: “The important questions con-
cern the flow of objects and concepts” (Star and Griesemer [1989] 1999: 
507, their italics). These flows belong in the metaphor of ecology (of in-
stitutions or of knowledge). By juxtaposing boundary objects and OPP, a 
different metaphor for seeing science and society can be tried.  
 It is possible to ask about what happens if the flows and ecology of 
boundary objects are “metaphorically passed on” to the OPP. This ques-
tion is justified since the OPP was originally presented within the net-
work metaphor. It is, however, not impossible to envisage flows passing 
                                     
44   That is probably true for the original case studies too. Pure ants are hard to co-
me by. Many of them are more than agnostic. I am just very open about my 
conceptual bias. 
45   The notion of topological presupposition is borrowed from Mol and Law 1994: 642. 
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through one point of passage. Think of the reservoir at the service of a 
hydroelectric power station. Think of the heart’s role in the body’s circu-
lation of blood. The latter was Latour’s metaphor of flows, which I used 
to construct the ant. In doing so, I also applied it to The Pasteurization of 
France – one of the classic OPP stories. 
 Searching the literature, I have found one case where boundary objects 
and the OPP are combined. The paper is written by Véronique Vissac-Char-
les and exists in another version (both in French) co-authored by Latour 
(Vissac-Charles 1998, Vissac-Charles and Latour 1996). Both papers are 
based on two innovation projects, the processes of constructing an auto-
matic apple-picker and an electric steel foundry.  
 Combining approaches from different traditions is typical for ANT. 
Vissac-Charles does not address the theoretical differences between the 
original approaches. She adopts the notions to her own use of it. There 
are however important differences that could become obstacles – especi-
ally if generalized symmetry is misunderstood. Paying attention to these 
differences can shed more light on the issue of agency.  
 While Star and Griesemer’s approach puts nonhumans in focus by lo-
cating much of the coordination in the boundary objects, an important 
drawback and possible problem in the social worlds perspective (in rela-
tion to ANT) concerns the status of nonhumans. There is no ANT gene-
ralized symmetry in the former perspective. In spite of their focus on 
objects, Star and Griesemer do not place them on a level with humans. 
Boundary objects are, for instance, not identical to marginal people:  
Unlike the situation of marginal people who reflexively face identity and mem-
bership problems, however, objects do not change themselves reflexively or 
voluntarily manage memberships. (Star and Griesemer [1989] 1999: 519) 
Boundary objects cannot change themselves as people sometimes can. 
Have Star and Griesemer thus contradicted the generalized symmetry? 
There are (at least) three answers: yes, no, and no. Yes, Star and Griese-
mer’s approach does differ fundamentally from the generalized symme-
try. Social worlds does assume a more commonsense distinction between 
people and things tangible in the above quotation.  
 No, the generalized symmetry is not contradicted, because proponents 
of the social worlds approach also wish to include all sorts of elements in 
analyses of science and technology (Clarke and Fujimura 1992, especially 
5f). This is particularly obvious in the MVZ case study. By highlighting 
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the role of objects this is a good example of the practical thrust of gene-
ralized symmetry: What difference can objects make?  
 The second no depends on the varying importance of ontology in the 
two approaches. Social worlds theory does not discuss ontology and me-
taphysics in the way ANT sometimes does. The common goal of ANT 
and social worlds theory is to capture the role of all elements. ANT formu-
lates this as (among other things) a matter of ontology. Social worlds theory 
drives the same point for sociological studies, but does not formulate it 
in the same ontological manner. Star is more operational than ontological 
when she explains the common interests and tools of ANT and symbolic 
interactionism (and social worlds theory) under the joint flag of ecology of 
knowledge:  
If one adopts an ecological position, then one should include all elements of 
the ecosphere: bugs, germs, computers, wires, animal colonies, and buildings, 
as well as scientists, administrators, and clients or consumers […] The advan-
tages of such an analysis are that the increased heterogeneity accounts for mo-
re of the phenomena observed; one does not draw an arbitrary line between 
organism and environment, one can empirically “track” lines of action 
without stopping at species, mechanical or linguistic boundaries, and espe-
cially without invoking a reified conception of society. (Star 1995b: 13) 
In this introduction to a volume presenting studies drawing on ANT and 
social worlds, respectively, Star aligns the two approaches without invo-
king the strict ontology of generalized symmetry. The main purpose of 
the ecological position is not ontological, but to “account for more of 
the phenomena” and to “empirically ‘track’ lines of action”. Boundary 
objects are thus – paradoxically and contrary to the social worlds’ 
distinction between people and things – good examples of the work 
nonhumans can achieve between diverse actors. 
 I have observed – and argued for – differences and compatibilities be-
tween social worlds theory and ANT to remove possible obstacles, be-
fore putting the notions to use. Other differences between the two ap-
proaches will be treated later (see Chapter 4). The combination of OPP 
and boundary objects not only requires clearing the way. It also opens a 
way – in fact, two. First, it may be an answer to Mol’s inquiries about 
modes of coordination. Mol called for distinctive forms of coordination. 
There are already two such distinct forms out there, in the literature – 
the OPP and boundary objects. Considering that there is only (according 
to my searches) one case where they are combined, it is still an open and 
interesting question what such a combination may yield: What pheno-
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mena are accessible if the notions of obligatory point of passage and 
boundary objects, respectively, are applied to the “same” situation, e.g. 
the case of hESC research and politics in the USA prior to August 2001?  
 The issue is still sociotechnical reality, but now with a focus on the 
mode(s) of coordination: An ecology of multiple viewpoints or a funne-
ling through one group; entrepreneurial and strategic humans or flowing 
objects; total stabilization at stake or partial and relative stabilization? These 
questions should (hopefully) be answered in the coming chapters. 
Politics and ANT 
Juxtaposing the boundary objects and the OPP is one meta-theoretical 
issue. Another concerns politics, which is a feature overlooked in ANT. 
In spite of the assumed heterogeneity and intertwinement of science and 
politics, case studies have de facto treated explicit politics as a derivative or 
auxiliary factor in relation to where the real action lies, in laboratories 
and research. This is so even in cases where politics has obviously been 
crucial to the eventual success. The real sociotechnical action lies in local, 
constructive networks that are extended (Law and Callon 1995). ANT has 
made a point out of the politics of the laboratory, how the inside of labs 
is extended to the outside, micro is turned into macro. Latour was one 
such example (above), claiming that the Pasteurian laboratories “in poli-
tical terms” exercised a more far-reaching influence “without being clear-
ly seen as a stated political power” (Latour [1983] 1999: 268). 46 
 There is thus a meta-theoretical reason for analyzing materials relating 
directly to explicit politics. Unlike many ANT cases the political and public 
dynamics in hESC research is worth studying “on their own merits”. 
There seems to be an independent dynamic in public arenas. Actors en-
vision future scenarios of what the research could be and become, remi-
niscent of Callon’s actor-worlds. Callon’s usage of this notion is infor-
mative (Callon 1986a). The French Electricité de France (EdF) envisaged a 
network for the construction of an electric vehicle (the VEL). Other ac-
tors were positioned by EdF. Renault was, for instance, marginalized as 
merely a producer of car bodies for the VEL. Still not an actor-network, 
the EdF and this new definition of other actors constituted an actor-
world, according to Callon. What followed were several competing actor-
worlds in which actors such as Renault tried to establish other inter-
                                     
46   To distinguish between the politics of the laboratory/things and stated politi-
cal powers, I henceforth refer to the latter as explicit politics.  
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definitions between actors, and roles for themselves. EdF ultimately fai-
led to establish the necessary associations. The actor-world did not be-
come an actor-network. In Callon’s case there is very little material, labo-
ratory, or other construction-work going on. Alternative sociotechnical 
realities are envisaged, mainly by EdF and Renault. Associations are ne-
gotiated but very much as possibilities, rather than actualities.  
 Explicitly political actors, such as the state, were part in the actor-
worlds negotiations, but without any great potential. This is from the 1980 
version of the case study: 
Confronted by these actors, the state is powerless. It rarely has sufficient 
expertise to transform technical controversies into policy debate; it is under-
mined by internal divisions that prevent it from showing any coherent political 
will; it is trapped into deals that lead it to defend the most powerful groups. (Cal-
lon 1980: 358) 
Similarly, politics was auxiliary in the TSR 2 project (Law and Callon 
1995). The project started out by way of sociotechnical scenarios (somewhat 
resembling Callon’s actor-worlds). In this case there was a strong politi-
cal element, but it had little impact on the actual construction process. 
When the project was in motion there was an on-going coordination within 
and between two networks, one global and one local. Political parties, 
the cabinet, and funding decisions belonged in the global network. “[A] 
local network of designers, designs, production teams, management and 
subcontractors” was supposed to carry out the actual construction (Law 
and Callon 1995: 290). Because of a combination of political factors and 
construction issues, the project was ended six years after its inception. 
Politicians’ concerns were vital, but mainly to endorse the project, or – 
eventually – not.  
 It is an important question for ANT, how to deal with the impinge-
ment from explicit politics on the sociotechnical reality.  
(Meta-theoretical Question No 2): How can ANT account for the role of 
explicitly political actors in sociotechnical network attempts? 
In other parts of STS explicit politics is the main topic, but in ANT it has 
been neglected (Elzinga and Jamison 1995, Fuller 2000, Guston 2000, Rou-
se 1996). This is again an opportunity and maybe one that calls for new 
metaphors. Latour’s circulatory system makes the flow to politicians as 
important as the flow to colleagues or instruments. His example is Fré-
déric Joliot’s involvement in the production of the first artificial chain 
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reaction (Latour 1999b: Chapter 3). Political concerns were interacting 
more complexly here than in the case of the TSR 2. Joliot was put in 
motion by his friends in the Ministry of War, and the director of the 
French National Center for Scientific Research. They facilitated his con-
tacts with a Belgian mining company producing radioactive material. Joli-
ot was thus provided with research materials and funding. When Joliot 
later approached Raoul Dautry, the Minister of Armament, the latter offe-
red support, but also made demands. Dautry stressed the need to first 
produce a bomb and then pursue the (civilian) experimental reactor. Ex-
plicit politics was in this case more than a mere supporter. It modified 
the sociotechnical network considerably.  
Materials and methods  
There are by now two meta-theoretical issues: The juxtaposition and com-
bination of the OPP and of the boundary objects; the issue of political 
and public dynamics. To get started, one more thing is needed: an empi-
rical material. I will first discuss the role of the material chosen in rela-
tion to the meta-theoretical questions and my use of ANT. Then I will 
account for, and elaborate on, the empirical materials chapter by chapter. 
On the way some things need to be said about the methods used; how I 
have read and used various kinds of texts. 
ANT and textual materials 
The reality of hESCs and treating hESCs as making a pluripotent diffe-
rence can result in many studies. The main slogan of ANT, “Follow the 
actors!”, usually means approaching the messy, dirty, nuts and bolts of 
research preferably in laboratories, at conferences, or at least intervie-
wing somebody. There are, however, salient examples of ANT pursued 
on textual materials (Callon et al. 1986, Latour [1984] 1988). This study is 
based on texts (although with a whiff of laboratory and conference ex-
periences). Many of the texts were produced in or addressed to political 
settings, such as the Congress or the White House. There are also texts 
from scientific journals or reports. Most of these texts concern the politi-
cal and public dynamics in the USA prior to August 2001. Before accoun-
ting for exactly what texts I have studied and how I have found them, 
something about the role of textual materials from political settings in a 
study inspired by ANT. 
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 There are three reasons for selecting a textual material that relates to a 
general public and political dynamics in the USA. The first reason fol-
lows from my meta-theoretical interest in ANT and politics. Two more 
reasons have to do with the empirical and theoretical advantages of the 
US situation.  
 Above, the neglected role of explicit politics in ANT was described. 
Approaching hESC research in the USA is an opportunity to elaborate 
these aspects of ANT. Explicit politics in the USA is not only an add-on, 
but an integral part of the dynamics, i.e. it does not only provide a yes or 
a no to hESC research. In the period 1998–2001, it is even possible to say 
that explicit politics and debates constituted the predominant dynamics, since 
hESCs were still quite scarcely researched in the USA. There were only a 
dozen hESC lines out there. This is not to say that there were no labo-
ratory activities, but it justifies attending to the political and public dyna-
mics. Similarly, this study only attends to corporate dynamics as they 
appear in a public and political setting. I have not gone to the economic 
reports of companies, or examined the movements on the stock exchange.  
 There is a second reason to focus on the public and political dynamics: 
The US situation is a space for uncertainties and alternatives. Obviously, 
those features exist in other countries too (Gottweis 2004). One reason 
for studying hESC dynamics in the US, and not e.g. in Sweden, is the 
visibility and production of alternatives. Whereas the USA has an adver-
sarial way of negotiating public issues, Sweden has a more corporatist 
mode (Kulawik 2004). In the adversarial mode, issues are solved by pub-
lic disputes where opponents and proponents voice their opinions. In a 
predominantly corporatist milieu, negotiations mostly stay in the hands 
of official or semi-official bodies. The uncertainties in the stabilization 
processes are thus more readily picked up in the American political 
context of strong proponents and opponents. The ethical controversies 
on embryonic and fetal research in the USA make the choices more 
visible, at least for a while. In Sweden the dispute on hESCs was started 
and ended in less than 9 months in 2001 (Kulawik 2004). These issues in 
the USA are thus non-issues in Sweden, or at least they are public issues 
for a shorter time. This is not to say that there are no alternatives or 
disputes, but they are harder to access.  
 Third, the US visibility of controversy, uncertainties, and alternatives 
corresponds to a theme in an on-going critical assessment of ANT. So-
me scholars have pointed out that a focus on the stabilization of parti-
cular actor-networks will risk losing sight of the margins, the in-betweens. 
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Actor-networks do not include everything. Some actors, things, and view-
points are excluded (Fujimura 1996, Law 2004, Longino 1997, Star 1991). 
Analyzing the US situation is an opportunity to observe such exclusion.  
 After it has been decided to focus on the sociotechnical reality of hESCs 
as articulated in politics, public debates, and media reports the next ne-
cessary limitation is the time period. One obvious period that is not too 
close to the writing process is November 1998 to August 2001. It was 
begun by the announcements from two groups that they had cultured 
hESCs from humans (Shamblott et al. 1998, Thomson et al. 1998).47 It 
was ended by George W. Bush’s decision August 9 (2001) to fund the al-
ready produced hESC lines. Between these two events there were vivid 
debates in Congress, in media, and on the Internet.48 My reference to the 
political and public dynamics in the USA between 1998 and 2001 mainly con-
cerns those debates. I suggest, however, that such debates should not be 
viewed as merely discourse, representations, or beliefs. Because of the on-
going sociotechnical transformations (including the entanglement of signs 
and matter), scientific texts as well as other texts are more than discour-
se. In this study political, scientific, and other texts are assumed to be in the middle 
of sociotechnical reality, that is, parts of chains articulating reality. This suggestion 
is similar to that of Callon, Law, and Arie Rip, in Mapping the Dynamics of 
Science and Technology (1986), although they focused on scientific texts:  
texts make possible the construction of linkages between existing entities and 
the formation of novel entities and, if persuasive, thereby constitute an im-
portant method for attempting to control the environment. (Callon et al. 
1986: 11)  
A scientific text not only reveals the world-building strategy of its authors, but 
also the nature and force of the building blocks derived from the domain of 
science from which it draws and to which it contributes. The text thus pro-
                                     
47   More specifically, Gearhart’s group called their cells human embryonic germ 
cells.  
48   These are two events in a continuous flow of associations. It is hard to claim 
that Bush’s decision – to fund research on already existing hESC lines, but not 
on lines henceforth being derived – stopped the debates. However, after this 
point a tendency is visible. From the debates on the funding of hESC research 
the Congressional energy on hESC research related more to the issue of clo-
ning, or nuclear transfer. That issue was present before August 9, but after-
wards there was a shift in predominance. A policy for the federal funding of 
hESC research was in place and was being implemented. 
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vides access to the dynamics of science, to the shared worlds that constitute a 
means of mutual (and evolving) control. (Callon et al. 1986: 12) 
The above authors studied texts ”in order to understand the power of 
the laboratory” (p. 11). I am more open-ended. It may be that the study 
of these texts leads to the laboratory, or not. Political and public texts are 
articulations of sociotechnical reality without necessarily indicating the 
power of the laboratory. Powers, potencies, agencies are interesting whe-
ther in the laboratory or elsewhere. 
The empirical material of the study 
For a fundamental understanding of stem cells, I have used a standard 
text-book recommended by medical students whom I have met in stem 
cell laboratories (Alberts et al. 1994). In order to get a general overview 
of the field I have consulted books on stem cell research, ethics and 
politics.49 I have borrowed these books at university libraries, but mostly 
bought them on major Internet book stores.50 Most of these are collec-
tions of papers by people considered to be authorities or crucial actors 
(such as Thomson, Gearhart, or President Bush). I have also examined 
the popular science writing, which has been scarce, due to the relative 
novelty. These materials are – in theoretical respects – far from ANT 
and would thus normally be considered as other analyses of the same 
situation or “reference literature”. Since the topic is the public and poli-
tical dynamics of hESC research they are also source material. Each 
collection is a summary of the actors, analysts, arguments and facts that 
are regarded as important. They are part of network attempts, the socio-
technical reality of hESCs. 
 Chapters 2 and 3: To access Congressional politics I have used the Go-
vernmental websites on the Internet (http://www.gpoaccess.gov/ and 
http://thomas.loc.gov/) to download all of the Congressional hearings 
during this period that responded to the keywords “stem cells”. This 
search resulted in six hearings held between December 1998 and Sep-
tember 2001, by a Senate subcommittee of the committee on appropria-
tions for the departments of labor, health, and human services (DHHS), 
and education, and related agencies. There were six hearings, with in all 
                                     
49   See the introduction for specific references. 
50   I have utilized the libraries of mainly two universities, Göteborg University 
and the University of Minnesota. 
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twelve occasions, and eleven of these fall within the temporal constraints 
(November 1998 to August 2001).  
 Another source of information available via Internet has been the na-
tional panels and reports from the period. President Clinton requested, 
in November 1998, a review of the ethics of stem cell research from the 
National Bioethics Advisory Commission (NBAC). In September 1999, 
this resulted in the report Ethical Issues in Human Stem Cell Research (Sha-
piro et al. 1999). The American Association for the Advancement of 
Science (AAAS) and the Institute for Civil Society (ICS) finished a re-
port, Stem Cell Research and Applications: Monitoring the Frontiers of Biomedical 
Research, around the same time, in November 1999 (Chapman et al. 1999). 
A third national overview was pursued toward the end of the period, on 
June 22, 2001, by way of a workshop: Stem Cells and the Future of Regene-
rative Medicine. This was organized by two of the National Academies – 
the National Research Council (NRC) and the Institute of Medicine 
(IOM) – with the support of the National Academy of Sciences (NAS). 
The NAS is the central of these semi-official and advisory bodies. Apart 
from the resulting publication in 2002, I have listened to audio files from 
the workshop available on the Internet (Workshop on Stem Cells and the 
Future of Regenerative Medicine 2001). A final report that immediately 
preceded Bush’s decision was the Report for Congress from the 
Congressional Research Service (CRS): Stem Cell Research (Johnson 2001). 
I acquired this from the library at the University of Minnesota, and it is 
available on the Internet.51 
 All of these hearings and reports are, as it were, an already sifted sour-
ce. The committees prepare bills for the two Houses and in this respect 
may have a semi-legislative power (US Senate 2005). At their service they 
have a number of subcommittees. Public Congressional hearings are a 
source of information for the preparation of bills in Congress and for the 
interested public. In the selection of witnesses the committees or sub-
committees are independent, but they are supposed to call advocates re-
presenting a wide range of opinions. However, it sometimes happens 
that committees or subcommittees are accused of being partisan in the 
selection process. Likewise, the reports are the result of selection proces-
ses. The members of the NBAC were appointed by the President. The 
AAAS is a federation of scientific societies and also individual members, 
                                     
51   There were also other CRS reports during the period, in 2000. The 2001 re-
port was especially interesting because of the proximity to Bush’s decision. 
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which mentions first the furthering and facilitation of science in its self-
description (Chapman et al. 1999: 38). 52 The ICS was created in 1995 to 
“renew civil society” and strengthen community initiatives, e.g. by provi-
ding grants for grassroot initiatives (p. 39). The NAS and its related bo-
dies consist of “distinguished scholars engaged in scientific and enginee-
ring research” (Workshop 2001: iii). Speakers at the workshop were called 
by the NRC and IOM organizing committees. According to the website 
of the CRS (http://www.ncseonline.org/NLE/CRS/) it is “a branch of 
the Library of Congress providing nonpartisan research reports to mem-
bers of the House and Senate”. However, in spite of this declaration, the 
CRS report – just like the hearings, and the other reports – are sifted 
sources, one might say. The participants and scientific results are pre-
selected in the bodies. I am not selecting the actors. They have already 
been selected. 
 In order to understand the Congressional dynamics and learn more 
about the actors that appear in the Congressional material I have looked 
for media reports in a few major American newspapers, i.e. The New York 
Times and The Washington Post, and in Science and Nature. The media mate-
rial is also already sifted. A partisan background source to understand the 
political game and the panel deliberations is Ronald Green’s The Human 
Embryo Research Debates (2001). Green is a bioethicist and was a part of 
the working group for the AAAS/ICS report. In 1994 he was also a 
member of the Human Embryo Research Panel (see below). Green is 
supportive of hESC research, which is visible in the account.  
 A short detour is required, in order to clarify the status of this hete-
rogeneous material in an ANT-inspired study. The siftedness is not a 
problem, but necessary and deliberate. If anything the term sifted is a pro-
blem, because it could suggest that something more original has been 
slanted in a certain way, as a divergence or distortion. According to ANT 
there is no original reality, but articulations in which sociotechnical reality 
comes to be. More than sifted, the materials are articulations of a certain 
kind. Since the research question concerns the public and political dyna-
mics of hESC research, articulations from highly public and explicitly 
political processes are needed. In this case the articulations are a textual 
material, and in a few cases also graphic material downloaded from web 
sites, Congressional hearings, or photocopied from review papers. These 
                                     
52   The AAAS is probably the largest scientific organization in the world. It has 
existed since 1848 and is responsible for the journal Science.  
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are all articulations in one or two of the five loops of the circulatory sy-
stem of science, viz. the loops to allies and the loops of public representa-
tions. The articulations enforce certain associations between entities. The 
purpose is not to cover all associations or loops, e.g. the collegial, or in-
strumental looops. According to ANT, reality is all over the place (see 
above). Although many case studies have focused on the move from 
materials to signs – and thus one or two loops – sociotechnical reality is 
articulated in multiple loops. Reality is multiple, and the universe is 
pluriverse (Latour 2005: 115–120).  
 Now the loops are not all that separate from each other. Asking for 
the public dynamics will also involve scientific materials and some data 
about corporate activities – in so far as these are part of the public dy-
namics. Therefore I have also approached scientific articles that are men-
tioned in hearings etc. The most important ones are Shamblott et al. 1998 
and Thomson et al. 1998, but also overviews in which hESCs or non-
human embryonic stem cells are discussed. They have been found via 
Medline searches on the keyword “stem cells”. Of the many articles on 
stem cells I have selected reviews or articles by scientists who have ap-
peared in hearings, reports, or in the media. These articles have, in gene-
ral, been possible to download from journal databases accessible via uni-
versity libraries, or have been available in the libraries’ collections of scien-
tific journals. I have also “Googled” to find additional material about, or 
from, the actors who appeared in public.  
 It is important to note what can and what cannot be claimed on the 
basis of this material. Although the study is based on empirical material it 
is controlled by my meta-theoretical interests in the concepts of obliga-
tory point of passage, boundary objects, the metaphor of circulation, and 
the implication of politics for ANT. Empirical data has been gathered in 
relation to the conceptual explorations. This obviously affects the possible 
claims and contributions. There are no claims to cover the whole situa-
tion of debates between 1998 and August 2001 – whatever that might be.53 
Initially the contributions are more theoretical than empirical. So many 
commentators have already said so much about those debates, which 
posits no hindrance for the purpose. Seeing differently does not primari-
ly require new facts, but a new perspective.  
                                     
53   For one suggestion of what it might be (to cover most of the press/politics 
during this period), see Nisbet et al. 2003. 
 
 
 
64 
 This choice of material and temporal limitation could be (and in fact 
was) made quite early. It is after this that it becomes difficult to state any 
pre-existing selections or criteria. Of course, I could make a rational re-
construction of such selection processes, but this would go against the 
method and purpose of the study.  
 For the later chapters (5–7) the empirical process has been guided by 
unpacking. Unpacking is similar to the job of a private detective finding a 
dead body in the library. The process goes backwards clue by clue, with-
out knowledge of what sort of people, materials, relations the search will 
lead to. In ANT terms unpacking is to open black boxes and stable ele-
ments, and follow the associations and articulations (= clues) that have 
contributed to the stabilization (= corpse). Detective stories can run for-
ward, but there is definitely a point in telling the story backwards without 
revealing the whole plot beforehand. The same pertains to this under-
standing of the public and political dynamics of hESC research.  
 Chapter 5: From 1998, I go backwards in order to see whether and how 
three elements of hESC research have appeared together earlier, in pub-
lic and political dynamics. The unpacking searches for articulations that 
offered a “contrasting continuity” to the 1998–2001 situation; continuity, 
since without this, the two situations would not be connected in any sen-
se; contrasting, since if the situations were totally similar there would be 
no point in speaking of two situations, or of unpacking.54  
 The task might seem impossible since hESC research is sometimes held 
to have dawned on a public awareness and the political process in No-
vember 1998. Going backwards from the debates in 1998–2001, there 
was one public and political event that many actors referred to: The Hu-
man Embryo Research Panel (HERP) convened in 1994. A copy of the 
report was ordered from an American library to Sweden. Some of the 
testimonies in the HERP sessions I found on the Internet. Although the 
report concerned what its title says, the hESCs existed as an articulated 
expectation between its covers. In order to capture the public dynamics 
in relation to the HERP, I searched the Internet by way of Google on 
the keywords “HERP”, “human embryo research panel” or “embryo re-
search”. 
 I also searched the Congressional database for the keywords “em-
bryo*” and “embryo research” to find out whether and how Congres-
                                     
54   This phrasing is indebted to Fujimura 1996 and her traces of continuity, pp. 
16 and 136. 
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sional debates handled the issue. There were a number of mentionings in 
Congress, but I found only one exchange in which several representati-
ves had an animated discussion, in the House of Representatives, July 
1996 (House of Representatives 1996).  
 Again, the aim has not been to cover all actors or all statements. My 
unpacking has been oriented toward contrasting continuity between the 
HERP situation and the articulations of hESCs, 1998–2001. This means 
that I have halted after finding enough to shed a contrasting light on the 
later situation and to guide me further back. 
 The study continues in order to understand why some commentators 
referred to IVF embryos and transplantation therapies as a solution to 
the disputes in 1994–1996. From the HERP the trails branch off back-
wards toward two different elements resulting in different material.  
 Chapter 6 (IVF and ”spare embryos”): To capture the sociotechnical 
reality of “spare embryos” and understand their role after 1994, my first 
clue was Louise Brown, considered to be the first baby born by means of 
in vitro fertilization (IVF). Her scientific fathers were Robert Edwards 
and Patrick Steptoe. Consequently, I searched for publications by, or about, 
these. There were four sorts of documents: popular books, journal artic-
les by scientists and by ethicists, political documents, and statistical re-
ports. My first source was Edwards and Steptoe’s autobiographical A 
Matter of Life (Edwards and Steptoe 1980). It is a partisan contribution in 
which the two authors represent themselves as successful pioneers – 
against all odds. However, their victors’ voices guided me to what they 
saw as the main opponents and obstacles. These were textual linkages to 
other ethical and scientific references. That was also how I continued, by 
way of textual associations. Sometimes they were direct associations. So-
metimes they were hints in a certain direction. I was an ant crawling from 
text to text. In this respect the search was not systematic, but network-
ish. Some of the associations led to the British debates; trails which I 
could not follow due to the US focus.  
 The main political documents were produced in the policy processes 
directly after the Supreme Court’s 1973 interpretation of the constitu-
tional implications of abortion (Roe vs. Wade 1973): the 1979 report 
issued by the US Department of Health, Education and Welfare (DHEW) 
and the earlier policy process visible in the Federal Register (FR) (US 
DHEW 1974, US DHEW 1979). In the FR proposed policies and public 
responses are notified. Especially the latter are interesting in order to 
understand the public dynamics. The Congressional activity increased to-
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ward the end of the 1980’s, when several national reports were produced 
and Congressional hearings held (House of Representatives 1987, House 
of Representatives 1988, Office of Technology Assessment 1988, US 
Congress 1989). All of these documents were possible to order from Ame-
rican libraries. Statistical data about the general use of fertility services 
were published by the National Center for Health Statistics on several 
occasions in the 1980’s (Hendershot and Bauman 1981, Mosher and 
Pratt 1990). Although these statistics said something about the general 
reproductive status usually very little is said about the clinical realities. 
The latter became more and more important when I found out that the 
“spare embryos” were not there from the beginning. To find out where 
the procedures that produced them came from, I turned toward the scien-
tific papers.  
 The two main journals for following the development of IVF tech-
niques in the 1980’s are Fertility and Sterility and The Journal of In Vitro Fer-
tilization and Embryo Transfer (existing from 1984). The first is available at 
the Göteborg University library. The second I ordered from outside li-
braries. In this journal reports appear from the Conferences on In Vitro Fer-
tilization and Embryo Transfer and the Congress of Future Aspects in Human In 
Vitro Fertilization. The former were held for the first time in 1980 and 
then followed by annual or biannual conferences at several locations (Jo-
nes Jr. and Schrader 1988, Seppälä and Edwards 1985). In the early 
1980’s there are a number of collections produced to capture the state-
of-the-art and bring together the medical, ethical and social issues (Big-
gers 1984, Mazor and Simons 1984). Probably due to the federal non-
involvement there were no systematic survey and statistics in the 1980’s 
about the clinical use of various IVF techniques, such as excess produc-
tion of embryos and subsequent freezing. In conference material I found 
an international survey (Van Steirteghem and Van den Abbeel 1988).  
 To compensate for this gap, I turned toward traces of IVF procedures 
in comments from bioethicists in articles and books. By way of defen-
ding IVF these authors articulated what they perceived as standard IVF 
procedures during the 1980’s (Robertson 1986, Singer and Wells 1984, 
Steinbock 1992). These are treated for what they are: articulations of 
perceptions. As such, they are part of the public and political flows of 
IVF. 
 The situation is more clear after 1992, when the Fertility Clinic Success 
Rate and Certification Act required the Centers for Disease Control and 
Prevention to publish annually an Assisted Reproductive Technology suc-
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cess rate report. These reports are available on the Internet (US DHHS 
1998, 2000, 2001a, 2005).  
 Chapter 6 (transplantation therapies): In the inquiring about the importan-
ce of transplantation therapies in fetal tissue research, political texts were 
again basic. The one event that was mentioned repeatedly in the negotia-
tions after 1994 and 1998 was President Clinton’s change of fetal tissue 
research policy in 1993. Therefore I investigated the Congressional bills 
that accompanied this change, again via the Congressional web sites. By 
reading these debates I was also led on to earlier debates, in the media 
and in Congress. The “leads” were provided by the appearance of certain 
Senators or Representatives and the way they referred to earlier events. I 
also used free search motors, such as Google and Find Articles (www. 
findarticles.com) using the keywords “fetal tissue”, “fetal tissue research”, 
“fetal tissue transplantation”. By means of the library databases I found 
commentaries and overviews on fetal tissue research from the period 
(Hanna 1991, Sobelsohn 1989, Vawter et al. 1990).  
 In actors’ articulations, one landmark was the 1988 report from the 
Human Fetal Tissue Transplantation Research Panel (HFTTRP) (Adams 
1988). This was acquired from the University of Minnesota library. My 
searches continued along two flows from the HFTTRP. One direction 
led to the media reports, and previous, political debates. The latter even-
tually led to the Supreme Court’s decision on abortion, via the 1975 fe-
deral report Research on the Fetus (US DHEW 1975). This was ordered 
from US libraries. Another direction led to scientific trails of references. 
Within the report, as well as in other material, scientific work was refe-
renced. These papers constituted what was regarded as the science of fe-
tal tissue research for the panel’s (and others’) ethical deliberations. From 
public and political loops the material led to laboratory and collegial loops 
– still only by way of texts. I followed these flows from one citation and 
reference to the next. I was guided by the interest in alternatives and un-
certainties (outlined above). To understand the centrality or marginality 
of uncertainties in the scientific material I kept close to the major jour-
nals such as The Journal of the American Medical Association (JAMA), The 
New England Journal of Medicine (NEJM), The British Medical Journal (BMJ), 
and The Lancet. After a number of articles I found that some researchers 
occurred more frequently than others. Without scientometric measures I 
searched on these names specifically.  
 Chapter 7: When the study returns to the 1998–2001 dynamics, the 
same material as earlier appears again. Now the attention is radically dif-
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ferent because of the unpacking performed in the preceding chapters. 
One group of materials is added. Due to the focus on the definition of 
the term pluripotency more material from scientific articles is included. I 
found articles on adult stem cells by drawing on my laboratory expe-
riences from 2002 and onwards. In the field of stem cell research (adult 
and embryonic) there was by then a quite explicit canon of the adult stem 
cell findings that had appeared in 1998–2001. This was salient in conver-
sations and at conferences. Apart from also being mentioned in the Se-
nate hearings, these “plasticity” papers are often a part of the introduc-
tion or discussion sections in later papers.  
 At one point in Chapter 7 I recount a database search of scientific ar-
ticles using the terms pluripotency and/or totipotency. This search is 
done in order to capture general tendencies in the scientific community. 
It is thus a step away from the interpretative work of finding associations 
and flows. For this mathematical exercise I used the reference program 
EndNote to search the database Medline/Pubmed accessed via the Göte-
borg University library. I searched the occurrence of the truncated terms 
“ES cell*” and “embryon* stem cell*” (thus covering ES cell and ES cells, 
embryonic and embryonal stem cells) in combination with “pluripoten*” 
and “totipoten*” (thus covering pluripotent, pluripotential, and pluripo-
tency, etc) regardless of the context of use in articles. The search was 
conducted November 15, 2005.  
 The above account – although complicated as it stands – is by neces-
sity a retrospective simplification of how I acquired and interpreted a bo-
dy of empirical material. Common to all of these text studies is that the 
straightforward “Follow the Actors!” is modified. In the next chapters I 
will follow trails in texts, not in labs. Sometimes there are explicit links 
going from paper to paper, from report to report. More often I will have 
to reconstruct associations, trails, and flows of references, entities and 
actors from textual materials. This also accounts for the unsystematic ac-
quisition of source material. The empirical work is interpretative, modi-
fying itself while moving forwards/backwards – quite like an assemblage 
– and as such can only be assessed in retrospect, not defined beforehand.55   
 Many of us are used to thinking in terms of a temporal line going from 
the Beginning to the End. However, a crucial point in putting ANT to 
                                     
55   I would guess that the same interpretative work has to be done when follow-
ing human actors around in the laboratories; cf. the anthropologist of Labo-
ratory Life by Latour and Woolgar 1979.  
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work is to let the ant create a new chronology by following associations. 
Instead of starting with a year-based linear chronology that the author – 
after doing the study – is able to reconstruct, it is integral to the ANT 
seeing of the world to let the ant do his work (i.e. start with the corpse in 
the library). Revelations and chronologies have thus been provided 
reluctantly and go against the ant’s approach, the methods of his moves.  
The research questions 
According to the notion of assemblage presented already in the Intro-
duction it is hard to formulate research questions in advance. ANT is 
about unpacking or understanding a phenomenon. More than a soccer 
field this is a hike in the mountain. We still don’t know what will be 
around the next corner – in the next black box. If the questions are posed 
beforehand it means the phenomenon is already known. Research ques-
tions thus come one by one. One of these resulted from applying ANT 
to the initial puzzle about stem cell research and politics.  
(ANT-Question No 1) What is the sociotechnical reality of hESCs? 
ANT is used to find associations between heterogeneous elements in 
actor-networks. This was introduced above together with the notion of 
sociotechnical reality. However, this task is pursued in relation to the 
meta-theoretical interests. One question resulted from applying existing 
critiques of ANT.  
 (Meta-theoretical Question No 1) How can the notions of obligatory point of 
passage and boundary objects be put to use in order to understand the socio-
technical reality of hESCs? 
Another meta-theoretical question was raised because of focus on the 
public and political dynamics:  
(Meta-theoretical Question No 2): How can ANT account for the role of ex-
plicitly political actors in sociotechnical network attempts? 
When these three questions are combined with the empirical material, 
the textual materials from 1998–2001, they make up the detailed aim that 
was mentioned in the Introduction: 
 To explore ANT in order to understand the sociotechnical reality of 
hESCs in the USA prior to August 2001 – in particular with regard to the 
public and political dynamics.  
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 This is, in turn, one way to approach the basic, underlying aim to 
exercise seeing differently. All of these questions guide part one of the study, 
spanning the three next chapters (Chapters 2–4). After finding a first 
answer to the question the study continues with a second research ques-
tion that relates to the general aim. In accordance with ANT, it is pos-
sible to unpack stabilized object and actor-networks to find out how 
socio-technical reality has come to be. This was formulated above as a 
second ANT-inspired research question.  
(ANT-Question No 2) How has the sociotechnical reality of hESCs come to be? 
Together with the temporal focus above, this question is now specified. 
(Temporally limited ANT-Question No 2) How did the sociotechnical reality 
of hESCs in the USA 1998–2001 – and especially the public and political dy-
namics – come to be? 
Obviously this is a very general question, and it would be impossible to 
answer without qualifications. Such qualifications exist after part one, 
meta-theoretically and empirically. What will then appear as central to 
the sociotechnical reality of hESCs (1998–2001) are the unhindered flows 
between actors, together with a specific combination of elements in hESC 
articulations. The flows will be the result of meta-theoretical elaboration. 
The three elements are the result of following the public and political ar-
ticulations of hESCs. In part two, the analyses are thus guided by a second 
modified question: 
(Meta-theoretically modified Question No 2) How were the flows between 
actors and the three elements – frozen embryos, transplantation therapies, and 
pluripotency – of hESCs mutually stabilized? 
 PART I 

2.   Attempts to Establish an Obligatory Point of Passage:  
The 1998–2001 Negotiations of Federal Funding  
Introduction 
In November 1998 two laboratories announced that they had ”derived” 
and cultured pluripotent embryonic cells (Shamblott et al. 1998, Thom-
son et al. 1998). More than two and a half years later, on August 9, 2001, 
President George W. Bush addressed the American people from his ranch 
in Texas and became the first Republican President to approve of federal 
funding for embryo research. Bush’s decision was one end-point (cer-
tainly not the last) of the negotiation process set in motion in November 
1998. I approach this negotiation wondering: What were human embryo-
nic stem cells (hESCs) during those two and a half years? Drawing on 
actor-network theory and theory of science the question becomes: What 
was the sociotechnical reality of hESCs during that time?  
 This question opens for theoretical and empirical issues. Empirically, 
the question concerns what associations and articulations made up this 
reality. Theoretically, three issues follow from this, according to Chapter 
1. A first one is the network’s degree of stabilization. Another is how en-
tities are related to each other, i.e. the mode of coordination. A third con-
cerns which actors were more or less responsible for coordination, i.e. 
how agency was distributed. Actors may be funneled to take a detour or 
remain in their worlds. Entrepreneurial humans may be positioned as an 
obligatory point of passage for the emerging actor-network, or boundary 
objects may coordinate people through the flexible uses involved in di-
verse practices. 
 In this chapter I focus on how one specific relationship is articulated, 
viz. the association between the Federal administration and hESC research. 
This relationship is probably the most controversial and conspicuous 
feature of hESC research in the USA, between November 1998 and Au-
gust 2001. Before any other issues or elements are investigated the fede-
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ral funding must be understood, or at least approached. Here, this is do-
ne in two parts. First the proponents of federal funding are given space, 
and then the opponents.  
Associations of a new reality 
In an attempt to understand the sociotechnical reality of hESCs in the 
USA 1998–2001 it is impossible to bypass the role of the government 
and Congressional politics. Even internationally, the disputes about whe-
ther to support hESC research with federal funds, or not, are well known. 
The Federal administration is either associated with, or dissociated from, 
hESC research.  
 A few words are needed about how this study treats the Federal ad-
ministration. No individual is solely identifiable with it, not even the Pre-
sident of the USA. During this period, November 1998 to August 2001, 
there is great uncertainty about the role of the Federal administration in 
relation to hESC research. The President may do one thing, executive 
agencies such as the The National Institutes of Health (NIH) another thing 
and Congressional committees and individual senators a third, fourth and 
fifth thing.56 All of those actors are closely tied to the Federal administra-
tion and may each articulate its role differently. Only at the end of the 
period (August 9, 2001), does Bush’s decision define this role. There are 
some other decisions, but these are never put to work during the period. 
In order to understand the role of the Federal administration in this pe-
riod of uncertainty it is useful to not deal mainly with decisions, but to 
treat the Federal administration as an aggregated actor that can be arti-
culated in a number of ways, decisions included.  
 This way of dealing with the Federal administration differs from an 
exclusive focus on decisions and actual policies. If this were a study in 
political science one aim could have been to explain Bush’s political 
decision.57 However, the purpose of this analysis is not to explain poli-
tical decisions, but to understand the sociotechnical reality of hESCs 
(which may, however, lead to improved understanding of political deci-
sions). So many articulations of the stem cells are also articulations of 
                                     
56   The NIH is a part of the US Department of Health and Human Services and 
the main agency for Federal support of medical research. 
57   It is probably too early and too difficult to pursue such a study at the present 
time, especially from Sweden. There are too many factors of Washington 
political power-games for a good answer to be found.  
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what the Federal administration is and should do. It is in this respect that 
the role of the Federal administration is crucial, and not only in official 
Presidential and Congressional decisions, but through others such as scien-
tists, patients, politicians, corporations and bioethicists. Indeed Bush’s 
decision and other decisions are interesting as articulations – among others 
– of what the Federal administration and hESCs are. Often the latter are 
also endowed with capacities and implications such that they were, in 
effect, also an actor.  
 In ANT terms there are alternative patterns in these articulations. In 
one cluster of articulations the Federal administration is made responsib-
le for the hESCs as if it were the main actor. This responsibility is con-
structed together with the agency of hESCs.  
Stem cell actions 
As soon as the hESCs were announced they were associated with a 
federal course of action, and sometimes more than that. Sometimes the 
stem cells seemed to have direct political consequences, at least accor-
ding to editorials in Nature and The New York Times: 
Last week’s announcement on human embryo stem cells requires a change in 
the US law on embryo research. (Nature 1998: 97)  
The breakthrough in growing human stem cells in laboratory with private fun-
ding is not only a remarkable achievement, it is a rebuke to Congress for ban-
ning Federal funding of this exciting new research. (The New York Times 1998) 
Although less explicitly President Clinton also responded to the stem cell 
reports from Thomson’s and Gearhart’s groups (and ACT’s announce-
ment of cloning experiments), in November 1998. He wrote a letter to 
the National Bioethics Advisory Commission (NBAC), asking for a re-
port about the ethical and medical implications of the research.58 In his 
letter Clinton presented the policy situation and mentioned the ethical 
concerns. He recapitulated the 1994 ban on federal funding of embryo 
research and the balance between the then-anticipated medical benefits 
and “immediate ethical concerns”. 
                                     
58   President Clinton’s letter of November 14 was addressed to Dr. Harold T 
Shapiro, Chair of the NBAC. The commission first reported back to Clinton 
November 20 after consulting Dr. Ralph Brinster and Dr. Michael West. The 
more extensive report, delivered in September 1999, included a wider range of 
perspectives. 
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Four years ago I issued a ban on the use of federal funds to create human 
embryos solely for research purposes. The ban was later broadened by Con-
gress, which will prohibit any embryo research in the public sector. At that 
time, the benefits of human cell research were hypothetical, while the ethical 
concerns were immediate. (Shapiro et al. 1999: 88)  
The research was already constitutionally and legally possible, with private 
funds. The specific ban on federal funding was due to Congressional ac-
tion, and without support from the Republican-dominated Congress Clin-
ton could not change this even if he wanted to.59 According to the con-
tinuation of his letter he now did not have to enact a change on his own. 
The new developments in hESC research motivated a new review of the 
issues.  
Although the ethical issues have not diminished, it now appears that this re-
search may have real potential for treating such devastating illnesses as cancer, 
heart disease, diabetes and Parkinson’s disease. With this in mind, I am also 
requesting the Commission undertake a thorough review of the issues associa-
ted with such human stem cell research balancing all ethical and medical con-
siderations. (Shapiro et al. 1999: 88)  
Gearhart’s and Thomson’s announcements in November 1998 became a 
starting-point for renewed considerations and disputes on the ethics and 
policy of embryo research; at least this is the point of Clinton’s request 
to the NBAC (US Senate 1999a: 14–16, 1999b: 66–68, Shapiro et al. 
1999). According to the President the consequences of the stem cells had 
moved from “hypothetical” to a “real potential”. He was joined by others. 
Apart from NBAC, the NIH also drafted guidelines for hESC research 
in 1999, and sought public comments between December 1999 and late 
February 2000. The NIH released the finalized guidelines in 2000 (NIH 
2000). There were differences between the NBAC and the NIH in rela-
tion to how much the administration should be involved in the actual 
and original production of hESC lines. The NIH took the more restric-
tive line and claimed that federal funds should not be used to destroy 
embryos, but only for work on (already produced) cell lines. Those diffe-
rences aside the two bodies were both in support of federally funded re-
search on hESCs. They both argued for the responsibility of the Federal 
administration based on the capacities and promises of hESCs. It was no 
                                     
59   The Dickey-Wicker amendment had been attached to the DHHS appropria-
tion in 1996 (Public Law 194–99) and in 1998 was encoded in Public Law 
105–78, § 513. See more about the Dickey-Wicker amendment in Chapter 7. 
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big surprise. Clinton had himself appointed the NBAC. The NIH is a fe-
derally controlled authority.  
 Faster than the NBAC and the NIH, Senators Tom Harkin and Arlene 
Specter acted. They were the leading senators in the Senate Subcommit-
tee on labor, health and human services.60 It is worth noticing the speed 
with which the Senate hearings were called. Only four weeks after the 
announcements by Thomson and Gearhart the Senate subcommittee 
gathered a first hearing on stem cell research and cloning technology.61 In 
these hearings many of the central scientists, patient organizations, bio-
ethicists, corporate and religious representatives, and Senators appeared. 
The opening remarks of Senator Specter, the chairman of the sub-com-
mittee repeated the formula: 
The subject matter on our hearing today arises from a provision of the legi-
slation reported out by this subcommittee last year, which limits the use of 
Federal funds for research on human embryos. That is an issue which has co-
me into sharp focus with very dramatic recent medical developments, warran-
ting a closer analysis or perhaps a reanalysis of that question. (US Senate 
1999b: 1) 
The NBAC, the NIH guidelines and the subcommittee hearings were all 
official sites in which the two actors – the Federal administration and the 
hESCs – were articulated. In all of those sites the Federal administration 
was apparently deeply affected by the hESCs, which were usually articu-
lated as a powerful actor. The absolute majority of the testimonies in the 
first three Senate hearings (December 1998 – February 1999) argued for 
the federal funding of hESC research.  
Pluripotent agency 
What are the powers of the hESC actors and how do they affect the 
Federal administration? They have effects in several steps. First, there are 
the fundamental capacities of the cells, sometimes articulated in images. 
The following is from Geron Corporation in the Senate hearings (US 
Senate 1999b: 61): 
                                     
60   Committee on appropriations. 
61   It was the first of a total of three such occasions within two months, and twelve 
in the next two years.  
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 My introductory explanation of stem cells reproduced another (graphi-
cally more sophisticated) illustration from the University of Wisconsin web 
site (see Introduction). It was doing the same thing. Both cases feature 
the biological potential of the cells, their developmental potential and 
result in visible tissue types, such as muscles, nerve cells or blood cells. 
These tissues are transformable says the Subcommittee chairman, Sena-
tor Specter: 
The recent advances have shown that the stem cells have potential to grow 
into any kind of bodily tissue and have, at least reportedly, enormous potential 
on a wide variety of very serious ailments – heart disease, diabetes, Alzhei-
mer’s, cancer, spinal cord. (US Senate 1999b: 2) 
The recent advances are the two reports from Thomson’s and Gearhart’s 
groups. This is from the latter: 
Human pluripotent stem cells, with their potential to differentiate into a wide 
variety of cell types in culture, would be invaluable for studies of some aspects 
Figure 4: Differentiation (development) of hESCs into Three Germ 
Layers. Reproduced from (US Senate 1999b), by courtesy of Geron 
Corporation. 
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of human embryogenesis and for transplantation therapies. (Shamblott et al. 
1998: 13731) 
The mentioned differentiation potential is one definition of pluripotency. 
Shamblott et al. link it directly to studies of human embryogenesis and 
transplantation therapies.  
A pluripotent transformation of the USA 
Pluripotency is extended from stem cells to therapies to individual pa-
tients and the whole nation. Actors are not merely articulating the use of 
stem cells in therapies. Through their use in transplantations the stem cells 
are capable of transforming people’s lives, medicine and even the USA 
and the world. This is done by stressing the qualitative and quantitative 
change on an individual and collective level. Examples of the two most 
common needs linked to the use of hESCs in transplantation therapies 
come from Richard Pikunis and Doug Melton. Pikunis appears in the 
second hearing. He is a Parkinson patient, a lawyer, a doctor, and only 27 
years old, and thus much younger than PD patients usually are. His account 
is touching, not least because of his age.  
it [the research on hESCs] holds my future in its hands. My son celebrated his 
first birthday and is learning to walk as I am slowly losing my ability to do so. 
I wake up every morning barely able to move until my medication kicks in. 
(US Senate 1999b: 103) 
Pikunis does not associate himself with the stem cells, but anchors his life 
and his hope in them.  
Only you can help put an end to the human suffering associated with Par-
kinson’s disease. Do not let me become a burden to my loved ones and socie-
ty. Let me live my dream of an optimistic future with my wife and family. (US 
Senate 1999b: 104) 
Dr. Doug Melton combines a scientific identity with a personal relation-
ship to diabetes by being both a molecular biologist and the father of a 
diabetic son. He is involved in The Juvenile Diabetes Research Founda-
tion (JDRF).62  
                                     
62   JDRF is a patient organization devoted to patient support, advocacy and rai-
sing funds for research relating to type I diabetes. It was started in 1970. 
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I am sorry to say that I cannot recall a night of peaceful sleep since Sam was 
diagnosed nearly 7 years ago, and I am unwilling to accept the enormity of the 
medical and psychological burden […] (US Senate 1999b: 99) 
today I look to science praying it will be able to save my life. (p. 102) 
These are personal needs and conditions which the hESCs – by being 
used in transplantation therapies – are thought possible to relieve. By stres-
sing the gravity of these conditions a possible reality is articulated. Apart 
from qualitative, there are quantitative articulations.  
 CEO of Geron Corporation, Thomas Okarma, presented one list of 
possibly affected people: 5 million congestive heart patients, 1 million ca-
ses of invasive cancer/year, atherosclerosis, 650,000 deaths/year, 1.4 mil-
lion diabetes patients, 1 million Parkinson’s patients, 500,000 stroke vic-
tims and 4 million Alzheimer’s patients (US Senate 1999b: 53).63  
 To support stem cell research, in May 1999 34 patient organizations for-
med an umbrella organization Patients’ Coalition for Urgent Research (CURe), 
with the explicit goal of supporting the federal funding of hESC research. 
According to their estimates more or less every second American could 
be affected by the research. 
Cardiovascular diseases  58 million  
Autoimmune diseases  30 million  
Diabetes      16 million  
Osteoporosis    10 million  
Cancer      8.2 million  
Alzheimer’s disease   4 million  
Parkinson’s disease   1.5 million  
Burns (severe)    0.3 million  
Spinal cord injuries   0.25 million  
Birth defects     150,000 (per year)  
Total      128.4 million 
(Perry 2000) 
The fate of these numbers is an interesting history in itself. In several 
places they became the quantitative need for hESC research. The Ameri-
                                     
63   Also see US Senate 1999b: 99, for quantitative articulations. 
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can Association for the Advancement of Science (AAAS) and the Insti-
tute for Civil Society (ICS) picked up on these numbers in their joint re-
port where they stated “Virtually every citizen is affected directly or in-
directly” (Chapman et al. 1999: 4). When Republican and Pro-life Sena-
tor Orrin Hatch wrote to President Bush and the Secretary of Health, 
Tommy Thompson, in June 2001, he used the same numbers – and for-
mulations.  
Potentially, stem cell research can help virtually every American family. It has 
been estimated that over 128 million American [sic!] are afflicted with con-
ditions that may benefit from embryonic stem cell research. (Hatch 2001b) 
The AAAS/ICS report did refer to other sources, e.g. numbers from the 
American Diabetes Association estimating the cost of treating diabetes at 
$100–140 billion in the USA. (Chapman et al. 1999: 4). Whatever the sour-
ce and the flow of numbers, these actors use them to articulate a total 
transformation of millions of lives. The actors are not merely discussing 
a therapeutic option, or a change in medicine. Patients’ lives will be to-
tally transformed, and the numbers of Americans affected are huge.  
The missing link 
Together with the articulation of hESCs as a powerful actor a specific 
agency is attributed to the Federal administration. The hESCs and the 
Federal administration are co-constructed. By bringing in the pluripotent 
transformation, a new reality was allegedly made possible because of the 
pluripotent stem cells – on one condition. 
But all of these benefits could be delayed or even denied to patients without a 
healthy partnership between the private sector and the Federal Government. 
[---] The only way to ensure that this research is conducted is to allow NIH to 
support it. But unfortunately, as the American Society for Cell Biology writes 
in a recent letter, the ban on human embryos research “has the effect of ex-
cluding the majority of the Nation’s most prominent researchers who are sup-
ported by the NIH and limits the development of new therapies”. [---] The 
research conducted by the distinguished scientists sitting before us today 
holds such hope and such potential for millions of people around the world 
who are sick and in pain that I believe it is morally wrong for us to prevent or 
delay our world-class scientists from building on this progress. (US Senate 
1999b: 3) 
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The hESCs and their capacities are brought to bear on the Federal admi-
nistration by extending pluripotency to the whole nation and the whole 
World, according to Harkin. At stake here is not hESCs but a new world, 
dependent on the condition of federal involvement. Harkin, the Ameri-
can Society for Cell Biology (ASCB), and other professional organiza-
tions, e.g. the Biotechnology Industry Organization (BIO), claim that the 
private sector lacks financial motivation for a lot of the fundamental re-
search needed to advance treatments that will only be realized in the very 
long term. The pluripotent transformation of the USA may be obstruc-
ted if the Federal administration does not take its responsibility. What 
will happen then? 
Industry can target one or two or a couple and get it done in a reasonable 
time. The more difficult ones will just be left undone.  
Senator HARKIN. So you are saying, again, with this research there could be 
all kinds of breakthroughs later.  
Dr. THOMSON. Take diabetes as an example. [---] That is likely to be a more 
difficult cell to derive from embryonic stem cell. It requires a lot of basic 
research, and the Government has the job of doing basic research. (US Senate 
1999b: 33)  
Dr. Goldstein, a stem cell scientist, was asked about the time-line for 
treatments of Alzheimer’s.  
Alzheimer’s is a very tough problem, Senator, and I do not think we have a 
very good sense of how long it will be. I guarantee you that every day we delay 
is another day that the clock ticks and we are not making progress using this 
vital research need. (US Senate 1999b: 113) 
Dr. Doug Melton, a molecular biologist, father of a diabetic son, and 
involved in the JDRF comments as a scientist and urges for federal 
funding with reference to “the research trenches”:  
What I can see, speaking from the scientist’s point of view in the trenches, is 
that there are many people with very good ideas about how to actively pursue 
this research, and we are anxious for Federal funding. (US Senate 1999b: 112) 
Again and again federal funding is the missing link between pluripotency 
and difficult diseases, and more, since a pluripotent transformation is at 
stake. Thomson, Melton, Goldstein, Hatch and Okarma all claim that it 
is insufficient to keep hESC research in the private sector. 
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 In addition to the hESCs and a transformed USA the Federal admini-
stration is articulated. There is a simultaneous construction going on here 
of hESCs, a new US reality, and the Federal administration. The path 
from pluripotency to cures of difficult diseases leads to a transformed 
USA, but on this path one actor is given a choice. Because of hESC 
pluripotency the Federal administration has been given an opportunity to 
act on these diseases for the benefit of the many. It is not only the 
hESCs that become a specific and powerful actor in these articulations. 
The Federal administration also becomes a powerful actor as a direct 
consequence of hESC pluripotency. The agency of the Federal admini-
stration is directly derivable from the agency of the hESCs. Only if the 
humans in decision-making positions allow federal funding can the capa-
cities of hESCs be released. Here is a last example of how these articu-
lations of stakes and the gravity of transformation are said to affect other 
elements too, for instance the source material. Bioethicist Arthur Caplan 
quotes his son on the ethical dilemmas: 
I think it is true that the goal of our public policy should be to tell that person 
in a wheelchair we are going to try and weigh tradeoffs morally ethically, 
between the hard choices that have to be made […] and that it is wrong in the 
end if we cannot come up with a policy that says we will not hold that person 
in a wheelchair hostage to our moral concerns about tissue that will otherwise 
be destroyed, tissues that are not going to be turned into human beings under 
any circumstances, or cells and tissues that, because we misunderstand or 
misdescribe them, are going to wind up being misclassified as potential people 
or possible human beings. (US Senate 1999b: 36) 
This is the agency resulting from the cells’ pluripotency and their pluri-
potent transformation: that if the use of embryos for producing hESCs is 
prohibited it is holding people hostage to moral concerns.  
An obligatory point of passage  
The all-encompassing transformation implied in hESC research accor-
ding to these articulations resembles the three case studies by Latour, 
Callon, and Law and Callon in which a new actor-network appears all in 
a seamless web. A new system is set up in which knowledge, truth and 
society are remade, whether it be the Pasteurization of France, the inter-
play between scallops, fishermen and researchers, or the military aircraft 
TSR 2.  
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 Apart from the resulting dominating actor-network the OPP cases 
display some common traits regarding the mode of coordination and the 
distribution of agency. The coordination builds on a funneling translation 
of actors’ goals. All actors ultimately accept that a detour through the 
OPP (as a funnel) is the best way to achieve their goals. In the OPP the 
central group functions as an entrepreneurial force driving the actor-net-
work with an almost Machiavellian agency, while other actors either accept 
or deny the suggested network-formation. This either-or response is 
closely tied to an extensive sociotechnical transformation. If the necessary ac-
tors accept the translation a new reality is established through the OPP. 
If someone or something does not collaborate the actor-network fails. 
These three features have thus characterized an OPP coordination 
according to Callon, Latour and Law: an extensive transformation achie-
ved by funneling heterogeneous actors through one central and entrepre-
neurial actor (or group of actors).  
 In this case the USA is involved in a pluripotent transformation. Ac-
tors envision a sociotechnical reality of stem cells, and the stem cells are 
the human embryonic ones. Because of the capacities of hESCs the ca-
pacities and responsibilities of the federal government increase, and vice 
versa. The realization of hESC pluripotency in the USA for all the patients 
in need, is made possible because there is a Federal administration with 
strong means to funnel the actors. With money and laws the Federal ad-
ministration has the capacity to stabilize a research practice and sub-
sequently to spread its objects and facts. The network of research facili-
ties and medical clinics that is maintained by federal means is a huge po-
wer for social transformation all by itself – even without hESCs. In this 
case its power is expanded through the power of hESCs; its agency is 
made even more important because of the agency of hESCs. Latour has 
used Archimedes motto – “Give me a place to stand and I will move the 
world” – to explain the power of the laboratory. With a lever and one 
stable spot one weak man could move a heavy world. In this case it is 
more than one weak man. The agency of the Federal administration is al-
ready considerable. A government can translate people’s goals through 
the simple means of prohibitions and payrolls. It is therefore hardly an 
actor like any other. It is a center for stabilization with the capacity to 
force a number of actors to do or to not do certain things; to funnel 
other actors into a specific understanding of a situation. The already con-
siderable agency of the Federal administration is reinforced by the pluri-
potent agency of hESCs. If the co-construction of hESCs and the Fede-
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ral administration is successful then the stem cells will be supported by 
all tax-payers in the USA, by way of the administration’s authorization of 
the research, and spread out to the whole country (or at least every se-
cond American) through the institutional network of research universities, 
publicly funded laboratories, and ultimately patients in clinics (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Among numerous articulations this first part of the chapter has fo-
cused on the relationship between hESCs and the Federal administra-
tion. So far only the articulations proposing an association of the two en-
tities have been investigated. A striking pattern has been the attempt to 
establish a transformation of the USA through the co-construction of two 
strong actors, the hESCs and the Federal administration. There is also a 
funneling aspect to this coordination as a result of the powerful center 
constituted by the combined agency of hESCs and the Federal admini-
stration. The stabilization at stake through a centralized funneling is ty-
pical for an OPP coordination.  
Figure 5: The pluripotent transformation 
envisioned together with the association of hESC 
research and the Federal administration. 
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Dissociations 
An OPP attempt is not necessarily successful, or without resistance.64 In 
Callon’s study one linkage failed – the one to the scallops, which rejected 
the attempted OPP coordination. Law and Callon’s military aircraft pro-
ject ultimately failed since the proposed OPP could not be sustained. In 
the Pasteurization two physicians, Koch and Peter, and also the medical 
profession as a whole opposed the OPP. Koch could be marginalized, but 
the doctors had to be convinced through the distribution of vaccines and 
serums directly to the clinics, instead of forcing them to take a geogra-
phical detour to l’Institut Pasteur. Just as in other cases of OPP some ac-
tors in this case resisted the attempted actor-network. By following the 
opponents’ arguments some things about the existing and attempted coor-
dination may be revealed. The actors who objected to hESC research did 
so to stop the involvement of taxpayers’ money in the usage of embryos 
in stem cell (and related) research.  
 Although the decision to allow federal funds for hESC research is po-
litical and is ultimately taken in Congress or the White House, non-politi-
cians are very important. Some of the articulations from scientists and 
patient representatives were presented above. Individual persons suppor-
ted or opposed federal funding as spokespersons for other actors. A se-
nator’s role as representative is obvious. S/he is elected and usually in-
teracts continuously with voters from her/his constituency. But, other 
actors also “represented”, as they opposed or supported federal funding. 
These acts of representation are dependent on the relationship between 
the individual actor and the group he/she/it represents and the strength 
of the group. Because of the lack of strong party structures in the USA 
social movements have achieved an important role, quite distinct from 
how the parliamentary systems of European countries have traditionally 
worked. Originally there was no direct connection between the two main 
parties and the abortion movements (whether pro or anti). In 1980 the 
Republican party created a “pro-life platform” and the Democratic party 
soon made “pro-choice” a major priority (National Right to Life 2005). 
                                     
64   A few words about resistance in OPP cases: As a result of the central actors’ 
strength the other actors in classic OPP studies have been somewhat bivalent, 
or two-dimensional. In such studies actors exist in relation to the OPP. They 
can accept or reject a new understanding of a situation; accept or reject the 
offer to make a detour through the OPP to reach their goals. Their two-dimen-
sional agency, “yes or no”, is a consequence of the attempted funneling. 
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Still, parties are less important than social movements when it comes to 
public attention, and political pressure and action (Ferree et al. 2002). Con-
gressmembers are in general more tied to their constituencies and social 
movements than to a party line. This is the importance of individual ac-
tors relating to the cells. They stand for whole clusters of other people 
and resources that may (or may not) be significant potential allies in the 
political game. 
 The pro-life movements have been well organized and capable of ga-
thering people from, largely, diverse Christian viewpoints and denomi-
nations. The pro-life movement is a stretched-out network, ranging from 
state-by-state groups to well-funded national lobby organizations, such 
as the National Right to Life Committee (NRLC) and the National Con-
ference of Catholic Bishops and its secretariat for pro-life activities. So-
me are tied to scientists and doctors, e.g. Do No Harm – the coalition of 
Americans for research ethics, and others explicitly address the political 
arena by forming Political Action Committees (PAC), such as the Repub-
lican National Coalition for Life (RNC/Life). The significance of single 
actors being called to hearings or interviewed in newspapers relates to 
the strength of the groups they represent. There is no way to cover all of 
the pro-life activities touching on the issue of hESC research, but many 
of the actors have been converging. Some of them will be mentioned, 
especially those showing up in Congress, the Senate hearings and in pa-
nels and major newspaper debates. For the most part, three main objec-
tions raised by opponents will be treated. All of these serve to dissociate 
the hESCs from the Federal administration, and from the envisioned plu-
ripotent transformation. The first objection is legal, the second is moral, 
and the third is scientific.  
Reactions to funneling 
The opponents of federal funding did not deny the authoritative and 
central importance of federal funding, but they could claim that there were 
already legal obstacles to federal involvement.  
“There are no instances in which I feel the ban on federally funded research 
on human embryos should be lifted,” says Dickey. ”The language of this ban 
prevents taxpayer funding for bizarre experiments, such as cloning. Even-
tually, I could see the embryonic stem cell technology going in this direction.” 
(Butler 1998: 104) 
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Congressman Jay Dickey had been instrumental in the then-existing ban 
on embryo research (the Dickey-Wicker amendment). Another pro-life 
actor in the hearings opposing the cells was Richard Doerflinger. He of-
ficially represented the National Conference of Catholic Bishops (NCCB) 
and its secretariat for pro-life activities.65 In the dialogue below, Doer-
flinger is approached by Senator Harkin in the first Senate hearing on 
stem cells (December 1998). The issues are the legal and moral status of 
existing stem cell lines. They are not “organisms”, Harkin claims, and the 
ban on federal funding thus should therefore not apply. Doerflinger dis-
approves of the question. 
Senator HARKIN. [---] I asked all of the scientists who were here before the 
question of whether or not these stem cells are organisms. And I believe the 
record will show they all said no, it is not an organism. [---] Let me ask the 
nonscientist. Mr Doerflinger? 
Mr. DOERFLINGER. Thank you. Stem cells are not organisms. However, 
two of the three experiments that were discussed here were not experiments 
on stem cells. They were experiments to get stem cells, by in one case creating 
and then destroying embryos [ACT], organisms, and in the other case taking 
embryos already in existence and destroying them [Thomson et al.]. (US 
Senate 1999b: 71)66 
Doerflinger agrees about the status of the existing stem cell lines. They 
are, like any tissue outside of the body, not organisms. He shifts the 
focus. The problem is the “derivation” of stem cells, which destroys the 
                                     
65   The members of the NCCB (now: USCCB) are the Catholic bishops in the 
USA. It is driven as a corporation by a staff of 350 people. According to bio-
ethics professionals, the USCCB is one of the most powerful lobby organiza-
tions in Washington, DC. This is also suggested by its presence in the hearings. 
According to the USCCB its purpose  is: 
  To unify, coordinate, encourage, promote and carry on Catholic activities in 
the United States; to organize and conduct religious, charitable and social 
welfare work at home and abroad; to aid in education; to care for immi-
grants; and generally to enter into and promote by education, publication 
and direction the objects of its being. (The US Conference of Catholic 
Bishops 2005) 
66   The conversation is from a Senate hearing in December 1998, although the 
US Senate reference is from 1999. There is generally a delay between the 
actual hearings and their publication, cf. US Senate 2001. 
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source embryo.67 Harkin disagrees, although he also (earlier in the 
hearing) recognizes that the research should be conducted “in an ethical-
ly validated manner” (US Senate 1999b: 4).  
 His second argument is that the ban should be lifted anyway and be 
replaced with guidelines to regulate the research on stem cells. His ex-
ample is how guidelines were substituted for the fetal tissue research ban. 
Doerflinger again does not accept the suggested solution, and returns to 
the issue he represents.  
Mr. DOERFLINGER. I do not know, if I can respond to that question […]. 
I think guidelines may be appropriate in cases where you are dealing with 
tissue that is already tissue, it is already from someone who is already dead. 
What they are talking about is setting guidelines for how and when to make 
and destroy human embryos, and I do not think guidelines alone are sufficient 
for that. (US Senate 1999b: 73) 
If you ask are the stem cells an organism, the answer is no. If you take my 
heart out, it is not an organism, either. But the question is the experiment 
involves ripping out the cells from what was before a living organism. (US 
Senate 1999b: 73) 
Doerflinger was invited as a representative of one of the most influential 
pro-life groups in Washington DC. The concerns of the NCCB and 
other pro-life actors were whether the source of the stem cells, which are 
embryos and organisms, are destroyed or not. They claimed that this was 
also the concern of the existing ban, and that they therefore were sup-
ported legally. When the Department of Health and Human Services, 
and its general counsel Harriet S. Rabb, shortly after the hearing reinter-
preted the ban and drafted guidelines for federally funded hESC research 
this was opposed on legal ground not only by Republican congressmem-
bers, but also eight Democrats in the House of Representatives. Accor-
ding to the totally 70 congressmembers the new interpretation ”would 
violate both the letter and spirit of the Federal law” (Wade 1999b); the 
existing ban was the legal hindrance for using taxpayers’ money for 
hESC research. The guidelines were not put into full use before the 2000 
election, when they became an issue. George W. Bush promised to re-
verse the legal ruling by Rabb if he became President (Taylor 2001a).  
                                     
67   Derivation is the process of pulling out the stem cells from the inner cell mass 
of the blastocyst/embryo. See Introduction: Figure 1, the arrow between step 
3 and 4. 
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 These disagreements about the existing ban point to the funneling 
aspect of the coordination process. Because of the fiscal and legal means 
of the Federal administration the latter may force actors. As already 
noticed (above) this is one of the features of governments. It may be 
used or not. Not only can they force actors through various means but 
such strength may also force other actors to react “bivalently”, to either 
accept or reject the attempted coordination. As predicted from the OPP 
model Doerflinger and the 70 congressmembers play this role and reject 
the coordination. In so doing they say something about how the federal 
means were put (or attempted to be put) to use. Under the Clinton ad-
ministration some actors reacted to what they saw as a funneling at-
tempt. Among them there was an already existing understanding of what 
was allowed and what was prohibited. The suggestion to fund hESC 
research confronted many actors’ understanding of embryo research; an 
understanding that, except for the legal aspects already treated, also in-
cluded moral issues.  
 Doerflinger, together with other actors representing pro-life views, did 
not accept ethical guidelines for something that they found wrong in the 
first place: the use of embryos in research.68 Senator Brownback expres-
sed this view in the hearings in 2000. Brownback identifies embryos as 
humans. His example is the holocaust: 
You had the Nazis in World War II saying, of these people, they are going to 
be killed. Why do we not experiment on them and find out what happens 
with these experiments? They are going to die anyway. 
Senator SPECTER. But they were living people unlike the embryos. 
Senator BROWNBACK. These are living embryos. These are living embryos. 
And they are being treated in this case as property. 
Senator SPECTER. But the people whom the Nazis experimented with in the 
abhorrent way in the holocaust were living. 
Senator BROWNBACK. These are living embryos. You are taking living 
embryos. (US Senate 2001: 30)  
The moral objection to federal funding of hESC research articulated by 
Dickey, Brownback, and Doerflinger was based on their views on the 
embryos. Whether moral or legal arguments, they all concern the OPP. 
Doerflinger, Brownback, Dickey and others rejected the attempt to open 
the federal resources for hESC research and thereby draw all taxpayers 
                                     
68   See also David Prentice in US Senate 2001:61ff. 
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into supporting it. Just as in other OPP cases actors are given an either-
or choice, to accept or reject the funneling from the central actors, in this 
case the Federal administration. The opponents of federally funded hESC 
research have confirmed the centrality of the Federal administration and 
its attempted legal and moral funneling. Together with the attempted do-
mination, these two aspects reinforce the resemblance between hESCs in 
USA 1998–2001 and other cases of OPP.  
Alternative pluripotency  
Doerflinger devoted most of his time in the first hearing, in December 
1998, to the legal and moral aspects (US Senate 1999b: 73). While those 
aspects responded to the funneling and central actor propelling the at-
tempted domination (the Federal administration), the third line of argu-
ments addresses the hESCs and stem cell science. In the first hearing 
Doerflinger briefly mentioned alternatives to hESCs. In his next appearan-
ce, three months after the first hearing, the alternative had increased in 
importance for him. hESC research is not necessary to achieve the 
sought-after therapeutic potential, he now maintains.  
This subcommittee has now held three hearings on one narrow avenue of 
research, precisely the avenue that raises the most obvious moral and legal 
problems, so far to the exclusion of all other alternatives, even when those 
avenues may be more promising. The use of adult stem cells, for example, is 
said to promise the complete avoidance of the tissue rejection problems that 
Dr. Varmus has noted still need to be solved using embryonic cells. I would 
urge the subcommittee to expand its vision, to explore the alternatives that 
will advance medical progress and the wellbeing of patients without demea-
ning human dignity. (US Senate 1999b: 132) 
Adult stem cell (ASC) research is proposed as an alternative that may be 
more promising than hESC research. His appeal is supported by findings 
reported in Science and discussed in major papers like The Washington Post 
and The New York Times. Doerflinger refers to cells from the bone mar-
row: 
Their versatility was recently found to be even greater than once thought. For 
example, given the right environment bone marrow cells can be used to 
regenerate muscle tissue, opening up “a whole avenue of potential therapies 
that didn’t exist before” for muscular dystrophies. (US Senate 1999b: 50) 
In this case the authors believed that the cells responsible for muscle re-
constitution were a species of multipotent mesenchymal stem cells (Ferrari 
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et al. 1998: 1530). The bone marrow is merely one tissue of the adult 
body that hosts cells that seem to have multi- or pluripotent abilities. 
Papers from 1998 and onwards in high profile journals (Science, Nature, 
Cell) accounted for a new kind of experiment. In these papers research 
groups marked and traced cells injected into an alien tissue. The conclu-
sions and interpretations pointed to a hypothesis about somatic cell de- 
and transdifferentiation and an increased plasticity of specialized stem 
cells.69 Doerflinger again: 
An adult body cell can be “de-differentiated” surprisingly easily and regressed 
all the way back to a stage at which it can provide the nucleus for a new 
developing embryo. The question is: Can this regression be done to a point 
short of this, so an adult cell becomes the basis for cells that are like embry-
onic stem cells but never came from an embryo? (US Senate 1999b: 50) 
Doerflinger’s answer is that there is enough scientific evidence pointing 
in that direction. There are scientific reasons for not allowing federal funds 
for hESC research.  
Independent entities 
The legal and moral concerns responded to the funneling of a central 
actor, the Federal administration, and thus confirmed my use of an OPP 
model for understanding the sociotechnical reality of hESCs in the USA 
1998–2001. However, Doerflinger’s appeals to alternative stem cells do 
not fit the OPP, at least not right away. There are three implications of 
the articulations of alternative stem cells and alternative pluripotency. 
One concerns the visions of a USA transformed thanks to pluripotent stem 
cells and federal intervention. Another concerns the character of the Fe-
deral administration and its relationship to hESCs. A third one concerns 
the stabilization of hESCs aside from their association with the Federal 
administration. The pluripotent visions, the Federal administration, and 
                                     
69   These phenomena were hypothesized partly because of the success with the 
cloned sheep Dolly, Wilmut et al. 1997. In the creation of Dolly a somatic cell 
(from the udder of Dolly’s genetic twin/mother) functioned as a nucleus in a 
denucleated egg. The somatic cell proved to have an ability to instruct the re-
sulting cell (egg and nucleus) into becoming a seemingly normal sheep em-
bryo; i.e. sufficiently normal for it to develop to term including the differen-
tiation of all cells in a newborn lamb. A somatic cell thus displayed an unex-
pected versatility, raising hopes for the pluripotency of adult cells. 
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the hESCs are all much more independent than the classic OPP cases 
predict.  
Pluripotent transformation   
A first implication of Doerflinger’s objections is the commonalities be-
tween the claims about alternative stem cells and the claims about hESCs. 
In fact there are shared commitments in the opposing claims about the 
best stem cells. Just like the supporters, the opponents articulate a pluri-
potent transformation. Pluripotency and its effects are not questioned 
per se. hESCs are also not questioned per se, only the appropriateness of 
federal funding for this specific stem cell. The importance of transplantation 
therapies based on pluripotent cells is sometimes questioned, but the ar-
guments drawing on adult stem cells hinge on the very relevance of such 
therapies and the role of the federal government. By referring to alterna-
tive stem cells with equal or almost equal capacities to those of the 
hESCs, the pluripotent transformation may be possible with federal funds. 
There is still the crucial role of the Federal administration, but the pluri-
potent transformation of the USA does not stand or fall with the hESCs. 
This is an odd implication with respect to the OPP suggestion. In the 
classic ANT cases whole networks have been at stake. The scallops said 
no, and the OPP failed. The doctors said no, and they had to be enrolled 
in order to enable the total Pasteurization of France. Here, the hypothe-
tical chain from pluripotent cells, to transplantation therapies, to patients 
all over the USA and the world, via the Federal administration, is dis-
sociated from the hESCs. The latter are said to be merely one of several 
means to achieve the new medical treatments and their far-reaching con-
sequences for many Americans. hESCs are one kind of stem cells, but 
not necessarily the stem cells of America.  
The Federal Administration 
While the first implication concerned the independence of the pluri-
potent transformation, the second implication relates to the indepen-
dence of the Federal administration. Just as in the Pasteurization of 
France the coordination of actors in the hESC case is focused on a cen-
tral actor with funneling capacities. In Latour’s case the centrally organi-
zed coordination is dependent on an entrepreneurial activity in which 
nonhumans and humans (microbes and Pasteur) are wed to each other. 
The authority of the latter is entwined with the significance of the for-
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mer. Thus in this and other OPP cases the authority and centrality of the 
OPP is not an isolated human actor, already in power. The centrality of 
the OPP is the result of successful entrepreneurial action, not an already 
existing feature. One point of the OPP-transformation is that it is achie-
ved by sociotechnical engineering, in which heterogeneous actors are coor-
dinated.  
 Pasteur and the Pasteurians built the new actor-network in close con-
nection with the introduction of the new nonhuman agent, the microbes. 
By introducing a new agent a new source of political power was created, 
Latour claims. Because of their control over these agents Pasteur and the 
Pasteurians became a new political, economic and scientific authority (La-
tour [1984] 1988: 52–58). Attempts to oppose Pasteur and attempts to 
oppose the theory of germs accordingly addressed the same OPP. There 
is no way to separate Koch’s and Peter’s resistance to Pasteur from their 
resistance to his microbes. They simultaneously challenged the authority 
of Pasteur and the “microbic furia”, Latour claims (pp. 29–31). Louis 
Pasteur was “Pasteur of the Microbes” meaning that while he was shep-
herding the microbes they also defined his identity.70 If the microbes had 
been successfully challenged, then Pasteur’s authority would have been 
challenged too.  
 In contrast, Doerflinger’s (and others’) attacks on the exclusivity of 
hESC pluripotency is combined with an acknowledgement of the funne-
ling capacities of the central actor, i.e. the Federal administration. Accor-
dingly, the central human actor is dissociated from the central nonhu-
mans. It is true that the responsibility attributed to the Federal admini-
stration because of the pluripotency of hESCs is an attempt to turn the 
former into a sort of entrepreneur for the latter. Some actors attempted 
this because of the already dominating and funneling capacities of the 
Federal administration. The moral and legal objections also built on this 
fact – that there is a human strategic agency that is not dependent on the 
agency of the hESCs. It may also be true that Presidential and Congres-
sional candidates were in part dependent on the stem cell issue (among 
other issues) in campaigns and elections. In this sense the hESCs may 
have directly affected individual people’s position and influence. How-
ever, even if George W. Bush’s, Al Gore’s or some Senators’ status as ac-
tors was affected by the hESC issue (e.g. in the 2000 Presidential and 
Congressional elections), the power of the Federal administration that 
                                     
70   In a paraphrase of the title of his Chapter 2, Latour [1984] 1988: 59. 
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they sought, was not threatened by the hESCs. As already mentioned, 
the responsibility may have been increased depending on the hESCs, but 
the total federal budget, structure, or existence was not at stake. In 
Latour’s case the identity and agency of Pasteur were close to inseparable 
from the role and agency attributed to the microbes. This does not 
correspond to the hESC case. The authority of the Federal admini-
stration does not stand or fall with the success of hESCs, as did Pasteur. 
With or without hESCs the administration is a central actor in USA.  
 Hence, I suggest that Doerflinger’s objections not only dispute the ar-
ticulations of hESCs as the only way to a pluripotent transformation, but 
also disturb my attempt to apply the OPP model to the 1998–2001 situa-
tion. Particularly the notion of a central entrepreneurial actor whose fate 
is tied to the fate of the negotiations. A political, already existing actor, 
such as a government or Congress, cannot immediately be juxtaposed with 
a scientist or a group of researchers achieving economic, political and 
social transformation through the extension of e.g. laboratory objects. In 
the case of hESC research neither Clinton nor Senators Harkin and Specter 
were entrepreneurs in the Pasteurian sense. They were indeed strategic, 
and central for future stabilization, with the capacity to funnel other ac-
tors into a transformation of medicine and society. A Federal administra-
tion can translate people’s goals by the simple means of money and laws, 
but these capacities were not dependent on, or uniquely bound up with, 
the hESCs. 
 This is an interesting observation considering ANT’s view of actors. 
According to ANT, actors’ identities are defined in networks of other 
entities, by and by, association by association. A main point of case stu-
dies has been that the importance of stated political powers have been 
less powerful than sociotechnical network formations (Callon 1980, La-
tour [1983] 1999). In this case the negotiations presuppose that the Fede-
ral administration is a strong independent actor. It is, however, not an 
absolute independence. Above, it was obvious how a specific responsibility 
for alleviating suffering was ascribed to the Federal administration.  
Human embryonic stem cells 
There were other possible entrepreneurs linked to the hESCs. Thomson 
and Gearhart with their respective co-workers were, together with Geron 
corporation, closest to the stem cells before the public announcement in 
November 1998. In this sense they were entrepreneurs, much like Pa-
steur, the scallops researchers or Hughes’s system-builder Edison. The 
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first scientific articles correspond to Edison’s visions. When Thomson et 
al. published their results in 1998, little of what was claimed about the 
potentiality of hESCs had been realized in laboratories, in clinics, or with 
patients: 
Screens based on the in vitro differentiation of human ES cells to specific 
lineages could identify gene targets for new drugs, genes that could be used 
for tissue regeneration therapies, and teratogenic or toxic compounds. [---] 
The standardized production of large, purified populations of euploid human 
cells such as cardiomyocytes and neurons will provide a potentially limitless 
source of cells for drug discovery and transplantation therapies. Many di-
seases, such as Parkinson’s disease and juvenile-onset diabetes mellitus, result 
from the death or dysfunction of just one or a few cell types. The replacement 
of those cells could offer lifelong treatment. (Thomson et al. 1998: 1146f) 
Three “coulds” and one “will” in four sentences of this quotation say 
something about its vision-casting character. James Thomson was the lea-
ding scientist in the team and he was in this sense an entrepreneur. He 
found the hESCs too important to not try to derive and culture them 
(Whitaker 2002). Just like Pasteur Thomson has had a unique consul-
tative role in questions about the nature of the stem cells. In panels and 
hearings he has been the obvious “representative” for the cells. In this 
sense he has been defined through the hESCs, and he has “shepherded” 
them, but not to such a large extent outside of the culture dishes, as did 
Pasteur. He has not pursued apologetics on behalf of the cells. Geron con-
tacted him. He has consistently answered to questions about the hESCs, 
rather than enrolling other actors himself. In these respects Thomson is 
no entrepreneurial builder of actor-networks.  
 Geron Corporation consisted of entrepreneurs who saw the financial 
potential of hESCs. Just like Pasteur, Geron’s existence is interdependent 
with the success of hESCs. Initially, they tied the cells exclusively to the 
company and tried to earn a profit on the distribution (Thomson 2002). 
This strategy of funneling actors through Geron was however limited 
and later changed. In Senate hearings they advocated public involvement 
in the research, claiming that private resources would not be sufficient. 
Also the procedures were not specific enough to keep the hESCs as an 
exclusive property of Geron.71 Other laboratories in the USA and else-
where were producing their own hESCs.  
                                     
71   Cells are usually not patentable per se. In this case Geron only had the owner-
ship of the actual hESC lines, not the procedures or the specific kind of cell. 
 
 
 
97 
 Neither Thomson nor Geron alone thus took on a Pasteurian role in 
the stabilization of hESCs. They were also only a few compared to the 
many that immediately appeared and articulated the cells. Patient organi-
zations, ethicists and politicians argued for the benefit of cells for society 
as a whole. As early as a month after the announcement, so many and di-
verse actors were arguing for their own particular uses of the stem cells. 
The visions in November 1998 did not come from scientists or corpora-
tions alone. No specific group of people became the entrepreneurs or 
the representatives of the cells.  
 The Federal administration was central but not an entrepreneurial ac-
tor dependent on, and driving, the stabilization of hESCs. Clinton and 
Senators quickly responded to Thomson’s and Gearhart’s articles, but to 
respond is not to be a primum movens behind the stem cells. Thomson and 
Geron had such entrepreneurial functions, but the first didn’t sell his cells 
and the second did sell them, but ultimately did not successfully claim 
exclusive rights to the future fate of the cells. Around the world and 
around the USA the hESCs popped up in laboratories independently of 
Geron. The absence of any major representatives or entrepreneurs of the 
cells, and the absence of any site or group exclusively claiming the rights 
to them co-incide with a third implication of Doerflinger’s objections in 
the Senate hearings: The hESCs at this time were already somewhat in-
dependent of any specific actor. Even the fiercest opponents of hESC 
research did not question the scientific qualities of the hESC reports or 
the existence of the cells. Legal, moral or scientific concerns could be 
used to oppose the federal funding, but nobody questioned the quality of 
hESC research. Next to – not together with – the Federal administration, 
the most central actor in the whole situation may well have been the 
hESCs themselves.  
 Above (in the first part of the chapter and in Figure 5), the entities of 
the sociotechnical network were few and tightly fitted to each other in 
order to achieve the pluripotent transformation. In this section and in 
the below Figure 6 the network is more complex. The entities are not de-
pendent on one association, but exist somewhat independently.  
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The hESCs, the pluripotent transformation, and the Federal administra-
tion are affected by their prospective associations. However, the network 
as a whole does not stand or fall with the success of any specific point of 
passage. In this sense it was not a an OPP coordination. In other re-
spects it was.  
 I have related the case of hESCs closely to the classic OPP case stu-
dies, as if the latter were theoretical black boxes to take down from the 
shelf. Although the hESC case does not fit these cases exactly, important 
traits in the coordination of entities have been brought up. The nego-
tiation of federal funding of hESC research bore some similarities with 
the classic OPP cases. Actors articulated a pluripotent transformation of 
America reminiscent of the pasteurization of France: a seamless vision of 
federal funding, stem cell research, applications, patient needs, and eco-
nomic effects. Through one center, consisting of the combined agencies 
of hESCs and the Federal administration, a number of actors can be fun-
neled by the means of money, laws and pluripotent promises. Oppo-
Figure 6: Increased complexity of associations 
between independent entities. 
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nents confirm the funneling character of the coordination. These are all 
OPP-like traits. However, opponents also point to the seams in the cloth: 
the independence of the Federal administration, the hESCs and the envi-
sioned transformation. Unlike the classic cases the new actor-network 
attempted through the OPP does not stand or fall in its entirety. Specific 
associations are negotiated, but not a whole network. No specific group 
had their identity or fate defined exclusively in relation to the agency and 
fate of the cells, as in the classic OPP cases. There was no center, or in-
stead, there were many centers.  
The failure of the OPP 
Even when accepting an OPP-like cordination a last empirical and ana-
lytical blow to the suggested parallell was dealt by George Bush’s deci-
sion at the end of the selected period, 1998–2001. In the first part of the 
period Clinton was approaching the end of his term and a new election 
was coming up in 2000. The new NIH guidelines for federally funded 
research on hESCs were not put to work on the eve of the election. 
hESC research was thus not federally funded during the Clinton period. 
George W. Bush promised to make a decision when he was elected Pre-
sident. On August 9, 2001 he signed an executive order to allow federal 
funds to some hESC lines, but not all. hESCs were thus not endorsed in 
the wholesale manner suggested by the proponents (and the opponents) 
of federal funding. The hESCs were kept as one option to be investi-
gated but not in a full scale as the option for research leading to trans-
plantation therapies. Only some hESC lines could be funded and no new 
hESCs could be produced with federal support or even in buildings thus 
funded. Bush used his agency to associate with hESC research, but only 
partially, and without the total authorization hoped for by supporters. 
Adult stem cells were the main option, receiving more than 8 to 10 times 
more than hESC research in the following two budgets (for 2002 and 
2003).72 Federal funding of hESCs was envisaged as a funneling of actors 
into a dominating network thereby authorizing and stabilizing the hESCs, 
but this did not happen, because of Bush’s decision.  
 The OPP-like traits of the coordination attempt – i.e. a funneling and 
dominating coordination – did not empirically succeed in 2001 or later (in 
2006). Bush’s decision meant that hESCs did not achieve a dominating 
position in combination with a centralized and funneling coordination of 
                                     
72   One reason for this was the lack of hESC research proposals.  
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actors. Empirically, the end of the story was not an OPP. In the analytical 
respect, Bush’s decision added to the discrepancy between OPP cases 
and the coordination of actors in the hESC case. If this had been an 
OPP in the sense described by Callon, Latour, and Law, the hESC coor-
dination would have stood or fallen with the success, but it didn’t. Yes, 
the federal funding was important, but nothing in the later history indi-
cates that hESCs will disappear because of the merely partial support 
from the Federal administration. In 2003 24.8 million federal dollars we-
re used for hESC research, which scarcely implies their disappearance. 
Linda Hogle has shown how new organizational forms, including part-
nership between state government, private enterprises and foundations, 
have emerged strongly, equaling or exceeding the federal support, to en-
able more research on hESCs (Hogle 2004). Thus, the sociotechnical rea-
lity of hESCs cannot ultimately be captured empirically or analytically in 
terms of the OPP model, at least not as this has been used by Callon, La-
tour, and Law.  
Summary 
This chapter has focused on the negotiations of federally funded hESC 
research. A number of OPP-like traits have been found in these negotia-
tions. According to Harkin, Specter, Hatch, Okarma of Geron, and others 
the hESCs are the saviors for almost every (or at least every second) 
American and are thus the Stem Cells of America. Bringing out the domi-
nation efforts are one result from my application of the OPP model. 
Another one is the occurrence of funneling, due to the powerful means 
of the Federal administration as a central actor. These aspects were there, 
although without the marked entrepreneurial traits. 
 However, there have been three negative results of the attempt: Firstly, 
there is no Pasteur of the hESCs. The coordination is not explicable with 
reference to a central entrepreneurial actor whose fate and role are irre-
versibly bound up with the cells. Although the Federal administration (and 
individual politicians) and its responsibility (as articulated by some ac-
tors) are affected by the hESCs, its centrality and general capacities are 
independent of any particular stem cell. Secondly, the envisioned pluri-
potent transformation does not stand or fall with the success of hESCs. 
Proponents and opponents of federally funded hESC research endorse 
transplantation therapies of pluripotent stem cells. Thirdly, as the oppo-
nents display, and the later history too, the quality of hESC research, the 
existence or capacity of the cells are not threatened per se because of the 
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failed attempt to establish domination. More than an either-or, the socio-
technical reality of hESCs is of a relative kind. But, not only is it relative, 
it is also multiple and pluralist in virtue of divergent and contradictory arti-
culations. 
 Initially in this chapter the first research question of the study – to 
understand the sociotechnical reality of hESCs – was put forward in 
terms of the degree of stabilization, the mode of coordination, and the 
distribution of agency. After my attempt to apply the OPP model the 
reality of hESCs is marked by (at least seemingly) contradictory features. 
Firstly, the hESCs’ degree of stabilization: The stem cells do exist and 
link up to other (non-federal) actors without totally dominating or totally 
failing, as conditioned in the OPP model. Simultaneously, they are invol-
ved in a total pluripotent transformation of the USA, although not ne-
cessarily as the only and exclusive stem cell. How could the hESCs’ de-
gree of stabilization be mapped while paying attention to the relative exis-
tence and the total transformation at stake? Secondly, the stabilization of 
hESCs is not tied to the performance of any central and entrepreneurial 
human actor, as in the classic OPP cases. All the while the funneling 
capacity of the Federal administration is there and is a non-dismissable 
factor in the negotiations in hearings and elsewhere. Understanding the 
coordination of hESCs will have to account for the non-entrepreneurial 
features and the funneling potential of the Federal administration. Third-
ly, in the understanding of the coordination, the agency of humans and 
nonhumans is distributed much more and in much more complex pat-
terns than in the classic OPP studies. There is no central site to go to in 
which a human agency is at work master-minding other actors including 
nonhuman ones. In addition, actors disagree about the agency of nonhu-
mans, struggling over which cell is most pluripotent.  

3.   Outlining a Boundary Objects Coordination: Diverse 
Actors and Multiple Uses  
Introduction 
Even if the Federal administration was one important actor of the reality 
of hESCs 1998–2001, it was evidently not the only actor relating to the 
cells. The funding at stake certainly framed many of the interactions, but 
as we saw after Bush’s partial commitment to fund hESC research there 
was more to stem cell research than this relationship. This chapter is to a 
large extent based on the same source material, but instead of focusing 
on the articulation of hESCs and the Federal administration the attention 
is focused on the associations already established, already there. An actor 
negotiating federal funding is not only attempting to stabilize a specific 
linkage between hESCs and the administration, but simultaneously arti-
culating his/her relationship to hESC research. This chapter asks about 
the sociotechnical reality of hESCs in relation to the latter, existing asso-
ciations rather than the former, attempted ones. 
 The attempts to understand the federal negotiations as an OPP effort 
narrowed down and specified some characteristics of the political and 
public dynamics of hESCs between 1998 and 2001. The stabilization is 
not total, but relative and partial. Funneling is part of the mode of coor-
dination, but there is no entrepreneurial center exclusively linked to the 
stem cells. With respect to agency no human is masterminding everybody 
else and the relative capacities of nonhuman actors (the hESCs compared 
to adult stem cells) are disputed. Alternative (or complementary) models 
are needed to capture the sociotechnical reality of hESCs, 1998–2001.  
 The first part of this chapter continues the previous chapter’s obser-
vations of relatively independent entities by examining the many diverse 
actors that were in fact linked to hESC research. The second part asks: 
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What is the nature of this reality, of these linkages between actors? How 
are the actors coordinated?  
A relative reality 
It is true that in many articulations the hESCs, their pluripotency and a 
possible pluripotent transformation were allegedly dependent on federal 
funding. The same articulations, however, are also traces of an already 
existing actor-network of hESCs. Although the advocacy for federal fun-
ding certainly influenced these linkages they also have a life of their 
own.73 As much as possible, the Federal administration as the crucial link-
age is now left out of the picture.  
 What is conspicuous in the established linkages to hESCs is the diver-
sity of actors and their commitments to the stem cells. During the period 
1998–2001 scientists, corporate representatives, patients, bioethicists, po-
liticians and administration officials testified in Senate hearings. It is pos-
sible to see two things in these articulations. Their references to the hESCs, 
pluripotency, embryos and transplantation therapies or other uses, may 
be of an “absolute” nature, i.e. as being certain, indisputable or urgent. 
However, the articulations they perform by linking to the cells are not as 
absolute, meaning that they hope for effects and in some cases transfor-
mation, but can either manage without hESCs or do not commit themselves fully 
to the research. This last clause is important, since it contradicts the “new 
reality” articulated in their reference to the hESCs and a pluripotent trans-
formation (see Chapter 2). Articulating stem cells makes them real in 
relation to other actors or elements, but this can happen in two ways: 
Both by actors’ references to the cells and through their linkages to them.  
Scientists 
The first publications on successful production of hESCs came from 
John Gearhart’s group at Johns Hopkins (Shamblott et al. 1998), and 
James Thomson’s group at the University of Wisconsin (Thomson et al. 
1998). Here the authors accounted for the “derivation” and culture of 
human pluripotent embryonic stem cells, which form the basis for sub-
sequent research on the cells. There is no need to state that the two 
                                     
73   Since Bush’s decision in 2001 this has also been apparent. States and private 
initiatives have tried to increase hESC research without Federal support. In 
the state of California, citizens, in a 2004 referendum, approved a $3 billion 
funding of hESC research over 10 years, Finkelstein 2004. 
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groups at Johns Hopkins and the University of Wisconsin were strongly 
linked to the hESCs. An important question is, however, to what extent 
the cells were successful outside of the two laboratories.  
 The articles, like most scientific articles, point towards other scientific 
linkages. Most of the papers are devoted to the technical details and re-
sults of experiments. Each compound or substance that is used, con-
nects to companies, earlier research and other laboratories. Just the fact 
that the papers had been published in high-prestige journals was a recog-
nition. However, many published papers are never further quoted or 
picked up by others. In this case other scientists did in fact endorse the 
stem cells and even produced them on their own. Thomson and Gear-
hart were the first – but not alone (Freed et al. 1999, Pesce et al. 1999, 
Smith 2001a).  
 A year later, the journal Science hailed stem cells, including human em-
bryonic ones, as the breakthrough of the year (Vogel 1999).74 The Ame-
rican Association for the Advancement of Science (AAAS) endorsed 
hESCs (Chapman et al. 1999) and two years later the NIH issued a re-
port on hESCs in which 50 stem cell scientists were interviewed and 
1.200 papers were reviewed (US DHHS 2001b). 
 At the same time, in early summer 2001, the National Academy of 
Sciences gathered a workshop on stem cells in which scientists explained 
the value of hESCs (Workshop on Stem Cells and the Future of Regenerative 
Medicine 2001). Both the report and the workshop (and its subsequent 
publication) were hugely supportive of hESC research, not least in 
relation to adult stem cells. In all of these reports and conferences 
scientists expressed their support for hESCs. It is, in fact, hard to find 
resistance to the hESCs among stem cell scientists. They may advocate 
federal funding or not, but they do hail the cells as a scientific achieve-
ment. How about non-scientists?  
Business 
Many companies were (and are) engaged in hESC research. Other scho-
lars in the STS community are specifically engaged in mapping how the 
corporate sector is re-structuring and transforming in order to adopt 
stem cell technology (Hogle 2004, Waldby 2004). Two of the companies 
should be mentioned here since they were the most visible initially and 
were invited to the hearings. Other companies responded to the possibi-
                                     
74   The designation concerned stem cells, both human embryonic and adult. 
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lities in hESC research, for instance through the Biotechnology Industry 
Organization (US Senate 1999b: 104).  
 Advanced Cell Technology (ACT) had appeared a lot in relation to clo-
ning technologies. Its CEO, Michael West, had driven much of Geron’s 
investments in stem cell technology before coming to ACT. Geron Cor-
poration was a biotech company that had specialized in the derivation of 
hESCs and had vested interests in both Thomson’s and Gearhart’s pro-
jects. The importance of Geron was partly due to the restrictions put on 
human embryo research in the USA. Because of the restrictions on the 
federal funding of human embryonic research, Thomson had to set up a 
whole laboratory separate from his usual facility. At the time nothing 
from the federally financed buildings or materials could be utilized for 
embryonic research. With financial support from Geron Corporation, and 
an alumni foundation at the University of Wisconsin (WARF), Thomson 
did the hESC work in the parallel facility. Gearhart’s group also worked 
with funds from Geron. Without the support from Geron the actual 
work on hESCs would at least have been delayed. The corporate linkages 
are more dependent on the success of hESCs than the others. However, 
they were established without federal support, and continued to be so. 
The very coming to being of hESCs bears witness of corporate interest 
in the cells without the total endorsement from the administration. 
Patients 
Among patient advocates the most famous examples may be Michael J. 
Fox and Christopher Reeve. Fox suffers from PD and Reeve was paraly-
zed because of a horseback riding accident, and died in October 2004. 
These patients related to the hESCs in a particular way. By already being 
icons of successful persons and famous TV and movie stars they are 
familiar to people (with or without diseases) watching TV and movies. 
Many people know them and may be more easily moved by their situa-
tion and their advocacy. By appearing as patients and suffering and advo-
cating hESC research Fox and Reeves not only linked as individuals but 
probably linked many in the public to the research.  
 Both of them inspired, headed and donated to research foundations, 
the Christopher Reeve Paralysis Foundation and the Foundation for Par-
kinson’s Research, respectively. They also gathered together other organi-
zations to enforce their demands for federally funded hESC research. 
When Reeve testified in the hearings in 2000 he did so with the support 
of more than 100 professional and patient organizations (US Senate 2001). 
 
 
 
107 
Other patient representatives who supported hESC research represented 
the Alliance for Aging Research, the Juvenile Diabetes Research Founda-
tion, Project ALS, and Paralyzed Veterans of America.  
 Except in two cases the patients in stem cell hearings supported the 
research completely. In many cases their lives (allegedly) hinged on fede-
ral support of hESCs; Michael J Fox was one of these. However, when 
he appeared in a hearing on Parkinson’s disease he did not even mention 
stem cells (US Senate 2000). In one setting hESC research was necessary 
and urgent. In another setting, although still a context of negotiation, hESC 
research was invisible. There are other examples of how various modes 
of articulation co-exist. 
 The previous chapter accounted for Patients’ CURe and their activities 
in gathering many of the patient organizations below one lobbying roof. 
For this purpose the coalition presented estimates of large numbers of po-
tential patients. Virtually every American was somehow to be affected by 
hESC research. Interestingly, CURe also wanted to combine these great 
expectations for every other American with ‘tempered optimism’. 
In general, the patients and their advocates who are active for CURe display 
tempered optimism when it comes to appraising the chances of anyone’s 
health benefiting soon from applications of stem cell research. (Perry 2000)  
Many of the organizations had existed for several decades, e.g. the Ame-
rican Diabetes Association for six decades (American Diabetes Associa-
tion 1990), JDRF for three decades (US Senate 1999b: 100). They have 
million-dollar budgets and have been funding and doing research since 
long before the hESCs arrived. Although zealously arguing for hESC re-
search their research portfolios were not dependent on hESCs. They we-
re strong lobby actors, but also somewhat independent of federal fun-
ding. There is a doubleness between their articulations and their actual 
linkages (which are also articulations). 
 In spite of the massive mobilization (34 patient organizations coope-
rating) others did not want to join. Soon after the coalition was founded 
the American Cancer Society withdrew its sponsorship, either because of 
Catholic pressure or due to families who returned pledges, or both (Wa-
de 1999a). There were also examples of individual patients who distan-
ced themselves from hESCs (US Senate 2001: e.g. Owen, 23ff and Hea-
gy, 93ff). Not all patients or patient organizations were enthusiastic about 
hESCs. “Patients” was not a homogeneous category. Putting together 
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Patients’ CURe was a part of a homogenizing movement for the purpose 
of putting pressure on law-makers (Perry 2000).  
Bioethicists  
In the hearings Arthur Caplan, Eric Meslin, and Glenn McGee suppor-
ted hESC research. Elsewhere a large community of bioethicists also en-
dorsed the stem cells (American Journal of Bioethics 2001, Green 2001, 
Holland et al. 2001). Another actor, also appearing in the hearings either 
indirectly or directly through consultation, was the National Bioethics 
Advisory Commission (NBAC). James Childress, commissioner on NBAC, 
testified. After its report was issued the Commission functioned as an 
aggregated actor, subsuming 17 bioethics professionals and numerous con-
sultants in one document and one set of recommendations (Shapiro et al. 
1999). It is one striking example of how a lot of bioethicists supported 
federally funded hESC research in one way or the other, and vice versa, 
how bioethicists were sustained by the controversy.  
 Mary Leinhos has claimed that the NBAC was set up much like a boun-
dary organization, making room for negotiations of the boundaries be-
tween science and politics, and between philosophical ethics and public 
policy (Guston 2000, Leinhos 2005). One of her observations is that the 
NBAC’s recommendations largely reflected the views of the scientific 
community and the Administration and less those of pro-life opponents 
(which could have to do with the fact that the Commission was 
appointed by President Clinton). According to Leinhos the NBAC re-
commendations served the mutual interests of science, government, and 
their mediators (the commission, and the field of bioethics), and specifi-
cally the latter by continuing the call for their services, and legitimating 
the bioethics concepts and techniques deployed (Leinhos 2005). 
Politicians and temporality 
With respect to politicians, dissociation from the issue of federal funding 
is impossible. However, some linkages to politicians, in spite of the sta-
kes of federal funding, did contribute to the relative reality of hESCs and 
not the dominating versus avoiding coordination displayed in the pre-
vious chapter. 
 The support from some, such as President Clinton and the Subcom-
mittee Senators Specter and Harkin, was clear from the previous part of 
this chapter. They followed a pattern of polarization between Democrats 
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and pro-life Republicans. However, not all of the pro-life congressmem-
bers were against the research and refused to give up their pro-life iden-
tities. In a letter sent to George W. Bush in 2001, Orrin Hatch pointed 
out these associations between pro-life Republicans and hESC research.  
Mr. President, once you have considered the complexities of the questions at 
hand, I hope you will conclude, as other pro-life, pro-family Republicans such 
as Strom Thurmond, Gordon Smith, Connie Mack, and I, that the best course 
of action is to lead the way for this vital research. (Hatch 2001a) 
Hatch was thus not alone. Except for the Senators mentioned in the 
quotation Nancy Reagan, former First Lady, wrote to Bush in support of 
hESC research. Senator Bill Frist was considered an important suppor-
ter, partly because of being one of the few in Congress with medical trai-
ning (and partly because of being considered close to the President) (US 
Senate 2002: 14–18, Smith 2001b, Taylor 2001b). Below is Frist’s sugges-
tions for hESC research policy in early summer 2001:  
1. a ban on the creation of embryos for research purposes;  
2. the continuation of the present ban on federal funding of the deriva-
tion of embryonic stem cells; 
3. a ban on all human cloning; 
4. an increase in adult stem cell research funding; 
5. funding for embryonic stem cell research only from blastocysts that would 
otherwise be discarded; 
6. a rigorous informed consent process; 
7. a limited number of stem cell lines; 
8. a strong public research oversight system; 
9. ongoing, independent scientific and ethical review; and 
10.  strengthened and harmonized fetal tissue research restrictions. 
(Frist 2001: 172) 
With this manifesto Frist articulated support for hESC research without 
giving in to a domination attempt. It was a moderate endorsement. The 
suggestions were echoed in Bush’s August decision partially committing 
himself (and the Federal administration) to hESC research, but on strict 
conditions. Just because the administration ultimately did not fully embrace 
all hESC research with federal funds, they did contribute to a relative 
reality. In comparison to the domination attempt these partial endorse-
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ments are especially interesting. The partial acceptance from Bush and 
Frist – although concerned with federal funding – do not ‘fit’ into the 
domination attempt, since they denied giving the research a blank check 
(to perform the pluripotent transformation).  
 There is a temporal aspect to the pro-life support for hESC research 
that must be noted. The domination attempts and the alternatives were 
there almost from the beginning of the period, in 1998, which is true for 
most of the linkages to the actors presented above. However, the group 
of pro-lifers mentioned by Hatch, and others “came out” as the time 
went on, until August 2001, when Bush made his partial commitment to 
the research. In this sense hESCs were “more” a relative reality by Au-
gust 2001 than in 1998, when pro-life politicians had still not come out 
in partial support. Their “coming out” constitutes a temporality in a 
situation that has so far provided two diverging patterns of coordination, 
one polarized, either-or, and another more relative, e.g. both pro-life and 
hESCs. So far, the most tangible dynamics is the slight tilting, no radical 
shift, from an OPP-kind of coordination to partial connections, a more 
relative reality.  
 Many other actors also supported hESC research. The purpose and 
claims here are not all encompassing, but meant to indicate the diversity 
of actors contributing to a relative stabilization of the stem cells. This 
stabilization differed significantly from the articulations in the previous 
chapters by prevailing even though the sought-for domination were not 
immediately realized, and by in practice being less unconditional. Patients 
were a big support, but paradoxically the size of organizations also indi-
cated that they had been thriving before and without hESC research. Pa-
radoxically the corporate interest in the stem cells and in federal funds 
(see the previous chapter) proved a relative stabilization that did not hinge 
on the administration’s decision. Pro-life politicians’ partial commitments 
also contributed to a relative reality of hESCs and not a dominating, 
either-or kind. There was more to the stem cells than the attempt to 
achieve federal funding and set in motion a “pluripotent transformation 
of America”.  
A boundary objects coordination  
After observing these many associations to the hESCs, the question is 
how this coordination of diverse actors should be understood. None of 
the supportive actors could (or in the case of Bush chose to) themselves 
funnel all the other actors. None of them were themselves in the center 
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or could claim to be the sole “source of the general movement” (Latour 
1987: 118). So was there any “source” or cause of the coordination? Ac-
cording to the actors their associations were due to the hESCs. They ex-
plained their linkages to the hESCs with reference to the hESCs.  
 Should the actors be taken at their word? 75 In the absence of any cen-
tral human entrepreneurial actor the actors’ articulations are worth a try. 
In addition actors’ explanations to some extent converge with Star and 
Griesemer’s case study of the Museum of Vertebrate Zoology (MVZ) (Star 
and Griesemer 1989). In the MVZ case diverse actors collaborated with-
out agreeing about every detail of the situation, i.e. without accepting the 
same translation. The collaboration happened through the flow of cer-
tain objects, “boundary objects”, without any central entrepreneur ma-
king everybody agree. Multiple uses of the boundary objects spoke diffe-
rently to various actors and practices without moving anyone out of their 
path or imposing one single view on the world. The circulating objects 
“did the job” rather than any human. These similarities suggest that the 
diverse actors were coordinated by the hESCs as boundary objects. A 
way to approach the suggestion is to ask what such an understanding 
would imply. 
 The materiality is notable in Star and Griesemer’s approach. Material 
traces bear witness to the coordinating process achieved by the “flow of 
objects and concepts through the network of participating allies and so-
cial worlds” (Star and Griesemer [1989] 1999: 507). Between November 
1998 and August 2001 hESCs existed in culture-dishes in a few labora-
tories. Although the hESCs were successfully linked to other actors and 
uses, they could obviously still not be materially circulated. Materially they 
could not coordinate actors.  
                                     
75   A certain justified puzzlement may arise concerning the following of actors: 
Can the analyst be fooled by this recommendation and start believing the 
actors’ truths? Will the analyst be limited to the actors’ definitions of the 
situation? Yes (to the latter version of the question) and no (to the former 
one). Yes, the analyst has to follow the actors since s/he does not have any 
other-worldly access or capacity. But, no: To follow the actors’ associations 
does not necessarily mean being fooled into believing that this reality is ne-
cessarily the only or the final version of things. The purpose is not to find the 
Truth or prove the actors to be right/wrong, but to see how one or several 
realities are stabilized among actors, without claiming it/them as the final 
answer about reality.  
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 The 1998–2001 situation is marked by coordination on a very general 
level. Initially we are not talking about coordination through the flow of 
the hESCs themselves (they still existed mainly in Thompson’s and Gear-
hart’s laboratories). But, this provokes the questions: In what sense are 
the cells then boundary objects? In what sense do the cells “flow through 
the network of allies”? The materiality of boundary objects should not be 
understood narrowly. Also “concepts”, “platonic objects” or “ideal ty-
pes” are boundary objects that flow through the network.  
This is an object such as a diagram, atlas or other description which in fact 
does not accurately describe the details of any one locality. It is abstracted 
from all domains, and may be fairly vague. However, it is adaptable to a local 
site precisely because it is fairly vague; it serves as a means of communicating 
and cooperating symbolically – a “good enough” road map for all. (Star [1989] 
1999: 518) 
In the above sections diverse actors testified about their uses of some-
thing that they all called “human embryonic stem cells”. Their particular 
reasons shifted, but they all referred to the same word. This is a first 
trace of coordination. The term “human embryonic stem cells” is used in 
communication across a variety of practices, much as Annemarie Mol 
has described the use of the term “atherosclerosis” between groups in a 
hospital: 
But “atherosclerosis” is the word they use when they want to talk to one 
another. The term is a coordinating mechanism operative in conjunction with 
the various distributions. It bridges the boundaries between the sites over 
which the disease is distributed. It thereby helps to prevent distribution from 
becoming the pluralizing of a disease into separate and unrelated objects. (Mol 
2002: 117)  
The term “human embryonic stem cells” thus participated in diverse 
actors’ articulations. However, this is a slender linchpin for making a full 
analogy with the boundary objects of Star and Griesemer. In addition to 
the already mentioned vague qualities, another complementary set of 
characteristics is needed to serve cooperation. 
Boundary objects are both plastic enough to adapt to local needs and con-
straints of the several parties employing them, yet robust enough to maintain a 
common identity across sites. They are weakly structured in common use, and 
become strongly structured in individual-site use. They may be abstract or 
concrete. They have different meanings in different social worlds but their 
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structure is common enough to more than one world to make them recogniz-
able means of translation. (Star and Griesemer [1989] 1999: 509) 
If the hESCs do coordinate actors they should not only be vague and 
weakly structured but also be more constraining and defining (“strongly 
structured”) in individual-site use. There should be more to it than a name 
used by diverse actors. hESCs should be adaptable “to local needs and 
constraints”. One cell should take part in multiple practices and thereby 
coordinate actors. This is exactly what is indicated already in the first 
reports, and was soon reciprocated by other, diverse actors.  
Multiple uses 
While the first part of the chapter outlined some of the actors, this part 
will look at the specific uses that spoke to actors. As early as in the No-
vember 1998 papers in Science and The Proceedings of the National Academy of 
Sciences, the stem cells’ multiple uses had been articulated. The hESCs are 
associated with “outside” actors, i.e. non-scientists. In the abstracts, the 
introductions and the conclusions, the stem cells are said to be suitable 
for certain uses.  
These cell lines should be useful in human developmental biology, drug dis-
covery, and transplantation medicine. (Thomson et al. 1998: 1145) 
Transplantation therapies together with basic research in developmental 
biology (“human embryogenesis”), and drug discovery/screening, are the 
three most frequently mentioned uses in scientists’ accounts. These three 
areas are not only scientists’ concerns. They can be, and are repeatedly, 
linked to many people’s lives. Thomson et al. indicate the linkage from 
the usage in developmental biology to that with people.  
Human ES cells should offer insights into developmental events that cannot 
be studied directly in the intact human embryo but that have important conse-
quences in clinical areas, including birth defects, infertility, and pregnancy loss. 
(Thomson et al. 1998: 1146) 
Developmental biology is usually seen as basic science, as opposed to 
applied, which is regarded as the more user-oriented form of research. In 
Thomson et al.’s paragraph the use of developmental biology does not 
remain within the scientific world. Birth defects, infertility and pregnan-
cies happen to people, not merely to cells or things in a biomedical lab. 
That’s the message.76 In the quote that I used above (p. 96) to display the 
entrepreneurial and prospective character of Thomson’s work, the uses of 
hESCs in drug screening/discovery and transplantation therapies were ex-
plained in several steps. First, the in vitro differentiation of hESCs forms 
a base for screens, which “could identify gene targets for new drugs, 
genes that could be used for tissue regeneration therapies, and teratogenic 
or toxic compounds” (Thomson et al. 1998: 1146). Thomson’s and 
Gearhart’s articles are the first step towards differentiation, which will 
then be useful in the screening performed by companies and in university 
laboratories. In the next step the engineers are connected via their role in 
the “standardized production of large, purified populations of euploid 
human cells such as cardiomyocytes and neurons” (p. 1146f). The 
anticipated result, such as a limitless source of cells, speaks to drug com-
panies and transplantation doctors. And, lastly:  
Many diseases, such as Parkinson’s disease and juvenile-onset diabetes mellitus, 
result from the death or dysfunction of just one or a few cell types. The 
replacement of those cells could offer lifelong treatment. (Thomson et al. 1998: 
1147) 
The beneficiaries of transplantation, we learn, are Parkinson’s and diabe-
tes patients. Lifelong cures are on the line.  
 There are many uses of hESCs implicated in the seminal articles. The 
uses picked out are, however, not arbitrary. Each of the uses appeals to 
other actors, whether scientists or non-scientists. Other scientists, corpo-
rations, bioethicists, politicians and patients did confirm their own need 
of the three uses indicated in the original papers.  
General responses 
The three uses were regularly picked up in many review articles (e.g. 
Odorico et al. 2001, Smith 2001a). Sometimes they were repeated as a 
formula by actors, for example as below in Senator Harkin’s words:  
I want to thank Dr. West for his commitment to a public discussion of the 
ethical implications of stem cells research and to commend Doctors Thomson 
and Gearhart for their groundbreaking accomplishments. From enabling the 
development of cell tissue transplantation to improving and accelerating phar-
maceutical research and development, to increasing our understanding of hu-
                                     
76   The reason that the early developmental events cannot be studied without the 
hESCs is of course that the events usually take place in the womb under 
extremely precarious conditions. 
man development and cancer biology, the potential benefits of this work are 
awe-inspiring. The cell lines they have isolated and kept alive could reduce the 
demand for organ donors and pave the way for many life-saving therapies. 
(US Senate 1999b: 2f) 
The NIH issued a graphic illustration in order to explain the use of hESCs, 
which confirmed the three uses (Figure 7).77  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The stem cells are in the center and can be turned to a number of uses, 
via tissue differentiation. The hESCs are doing the job, coordinating the 
actors because of their plasticity and capacity to adapt to local needs. 
 Six months after Gearhart’s and Thomson’s respective reports Cells 
Tissues Organs featured a special issue on the use of ES cells (human and 
nonhuman) as a developmental model. In one of the papers an illustration 
(Figure 8) described the uses and technologies that were linked to pluri-
potent embryonic stem cells (ES) or embryonic germ (EG) cells (Prelle 
et al. 1999).  
 
                                     
77   It is now not available on the NIH web site. It has been used in (at least) two 
other presentations of hESCs, Lewis 2001, Terpstra 2002: 13.  
Figure 7: Illustration of three uses of pluripotent stem cells (NIH 1999). 
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Figure 8: The uses of stem cells (Prelle et al. 1999).  
(By courtesy of S. Karger AG, Basel.) 
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Just as in the NIH illustration the path from ES cells to uses is 
articulated. This time the three uses of hESCs are one small part of a 
larger map. Apart from the uses for humans the arrows lead to applica-
tions in animals. 
 As the stem cells flow from one application to the next, specific tech-
nologies are included, such as gene therapy and nuclear transfer. Although 
the latter picture is more complex they are both articulations of three 
uses that follow from the hESCs: transplantation therapies, drug testing 
and developmental biology.  
 The National Bioethics Advisory Commission was one striking exam-
ple of how a lot of bioethicists linked themselves to hESC research by 
responding to the three suggested uses of the cells:  
It is the potentially unique versatility of the ES and EG cells derived, respec-
tively, from the early stage embryo and cadaveric fetal tissue that presents 
such unusual scientific and therapeutic promise. Indeed, scientists have long 
recognized the possibility of using such cells to generate more specialized cells 
or tissue, which could allow the generation of new cells to be used to treat 
injuries or diseases, such as Alzheimer’s disease, Parkinson’s disease, heart di-
sease, and kidney failure. Likewise, scientists regard these cells as an important 
– perhaps essential – means for understanding the earliest stages of human 
development and as an important tool in the development of life-saving drugs 
and cell replacement therapies to treat disorders caused by early cell death or 
impairment. (Shapiro et al. 1999: 1) 
There was awareness of the ethical controversy, but in the end the medi-
cal and scientific promises echoing the three first uses also indicated abo-
ve, in the original scientific articles, motivated the NBAC’s endorsement 
of hESC research (Leinhos 2005). 
 The specific element in the business articulations of the hESCs and their 
relationships to actors is the expected profits. Geron and ACT are no 
charity organizations. They are accountable to stockholders. The mone-
tary dimension of the cells is not exclusive to the business world. Poli-
ticians and patients mention money more in statements. Geron and ACT 
representatives emphasize the need of hESCs for other actors, though 
their own activities, to some extent, have to be profit-oriented. When Tho-
mas Okarma, vice president of R&D at Geron, appears in the hearings in 
a Senate subcommittee he confirms the scientists’ (Thomson, Gearhart, 
and West) characterization of the hESCs and the multiple uses (US Se-
nate 1999b: 51). This is natural. Geron was associated with the stem cells 
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via the scientists and can earn money if others accept the hESCs’ mul-
tiple uses.  
 Business actors, bioethicists, and politicians thus concurred with the 
multiple uses indicated by scientists. Even if there were multiple defini-
tions of what a hESC is, the multiple uses were a general structure shared 
between actors, in graphic and textual form. Some actors were specifi-
cally involved with one or two of the uses.  
Developmental biology 
One trace of how scientists related to the cells because of their use in 
developmental biology comes in illustrations. Figure 9 from Austin Smith’s 
review of research on (non-human) embryonic stem cells (ES cells) and 
hESCs, draws on the parallel between ES cells and embryonic develop-
ment (Smith 2001a). The grey arrows between the ES cell culture dish 
and the inner cell mass and epiblast indicates the embryonic stage that 
the ES cells are perceived to equal.  
 
 
  
 
 
 
 
 
Figure 9: The parallel between mouse embryogenesis (development) and 
embryonic stem cell development (Smith 2001a). (Reprinted, with 
permission, from the Annual Review of Cell and Developmental Biology, 
Volume 17, © 2001 by Annual Reviews, www.annualreviews.org). 
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According to Smith’s illustration the developmental potential of ES cells 
is not equal to the fertilized egg, but to the inner cell mass or epiblast.78 
The illustration builds on the general structure of the flowing cells, but 
instead of multiple uses, the cells result in multiple tissues that parallel em-
bryonic development. Another example again comes from the issue of 
Cells Tissues Organs on ES cells as a developmental model. Although this 
issue mainly concerned non-human ES cells the guest editors Anna Wo-
bus and Kenneth Boheler explicitly assumed that their use for develop-
mental biology would soon be extendable to hESCs. Article after article 
approached specific practices in which ES cells were involved. Wobus 
and Boheler introduced these articles.  
The first two chapters are dedicated to molecular mechanisms regulating self-
renewal and differentiation of ES cells […] and the expression pattern of Oct-
4, a key regulator of totipotency during the mammalian life cycle […] The fol-
lowing articles review the present knowledge of ES cell-derived neurogenesis 
[…], adipogenesis […] and hematopoiesis […] on tissue-restricted gene and pro-
tein expression. To study developmental aspects of ion channel formation and 
signalling cascades during early developmental stages, one chapter is devoted 
to confocal imaging and patch clamp analyses of differentiated cells derived 
from ES cells […] The use of differentiation factors and signalling molecules 
for selective differentiation of ES cells will become more and more important; 
therefore, the effects of retinoic acid on stage-dependent differentiation of ES 
cells is summarized […] Another article describes the use of ES cells in an in 
vitro embryo toxicity screening system, which is already part of a validation 
study of the European Union […] Two chapters summarize the attempts to 
establish pluripotent cell lines from species other than mouse […], including 
the most recent strategies to introduce genetic modifications into livestock by 
nuclear transfer […] (Wobus and Boheler 1999: 130) 
What is remarkable about this outline is that it conveys the multiple uses 
of the same type of cell, ES cells. Wobus and Boheler articulate the mul-
tiple uses of ES cells as they lay out the content of the special issue by 
presenting chapter by chapter. In respective chapters, the cells’ signifi-
cance for understanding the development of specific tissue-types is dealt 
with. The “molecular mechanisms regulating self-renewal and differen-
tiation” concern the pluripotent state that ES cells are arrested in. Oct-4 
is a transcription factor expressed by cells as long as they are toti- or plu-
ripotent. The development of ES cells into specific tissues such as neu-
                                     
78   In the Introduction this stage of the embryonic development was called 
blastocyst (step 3 in Figure 1).  
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ral, fat and blood cells (neurogenesis, adipogenesis, and hematopoiesis) is 
treated in the following chapters. Each of these cell-types visible in the 
illustrations above are articulated by Wobus and Boheler in textual form. 
Each cell-type require specific practices. Cells Tissues Organs is a scientific 
publication and the contributing authors are all scientists. All of the artic-
les address specifics of ES cells. Irrespective of specialties the various scien-
tists all use the same type of cell.  
 Basically all of these uses and practices also apply to the hESCs. When 
Wobus and Boheler extend the use of ES cells as a developmental model 
to hESCs, this concurs with other scientists, e.g. Smith. When Thomson 
and Gearhart explain the capacities of the hESCs they link this explicitly 
to the earlier work on non-human ES cells. According to Gearhart their 
reported experiments are just the application of already established know-
ledge of ES cells:  
I want to emphasize that this technology was first developed in the mouse and 
we adapted it to the human. We did not have to work it out in the human per 
se, just adapt it. (US Senate 1999b: 12) 
 
Transplantation therapies 
Patients are constantly included in actors’ articulations. All actors refer to 
possible patients and to all who may need new drugs, or suffer from 
infertility, pregnancy loss, or neuro-degenerative and cardio-vascular di-
seases, and cancers. When the patients appear themselves they do not 
contradict the “formula” of the three uses. However, one usage is more 
important than the others for patients: transplantation therapies. In effect, 
the transplantation therapies are not only one usage. Transplantation thera-
pies are one concept that opens for a number of ailments and ways of 
dealing with those conditions. 
 Even if Reeves, Fox, diabetes patients and relatives, and another 100 
patient and professional organizations, all support hESC research they 
are not all hoping for the same treatment, but multiple treatments that alle-
gedly result from the use of hESCs for transplantation therapies. In the 
previous chapter Pikunis and Melton articulated the needs for Parkin-
son’s disease and juvenile diabetes. In the laboratory, or in the clinic, there 
are huge differences between therapies for Parkinson’s disease, Alzhei-
mer or heart disease. As the hearings unfold the many therapeutic prac-
tices are all assumed to be approachable by means of the hESCs. For all 
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of the supportive patients the transplantation therapies are central al-
though articulated differently dependent on the patients’ conditions. 
 Although the use of hESCs in drug screening may be thought to ap-
peal to companies, transplantation therapies are presented as the major 
reasons for corporate involvement. When Okarma in hearings 1998–1999, 
and at a workshop in 2001, explained why Geron sponsored the initial 
hSEC research the major reason was transplantation therapies, and not 
drug screening (US Senate 1999b, Okarma 2001). This was also the focus 
of ACT, although with a greater emphasis on cloning technology. The Bio-
technology Industry Organization supported hESC research with refe-
rence to the uses of hESCs in developmental biology and in transplan-
tation, but sidestepped the drug discovery aspect (US Senate 1999b: 104). 
 In the NBAC’s recommendations the multiple uses were repeated. How-
ever, when other bioethicists appeared at the hearings, such as Arthur 
Caplan, the transplantation therapies were the main issue and those in 
need of such therapies the main justification for federal funding (US 
Senate 1999b: 36). Coming from the opposite side of the pro-life/pro-
choice camp, Republican Senators linked to the cells because of their use 
in transplantation therapies. Here Republican Senator Thurmond explains 
his support for hESC research: 
There is great optimism that lifesaving therapies might be produced. Cells and 
tissue capable for transplantation could include insulin producing cells to cure 
diabetes, heart cells to rebuild damaged hearts, or new brain cells for victims 
of Parkinson’s disease or other neurological disorders. 
 As a father of a daughter with juvenile diabetes, I know first-hand the 
devastating nature of this disease. In addition, during my service in the Senate, 
I have heard the personal pleas of thousands of constituents who are affected 
by various diseases and disorders. (US Senate 1999a: 19) 
Thurmond is one among many. Not only do patients pick out this one 
usage from the multiple uses indicated by scientists. Senators, businesses, 
and bioethicists explain their own interests in the cells by referring to the 
cells’ use in transplantation therapies.  
Ethical use of IVF embryos 
There is a fourth use of hESCs that in particular addresses the previously 
mentioned pro-life actors in Congress and in the White House. IVF and 
the remaining embryos contributed to coordination in three ways in 1998–
2001. A number of actors opposed the use of already existing embryos, 
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but would not come out in opposition to the practices of producing and 
storing the embryos. It was thus a case of non-opposition to their exis-
tence. Another linkage between embryos and pro-life actors was the ex-
plicit endorsement of using already existing embryos in research to achie-
ve important medical treatments. This was justified with the necessity of 
producing extra embryos for IVF. A third was the endorsement of hESCs 
already produced from supernumerary embryos. 
Non-opposing contribution 
Some opponents questioning the use of embryos in research did not 
question the practice of in vitro fertilization (IVF) that had produced the 
embryos. Instead they avoided the issue. In a hearing in 2000 Senators 
Brownback and Specter had a conversation. Brownback brought up the 
holocaust to oppose research on embryos and Specter objected that the 
experiments during World War II were on living people. Brownback re-
sponded that “[t]hese are living embryos. You are taking living em-
bryos”. In their conversation the moral status of embryos and the issue 
of IVF stands out bluntly. Embryos as living persons confront the IVF 
practice. 
Senator SPECTER. Let me ask you, Senator Brownback, do you oppose in 
vitro fertilization? 
Senator BROWNBACK. I have not thought through that one, and I am not 
prepared here today to talk about that particular issue. The issue in front of us 
is you have a live embryo. 
Brownback tries to separate the IVF issue from the hESC issue. He is 
not willing to take a stand on the former, only on the latter. Specter’s fi-
nal argument in the exchange with Brownback refers to IVF and what is 
thereby presupposed.  
Senator SPECTER. I raise the in vitro fertilization issue – and you are correct. 
It is not before us. We are exploring the matter today, but we are going to 
have an opportunity to discuss it on the Senate floor at greater length. But I 
raise the in vitro fertilization issue because there are some who do object to 
that, and it is a consequence of in vitro fertilization that these embryos are 
created. There might be an argument that every one of these embryos is 
entitled to life. But the process of in vitro fertilization is to have a large group 
and then to use some but not to use others. So, this is something we will be 
getting into. (US Senate 2001: 30)  
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Brownback is not alone in trying to avoid definite statements on the 
issue of IVF (US Senate 2001: 74). Many oppose the use of embryos for 
stem cell production, but Specter’s point here is not dealt with: “But the 
process of in vitro fertilization is to have a large group and then to use 
some but not to use others”. It is not brought up in any elaborate way in 
the hearings.79 Doerflinger and the official Catholic doctrine are clear on 
their dissociation from IVF (US Senate 1999b: 144f), but the lobby orga-
nization he represents has not acted in any way against the procedure 
(Wade 2001). The case is similar with other pro-life actors.80  
Supportive contribution 
Toward 2001 other pro-lifers did not only “not oppose” IVF but expli-
citly found it justified to use it in hESC research. This is the second sort 
of contribution from embryos to coordination. Next time Brownback 
appears, in 2001, he is involved, together with three other pro-life sena-
                                     
79   Dr. Prentice’s testimony in US Senate 2001: 74, and Dr. Caplan’s testimony in 
US Senate 1999b: 39, both bring up the IVF industry as a part of the “spare 
embryo problem”, but without going into the problem in depth, or providing 
any solutions. William L Pierce, PhD Senior Fellow, Discovery Institute for 
Public Policy is an exception when he suggests an unpacking of IVF in the 
2001 hearings: 
IVF techniques themselves could be changed to provide that reproduc-
tive medical experts no longer extract more ova than can be safely fer-
tilized and implanted, without freezing. Let’s urge those contemplating 
IVF to take a different approach, one that may impact consenting adults 
rather than embryos who cannot give consent. (US Senate 2002: 72) 
80   Observed by Nicholas Wade of the New York Times:  
Douglas Johnson, the legislative director of the National Right to Life 
Committee, said that in-vitro fertilization ”is outside of our purview.” 
His committee has not taken a position against fertility clinics, Mr. John-
son said, because “we don’t get into passing judgment on the conception 
of any person.”  
 Richard Doerflinger, the chief lobbyist for the National Conference of 
Catholic Bishops, said that the church’s moral opposition to in vitro 
fertilization ‘‘has been pretty clear from the outset, but in terms of poli-
tical action we have to choose the issues that are raised for us.’’  
 Sean Tipton, the public affairs director of the American Society for 
Reproductive Medicine, said, ‘‘We have not seen any opposition from 
the Catholic bishops to put a stop to in vitro fertilization.” (Wade 2001) 
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tors, in a conversation with Senator Harkin and explicitly refrains from 
opposing IVF. 
Senator HARKIN. You are not opposed to in vitro fertilization? 
Senator FRIST. No, sir. 
Senator HARKIN. Senator Smith? 
Senator SMITH. No, sir. 
Senator HARKIN. Senator Hatch? 
Senator HATCH. No, sir. 
Senator HARKIN. Senator Brownback? 
Senator BROWNBACK. No. 
Senator HARKIN. No. I guess my question is that obviously in vitro 
fertilization is going on right now. 
Senator FRIST. Yes, sir. 
Senator HARKIN. So there will be, as you point out, left-over embryos, in 
essence. 
Senator FRIST. Thousands and thousands and thousands. 
(US Senate 2002: 31) 
Harkin’s orchestration of bipartisan support for IVF is persuasive. How-
ever, Frist, Hatch and Smith were not as hard-pressed as Brownback. They 
were among the pro-life actors who not only accepted IVF, but delibe-
rately linked it to hESCs in order to justify their own support of the re-
search in spite of “pro-life values”. Some of the strongest articulations of 
hESCs come from these pro-lifers. They represented pro-life values and 
voters.  
 However, keeping an identity as a “pro-life congressmember” is not a 
straightforward thing. Pro-lifers outside of Congress are keeping track of 
and classifying votes in Congress as being more or less pro-life (Taylor 
2001b). To maintain a pro-life identity these congressmembers referred 
not only to the therapeutic promises and the pluripotent properties of 
hESCs, but also to a specific source of cells, the embryos resulting from 
in vitro fertilization. One clear example of this is Orrin Hatch: 
I am proud of my strong pro-life, anti-abortion record. I commend the Bush 
Administration for its strong pro-life, pro-family philosophy. In my view, 
research on stem cells derived from embryos first created for, but not ultima-
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tely used in, the process of in vitro fertilization, raises questions and conside-
rations fundamentally different from issues attendant to abortion. (Hatch 2001b) 
Hatch had credibility thanks to his Senate voting record. In his separa-
tion between abortion and embryo research he draws on “the embryos 
first created for, but not ultimately used in, the process of in vitro fertili-
zation” as elements that are stable in virtue of their actual material exi-
stence. The embryos are already there and, together with human actors, 
can take some of the responsibility for the endorsement of hESC re-
search. Senator Bill Frist was also pro-life and is one of the few medically 
trained in the Senate. 
Senator FRIST. We are getting pretty technical there. In my own mind, IVF 
involves the creation of surplus – and these words are hard for people, 
discarding, disposing, and surplus. But that is the nature of in vitro fertili-
zation today. You have to, and so you are going to have 10 or 15. People elect 
either to freeze them or to discard them immediately. (US Senate 2002: 31–32) 
Frist not only appealed to frozen embryos, he appealed to “the nature of 
in vitro fertilization”. Again, as in Specter’s lines above, IVF is an already 
defined technology here and “people” can only elect to either freeze or 
discard. The options are limited because of the technology. In this sense 
the process of IVF is a “black-boxed” or “frozen” element. When articu-
lated together with embryos it changed their meaning and status. The re-
sulting number of embryos was regarded as a pre-given, as “already 
there”. The IVF practice was in place and producing a specific and in-
evitable outcome that was used by some actors when they supported the 
hESCs.  
Minimal contribution 
The third sort of contribution to the coordination was offered by Presi-
dent Bush, in his August 9 decision (2001), as he explained his own task. 
My administration must decide whether to allow federal funds, your tax 
dollars, to be used for scientific research on stem cells derived from human 
embryos. A large number of these embryos already exist. They are the product 
of a process called in vitro fertilization, which helps so many couples conceive 
children. When doctors match sperm and egg to create life outside the womb, 
they usually produce more embryos than are planted in the mother. Once a 
couple successfully has children, or if they are unsuccessful, the additional 
embryos remain frozen in laboratories.  
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 Some will not survive during long storage; other are destroyed. A number 
have been donated to science and used to create privately funded stem cell 
lines. And a few have been implanted in an adoptive mother and born, and 
are today healthy children. (Bush 2001) 
Bush accepted the process of IVF as producing “additional frozen em-
bryos”. But, he also mentions an alternative fate for the embryos. De-
struction and donation to science are not necessary end destinations, fol-
lowing Bush’s articulation. “A few” of the embryos had been implanted 
in an adoptive mother and then born. According to Bush, frozen em-
bryos were not sufficient to justify support of hESC research.  
I have concluded that we should allow federal funds to be used for research 
on these existing stem cell lines, where the life and death decision has already 
been made. (Bush 2001) 
All remaining embryos must not be used for hESC research. However, in 
the cases where the embryos had already been destroyed to produce lines 
of hESCs, federal funds could be used. Much media space has been used 
to debate Bush’s decision as a balancing act between pro-life and the pres-
sure for future cures. This is not the place to add to those speculations. 
Whatever the intentions, tactics or strategery on Bush’s part, the frozen 
embryos did occupy a responsible role in his support for hESC research. 
As he explained his decision IVF was a black box producing additional 
embryos in the process of “helping so many couples conceive children”. 
Although Bush only supported hESC research on embryos whose fate 
had already been sealed, the practice of IVF was explicitly linked to the 
embryos. He was not supporting the deliberate creation of embryos for 
research. For some pro-lifers his decision was still not sufficiently restric-
tive, but representative of a “moderate pro-life position”, according to 
Jameson Taylor, pro-life author. Here in a newsletter from Children of 
God For Life (an associate of the American Life League). 
Perhaps the most disturbing upshot of the embryonic stem cell (ESC) debate 
has been the shameless co-option of pro-life language by a number of so-
called pro-life politicians. (Taylor 2001b)  
Taylor’s critique is interesting because it highlights how the hESCs 
became a part in the creation of a new position among (“so-called”) pro-
lifers. The moral status of embryos was a hot and fluid issue. In spite of 
this, embryos contributed to the coordination of diverse actors, at least 
according to some actors’ articulations. Heated polarization was some-
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what cooled down as actors, especially from the pro-life side, used the fro-
zen embryos and the black-boxed IVF procedure to explain their own sup-
port for the cells (although this stance did draw heated criticism from “less 
moderate” pro-lifers). The use of already existing embryos as source for 
hESCs was a reason for coordination.  
Boundary object implications 
All of these multiple uses are held together in the hESCs. Through the 
hESCs as mediators a scientist interested in developmental biology can 
join hands with patients and pro-life Senators. From the original articles 
to the hearings the hESC articulations were picked up, confirmed and sent 
on to other actors. The cells are not doing the same things for busines-
ses, patients, politicians, ethicists and scientists. Patients endorse the cells 
because they promise cures to diseases such as Parkinson’s and Alzhei-
mer’s. Corporations support hESC research since they expect a profit via 
transplantation therapies. Bioethicists gain more influence as a profession 
because of the ethical problems connected with the stem cells. Scientists 
obviously benefit from all of the uses which speak to other actors, but 
more uniquely from the use in developmental biology. Pro-life politicians 
attempted to stay pro-life with various references to the already existing 
embryos. 
 Applying the boundary object approach has implied a relative reality, 
and another mode of coordination and distribution of agency. Unlike the 
OPP cases a sociotechnical reality can be analyzed without supposing 
any central human entrepreneur and without a totally dominating coordi-
nation. The Museum of Vertebrate Zoology (MVZ) was not dependent 
on an expansionist agenda. Not all actors, all museums or all of Califor-
nia had to be remade to make the museum work. The collectors’, and the 
trappers’ and the university administration’s concerns did not have to be 
reframed or remade. By managing repositories, coincident boundaries or 
standardized forms, i.e. the boundary objects, each actor could remain 
partially in control, with partial jurisdiction over the coordination. These 
objects transcended and travelled across the boundaries of diverse social 
worlds and actors. 
 The hESCs were involved in a coordination in which many of these 
features were repeated. As in the MVZ case, diverse actors in 1998–2001 
could endorse the hESCs without having to be remade. Patients, corpo-
rations, politicians, bioethicists, and scientists, all could have the hESCs 
serve their purposes to get well, make money, satisfy voters or remain in-
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fluential. No central human entrepreneur managed these actors. Instead 
the hESCs were the main character, and although the stem cells were not 
entrepreneurial, these nonhumans were the center of associations, the 
main factor. 
 However, this does not necessarily mean that it was a centralized coor-
dination. After the failed domination attempt (in one respect ended with 
Bush’s decision) the hESCs were still linked to diverse actors who 
continued to realize them. Rather than seeing how a total (pluripotent) 
transformation is at stake – or not – the boundary object approach con-
siders each association to, and each use of, the hESCs. More than a sys-
tematic, seamless change and total alignment of actors, multiple practices 
are facilitated and coordinated through the flow of hESCs. The cells we-
re thus involved in a distributed coordination. They were boundary objects in 
relation to the diversity of actors that was bridged. Scientists, pro-life or 
pro-choice politicians, patients, bioethicists and corporations could meet 
in a new space made up of the hESCs.  
 This changes the notion of reality in two ways. From one tightly defi-
ned singular reality, the hESCs are involved in a relative and multiple 
reality. In the above, the reality of hESCs is not an either-or but the num-
ber and nature of various linkages. Each possible use that was envisio-
ned, welcomed and associated with actors, adds to the reality of hESCs. 
In the previous chapter there were two alternatives: The reality of hESCs 
either became all-encompassing, or failed. A success would allegedly have 
created a pluripotent transformation, a US of the human embryonic stem 
cells, and in this sense a singular, seamless whole (see Figure 5, Chapter 
2). Instead of the whole and unified reality resulting from a totally suc-
cessful OPP, the hESCs are involved in a reality as multiple as the many 
uses of hESCs among diverse actors, but not necessarily fragmented and 
pluralist.81 In this sense the reality of hESCs was more than one, but less 
than many, to use Marilyn Strathern’s and Annemarie Mol’s phrase (Mol 
2002: 82). The hESCs did not require actors to agree. Bush still does not 
agree with Specter, Caplan and Thomson, but they could all associate to 
                                     
81   I use and define these words very much in accordance with Annemarie Mol’s 
study of atherosclerosis: 
This, then, is what I would like the term multiple to convey: that there is 
manyfoldedness, but not pluralism. In the hospital the body (singular) is 
multiple (many). (Mol 2002: 84) 
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the hESCs. Because of the multiple uses of hESCs the actors hung 
together without making up a unified whole. 
Summary 
This chapter has answered two issues that lingered from the previous 
chapters: One concerning relative reality and one concerning the absence 
of any central entrepreneurial human actors. In contrast to the OPP mo-
del the boundary-object approach gave space for a partial stabilization in 
terms of a number of linkages, without achieving total domination. This 
relative reality was not dependent on any strong human entrepreneurial 
activity, but due to a distributed kind of coordination. Diverse actors we-
re coordinated by the multiple uses of the hESCs. Without agreeing to-
tally or systematically, actors could collaborate through the hESCs. Just 
as in Star and Griesemer’s case the hESCs combined a general common 
identity and specific uses in individual sites. 
 There are now two answers to the question about the sociotechnical 
reality of hESCs in 1998–2001, building on two diverging models posi-
ting two modes of coordination and two ways of approaching reality. Too 
many “twos” answering one question about the reality of, in the singular. 
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4.   Theoretical Tensions and Innovations: A Boundary 
Package in Multiple Loops 
Introduction 
This chapter is a (mostly) theoretical interlude taking stock of the pre-
vious chapters and reloading for the following chapters. The first part 
makes a break in the Chapter 3 analysis of hESCs as boundary objects, 
to see how the partial connections, and relative reality of flows can be re-
conciled with the OPP approach used in Chapter 2. In the previous 
chapters hESCs have been involved in two kinds of sociotechnical net-
work attempts and two modes of coordination that have been presented 
as two separate processes. It is now time to see if and how these (at least 
apparently) different sets of hESCs hang together.  
 To do so, the chapter starts in the theoretical tensions between the 
ANT obligatory point of passage and the boundary object from social 
worlds theory. There are fundamental differences between the two ap-
proaches that may be put to good use by applying Latour’s concept of 
multiple loops. In order to flesh out such a concept, several modes of 
coordination have to be utilized. OPP and boundary objects can be such 
modes, but this requires a more localized application of the concepts.  
 In the rest of the chapter, the similarity between boundary objects and 
hESCs are challenged. The stem cells are clearly involved in a boundary 
object-like coordination, but this does not immediately turn them into 
boundary objects. This challenge will not concern the basic mode of co-
ordination observed by way of the multiple uses, the partial connections, 
and the relative reality. However, I will claim, these traits can be present 
without a total similarity between the hESCs and Star and Griesemer’s 
boundary objects. The solution will be an innovative addition to the 
notion of boundary objects. Lastly, the requirements for future analysis 
will be outlined. 
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Theoretical tensions 
From Chapter 3 one lasting observation is that by 2001 hESCs had 
become a boundary-transcending object and a meeting-point for diverse 
actors. In relation to Chapter 2, the observation of a boundary-trans-
cending position is both coherent and puzzling; coherent, since already 
in Chapter 2 there was more than disputes to the hESCs. In order to 
fight, two parties usually have to share some assumptions and some 
views, while disagreeing about others. The commonalities – such as the 
acceptance of transplantation therapies and need for pluripotent cells – 
between all parties were in a sense boundary-transcending and point to-
ward coherence between the two chapters. Still, the observation of hESCs 
as objects of boundary-transcending coordination was puzzling, since the 
negotiation of federal funding in Chapter 2 clearly involved high stakes, 
and a mode of coordination marked by funneling, domination, and ex-
clusion. In one chapter the hESCs were objects of dispute and in the 
other chapter an object of coordination. Two new questions have resul-
ted from the exploration of how to put the two approaches to use, in 
order to understand the sociotechnical reality of hESCs and especially 
the public and political dynamics. 
 How can the observation of a total transformation at stake be recon-
ciled with the observation of partial stabilization?  
 How can the observation of funneling through hESC research be re-
conciled with the open-ended coordination of ecological flows? 
 A first answer turns on timing and involves actuality vs. potentiality. 
The hESCs as a meeting-point were most visible at the end of the pe-
riod, in 2001, as an actually achieved coordination – a partial stabiliza-
tion. It was at this time that Bush endorsed some hESC lines supported 
by a number of pro-life members of Congress. However, as early as in 
1998 the hESCs were articulated much like a boundary object together 
with funneling and exclusion, traits of a potential and attempted coordi-
nation. In this respect OPP was present, but not achieved. Actuality vs. 
potentiality is nevertheless only one aspect, and does not exhaust the 
puzzle of hESCs as objects of disputes and objects of coordination.  
 Although Latour and Callon’s OPP did not match every detail of the 
negotiations of federal funding (in Chapter 2) their notion did capture 
some things not covered in Chapter 3. The latter built on actors who we-
re not dependent on the cells and who, because of the multiple uses, 
supported research on the cells. However, it is impossible to sidestep the 
role of the federal government, its centrality for American research and 
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its subsequent potentially funneling effects on the fate of medicine. In 
the articulations from both opponents as well as proponents a strong 
either-or was tangible; domination or failure was at stake. While these 
aspects corresponded to the OPP, the relative stabilization of hESCs 
among diverse actors suggested the boundary-object approach. Before 
this work can continue to map the reality and the stabilization of hESCs 
these observations and the theoretical tools need to be reconciled.  
 Combining the two previous chapters raises the questions: Can the 
phenomena be saved? Can the hESCs be involved in both kinds of co-
ordination? In principle yes, as two separate perspectives on the hESCs. 
Boundary objects and OPP come from two distinct approaches, social 
worlds versus actor-network theory. They could be presented alongside 
each other as theoretical “frames” for how the understanding of hESCs. 
However, in this study I have already started to combine the two models 
within one framework. The previous chapter drew on the boundary object 
approach. It was done in terms of an ANT study, not a social worlds or a 
symbolic interactionist one. At the end of Chapter 3 it was furthermore 
indicated that the actors’ articulations of the hESCs as a boundary object 
happened in a situation of advocacy and in the face of a potential OPP, 
i.e. the high stakes of a federal funding with funneling and dominating 
consequences, and definite opposition from pro-life actors. Not only are 
the two perspectives thus presented alongside each other, but together, 
as two co-existing – and even co-producing – modes of coordination. 
Stressing divergence: heterogeneity and diversity 
One way to consider the differences between ANT and social worlds is 
to analyze the notions of diversity and heterogeneity. The hESCs as boun-
dary objects are said to coordinate diverse actors. In what sense is it mea-
ningful to speak of actors as diverse at all in an ANT study? Chapter 2 was 
in fact structured according to diversity: scientists, corporations, patients, 
politicians. According to ANT, actors are heterogeneous, implying that their 
identities are not given. Identity is only achieved through hard work, 
enrollment, alignment and maintenance (Callon 1986b: 24). The reference 
to diverse actors comes from Star and Griesemer’s article and has to do 
with the social worlds in which actors move, work and are active in prac-
tices. The boundary objects are used in order to explain how actors can 
cooperate, not within the same social world but between different ones. 
Applying the boundary object approach thus actualizes a difference be-
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tween social worlds perspective and actor-network theory in terms of 
diversity and heterogeneity.  
 The social worlds perspective adds the influence of collectives to the 
processes of articulation. What are these collectives? In one oft-quoted 
passage Anselm Strauss defined social worlds: 
In each social world, at least one primary activity (along with related activities) 
is strikingly evident, i.e., climbing mountains, researching, collecting. There are 
sites where activities occur: hence space and a shaped landscape are relevant. 
Technology (inherited or innovative means of carrying out the social world’s 
activities) is always involved [---] In social worlds at their outset, there may be 
only a temporary division of labor, but once underway, organizations inevitably 
evolve to further one aspect or another of the world’s activities. (Strauss 1978: 
122) 
Talk of specific activities, sites, technology and organization is not alien 
to ANT. What has been alien to ANT is the analytical presupposition of 
delimited units of the world in which these things take place collectively 
and somewhat uniformly. According to Adele Clarke “[s]ocial worlds form 
fundamental building blocks of collective action and are the principal 
affiliative mechanisms through which people organize social life” (Clarke 
1990: 18). Social worlds are not only units in the world but also the unit 
of analysis (p. 20), in fundamental contradistinction to the actor-networks 
of ANT. The analytic advantage of the latter is precisely the doing-away 
with prejudices about how and where which actors are aligned around 
what activities. This has been called heterogeneity, and the scientists of 
such a world have been called heterogeneous engineers – because of their 
management of heterogeneous elements in contrast to so-called “purely 
scientific” ones (Law 1987, Law and Callon 1995).  
 Heterogeneity is also part of an ontological distribution among all 
actors in a somewhat “democratic” way.82 In social worlds, and for a 
                                     
82   In Latour’s own terms: 
The ontological activity that is no longer capitalized at the two extre-
mities may be redistributed among all the actants. It was the necessity of 
the dual system of appeal either to nature or to society that in the Kan-
tian framework caused all the agencies to be assigned to two and only 
two lists. Now that we are freed from this necessity, we are allowed to 
have as many poles as there are actors. This irreductionist principle is probab-
ly the most counterintuitive consequence of science studies but it is a ne-
cessary and a coherent one. [---] Dignity, activity, and world-making abi-
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study of social worlds, boundaries are important. In actor-networks and 
in ANT, there are no boundaries, only links that are established or not. 
In one respect Star and Griesemer’s talk of the coordination of diverse 
actors is an ANT tautology. What actors are not diverse in a heteroge-
neous world? In another respect diverse actors are contradictory to ANT, 
since the notion presupposes the opposite of heterogeneity, viz. funda-
mental similarities between some actors (the actors who share the same 
social world). According to this reading of the two perspectives there is 
thus a difference between the diversity of social worlds and the hetero-
geneity of actor-networks. 
 Just as in the case of agency and generalized symmetry (see Chapter 1) 
it is a good idea not to build theoretical contradictions that the respective prac-
titioners (of the theories) themselves do not stumble on. The social 
worlds theory resembles ANT precisely in virtue of their heterogeneity, 
“antideterminism”, and their interest in practices (Strauss 1978: 121). 
From the vantage point of ANT it is possible to understand the main 
feature of boundary objects (that they “coordinate diverse actors”) as 
merely saying that actors – who, in ANT, are never a priori similar or 
identical – are coordinated. Boundary objects are then basically nodal 
objects with a capacity to align people and things through their com-
bination of flexibility and integrity. There is little need to import the 
notion from Star and Griesemer at all, if this is all it says. I want to claim 
that this is not all it says. Another interpretation of boundary objects 
may challenge ANT and answer questions (about actors’ differences, 
the strength of actor-networks and the epistemology of articula-
tions/translations) raised by Latour’s still undeveloped concept of the 
circulatory system of science. However, in order for this to happen the 
theoretical presuppositions underlying boundary objects have to be con-
sidered. The reference to diverse actors typically belongs to the social 
worlds perspective more than ANT. “Diverse actors” is a reference to 
actors from distinct social worlds, units that do not have independent 
and primary existence in an ANT world, at least not at the outset.  
                                                                                                                 
lity are reclaimed by those actants that are, nevertheless, fully nonhuman, 
and fully real. Mere intermediaries in the Modern Constitution, they be-
come full-blown mediators in the non-Modern, more democratic, one. 
(Latour 1992: 283) 
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Seeking convergence: multiple loops 
In his Pandora’s Hope (1999), Latour suggests that it is not enough to look 
at one chain of translations in which a reference can move back and 
forth. You also have to take into account the multiple loops of objects 
and references among various sorts of actors. Thus more and more 
actors are tied together through multiple flows. Latour’s example is 
Joliot’s work to establish a chain reaction during the second world war 
(see more above in Chapter 1). Five activities have to be linked together, 
Latour claims. 
All at the same time, Joliot must get the reactor to work; convince his col-
leagues; interest the military, politicians, and industrialists; give the public a 
positive image of his activities; and, last but not least, understand what is go-
ing on with these neutrons that have become so important to the parties he 
has interested in their fate. (Latour 1999b: 99) 
The treatment and the example resembles Star and Griesemer’s case 
study, and other social worlds studies, in one respect. Latour refers here 
to actors who are not chiefly heterogeneous but diverse. Actors’ identi-
ties are not made anew in network attempts, but are already part of larger 
clumps. Actors are lumped together as politicians, military, public, col-
leagues, etc. The circulatory system may be meant merely as a heuristic, pe-
dagogical device to understand actors’ movements in a heterogeneous 
world. Here the concept will, however, be taken more seriously, viz. as a 
means for better studying the linkages between actors who are diverse in 
specific and collective ways, restricting the (in principle) unpredictable 
and “agnostic” ANT view of reality presented above in Chapter 1 (Cf. 
Callon 1992, Latour 1999a).  
 To talk of multiple loops instead of a myriad of links is to back off 
from fundamental heterogeneity and inch towards diversity. Not all ac-
tors are equal from the outset. All linkages do not carry the same weight. 
Recruiting politicians and federal funding may for instance differ from 
recruiting a bioethicist. Different resources are set free. Different sorts 
and numbers of other actors may come with a politician in contrast to a 
bioethicist.  
 The circulatory system of science is presented in Chapter 3 of Pandora’s 
Hope as a direct continuation of Chapter 2 “Circulating Reference: Samp-
ling the Soil in the Amazon Forest”, in which one chain of circulation is 
mapped out. The Amazon soil is transferred and transformed to the pe-
dologists’ boxes and color codes, and ultimately to a diagram describing 
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the movement of the forest’s boundary. Although circulation is the issue 
of both chapters there are important analytic implications of going from 
one chain of translation to multiple loops. Latour wants to say that the 
scientific work of transforming earthly material to diagrams (or neutrons 
to chain reactions) is neither different nor separable from the handling of 
ministers and militaries. They all require translation and articulation.  
Was it one thing to persuade a minister to provide a stock of graphite, and 
quite another to persuade a neutron to slow down enough to hit a uranium 
atom so as to provide three more neutrons? Yes and no. For Joliot it wasn’t 
very different. In the morning he dealt with the neutrons and in the afternoon 
he dealt with the minister. (Latour 1999b: 89f) 
Stressing the principle of similarity cuts up the traditional epistemological 
gap between words and the world into many small heterogeneous trans-
formations. For each transformation there is matter and form, a piece of 
the world and words. The form of one transformation then becomes the 
matter for the next. No fundamental difference between the world and 
words then exists, but many minor differences bridged through the arti-
culation of linkages. “Knowledge about” is a new “reality of”. “Realiza-
tion of” is not a platonic insight but the becoming real. Apart from episte-
mology (or, in effect, ontology) the multiple loops are doing a sociologi-
cal job. Instead of separating internal and external factors, the scientists’ 
work of convincing neutrons and convincing ministers are inextricably 
bound together. Understanding science is understanding society. Follow-
ing scientists will take the analyst to neutrons and ministers. While the 
principle similarity of each linkage in the chain of translations is an im-
portant contribution to an age-old epistemological puzzle and a quite old 
sociological squabble, the stress on similarity is but one aspect of multi-
ple loops. Latour answered “Yes and no” in the above lines but barely 
manages to keep the two answers together. The “yes” relates to the simi-
larity and intertwinement of “persuading neutrons” and “persuading 
ministers” outlined above. The “no” has to do with the different pre-
occupations of the scientists. In Joliot’s case: the work with “colleagues, 
the military, politicians, industrialists, the public and neutrons”. 
 After the earlier unpredictability concerning the identity of actors, La-
tour’s model raises a question: Why refer to such clumps of actors as 
politicians, the public, and colleagues, with their specific resources, com-
petences and realms and not stick to linkages among heterogeneous ac-
tors? Without establishing a pre-determining scheme to be followed, mul-
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tiple loops is more than talk of heterogeneity in general. Managing the 
clumps are necessary for Joliot to “be a good scientist” and to “guaran-
tee the reference for what he says”. 
It is impossible, by definition, to give a general description once and for all of 
the unpredictable and heterogeneous links that explain the circulatory system 
that keeps scientific facts alive, it must nevertheless be possible to outline the different 
preoccupations that all researchers will hold simultaneously if they want to be good scientists. 
Let us try to enumerate the various flows that Joliot must take into account si-
multaneously and that together guarantee the reference for what he says. (La-
tour 1999b: 99, my italics) 
Instead of merely talking of heterogeneous actors and links “the various 
flows” are introduced because the differences between scientists’ preoccu-
pations are important. For Joliot to succeed, his ideas have to be trans-
formed into public trust, political decisions, financial resources, heavy 
water, etc. Each of these transformations entailed its specific challenge, 
Latour claims. That’s what makes the work of multiple loops so difficult 
and important. If politicians and the public could be treated just like 
neutrons or atoms there would be less point in “enumerating the various 
flows” that have to be managed in order for a new reality to take shape.  
 Accessing politicians, the public, or colleagues is important because 
politicians, the public and colleagues possess specific resources not pos-
sessed by other actors. This suggets that the very diversity between re-
sources and competences is crucial for the actors to achieve success and 
stabilization for their projects. Multiple and diverse loops in that case will 
affect the analysis of stabilization and reality. Stabilization is the result of 
actors linked up to each other. Accordingly, is stabilization measured by 
counting up the total number of actors? Or, may there be a difference 
between linking up to one person or one piece of technology rather than 
another person or piece of technology?  
 Maybe one actor can make up for ten other actors. How do you tell 
which actors are important? Critics of ANT has pointed out that the ana-
lysis of an actor-network’s strength is a purely retrospective and circular 
assessment: The winner had the strongest chain of associations (Yearley 
2005: 64). But, why was it stronger? Because it won out. There is thus no 
way to tell the difference between linkages with respect to the strength of 
associations (just as there has been no difference in various forms of arti-
culations). With multiple flows and the related notion of diversity some 
of this analytic weakness might be met. Actors are important not just as 
one more linkage, but with regard to their diversity – in competence, re-
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sources and position. Analytically, there has been no difference in prin-
ciple between aligning other colleagues and aligning politicians. How-
ever, the strength of a chain of associations differs if all of the actors are 
colleagues, versus if some are colleagues and some are politicians. Link-
ing some actors to an object “realizes” the object more (i.e. makes it 
more real) than associating to other actors depending on what loops are 
working or not.83 This is why Latour “enumerate[s] the various flows 
that Joliot must take into account simultaneously and that together 
guarantee the reference for what he says”. A project’s strength is directly 
proportional to not only the number of heterogeneous associations, but 
also to the diversity of the associated actors and their resources. 
 Especially in Chapter 3 the diversity of actors attached to the hESCs 
was visible. It is possible to say that the hESCs did circulate among these 
actors. That was one of the reasons for bringing in the boundary object 
approach. If not as batches, the hESCs circulated in diverse actors’ arti-
culations. Plainly put: Actors referred to hESCs. In the hearings, the di-
verse range of actors indicates the many aspects of the hESCs. Accor-
dingly, the hearings were a place where multiple loops of the hESCs 
could be established, manifested and articulated – in particular in relation 
to one crucial actor, the Federal administration. While the laboratory 
established the reference “human embryonic stem cells” by linking them 
to a corporation and to other laboratory work (such as the earlier ES 
cells with the adjacent markers, procedures and tools) the hearings sta-
bilized the reference by giving diverse actors the opportunity to articulate 
and circulate the “human embryonic stem cells”. 
Managing multiple loops: modes of coordination 
However, if the different activities needed to manage diverse actors are 
so important, then why are these preoccupations all subsumed under the 
rubric of translation and articulation? The new concept of multiple loops 
does not correspond to the traditional ANT understanding of how 
actors are linked together. In spite of the “different preoccupations” that 
are needed for the continuity of the scientific reference in multiple loops 
the process is still one and the same thing: translation. This is where 
Latour does not fully relate his two answers to each other. He says that 
“yes”, persuading ministers and neutrons is the same thing (that is, tran-
                                     
83   NB: The “socio-technical weight” of actors is still constructed, difficult to 
assess and never straightforwardly pre-given. 
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slation). And, “no”, they are not the same thing since the scientists are 
not limited to a scientific core, but pursue politics and public relations as 
well, in multiple loops. There thus seems to be a gap between the acknow-
ledgment of diversity and the understanding of how diversity is handled 
by actors. In the theory chapter I quoted Annemarie Mol’s call for forms 
of coordination. Coordination and associations are said to be either on or 
off. 
Each new and successful association makes a network larger. But however 
great the difference between the coherence in a network and logical coherence, 
to talk of ”associations” does have a homogenizing effect. Either an associa-
tion is made or it isn’t. An element is either inside or outside a network. Co-
ordination is established or not. There are no distinctive forms of coordination. 
(Mol 2002: 65f) 
I suggest that an advantage with the multiple loops is that distinctive 
forms of coordination may become visible. Various loops require, or fa-
vor, specific forms of coordination. Some things are needed for analy-
zing actors who are handling multiple loops. One goal must indeed be to 
not separate the activities into “scientific” and “political” ones. If negotia-
ting with neutrons is fundamentally different, epistemologically speaking, 
from handling politicians then the ghost of internalism-externalism may 
be revived. In a version of internalism, knowledge may then be deter-
mined through the former process (slowing down the neutrons) while 
the latter merely provides context (funding or not funding). In contrast 
the externalist may regard the political processes as the real causes for 
the underdetermined handling of neutrons. Considering this dichoto-
mous ghost any fundamental differences between the activities of scien-
tists are probably a bad idea.84 In this respect they should be “the same 
thing” (see Latour’s quote above). In order to capture the diversity of 
                                     
84   Latour has presented one such significant difference between two construc-
tion processes, yielding different results: hard and soft facts Latour 1987: 208–
210. Unfortunately these concepts get worryingly close to externalism and 
internalism. Hard facts are namely the usual technological and scientific way 
to form an alliance and result in short, limited networks. Soft facts are less 
techno-scientific and leave a wider margin of negotiation which on the other 
hand gives more stretched-out networks. Except for the distinction between 
scientists and non-scientists reminding one of internalism-externalism there is 
another drawback. The two notions refer to different facts (hard vs. soft) and 
actor-networks (short vs. long) and not different modes of constructing the 
same reference/fact in multiple circulations. 
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multiple loops the epistemological significance of activities cannot be 
decided beforehand. Latour agrees about this. The actor-network analyst 
should remain agnostic. Latour has subsequently shifted the signification 
of such processes with the explicit intention of not entailing how they 
can happen. In order to keep an open-endedness and keep away analytic 
prejudgment he has played around with different terms such as 
translation, articulation, construction, and production. These two goals 
should be set for matching multiple loops and the analysis of how actors 
handle them: First, the non-separation of science, politics and other 
areas, and second, the diversity and open-endedness of possible 
activities.  
 It may be that the multiplicity of terms does not meet the need to un-
derstand the management of diversity. While the concept of translation 
has been, and still is, formulated as non-prejudiced in theory, it has been 
less broad in practice. Callon, Law and Latour all practiced the transla-
tion model in case studies in which actors were linked together in one 
network. The actors were aligned by reformulating their goals so as to 
make them take a detour through one institution or one group of entre-
preneurs, i.e. the obligatory point of passage. The model assumed that all 
actors, whether politicians or microbes, were negotiated by the same fun-
neling movement. Thus, they (Callon, Law and Latour) avoided interna-
lism-externalism by showing how the effective processes were not either 
on the inside or on the outside, but in the very tying together of various 
actors, whether perceived as “social”, “political”, “economic” or “cogni-
tive”. But in contrast to the theoretical open-endedness, translation in 
the OPP model did in fact lock the way actors were handled. One group 
of entrepreneurs was the main agents. Other actors and their goals were 
displaced as they became part of the new, dominating and totally trans-
forming actor-network. Although there were many heterogeneous 
negotiations they all participated in one general pattern of coordination.85 
                                     
85   OPP may impose a shape on the network but there are still various transla-
tions achieving this shape. While OPP is a result and a pattern for network 
building there are many tiny negotiations establishing the linkages that end up 
in the OPP formation. It is true that the recruitment of actors in Pasteur’s 
France drew on the OPP, but still each negotiation was pursued differently, 
Latour [1984] 1988. Each translation required its own challenge. Farmers, 
politicians, hygienists, veterinarians had to be enrolled in different ways – al-
beit always with the goal to funnel them through one institution. In spite of 
the differences the OPP does in fact impose one similarity in all the coordi-
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 All loops do not work like this. Actors sometimes exist in networks or 
worlds that constrain the way they can be associated to other networks. 
What if the linkages between actors did not totally transform them all 
and in equal manner? Again, with reference to Mol: Studying an actor-
network as the associations of heterogeneous actors from the perspective of 
one single network formation may have a homogenizing effect, unsuitable 
for a reality of many networks and different kinds of associations: 
it may be that, at least in each empirical study, it is possible to follow the 
associations made within a single network. But what if there are two or more 
networks? How then to articulate the difference between associations within 
and between networks and – more important still – might it be the case that 
different networks hang together in different ways, are there different kinds of 
association? (Mol 2002: 70f) 
If multiple loops are meant to capture such differences, then the totally 
transforming and hegemonic character of the OPP model fall short – at 
least on its own. In Chapter 1, I explained the notion of multiple loops 
with reference to Latour’s The Pasteurization of France. The biggest pro-
blem probably arises when the translation model is elevated to be the 
main, or the only, way to understand how actors behave and coordina-
tion happens. There is now no need to do this, since there are other 
available ways sketched in the literature.  
 Mol exemplified how the disease atherosclerosis was enacted in many 
hospital practices, such as calibrating test results through correlation stu-
dies, thus creating common measures for incommensurable tests (p. 84). 
Another form of coordination is to add up test results that do not conflict 
or if they do, establish hierarchies for which test is most important. Also 
terms can be a mode of coordination. The disease is named differently 
depending on whom you talk to implying that none of the places and 
none of the practices have the privilege to define what atherosclerosis is 
for all the others. The disease is distributed on many practices, and mul-
tiplied, but still hangs together (p. 117). Mol’s description of atheroscle-
rosis and its multiplicity hanging together, without “pluralization” and 
separation, reminds of Star and Griesemer’s boundary objects. Diverse 
actors are coordinated without consensus through the flow of objects to 
multiple practices. The diversity of social worlds fits Mol’s multiplicity.  
                                                                                                                 
nation work: All actors are changed and they become so through the activities 
and conditions of the Pasteur Institute. 
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A dialectic of boundary objects and points of passage 
In the previous chapters the OPP model and the boundary object ap-
proach were both applied to the case of hESC research. I suggest that 
both of these accounts were correct, but concerned specific loops. OPP 
and boundary objects signify the modes of coordination in different loops. This com-
bination of OPP and boundary objects requires that the former does not 
concern all of the circulatory system of science and society.  
 In the classic studies by Latour, Callon, and Law, the OPP was the mo-
de of coordination. The OPP was a pattern for the attempt to form an 
actor-network out of heterogeneous entities. When I suggest that the 
OPP merely concerns one loop, and not all of the loops, I localize and 
relativize this mode of coordination to make it fit multiple reality. 
 This is also what Vissac-Charles suggested in her study of two innova-
tion projects: Rather than the description of one single network, the 
OPP is a pattern that emerges as several networks are combined, at the 
“butoir”, the gateway (Vissac-Charles 1998). Unlike the original OPP the 
notion here does not signify the stabilization of a whole network at once, 
but the association of two networks. Similar to the original cases, Vissac-
Charles’s OPP is an either-or with a lot at stake. The negotiations thus 
concern association or not, rather than differentiated or partial commit-
ments.  
 Crucial to her analysis is, however, also the delimitations of a project. 
It has an inside and an outside, and the construction of the boundary 
between them is essential. A project can interact directly with another 
network through a boundary object. Nevertheless, the object will also re-
late in a more indirect way to other, longer stretched-out networks, Vissac-
Charles claims. In those cases the object will be the recipient of prescrip-
tions from these other worlds, and vice versa: The object will convey pre-
scriptions for the surroundings.86 Such mutual, two-way prescriptions for the 
project and for the surrounding worlds are obligatory points of passage 
in Vissac-Charles’s terms (Vissac-Charles 1998: 299). The boundary ob-
ject and the OPP are mutually connected. If you choose a certain boun-
                                     
86   Vissac-Charles’s use of prescription refers to the notion of inscription presen-
ted by Akrich 1993. I will not elaborate on the full import of Akrich’s (or 
Vissac-Charles’s) notion of prescriptions. For the purposes below it is suffi-
cient to note that the configuration of boundary objects among some actors 
results in the OPP instructions or restrictions for other actors. Thus the two 
modes of coordination are linked to each other. 
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dary object you are also committed to a certain OPP. There is thus a 
choice, the configuration of the former actualizes and shapes the latter, 
the modifications of the former redefine the corresponding OPP. 
 Vissac-Charles’s approach can be used as one way to address the ma-
nagement of multiple loops. This is applicable to the case of hESCs. The 
hESCs are involved in an OPP and in a boundary object coordination. 
They coordinate certain actors within a project. For these actors the stem 
cells can mean a number of things and be turned into multiple uses. hESCs 
are real in proportion to the links to scientists, corporations, bioethicists, 
and patients. In November 1998 there are also a number of actors on the 
outside. The Federal administration is positive, but still at the time (pro-
bably, depending on the interpretation) prohibited from funding the re-
search. Because of this, the large institutional network of university de-
partments is on the outside (including laboratories, tools, and scientists). 
Also on the outside are the actors who explicitly position themselves as 
opponents. The Senate hearings are summoned in order to negotiate the 
boundary between hESCs and the outside. By bringing in the outside, 
another kind of association is at stake, including the funneling and do-
mination of federal funding, together with the staunch uncompromising 
mode of the pro-life opposition. It is in this way that hESCs become an 
obligatory point of passage.  
The localized OPP 
A combination of Vissac-Charles’s approach and Latour’s multiple loops 
provokes two questions: What is the relationship between the two 
“hESCs” – the hESCs as involved in a boundary-transcendent coordina-
tion and those of the OPP-like coordination? And, what do these two 
concepts now mean, in contrast to their original meaning? As already 
described above, Vissac-Charles uses the notion of OPP differently than 
in the earlier works by Latour and Callon. More than the description of a 
single network, the OPP denotes a pattern emerging in the combination 
of several networks at the gateway (or “butoir”). The notion thus does 
not signify the stabilization of a whole network at once, but two adjoining 
networks. As with the original notion, Vissac-Charles’s OPP does signify 
high stakes in an either-or mode. Negotiations aim for successful assso-
ciation – or not – instead of degrees of commitment.  
 Following Vissac-Charles, the OPP has two faces relating to two sides 
of a relationship. Inside and outside actors have to accept the prescriptions 
entailed in the OPP, respectively. From “the inside” (i.e. among suppor-
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ters) the hESCs were intentionally articulated in relation to federal 
funding. This choice underlies the hearings. Senators Harkin and Specter 
are frank about their intentions to insert hESC research into the federal 
institutional and financial network, as are the majority of testimonies. They 
are there to negotiate the association of federal funds to hESC research. 
The subject matter on our hearing today arises from a provision of the legi-
slation reported out by this subcommittee last year, which limits the use of 
Federal funds for research on human embryos. That is an issue which has co-
me into sharp focus with very dramatic recent medical developments, warran-
ting a closer analysis or perhaps a reanalysis of that question. (US Senate 1999b: 
1) 
The OPP in Vissac-Charles’s version is thus no longer a group of re-
searchers (cf. Callon), an institution, or a laboratory (cf. Latour). It is a 
passage from one network to another, a checkpoint on the common 
boundary of two networks that somehow do not communicate or co-
operate as directly as do the inside actors. Vissac-Charles describes the 
OPP-boundary object dialectic in her case study of the automatic apple-
picker Magali. 
For instance, the boundary objects “vision” and “arm” of Magali create the 
obligatory point of passage “flat trees”. This means that for the alliance with 
apple cultivators the robot can only pass through this type of tree, but 
reciprocally, the apple cultivators will have to agree with a kind of flat tree to 
connect to Magali. At each obligatory point of passage you can find corresponding 
alternatives: you passed through the flat trees but you could have passed 
through the round trees etc… (Vissac-Charles 1998: 300, her italics, my trans-
lation)87 
In Vissac-Charles’s case the OPP is not as potentially dominating as the 
federal funding of hESC research. The farmers can choose other solu-
tions. In the USA, taxpayers will not be able to avoid funding hESC re-
                                     
87   Because of the lack of authorized translation I attach the original quotation:  
Par example les objets frontières “vision” et “bras” de Magali créent le 
point de passage obligé “arbres plats”. Ce qui veut dire que pour s’allier à 
des arboriculteurs le robot ne peut passer que par ce type d’arbre mais 
réciproquement, les arboriculteurs devront se rallier à une forme d’arbre 
plate pour se connecter à Magali. A chaque point de passage obligé on peut faire 
correspondre des alternatives: on est passé par des arbres plats mais on aurait 
pu passer par des arbres en boule etc... (Vissac-Charles 1998: 300) 
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search if federal funding is allowed (unless they stop working or stop 
paying taxes). In addition, the latter has an authorizing and stabilizing 
effect for future stem cell research that is not covered in Vissa-Charles’s 
study. 
 The obligation of the OPP is two-way and consequently has two mir-
ror images on each side of the passage. For the project there is an 
obligation: The configuration of the boundary object creates a specific 
passage. Inside actors link to the outside through this particular object 
(robot for flat trees). The inside-actors cannot reach the farmers who use 
round apple trees. For the surrounding actors, the OPP prescribes that 
only certain actors can pass, and in certain forms (flat trees). The farmers 
must have flat trees to use the resources of Magali. The OPP is not a group 
of researchers or an institution, but the configuration of the gateway be-
tween two networks, between an inside and an outside. On the one side 
the OPP may involve a group of actors (apple cultivators) and on the 
other side there may be an object.  
 This is the answer to the above question of how the boundary object 
and the OPP can not only co-exist in the same study, but also co-produce 
each other. Settling for a specific boundary-object, or in this case the ob-
ject of a distributed coordination, will simultaneously create an OPP. 
And vice versa, the presence of a specific outside network may shape the 
distributed coordination of “inside actors”. While coordinating some ac-
tors in a distributed coordination the hESCs are also articulated as an 
OPP for the outside, consisting of pro-life actors and the Federal admi-
nistration. Articulations of hESCs are both prescriptions for action and 
descriptions of multiple uses and existing flows. But, vice versa, the federal 
network is constraining what sort of research is possible. The existing 
regulations are a narrow gateway for hESCs. In 1998–2001 many claimed 
that hESC research could not pass through the gateway without a legal 
change.  
 The ban on federal embryo research is the OPP from the one side. It 
“has come into sharp focus” – in the words of Senator Specter (US 
Senate 1999b: 1) – because of the development of hESCs, i.e. the other 
side of the OPP. The OPP is not an object (e.g. the hESCs), or an insti-
tution (e.g. the Federal administration). It is the point of contact between a 
network already involved in hESCs and a network (still) “on the out-
side”. If this definition sounds vacillating, it is correct. It is vacillating in 
the oscillating sense. Since the OPP notion is applied here to capture 
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how flows are interacting it should be a vacillating definition. OPP is 
used more locally and more fluidly than in the original sense.88  
 Applying the localized vacillating dialectic of boundary objects and 
OPP to the hESCs says something about how different the loops of 
hESCs are in relation to corporations, individual scientists with private 
funding, patient organizations, and bioethicists on the one hand and on 
the other hand in relation to the huge stakes and “bivalent” association 
of the Federal administration in the context of abortion disputes. The 
loops on the inside are all contributing with their linkages and it is 
difficult to assess whether one linkage is gravely more important than 
another. However, the outside circulation of federal funding is of another 
magnitude, not comparable to the other linkages. Its degree of 
stabilization is more far-reaching.  
 In my answer to the questions that started off this chapter, I suggest 
something similar to Vissac-Charles. However, now the OPP and boun-
dary objects are applied to the loops of the circulatory system of science 
and society. Boundary objects and OPP says something about how dif-
ferent the loops of hESCs are. The differences appear between corpora-
tions, individual scientists with private funding, patient organizations, 
and bioethicists on the one hand, and on the other hand the huge stakes 
and “bivalent” association of the Federal administration in the context of 
abortion disputes. The loops on the inside all contribute with their link-
ages and it is difficult to assess whether one linkage is substantially more 
important than another. However, the outside flow of federal funding is 
of different magnitude, not comparable to the other loops (see Figure 
10). Its degree of stabilization is more far-reaching. That is, unless the 
Federal administration decides to commit merely partially, as Bush did in 
August 2001. 
 
 
 
 
 
 
                                     
88   Vissac-Charles is not alone in using OPP in this localized fashion, Epstein 
1996, Law and Callon 1995. 
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An alternative point of passage 
 
 
 
 
 
 
 
The magnitude of stabilization at stake was also evident when federally 
funded hESC research was opposed. If federally funded hESC research 
was an attempted OPP, then what did opponents attempt, for instance 
Doerflinger?  
This subcommittee has now held three hearings on one narrow avenue of 
research, precisely the avenue that raises the most obvious moral and legal 
problems, so far to the exclusion of all other alternatives, even when those 
avenues may be more promising. The use of adult stem cells, for example, is 
said to promise the complete avoidance of the tissue rejection problems that 
Dr. Varmus has noted still need to be solved using embryonic cells. I would 
urge the subcommittee to expand its vision, to explore the alternatives that 
will advance medical progress and the wellbeing of patients without demea-
ning human dignity. (US Senate 1999b: 132) 
Figure 10: The hESCs as OPP and boundary  
objects in multiple loops. 
hESCs 
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According to Vissac-Charles, each OPP has corresponding alternatives: 
“At each obligatory point of passage you can find corresponding alter-
natives: you passed through the flat trees but you could have passed through the 
round trees etc…” (p. 300) Although of an “absolute” character the OPP is 
not necessarily the only alternative. This tallies with one of the few 
dogmas of the patchy field of science and technology studies, often in 
the words of interactionist sociologist Everett Hughes: “things could 
have been otherwise” (Fujimura 1996: 148).89 Vissac-Charles’s assertion 
about alternatives is a consequence of the contingency of nature and 
society. She does not take the final step to actually speak of alternative 
points of passage (APPs). I suggest that it is useful to not only speak of 
OPPs, but also of APPs. Such APPs are not mentioned in Callon and 
Latour, but fit well with the general scheme of actor-network theory.  
 The alternatives to the OPP may be more or less stable or important. 
If all the available points of passage are disputed and less stable the net-
work will split up (Vissac-Charles 1998: 300).90 In spite of the obligatory 
appearance of the OPP, “things can be otherwise”. Next to the OPP, an 
APP is suggested. Both passages concern the circulation of hESCs and 
federal funds. The two chapters have thus by means of the elaborations 
in this chapter resulted in a model of multiple loops and multiple modes 
of coordination. By means of this model the second meta-theoretical 
question is answered: 
(Meta-theoretical Question No 2): How can ANT account for the role of 
explicitly political actors in sociotechnical network attempts? 
ANT can account for the role of explicitly political actors by attending to 
the different modes of coordination that follows from specific actors. In 
the case of the Federal administration its influence may call for the use 
of an OPP model, whereas other actors are coordinated in other ways. In 
                                     
89   Facts and claims within natural science are not taken as being dictated by na-
ture herself. There are few necessities in the development of science, scholars 
have claimed. Here are a few examples that share this dogma: Bloor 1976, 
Cartwright 2000, Collins 1985, Giere 1999, Knorr Cetina 1999, Latour 1999b, 
Longino 2002.  
90   The Human Genome Project is one example of a split network. Instead of 
focusing on the federal funding, which wouldn’t go fast enough, Craig Venter 
chose to carry on by himself Fortun 1998. In the case of HGP it does not 
mean the abandonment or failure of the project but a modification of its 
course. 
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the case of hESC research the association to the Federal administration 
at first bore OPP-like traits (funneling and total transformation). Never-
theless, also the Federal administration can choose to connect in a more 
partial manner, as Bush did in 2001. There are no necessities here, but 
possibilities more or less actualized in various cases of coordination.  
A strong boundary object  
Above, the two chapters were reconciled in one model of multiple loops. 
It required localizing the OPP as one mode of coordination co-existing 
with boundary objects. In this final part of the chapter, the flows of the 
boundary object will be modified (the lower loops in Figure 10). I will do 
this by adding to the analysis in the previous chapter. 
 It does make sense to see the reality of hESCs in terms of the asso-
ciated actors and the possible uses, instead of an either-or depending on 
the success of a central entrepreneurial actor. However, in spite of these 
contributions there are four implications that challenge the analysis of 
hESCs as boundary objects. The first concerns the central status of hESCs 
in the analysis, resulting in a strong role for nonhuman agency. A second 
implication relates to the unit of analysis in Star and Griesemer’s case 
study. They did not investigate the stabilization of an object, but an insti-
tution, a museum. Thirdly, the hESCs have more content and agency than 
boundary objects have. A fourth problem is the role of the diverse actors 
and the multiple uses that are thought to address them. Together these 
make up glitches between the boundary object approach and the hESC 
case as it has been presented so far. Each problem also relates to central 
STS discussions about explanations. There are thus two issues at stake 
when the above analysis is scrutinized: the analogy with the boundary 
object approach and the explanatory value. While the problems may be 
terminal for the relationship between Star and Griesemer’s approach and 
the hESC case, they may also point out where to go next in the analysis 
of the sociotechnical reality of hESCs.  
 By seeing the hESCs as boundary objects involved in a distributed co-
ordination a new center is created. A responsibility and an agency are at-
tributed to the hESCs. In contrast to the OPP model the preceding sec-
tion did not explain the associations with reference to a skillful human 
but to the possible uses of a non-human object, the hESCs. Even if it is 
a distributed coordination, if one pays close attention to the multiple prac-
tices of diverse actors, the hESCs become an analytic and explanatory 
center.  
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 In one respect this is contrary to Star and Griesmer’s intentions. Their 
ecological viewpoint is antireductionist and thus they do not strive to find 
the cause behind coordination (Star and Griesemer [1989] 1999: 507). The 
sites are many and the translations too. No over-arching translation can 
explain coordination, they claim. But they also have clear explanatory am-
bitions. 
We see two major factors contributing to the success of the museum: methods 
standardization and the development of boundary objects. (Star and Griesemer 
[1989] 1999: 508) 
Museum workers managed both diversity and cooperation through boundary 
objects […] (Star and Griesemer [1989] 1999: 509) 
By finding the boundary objects, a factor contributing to coordination is dis-
covered. By drawing on the boundary objects analysis two things about 
the hESC case are suggested. The hESCs coordinated actors much as 
boundary objects did in the Museum of Vertebrate Zoology. An explana-
tion of an achieved coordination is thus offered, and it is done in terms 
of the central role of the hESCs. However, both of these suggestions can 
be challenged: Were the hESCs boundary objects? And does the analogy 
with Star and Griesemer’s case constitute an explanation? These ques-
tions will be explored below. 
The lack of management and project of hESCs  
To approach the question about boundary objects it is necessary to 
understand exactly in what way these were “a major factor contributing 
to the success of the museum” studied by Star and Griesemer. The 
boundary objects are not as “unproblemized” as the hESCs have been in 
this chapter. It is true that the boundary objects have an explanatory role 
and are one of the main factors, but it is the management of boundary 
objects that coordinates actors, in contrast to the translation of interests 
through one OPP. The nonhumans – repositories, ideal types, coincident 
boundaries and standardized forms – coordinated diverse actors by being 
suitable for multiple uses. However, the flow of boundary objects among 
diverse actors did not happen because of their inherent capacities. No, it 
happened because they were crafted, managed, and maintained – by 
humans – in order to fit the actors of distinct social worlds. Thus the 
boundary objects did not “do the coordination” by themselves. Their 
agency was in fact quite weak, compared to the managing humans. 
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 There may be management of the hESCs, but if so, the previous 
chapter did not described it. In this respect the hESCs are not boundary 
objects. If there is no management going on in either the actual, empi-
rical case or in the analysis, the boundary object analogy breaks down. 
What is left is a powerful object with the capacity to coordinate many 
actors through its multiple uses.  
 A second failure of the analogy concerns the purpose of the boundary 
objects. They “contributed to the success of the museum”. Boundary 
objects are important, but not the units of analysis and not the end 
product. “The unit of analysis is the whole enterprise…” (p. 507). The 
management of boundary objects is a mechanism to understand how an 
institution or a project is successful amid diverse actors. So far, no 
institution or project has been presented in which the hESCs were part. 
The previous chapter served to describe and understand a partial 
stabilization of hESCs: The coordination of diverse actors and their 
associations to the hESCs. But, if this is the project, then the hESCs are 
boundary objects in the project of coordinating actors around hESCs. 
The hESCs are the means (boundary objects) and the end (the project). 
That seems to be a circular explanation.  
 However, it is not primarily an explanation (in the strictly causal sense) 
but an analysis or understanding of how coordination happen. And, it is 
not that circular – more circulatory. The boundary-object approach made 
tangible the flow of hESCs among diverse actors by bringing out the 
multiple uses of stem cells which enabled the coordination. Multiple uses 
were in turn made possible by the capacity of pluripotency. Multiple uses 
in biology and medicine were complemented with the ethical use of fro-
zen embryos. More than a circular explanation, the multiple uses enabled a 
circulatory understanding by indicating the flows of hESCs among diverse 
actors.  
The elements of the hESC package 
This indicates a third failure of the boundary object analogy. Even if 
there may exist an underlying project of coordination drawing on hESCs, 
the latter are more than mere means. In Star and Griesemer’s case study 
the coordinating objects are barely constraining actors. That’s their 
advantage. Ideal types, repositories, standardized forms, and coincident 
boundaries, determine the forms of cooperation, by being weakly structu-
red in common use and open-ended about the ultimate content. Such boun-
dary objects are initially empty – more than black – boxes to be filled by 
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diverse actors. They are forms more than content. hESCs are not empty 
boxes, or merely forms or means. Seeing hESCs as boundary objects (in 
Star and Griesemer’s sense) is thus dissatisfactory for analytical and em-
pirical reasons.  
 Empirically, they have already, in this account, proven to be more than 
empty. The stem cells are indeed plastic and flexible, but considering the 
strong opinions this is not all there is to them. They are not only weakly 
structured in common use, but also constraining and defining. hESCs are 
clearly more than malleable boxes. They are flexible, i.e. pluripotent, but 
they are also constraining actors in specific ways quite unlike boundary 
objects. They are defined and constrain actors by way of three elements. 
 When examining the actors’ articulations of the hESCs, it is not as sim-
ple as in the Figure 10 above. hESCs are being circulated, but together 
with a number of elements. Three of these seem to be more crucial and 
more closely linked to the hESCs than many others. This was clear in 
both of the preceding chapters. Except for referring to the hESCs, as a 
common term central for their linkages, the hESCs that are circulated 
among actors are pluripotency, transplantation therapies, and ”spare em-
bryos”. There are others too, but I shall focus on those three here since 
they are not limited to one specific group, but appear in the articulations 
from diverse actors. 
 In Chapter 2, as actors extended the cells from the laboratories to 
people, businesses and medicine, they did so by referring to pluripoten-
cy. Because of pluripotency, they explained, hESCs can do a lot of things 
for patients. The alternative stem cells questioned the uniqueness of 
hESCs’ pluripotency. In Chapter 3 the point was that pluripotency resul-
ted in multiple uses. Apart from transplantation therapies, actors relate 
most easily to developmental biology. The third use in drug screening 
was not endorsed in more detail by many actors at the time. Whether in 
the OPP/APP-mode or in the boundary object mode of coordination, 
pluripotency was a stable linkage in two ways. Pluripotency was stable by 
being a resource for proponents and opponents. Nobody questioned that 
there was such a thing as pluripotency. It was stably linked to the hESCs, 
but maybe also linked to a different type of stem cell.  
 Another agreement between opposing actors in 1998–2001 was the ur-
gency and the possibility of transplantation therapies. When Doerflinger 
and others suggest adult stem cells in the hearings they do so because 
they accept the need for transplantation therapies. Some dispute this very 
need, but they are substantially outnumbered by the references to alter-
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native paths to reach the same goal. Alternative paths or not, hESCs are 
thought to result in such therapies. Whether actors agree about federal 
funding or not, the hESCs are articulated in relation to transplantation. 
Central to the analysis drawing on boundary objects in Chapter 3 was the 
stem cells’ transformation into multiple uses among diverse actors. How-
ever, the stem cells are not doing these multiple things to anybody yet, 
but they are circulated as expected mediators of multiple use. What are 
seen are still merely the references to multiple uses. Out of the multiple 
uses one use is more prominent than the others, viz. transplantation the-
rapies.  
 A last flow of the hESCs is the circulation of their source material, i.e. 
the already existing embryos. In Chapter 2 the ”spare embryos” were 
articulated in two ways in relation to the hESCs. Caplan exemplified the 
trade-off between ”spare embryos” and the “man in the wheel-chair”. 
Doerflinger exemplified the other articulation, but in the same mode of 
coordination: “But the question is the experiment involves ripping out 
the cells from what was before a living organism” (US Senate 1999b: 73). 
Embryos, whether “spare” or “living organisms”, are involved in a 
struggle and alternative, contradictory understandings. In Chapter 3 
another dimension of embryos was highlighted. They could contribute to 
the coordination in three ways. Some actors did not oppose IVF or the 
resulting left-over embryos, but still opposed their use in research. 
Others, notably some pro-life people in Congress, endorsed IVF and the 
resulting embryos, and therefore found hESCs in these embryos 
acceptable. Bush acknowledged the existence of already existing 
embryos, the IVF treatments, and hESCs from already discarded 
embryos. I called this a minimal contribution. As this element of hESCs 
circulates it is configured differently, but two aspects remain very stable. 
In all of these cases, when actors refer to the hESCs and their sources, 
they refer to the already existing or “spare” embryos. In most cases IVF 
and its production of such embryos is not questioned. The IVF over-
production of embryos is a stable element linked to the hESCs via the 
”spare embryos”.  
 It is notable how the elements play different roles. In spite of diffe-
rences on the use of embryos in research, most actors agree about the 
value of transplantation therapies and of pluripotency. The “spare em-
bryonic” element in articulations of hESCs is an element of disputes in 
the OPP/APP, but contributes to making the stem cells a boundary-
transcending meeting-point, especially for some pro-lifers. These three 
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elements were, in 1998–2001, more or less stably linked to the hESCs by 
the actors.  
 When the multiple loops, the distributed coordination and the three 
elements are combined, the hESCs were not necessarily one boundary 
object, but rather like a boundary package: The hESCs were involved in 
flows, but as a composite boundary object consisting of at least three 
elements.91 Latour posits multiple loops holding together one reference. 
There is still one reference here, but as soon as it is approached, it con-
sists of other elements. The hESCs are still involved in multiple flows, 
but as a composite entity. 
                                     
91   I use package here in a commonsense meaning, although inspired from the 
standardized packages of theory and methods in Fujimura 1992, 1996. How-
ever, Fujimura’s packages are much more structured than the boundary pack-
ages of hESCs ever were during the examined period. 
Figure 11: The multiple loops of the composite  
boundary object hESCs.  
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 Not only did the hESCs facilitate a distributed coordination, the stem 
cells were in addition themselves distributed objects consisting of three ele-
ments. In relation to patients, the transplantation therapies because of 
pluripotency were the great motivation, and in relation to scientists, plu-
ripotency opened up for new studies in developmental biology. For cor-
porations transplantation therapies and the economic gains were a major 
reason, and pro-life politicians could refer to the embryos that were al-
ready there the quite accepted practice of IVF. hESCs were thus distri-
buted in multiple flows by way of being composed of three elements.  
 Analytically, the hESCs could be treated as mere coordinators. Merely 
seeing hESCs as coordinators turn the phenomena – such as the “bio-
logical and political pluripotency” – into intermediaries for other agen-
cies, for the really real. This treatment is drawing close to a social explana-
tion. Biological representations are explained by means of social reality. 
The focus of this study is sociotechnical reality, including the multitude 
of agencies in the world. Boundary objects do have agency, but of a weak 
kind. Agency is what makes a difference. Star and Griesemer’s boundary 
objects are making a difference, but more as communicators and place-
holders than as constraining, defining objects with a specific content. 
From the theoretical choices made here the weak boundary objects offer 
a too limited kind of agency to account for the observed pluripotent 
agency of hESCs. I suggest that what we see is a strong composite boun-
dary object, a boundary package. 
 The absence of management, the lack of any explicit project, and the 
strong agency of hESCs are glitches between Star and Griesemer’s case 
of boundary objects and the hESC case of 1998–2001. If the purpose is 
to understand the sociotechnical reality of hESCs, the coordination and 
the distribution of agency, then the study does not stand or fall with the 
total similarity with earlier studies. Quite the opposite: hESCs provide an 
interesting case of boundary-transcending flows and a strong composite 
object. 
Risks for future unpacking analysis 
Harry Collins and David Bloor have each, on repeated occasions, accu-
sed ANT of “giving back” power to Nature, objects or scientific rationa-
lity (Bloor 1999a, 1999b, Collins and Kusch 1998, Collins and Yearley 
1992a, 1992b). By granting agency to nonhumans, ANT undoes what 
social constructivism, e.g. the Sociology of Scientific Knowledge (SSK), 
has achieved: the sociological explanation of scientific facts. According 
 
 
 
157 
to Collins the student of science and technology should do what s/he 
can, i.e. investigate social reality, in order to understand the natural reality 
represented by scientists. The analyst should not refer to natural objects 
in an unproblematic way, pretending to have the skills needed to inter-
pret them. Uses should also be relativized, representatives of the Social 
Construction of Technology (SCOT) have claimed (Bijker 1995). Just 
like scientific facts, the application of facts or objects should be relativi-
zed, and not be used as explanatory resources in an unproblematic way. 
To carry out natural realist or “diffusionist” explanations in terms of the 
capacities or uses of hESCs is the scientists’ task and competence. 
 To start with, the purpose of this work is not to explain in the causal 
sense suggested in SSK, but to understand, analyze, or unpack the reality of 
hESCs and how it came to be. Using OPP or the approach of boundary 
objects can be ways to see this reality differently. As this study continues, 
the explanatory import comes through re-describing, finding linkages 
between elements and actors, tracing stabilization, unpacking and seeing 
differently – not in finding causes. Still, the SSK critique is very useful 
for identifying how the analyst risks “reifications”, i.e. taking things for 
granted. I use SSK here as a help in improving my understanding.  
 Instead of involving boundary objects in the first place, the coordi-
nation of actors could have been sociologically and politically explained. 
There is a strong convergence among the human actors on the uses of 
hESC research, but this feature is in one respect not surprising. In fact, 
informed observers in November 1998 predicted a convergence among 
some actors on hESCs, for instance The Washington Post reporter, Rick 
Weiss. 
With the therapuetic potential of embryonic cells suddenly very real, advoca-
tes are calling for a reexamination of that ban, saying the development of life-
saving applications will be hindered if federal dollars remain off-limits. 
 Such a reexamination would pit antiabortion forces and other strong pro-
ponents of the funding ban against a powerful biomedical research lobby that 
has in recent years become popular with Congress and the public. (Weiss 1998) 
The exact meaning of the “biomedical research lobby” is not further de-
fined by Weiss, but there was a pre-existing coordination between vari-
ous research supporters. A coordination of scientists, politicians and pa-
tients had been initiated in the public negotiations of fetal tissue trans-
plantation starting ten years earlier, in the late 80’s. In these negotiations 
there had been polarization too, between two camps that agreed inter-
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nally, but not with each other. Patient organizations pooled their resour-
ces, and collaborated with scientists and politicians, around a therapeutic 
concept involving fetal tissue. Pro-lifers opposed. There were thus posi-
tions and alliances already shaped. These were not unique to the debates 
on hESCs.  
 “Antiabortion forces” and a “powerful lobby” – these are stuff for so-
ciological analysis of the reality of hESCs. Instead of attributing respon-
sibility to the hESCs the diverse actors’ interests and social positions 
could have been examined. What does it add to understand an already 
existing coordination of actors in terms of boundary objects (or 
packages)? And, what is the analytic role of the hESCs in the polarized 
American society in which allies had already been recruited?  
 If the coordination of actors merely followed a predictable political 
pattern, if the match was total between the abortion disputes and the hESC 
coordination, then an analysis drawing on the boundary object approach 
would say very little. However, the abortion debates were not identically 
repeated. Actors did not follow that pattern exactly. The major divergen-
ce was the pro-life actors who associated themselves with the hESCs 
even if they did not all fully support hESC research as a dominating and 
totally transforming activity. As the disputes of the previous chapter dis-
played, there was a polarization in the debates about hESCs. By exa-
mining the boundary-transcending features of the hESCs a third range of 
options comes into view in a space where actors can endorse the cells 
without agreeing about the total transformation. According to the analy-
sis of this chapter the space is due to the hESCs and their multiple uses. 
Whether this is an explanation or not, it is one positive result from ap-
plying the boundary objects approach: To get into view a space between 
and across the already existing boundaries between diverse actors. If it is 
not an explanation of the coordination, it still describes the relationships 
between actors via boundary-transcending objects.  
Already existing diverse actors and uses  
However, the boundary-transcending feature is not enough to make the 
hESCs boundary objects, at least not as Star and Griesemer defined 
them. As important as this contribution may be, it constitutes a fourth 
divergence between this chapter and the approach of Star and Griese-
mer. Their case study on the success of the MVZ was pursued as an eco-
logical analysis in line with Everett C. Hughes’s ecology of institutions. A 
central feature is that the institution “chooses its environment” (Star and 
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Griesemer [1989] 1999: 506). In the creation of an institution the sources 
of funds, clientele and personnel are chosen, created and not given 
beforehand, much as in actor-network theory. ANT has criticized earlier 
social explanations in terms of interests. Instead of assuming pre-existing 
social forces, such as interests, society should also be relativized. If not, 
the analyst becomes a natural relativist, but remains a social realist. 
Accepting the multiple uses of hESCs among diverse actors whose 
identities are already given is thus not only a misfit between Star and 
Griesemer’s case and the hESCs, but also constitutes a serious analytic 
weakness in relation to the frames of this work.  
 The boundary-transcending space created by the hESCs is due to the 
multiple uses that speak to diverse actors. In contrast to the ecology of 
institutions and the boundary-object approach, there is no sign, in the 
above analysis, of how this environment is chosen. Diverse actors are al-
ready there, and the multiple uses of hESCs address their needs. Accor-
ding to ANT “uses” and “actors” are not given beforehand, but are con-
structed. What is not answered by noting diverse actors and multiple 
uses, are how the identities of diverse actors were created and how the 
multiple uses became mutually recognized as uses. Even if the hESCs in 
1998–2001 clearly occupied a role and a space between diverse actors in 
the midst of a polarized American society it does not immediately make 
the cells boundary objects (or packages). Furthermore the empirical ma-
terial provides a tiny slice of articulations. It offers a snapshot account of 
an actor-network and distributed coordination. Due to this snapshot the 
process leading up to the flows of coordination are omitted.  
 Noting the central role of hESCs and their multiple uses in the co-
ordination of diverse actors is, in spite of these objections, not trivial. By 
applying the boundary-objects approach instead of the OPP model the 
partial stabilization, the relative and multiple reality, and the distributed 
coordination have been brought out. These aspects of the hESCs stand. 
However, in comparison with Star and Griesemer’s case study and in re-
lation to the theoretical issues of the literature these aspects are less of an 
explanation and more of an observation that needs to be unpacked. Such 
unpacking does not necessarily have to agree with Star and Griesemer, as 
long as it does not claim to do so. The boundary object approach is one 
tool, among many, to understand coordination. But, according to the theo-
retical commitment of this study, an understanding of hESCs should try to 
avoid dividing reality into a natural and social realm. Rather than making 
human or nonhuman actors unproblematic resources, they are the ones 
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in need of analysis. Where does the future investigation go to better 
understand the emergence of hESCs, their multiple uses, and the 
identities and linkages of the diverse actors?  
Stabilizing movements 
In ANT there is no outside explanation, no reduction of events to things 
that the actors themselves are not associated with. Following the actors, 
as is recommended by Latour, serves this purpose: to find the associa-
tions. This is why the actors were followed as they took the analysis back 
to the hESCs. It was the actors who attributed the responsibility for their 
linkages to specific uses of the stem cells. Sometimes they did more, 
directly referring to the multiple uses for other and diverse actors, almost 
as if they had read Star and Griesemer. Some of the illustrations (without 
the terms) could function as generic maps for the flows of boundary ob-
jects. Thus, the “boundary object-like explanations” of the coordination 
are offered by the actors. I have not intruded on the actors, only juxta-
posed their explanations with Star and Grisemer’s case. Based on this 
precedent I drew the implications for the reality of the hESCs, the modes 
of coordination and the distribution of agency. It is recommended in 
ANT to listen to the actors’ explanations, since they are usually doing as 
much sociology, or even socio-technology, as the analyst. If this is taken 
seriously (and actors are recognized as sociologists), SSK has asked, what 
then distinguishes the analyst from the actors? If the analyst merely 
follows the actors’ twists and turns, what then is the critical potential?  
 ANT is less naïve than its recommendations may at first seem. To see 
what sort of understanding this chapter amounts to, two movements in 
the coordination of actors should be distinguished. Going back to La-
tour’s study again, coordination was allegedly achieved by positioning 
Pasteur and his laboratory as an OPP. Latour’s concept works by captu-
ring two related movements in the building of facts and the coordination 
of actors.  
So as not to be confused, we should distinguish the recruiting of allies so as to 
build a fact or a machine collectively, from the attributions of responsibility to 
those who did most of the work. By definition, and according to our first 
principle, since the construction of facts is collective, everyone is as necessary 
as anyone else. Nevertheless, it is possible, in spite of this necessity, to make 
everyone accept a few people, or even one person, as the main cause for their 
collective work. [---] The two movements must be carefully distinguished […]: 
the recruitment of allies supposes that you go as far and make as many com-
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promises as possible, whereas the attribution of responsibility requires you to 
limit the number of actors as much as possible. (Latour 1987: 118–119)92 
Pasteur and his institute were an OPP as a result both of Pasteur’s entre-
preneurial activities and of other actors’ (chiefly the hygienists’) attribu-
tion of responsibility.93 OPP is Latour’s term, but all it does is to capture 
those two movements of the actors. Both movements were centered on 
Pasteur and his Institut, and were thereby mutually reinforced. Because of 
Pasteur’s skills in recruiting allies he could be attributed responsibility for 
what others wanted done and hence enable their recruitment of allies.  
 The OPP cases differ. When Star and Griesemer contrast their model 
with that of Latour, Callon and Law, they only point to the OPP as a 
way to recruit allies. The boundary objects are then another way of doing 
this. This juxtaposition fits Callon’s and Law’s cases, but less Latour’s 
since his OPP (Pasteur and the Pasteur Institute) resulted from both of 
the movements and their mutual reinforcement. What is overlooked when 
treating the boundary objects as an alternative mode of coordination is 
the existence of the second movement, the actors’ possibilities to attri-
bute responsibility.  
 While Latour is very explicit about the OPP as a combination of 
Pasteur’s behavior and others’ creation of The Pasteur, Star and Griesemer 
only focus on actors’ collaboration without any attributions of responsi-
bility. Interestingly, the previous chapter captured the latter movement in 
                                     
92   To streamline Latour’s extract I omitted the part of it that directly addresses 
Pasteur’s role in the two movements. 
Pasteur, for instance, not only recruited many sources of support, but 
also strove to maintain his laboratory as the source of the general move-
ment that was made up of many scientists, officials, engineers and firms. 
Although he had to accept their views and follow their moves – so as to 
extend his lab – he also had to fight so that they all appeared as simply 
“applying” his ideas and following his leads. (Latour 1987: 118) 
  What Latour does not mention here is the use the hygienists made of Pasteur 
as the authoritative source of the movement, [1984] 1988. Also, Latour focu-
ses on the separation of the two movements and slightly overlooks what I call 
their mutual reinforcement. 
93   In the rest of this section I will follow Latour’s use of attribution of responsibility. 
In relation to the terminology introduced in Chapter 1, and in the Glossary, 
attribution of responsibility would fall under the notion of delegation. Actors 
are delegating agency to Pasteur, or to hESCs, when attributing responsibility. 
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terms of a boundary object coordination. Rather than someone, actors at-
tributed responsibility to something(s), viz. the hESCs.94 Just as many ac-
tors, especially the hygienists in late 19th century France made Pasteur a 
saint, the hESCs are attributed responsibility for the multiple uses and 
the subsequent coordination of actors.  
 In 19th century France there were strategic gains in the hygienists’ attri-
butions of responsibility to Pasteur. He was an authority. Likewise there 
may be strategic gains as diverse actors explain their own linkages to the 
multiple uses of hESCs. Considering the domination at stake, and the 
polarization, the strategic gains may have been even greater in the USA 
1998–2001. Attributing responsibility to an object may be the best 
option to recruit allies, as there were few human actors that could rise 
above the pre-existing polarization.  
 In a pluralist society – and in relation to federal funding: a polarized 
landscape – diverse actors cannot hope to change each other fully, or 
make everybody follow one person. Thus it may be strategic to gather 
around an object that speaks to multiple needs and uses. It becomes 
important to create a society and nature, for instance socially diverse 
actors and natural, naturally existing objects. When the hearings are set 
up, a society in miniature is created by calling in representatives of busi-
ness, bioethics, patients, and scientists. The same happens in media, in 
panels, and reports. Diverse actors are continually appearing to represent 
groups of actors or social worlds. A natural reality is also set up that 
relates directly to this sociology. The multiple uses of hESCs are articula-
ted not only by scientists, but by other actors too. For all of these actors 
there are natural and technological causes behind their linkages. Together 
they are performing a socio-technical explanation of their coordination, 
attributing the responsibility to the hESCs and their multiple uses.  
 This does not mean that actors are lying or fooling the onlooker. Even 
if the actors thus enact social and natural realist explanations, nothing 
stops the analyst from going further. Attribution is related to the actual 
recruitment, at least in the case of Pasteur. He could be attributed re-
sponsibility because of the associations with microbes and other things 
that he had already achieved. Pasteur’s agency could be reinforced be-
                                     
94   Latour explicitly talks of attribution of responsibility to someone, not something. I 
dispose of this application of asymmetry between humans and nonhumans 
and assume, in full accordance with ANT, that something can be made re-
sponsible as well as someone.  
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cause it was already strong. The recruitment of allies and the attribution 
of responsibility mutually reinforced each other, producing the OPP. 
Was there a similar mutual reinforcement in the hESC case? If so, then 
the hESCs could be attributed responsibility because of an already achieved 
recruitment of allies. The actors’ ‘boundary object-like’ explanations point 
the way for further analysis.  
 After the criticisms from SSK about natural realism, and the ANT 
dissociation from social realism, it is clear what kind of understanding is 
desirable. Human and nonhuman actors – such as the hESCs, diverse 
actors, and multiple uses – are not resources, but objects of explanation. 
The big question, after following the diverse actors’ attribution of 
responsibility to the hESCs, is how and why these nonhumans could 
coordinate so many actors. Instead of taking for granted the multiple 
uses of hESCs, the question is where these uses came from. Instead of 
taking for granted the actors’ needs for those uses, the question is where 
their needs came from. Asking those questions is necessary in order to 
avoid both social realism and a naïve, natural realism, which is also to 
take Collins’s and Bloor’s challenges seriously. 
Summary 
This chapter has taken stock of the previous Chapters 2 and 3. From 
Chapter 2, the OPP attempt left loose threads of which some were pick-
ed up by the application of the boundary object approach in Chapter 3. 
The observation of a relative, non-centralized and distributed stabiliza-
tion fitted the latter approach. In this sense the hESCs were involved in 
a boundary object-like coordination. The funneling and central role of 
the government as well as the claims of wholesale transformation of Ame-
rican medicine were still best subsumed in the OPP model. While this 
could be conceived as separate actor-networks or separate treatments of 
distinct patterns of hESC articulations such a separation is difficult to 
uphold in relation to the empirical case. There was not only co-existence 
of the two patterns, but perhaps even co-production. Actors’ partial 
commitments and the relative stabilization of the hESCs may have been 
part of the OPP attempt. In any case the same actors were involved in 
both patterns. 
 Theoretically an answer to this puzzle amounted to stressing the diver-
gence between the two approaches. The OPP totally transforms and mo-
ves heterogeneous actors, while boundary objects coordinate diverse actors 
who are already engaged in practices and social worlds. In Pandora’s Hope 
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Latour steps back from fundamental heterogeneity and speaks of clumps 
of actors contributing to the stabilization process through multiple loops. 
Annemarie Mol has emphasized the need for several modes of co-
ordination instead of homogenizing networks of associations. OPP and 
boundary objects may be such modes of coordination. To combine the 
two modes in the same study they must be used more localized than in 
earlier case studies. They could, via Vissac-Charles’s example, be used to 
capture the connection points between networks – or multiple loops.  
 In the final section the analogy with Star and Griesemer was questio-
ned, as was the explanatory value of the analogy. Star and Griesemer 
looked for the mechanisms behind the success of a large institution, the 
Museum of Vertebrate Zoology. The management of boundary objects was 
a main factor in this success, by establishing the appropriate environment 
for the museum: the participating actors from diverse social worlds. So 
far, the analysis has neither included any management of the hESCs nor 
any purpose of the coordination (e.g. a larger institution or project).  
 The observations in Chapter 3 also called for an innovative addition to 
the boundary object. More than being merely forms and means for 
coordination the hESCs have a strong content, constraining and restric-
ting actors. This was evident when acknowledging the sources, the uses, 
and the capacities of the stem cells. It seems to be more of a boundary 
package than a boundary object. The partial stabilization and distributed 
coordination are boundary object-like traits. The coordination of diverse 
actors is brought out by drawing on Star and Griesemer’s case. Amid 
polarized actors the hESCs constitute a meeting-point, a space for colla-
boration, whether or not the stem cells were boundary objects. 
 Besides discrepancies between the MVZ and the hESCs the unpro-
blematic treatment of hESCs, their multiple uses and the diverse actors is 
open to criticism. In line with Collins’s and Bloor’s critique the analysis 
may treat hESCs in a natural realist manner. In contrast to the ANT in-
tentions of this study human actors are treated in a social realist manner. 
Both natural and social realism are probably consequences of following 
the actors’ attribution of responsibility.  
 After acknowledging the critique the question arises: What is the way 
out of this trap? Since there are no realities in ANT other than the articu-
lations and the association of actors, there is only one way out: To con-
tinue following the actors. This recommendation is further specified by 
the notion of boundary package. The boundary-transcending coordination 
comes with a package. Actors probably would not be able to attribute 
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responsibility for their linkages to the hESCs and their multiple uses, 
unless a collective work had already been done.  
 

 PART II  
 

5.   A Project, its Problems, and Prescriptions: The 1994 
Human Embryo Research Panel  
Introduction 
Discerning multiple loops, the two modes of coordination and actors 
thus associated with the cells is one way to capture the reality of hESCs 
in 1998–2001. In spite of disputes and varying modes of coordination 
the cells were involved in successful flows among actors. This was espe-
cially tangible in Chapter 3 as the boundary-transcendence of hESCs was 
outlined. The hESCs were picked up by several groups of actors, and 
ultimately, in 2001, by pro-life politicians. More than an extensive analysis 
the previous chapters’ use of OPP, boundary objects, and multiple loops 
still merely amounts to observations of a reality in need of further inquiries. 
In other words, the second ANT question – to understand how the so-
ciotechnical reality of hESCs in USA, in 1998–2001 (in particular the 
public and political dynamics) came to be – still remains unanswered. Af-
ter part one, this question now implies:  
(Meta-theoretically modified Question No 2) How were the flows between 
actors and the three elements – frozen embryos, transplantation therapies, and 
pluripotency – of hESCs stabilized? 
The next three chapters will be devoted to answering that question. One 
way to unpack the reality of hESCs could be to look more closely at how 
diverse actors were linked to the hESCs between 1998–2001. So far, only 
very public articulations, e.g. testimonies in hearings, have been presen-
ted as traces of associations. It would be possible to go into the details of 
lobbying activities, funding initiatives, and the relationships between me-
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dia, politicians, scientists, patient organizations and bioethicists.95 How-
ever, when faced with the negotiations of hESC research one pheno-
menon soon jumps out. Many of the linkages that were described in 
Chapter 2 and 3 were articulated a few weeks or even days after the stem 
cells were introduced to the public. When the cells were announced as 
successful laboratory cultures in November 1998, the linkages to diverse ac-
tors were there already.  
 Although George W. Bush or the pro-life people of Congress had not 
yet come out in support of the cells, Chapter 2 displayed how actors tea-
med up around the cells immediately. Within a month from their intro-
duction they were circulated among actors as if they had been there for a 
long time. Demands for political action were voiced on the day of the 
announcement. Hearings were organized within few weeks. Proponents 
articulated the cells almost in chorus; how appropriate the source mate-
rial was and the urgency of the medical promises. Later support from 
pro-lifers did not differ significantly from these articulations. The diffe-
rence lay in the degree of support, not in the understanding of what the 
hESCs were and why they were worthy of support. Most actors agreed 
about the package described in Chapter 3; that the three elements were 
intimately linked to the hESCs. To understand this early and rapid coor-
dination of actors and the configuration of the package it is not enough 
to look at the events between 1998 and 2001. Associations made from 
1998 and after, are only one part of the story. Another part must be the 
associations already forged. Pre-existing coordination and configuration 
of the hESCs therefore define the question that, in this chapter, will help 
me approach the stabilization of hESCs: What previous coordination of 
actors was there, and what previous traces were there of the elements of 
the hESC package? 
 To better understand how the multiple flows of hESCs were esta-
blished this chapter starts by going backwards to a point where the cells 
were still not laboratory objects, but nevertheless public entities.96 In 1994 
the hESCs were debated, although not separately, when they were a part 
of the deliberations of the Human Embryo Research Panel (HERP).  
                                     
95   To some extent this will be done in Chapter 7, mostly in relation to the re-
sponse within the scientific community and the management of scientific 
taxonomy. 
96   Although some scientists have in fact claimed that they had hESCs but did 
not fully characterize them, Parson 2004: 132. 
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 The first part of the chapter looks at these negotiations. The resulting 
mode of coordination could hardly have been more different in relation 
to the 1998 and, in particular, the 2001 situation. In striking contrast to 
2001, the negotiations of HERP did not result in partial stabilizations 
and an open-ended, boundary-transcendent coordination of actors, but 
in a total resistance to further research on embryos. This provokes a ques-
tion: How could the mode of coordination change so completely between 
1994 and 1998? One suggestion comes from the actors’ own attempts to 
improve the coordination after HERP. For those supportive of embryo 
research the outcome was regarded a problem in need of a solution. In 
their diagnoses of the perceived failure of HERP, two elements featured: 
embryos and therapeutic benefits. In relation to the change of coordina-
tion between 1994 and 1998, actors’ calls to reconfigure the benefits and 
source of embryo research are interesting, since the changes called-for 
correspond to the later articulation of hESCs and are thus an actually achie-
ved improvement in coordination.  
A human embryo research project 
Before 1994 the future use of hESCs was hypothesized, but such propo-
sitions were occasional and unsystematic (Bongso et al. 1994, Hollands 
1991, Pedersen 1994). Even in (non-human) ES cell research there was 
no major emphasis on the development of human ES cells. In the re-
search literature more time, energy and space were devoted to bovine ES 
cells for use in the cattle industry, or for developmental biology (Müller 
and Dzierzak 1994, Nakano et al. 1994, Schmitt et al. 1991, Trounson 
1994). This covert existence changes in 1994 when human ES cells were 
suddenly discussed more publicly for the first time in the USA. The 
public attention was due to the NIH panel, the Human Embryo Re-
search Panel. 
 Human embryonic stem cells were but a minor part. Quantitatively, in 
a word count, the share of hESCs was minimal. The 26-page chapter on 
the scientific and medical issues had one page on human embryonic stem 
cells. Of the four papers that were presented to the panel, that on scien-
tific aspects comprised 50 pages, of which three concerned hESCs (Van 
Blerkom 1994). Obviously this cannot be any exact measure of the role of 
ES cells in the deliberations. An ES cell biologist, Professor Brigid Ho-
gan, had been named science co-chair of the panel. The page number is, 
however, a reminder that the HERP concerned research on embryos, 
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which, among other things, included human ES cells. This was not least 
true for the subsequent legal developments. 
Embryo research moratoriums  
IVF research had been ineligible for federal funding since 1980 because 
of the absent Ethics Advisory Board (EAB). 97 This constituted a de 
facto moratorium on all embryo research. When Bill Clinton was 
installed as President in 1993 he lifted a then-existing moratorium on 
fetal tissue research. The Congress passed the NIH revitalization act 
together with new laws to enable federal funding on fetal tissue research 
from elective abortions (US Senate 1993b). It has been suggested that 
very few in Congress may have understood that a paragraph on embryo 
research was actually included in the act. The paragraph itself did not 
stick out. 
The provisions of section 204(d) of part 46 of title 45 of the Code of Federal 
Regulations (45 CFR 46.204(d)) shall not have any legal effect. (US Senate 
1993b: Title I, Subtitle A, Part III, Section 121, Paragraph [c]) 
“45 CFR 46.204 (d)” concerned the protection of human subjects. It was 
the requirement of an EAB approval for any project receiving federal 
funding, i.e. a crucial element of the de facto moratorium. According to 
Joseph Palca, of the National Public Radio, the removal of the paragraph 
was a new way to solve an old policy problem. 
For research administrators, it’s been frustrating not to be able to support a 
promising medical technology. Quietly, persistently, officials from NIH, 
particularly from the National Institutes of Child Health and Human Deve-
lopment, lobbied to end the moratorium. Their strategy was to convince their 
superiors in the Department of Health to reinstitute the Ethics Advisory 
Board.  
 In 1988 the plan nearly worked. The assistant secretary of health told Con-
gress there would be a new board, but plans for a new charter stalled, and 
when the Bush administration came into office, plans for a board were put 
back on the shelf. (Palca 1994) 
                                     
97   Since 1979, federal funding of embryo research had required the approval of a 
national Ethics Advisory Board. The EAB was set up in 1978. It was allowed 
to review one research proposal (from Dr. Pierre Soupart), Quigley and 
Andrews 1984. However, this board only considered one research application 
before it was disbanded and never reinstituted, Office of Technology 
Assessment 1988, US DHEW 1979, Fletcher 2001. 
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The “new solution” in 1993 was to simply remove the requirement for 
an EAB approval. According to Palca “[l]anguage doing that was slipped 
into the NIH Revitalization Act of 1993”. Whether Palca is right about 
the “slipping into”, or not (the inconspicuous nature of the paragraph 
does support Palca’s description), the legal change on fetal tissue trans-
plantation was used to remove the main obstacle for federal funding of 
IVF, the EAB requirement, and to de facto legalize federal embryo 
research. While there had been public debates and scientific disputes, 
that had mobilized new actors for or against fetal tissue research for se-
veral years, no such deliberations had preceded the legal change on em-
bryo research. A new law was literally packaged within the changing poli-
cies on fetal tissue transplantation, but very surreptitiously so.  
 There was no debate in Congress on 45 CFR 46.204 (d). Commen-
tators have suggested that very few in Congress knew about the lifting of 
the de facto moratorium at all (Engel 1994, Palca 1994, Tauer 1997). Pal-
ca wrote in the March/April issue of the Hastings Center Report to 
comment on the fact that NIH officials – in the absence of any EAB 
requirement – had decided to let another panel develop guidelines for 
future embryo research, now that it was legally possible.  
The panel is supposed to give a new set of guidelines to the director of NIH 
next June. After that, the government should start supporting a much broader 
portfolio of research in the new world reproductive technology. Quite an 
achievement for one small sentence. (Palca 1994) 
The achievement was however still not brought to a successful close. 
The attempt to implement a new embryo research policy together with 
the fetal tissue research policy suggested that the two sorts of research 
could be treated together and as, in some respects, the same. It was also 
built on the assumption that research on embryos could be included in 
the federal research portfolio without evoking substantial pro-life oppo-
sition. In spite of these implications the administration did feel a need 
for specific guidelines distinct from existing fetal tissue guidelines. By 
setting up the Human Embryo Research Panel for this purpose an exter-
nal, explicit deliberation of the tacitly changed policy could be brought 
into the open. Such a process of deliberation could involve a number of 
actors, including some with pro-life views. 
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The Human Embryo Research Panel – and problem 
The HERP had its first meeting, in February 1994, less than a year after 
the new fetal tissue policy had been passed and signed. The open hearings 
of the panel from February through June gave anyone inclined an oppor-
tunity to voice his/her opinions. Some were patients, some were repre-
sentatives of professional and other organizations. Most were opponents 
of embryonic research (Tauer 1995). Soon after the first hearings pro-life 
communities had been alerted about the new panel. According to Randy 
Engel, former director of the US Coalition for Life, “the national alarm 
was set off” (Engel 1994). Some 30–50.000 (depending on the source) 
written responses were sent to the panel (Charo 1995a, Green 2001: 59–
60, Schwartz and Devroy 1994). Philosopher participant of the panel, 
Carol Tauer, assumed that these were “linked to organized campaigns 
[…] since the wording was identical on hundreds of them” (Tauer 1995: 
31). This was an election year for Congress. Congressman Robert Dor-
nan, a conservative Republican, sent a letter in June to NIH Director 
Harold Varmus promising to block the recommendations of the panel 
through legislative action (Carmen 1996). Dornan already had thirty col-
leagues in the House of Representatives behind his promise. The pro-life 
rejection together with Congressional support was potentially dangerous 
in an election year.  
 The charge of the panel was research on the preimplantation embryo. 
Usually this means research on fertilized eggs that have still not been 
implanted.98 Three primary ethical considerations justified research on 
such embryos according to the “pluralistic ethical framework” accepted 
                                     
98   More specifically: the “extracorporeal” or “ex utero preimplantation 
embryos”. 
The Panel’s charge encompasses only research that involves extracor-
poreal human embryos produced by in vitro fertilization or from other 
sources, or parthenogenetically activated oocytes. Research involving in 
utero human embryos, or fetuses, is not part of the charge, since guide-
lines for such research are embodied in Federal laws and regulations go-
verning human subjects research. [---] Throughout this report, “ex utero 
preimplantation embryo” or “preimplantation embryo” refers to a ferti-
lized ovum in vitro that has never been transferred to or implanted in a 
uterus. (NIH 1994: ix) 
  “In utero” signifies “in the uterus”. Parthenogenetical activation is a way to 
make an egg divide without the actual fertilization of a sperm. 
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by the panel: 1. The promise of therapeutic benefits. 2. The difference in 
moral status between preimplantation embryos and an infant or a child. 
3. Although the embryo does not equal a child it still “possesses qualities 
requiring moral respect” enforcing the need for an ethical and scientific 
review of human embryo research that will be provided through federal 
funding (NIH 1994: x).  
 Based on the pluralistic framework balancing the benefits and the mo-
ral status of embryos, the panel recommendations were issued in three 
categories. One kind of research was judged to be unacceptable for fede-
ral funding, e.g. reproductive cloning and preimplantation genetic dia-
gnosis for sex selection (NIH 1994: xix). Another kind was said to war-
rant additional review and included the deliberate creation of embryos 
for research purposes. This could be done to  
answer crucial questions in reproductive medicine and that it would therefore 
not be wise to prohibit altogether the fertilization and study of oocytes for 
research purposes. […] the health needs of women, children, and men must 
be given priority. (NIH 1994: xii) 
Some of the research that would possibly answer such “crucial ques-
tions” concerned the maturation of oocytes and “investigations into the 
process of fertilization itself”. They would serve to increase efficiency 
and safety in the IVF procedures (p. xviii).  
 A third category involved the studies deemed acceptable for federal 
funding, such as research on the fertilization process and “studies aimed 
at improving the likelihood of a successful outcome for a pregnancy” (p. 
xvii). In this category also fell the creation of embryos for studies “po-
tentially of outstanding scientific and therapeutic value”. 
An example of studies that might meet this second condition is research to 
ensure that specific drugs used in reproductive medicine, such as those for 
inducing ovulation, have no harmful effect on oocytes and their develop-
mental potential and do not compromise the future reproductive health of 
women. (NIH 1994: xii). 
In relation to these three categories there were two versions of the hESCs. 
They were placed in the two latter categories depending on the source 
material. Research on stem cells from “embryos resulting from IVF for 
infertility treatment or clinical research that have been donated with the 
consent of the progenitors” were acceptable for federal funding (p. xvii), 
while “the development of embryonic stem cells from embryos fertilized 
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expressly for this purpose” was not ruled out, but warranted additional 
review (p. xviii).  
 What happened to these recommendations? Opponents objected to 
the panel’s view of embryos and its recommendations (Human Embryo 
Research Panel 1994). On October 12, 1994, the Advisory Committee 
(the ACD) to the Director of the NIH received the panel report and its 
recommendations, which included research on hESCs. In the November 
elections the Republicans gained majorities in the Senate and in the 
House, which strengthened the thrust of Dornan’s promise to block vo-
tes to turn the panel recommendations into effective policy. On Decem-
ber 2 the ACD decided to recommend the director of the NIH, Harold 
Varmus, to accept the panel guidelines. The same day, before Varmus 
could make a decision of his own, Clinton had issued a statement that 
“federal funds should [not] be used to support the creation of human 
embryos for research purposes” (Marshall 1994a: 1634). In fact, Clinton 
probably had decided this beforehand. Bioethicist Alta Charo accounts 
for the White House response to the Republican mid-term election sweep, 
and the public reaction: 
William Galston, deputy director of Clinton’s Domestic Policy Council […] 
reported that many White House senior staffers had been debating the Panel’s 
work since early summer, and that a consensus had formed among the 
political advisors that creating embryos for research exceeded the public’s 
(and their) tolerance for exotic research. (Charo 1995a: 14)  
The President heeded their advice. Post hoc, Patricia King concurred 
with Clinton’s decision, since it “was in tune with the public mood” 
(Marshall 1994a: 1635). King regretted not having stressed the point 
more forcefully in panel discussions in order to improve the chances of 
public acceptance (Carmen 1996: 102). Another anonymous panel parti-
cipant said that the “panel would have been more sensitive in matters of 
language and expression” had it known the results of the November 
elections (Schwartz and Devroy 1994).  
 In spite of Clinton’s rejection of embryo creation for research purpo-
ses, opposition was strong against all of the panel recommendations, in-
cluding research on hESCs (Frazier O’Brien 1994, Hoke 1994). None of 
the panel recommendations was ultimately realized. The public reactions 
and the political strength of these objections obliterated the panel report 
also for use by the original proponents of embryo research. In 1995, the 
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following year, a general ban on human embryo research was passed in 
Congress and signed by Clinton (i.e. the Dickey-Wicker amendment).  
 In relation to the legal outcome and explicit politics the difference 
between 1994 and 2001 could scarcely have been greater. Formally and 
technically, embryo research was, beginning in 1994, allowed. The HERP’s 
task was merely to outline what kinds of embryo research should be 
funded and not. However, the response did not concern what kinds of 
embryo research were appropriate or not, but opposed all embryo 
research. What started out as an attempt at an open-ended policy process 
ended in a wholesale rejection, ultimately even by liberal, democrat poli-
ticians.99 By 1996, laws precluded publicly funded research on hESCs. In 
2001, research on hESCs was endorsed not only by proponents of em-
bryo research, but also pro-life representatives critical of other sorts of 
embryo research.  
 The difference between the two situations did not only concern which 
actors were coordinated, but how they were coordinated. During 1994–
1996: from open-ended coordination to polarization. Ultimately there 
were two sides. On one side there were the panel recommendations with 
their “pluralistic ethical framework” and on the other side total restric-
tions of funding protecting the “sanctity of life”.100 During 1998–2001: in 
spite of polarization and attempts to establish either an OPP or an APP 
a boundary-transcendent coordination was strengthened by August 2001. 
Some actors in 1994 (e.g. the senders of “hate mail”) insisted that it was 
                                     
99   At least there was an expressed desire for public participation. Panel chairman 
Steven Muller formulated his view of the process of public policy develop-
ment in a media report: 
Proper public policy develops through a public process rooted in public 
participation. Public participation involves a multitude of interests, many 
in conflict with one another. The public process which produces public 
policy, therefore, must strive for a balance among divergent interests, a 
balance sufficient to obtain and justify public support. (Hoke 1994) 
  After confronting some of the letters received by HERP from opponents 
Muller found the public education for such public participation wanting. 
100  Here congressman Dickey, in 1996, when he defended the current policy (of 
the Dickey-Wicker amendment) against the proposed Lowey amendment: 
Mr. Chairman, this is not a bill about research or science; it is an attack on 
the sanctity of life. It is an attack on the moral conscience of our Nation. 
(House of Representatives 1996: H7339) 
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an either-or and this became the prevailing mode of coordination, at 
least legally. Vice versa, by 2001, some crucial actors supported hESC 
research and a pro-life position without posing an either-or.  
Diagnoses and prescriptions 
Clearly, from the vantage point of the HERP the resulting coordination 
of actors was a failure. Federal funding was not allowed. Actors were in 
fact coordinated, in one respect: to prohibit further federal research fun-
ding. In relation to the successful flows of hESCs among diverse actors 
in 1998 and in 2001 the flows were much thinner in 1994. This evokes a 
question: How could this difference in mode of coordination be under-
stood? An answer is given by the actors. Obviously, actors at the time 
did not know about this retrospective difference, but their actions assu-
med a gap between the actual situation and a more desirable future situa-
tion. Basically, some were dissatisfied with the mode of (non)coordina-
tion resulting from HERP and made “diagnoses” (to use a medical meta-
phor) of the perceived failure of coordination.  
 For the actors supportive of embryo research the outcome was regar-
ded as a problem in need of a solution. Even during and immediately 
after the panel deliberations in 1994, even proponents of embryo research 
criticized the HERP recommendations. The policy development was 
seen as the failure of an attempt or a project (of sorts). Palca (above) de-
scribed how scientists had been trying to lift the de facto moratorium in 
the 1980’s. Following Palca, the project was thus a long-standing one 
relating to the lack of federal involvement. By 1994 many scientists were 
eager to receive funding for embryo research (Hoke 1994, Marshall 1994b). 
I interpret this as a kind of project, although of a quite distributed kind, 
and less organized or delineated than a “project” would usually imply.  
 During and after the death of HERP, actors made diagnoses of the 
failed coordination. There were two points of criticism. It had been too 
much to recommend the deliberate creation of embryos for research; 
better to go for research on already existing embryos, or “spare embry-
os”. And, the research had not been linked to sufficiently pressing bene-
fits.  
Calls for the “spare embryo” 
Criticism of the recommendations was made evident within the final re-
port. There were three dissenting opinions. Patricia King, Carol Tauer, 
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and Bernard Lo all expressed satisfaction with the work of the panel, but 
disagreed on specific points. Tauer and King both objected to the delibe-
rate creation of embryos for research purposes (NIH 1994: A-3f and 
B-3)101. Tauer explained why:  
Because the issue of developing embryos for research is so morally sensitive 
and because of my concern that clear restrictions may be difficult to maintain. 
[---] While there may be therapeutic reasons for developing cell lines of a vast 
variety of human genotypes, stem cell research studies do not require that cells 
be utilized from such a variety of genotypes. It would be only after research 
has demonstrated that the differentiated cells are therapeutically beneficial that 
one would want to ensure that people of different ethnic backgrounds are not 
deprived of therapy because of problems in matching transplantation antigens. 
(NIH 1994: B-3) 
Tauer here articulates different source material for hESC research. She 
does not accept the need for the genomic variety following from creating 
embryos specifically for research. Considering the “moral sensitivities” 
embryos remaining from IVF are a sufficient source for hESCs.  
 Post-hoc, other commentators followed suit. In 1996 George Annas, 
Arthur Caplan and Sherman Elias attributed the impotency of the panel 
to its inability to realize the political constraints and possibilities (Annas 
et al. 1996). By adopting its “pluralistic ethical framework” on the status 
of embryos the panel didn’t recognize “the deep moral reservations about 
such research held by many Americans, including the President”.  
Thus, many people, like President Clinton, could approve of research using 
“spare” embryos created by in vitro fertilization without approving of the 
creating of embryos for that specific purpose. Provided with reasonable grounds 
for distinguishing research on spare embryos from research on embryos crea-
ted solely for the purpose, even the Republican-dominated House of Repre-
sentatives might have made the distinction. The House Appropriations Com-
mittee, for example, voted 30 to 23 in July 1995 to bar all federal funding for 
research on human embryos. A proposed amendment to permit such funding 
for research on spare embryos failed by a tie vote (26–26). It seems plausible 
that a more nuanced rationale for this distinction could have persuaded at least 1 
                                     
101  The panel recommendations were consistent with the primary considerations. 
If the decisions are based on the partial respect for embryos and the potential 
benefits, then there are reasons to accept cloning or the derivation of hESCs 
from created embryos. Tauer accepted the basic tenets but still objected to the 
deliberate creation of embryos out of respect for tax-payers’ sentiments. 
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of the 26 members who voted against the amendment to vote for it. (Annas et 
al. 1996) 
Annas et al. describe a political landscape in which some, but not all, 
research on human embryos could be politically pursued. The proposed 
argument focuses on embryos as the result of procreative activity. In the 
quote the example from the House Committee paints a political landsca-
pe in which some things are more feasible than others. Although conten-
tious, embryo research would probably be fundable if it were done on 
“spare embryos”, the argument goes, instead of creating new embryos 
deliberately for research. 
 Also other dissenting actors opposed the panel because of its inability 
to get things done in a perceived biopolitical landscape. The HERP’s 
considerations on the status of embryos were criticized for being merely 
ethical and not sufficiently political, or “biopolitical” (Carmen 1996, Charo 
1995a). The status of embryos, according to these commentators, is not 
a purely bioethical issue, but an issue of social and political relations and 
sensitivities.102  
 Subsequent Congressional action from research proponents seems to 
agree with the diagnosis. When changes to the Dickey-Wicker amendment 
were attempted, through the proposed Lowey amendment in 1996, the 
research creation of embryos was totally abandoned in favor of research-
                                     
102  No national panel, Ira Carmen claimed, can settle the ethical disputes about 
the status of embryos. Just as the President acted to manage political and pub-
lic reactions the HERP should have included the “realities of the Washington 
political game” in their deliberations, Carmen 1996. Alta Charo of the panel, 
afterwards suggested that instead of calling the panel deliberations bioethical, 
they were a species of political ethics. 
If the Panel had more explicitly acknowledged how much of its work 
was an exercise in political compromise, rather than definitive moral rea-
soning, its report might well have engendered less bemusement and out-
rage. [---] Indeed, by writing a report grounded in political ethics rather 
than bioethics, the Panel might have demonstrated an appreciation of 
the sincerity and passion of research opponents, even while their outrage 
must yield to the needs of those awaiting the experimentation’s benefits. 
It is their pain, rather than any dubious consensus on the status of em-
bryos, that is actually being balanced against the claims of infertile coup-
les, parents of children with birth defects, people seeking a cure for can-
cer, and third world women in desperate need of new contraceptive choi-
ces. (Charo 1995a: 12) 
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ing the “necessary and inevitable spare embryos”. The following is from 
the debate in the House of Representatives, July 11: 
Mr PORTER: Mr. Chairman, the creation of spare embryos is a necessary and 
inevitable part of in vitro fertilization and it seems to me, at the very bottom 
line, that given the potentials for addressing and overcoming and preventing 
human disease, their use in research gives meaning to their existence which 
would otherwise simply not exist. They would be discarded in the normal 
course of events. (House of Representatives 1996: H7340)103 
Porter, Lowey and other proponents of the bill did not succeed at that 
time. In this respect it was not sufficient to re-articulate the embryo to 
coordinate actors and the diagnosis was not “right”.  
 Not all the proponents agreed about the diagnosis. The aftermath of 
the panel focusing on the recommendation to fund embryo creation was 
unwelcome and hard to understand for former panel members. Brigid 
Hogan comments here on Annas et al.’s claims in the NEJM editorial:  
“This doesn’t reflect how we stressed the benefits of donated eggs and sperm 
[from couples undergoing in vitro fertilization, donated for research].” (Beno-
witz 1996) 
Opponents of embryo research also disagreed. Congressman Roger Wic-
ker (of the Dickey-Wicker amd.) did not support a claim about the politi-
cal viability of ”spare embryos” and even offered numbers to disprove it. 
Mr WICKER As a matter of fact, 76 percent of Americans oppose funding 
for the type of research that the Lowey amendment would sanction. This goes 
to the very profound questions of human life and to very sensitive questions 
of bioethics. (House of Representatives 1996: H7340) 
Wicker did not even accept the “necessity and inevitability” of “a spare-
embryo circumstance”, and attacked the underlying distinction.  
Proponents of the Lowey amendment say there is a distinction between spare 
embryos and embryos created for research purposes. But the leading experts 
say there is no distinction. Let me quote Dr. Robert Jansen of the National 
Health and Medical Research Council. He says, “It is a fallacy to distinguish 
between surplus embryos and specially created embryos in terms of embryo 
research. The reason I say this is that any intelligent administrator of an in vi-
tro program can, by minor changes in his ordinary clinical way of doing 
                                     
103  Also see other proponents in House of Representatives 1996. 
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things, change the number of embryos that are fertilized.” (House of Repre-
sentatives 1996: H7340) 
The diagnosis focusing on the specific creation of embryos for research 
came from actors who wanted federally funded embryo research, not 
from pro-lifers, and it is hard to see any clear-cut support for the claim 
about the political viability of spare embryos.  
 Taking a step back it is important to realize what these traces of actors 
are saying. The shift to already existing embryos did not necessarily 
correspond to a reality of pro-lifers out there. It may have or it may not 
have corresponded. Annas et al offered voting numbers, but none of the 
others refer to any data that supported the conclusion that research on 
”spare embryos” would be more acceptable public policy. Correspon-
dence or correctness is not the primary issue when following these ac-
tors. Whether they were right or not, they had similar perceptions of how 
research on embryos could become more acceptable. There was not one 
embryo to do research on, but at least two. One that linked strongly to 
pro-life opponents and a skeptical public. Another that – the critics hy-
pothesized – might be more acceptable. Embryo research might be 
politically feasible, but not the creation of embryos for research purpo-
ses. It has to be research on already existing embryos. Pro-life actors 
disagreed and could disagree with the panel since it recommended re-
search on embryos created deliberately for research, the diagnosis said. 
Not all agreed and apparently, pro-lifers could and did disagree also after 
the focus on “spare embryos”, in 1996. Accordingly, the critics here were 
not primarily right or wrong, but left traces of a “diagnosis” living among 
and coming from the supporters of embryo research.  
 A very clear example of this is the journal Science’s reports from the 
panel work. While the panel was still deliberating, in August 1994, Eliot 
Marshall reported from one of the meetings and referred to the recom-
mendation to create embryos for research.  
Those attacks [from the right-to-life movement] may well focus on what is 
likely the most controversial element in the panel’s report. Although the 19-
member panel is still at work, Science’s interviews of key panel members reveal 
that the panel’s version of the guidelines permit creation of a limited number 
of human embryos for research purposes. (Marshall 1994b: 1024) 
In this section the right-to-life movement “may well focus” on the crea-
tion of human embryos for research. In the next section, associate direc-
tor for the Catholic Secretariat for Pro-Life Activities Richard Doer-
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flinger “seized on this issue to denounce the entire NIH rule writing 
effort”. The tentative “may well focus” from one section to the next is 
turned into “seized on”. Marshall offers some quotes from Doerflinger’s 
testimony, but no support for the conclusion that the research creation 
of embryos was the particular thorn in Doerflinger’s flesh (Marshall 
1994b: 1024). In fact, there is no support for this conclusion in the testi-
mony (Human Embryo Research Panel 1994). The pro-life associate di-
rector questions research on already existing embryos and the specific 
creation of embryos equally. 
 I have found no evidence that pro-lifers in fact seized specifically on 
the creation of embryos. There may be such evidence or not. I have not 
come closer than the voting records referred to by Annas et al. There 
may also be such a thing as “political sensitivity”. Again, evidence or sen-
sitivity are less important than the fact that actors supportive of embryo 
research delegated a coordinating agency to the source material. These 
actors assumed an improvement of coordination by shifting to “spare 
embryos”.  
Spelling out benefits 
Another point made by the proponents of embryo research (but critical 
of the HERP) was the vagueness of the benefits. While Clinton was only 
rejecting a part of the panel’s recommendation, on December 3, an un-
identified member of the panel stated in The Washington Post: 
One member of the panel who asked not to be identified said that […] “Even 
the name ‘Human Embryo Research Panel’ turned out to be a red flag for 
antiabortion groups […]” Yesterday, members of Varmus’s advisory commit-
tee briefly discussed the idea of coming up with a name that stressed the im-
portance of the research to fertility and other medical advances […] (Schwartz 
and Devroy 1994) 
Later Jonathan Van Blerkom, biologist and author of one of the commis-
sioned papers, concurred with this analysis of the panel’s perceived failure. 
he contends that the panel’s inability to spell out the specific benefits from 
human embryo research – particularly regarding treating disease – contributed 
to its demise. (Benowitz 1996) 
However, several benefits had been clearly spelled out in the panel deli-
berations and the report. In the report there were a number of (allegedly) 
important uses for the research. The research portfolio that justified fe-
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deral funding was quite extensive and featured in several places in the re-
port. In the introduction specific kinds of research were enumerated. 
 
Studies aimed at improving likelihood for a successful outcome for a preg-
nancy. 
Research on the process of fertilization  
Studies on egg activation and the relative role of paternally derived and mater-
nally derived genetic material in embryo development (parthenogenesis with-
out transfer). 
Studies in oocyte maturation or freezing followed by fertilization to determine 
developmental and chromosomal normality. 
Research involving preimplantation genetic diagnosis with and without trans-
fer. Research involving the development of embryonic stem cells, but only 
with embryos resulting from IVF for infertility treatment or clinical research 
that have been donated with the consent of the progenitors.  
Nuclear transplantation into an enucleated, fertilized or unfertilized (but acti-
vated) egg without transfer for research that aims to circumvent or correct an 
inherited cytoplasmic defect.  
Research involving the use of existing embryos where one of the progenitors 
was an anonymous gamete source who received monetary compensation. [---] 
A request to fertilize ova where this is necessary for the validity of a study that 
is potentially of outstanding scientific and therapeutic value. (NIH 1994: xvii–
xviii)104 
This portfolio concerns only research acceptable for federal funding. There 
were other lists for research that warranted additional review and for re-
search that was deemed ineligible for federal funding. When the applica-
tions were listed in Chapter 1, there were eight of them.  
The process of embryo implantation, the maintenance of early pregnancy, and 
the prevention of early spontaneous miscarriages. 
Basic knowledge about normal early human development and the origin of 
certain birth defects. 
The preimplantation diagnosis of genetic or chromosomal abnormalities lead-
ing to severe inherited diseases. 
                                     
104  The two last applications were recommended for federal funding, but needed 
“special consideration” by a national ad hoc body that would have functioned 
for at least 3 years following the acceptance of new guidelines. 
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The origin of chromosomal abnormalities associated with infertility and with 
childhood cancers. 
Understanding the process of oocyte maturation and how eggs may be affec-
ted by environmental agents, including cryopreservation of oocytes from wo-
men undergoing chemotherapy or irradiation. 
The development of new contraceptives.  
Cancer and the process of metastasis. 
The development of pluripotent embryonic stem cell lines for generating dif-
ferentiated cells for transplantation and tissue repair. (NIH 1994: 2) 
Were the applications badly spelled out? At least they were meticulously 
spelled out. Six are applications that relate to pregnancy and infertility. 
Also included are the service to developmental biology and cancers (in two 
places). One concerns transplantation and tissue repair. In the second 
chapter on “Scientific and Medical Issues in Preimplantation Embryo Re-
search” again a list was presented – now in 13 applications (p. 7f). Of 
these, six related to infertility and pregnancy and four to issues in deve-
lopmental biology. Three points regard therapeutic use, viz. ES cells for 
transplantation, cancers and “the use of nuclear transplantation to circum-
vent disorders due to maternal inheritance of cytoplasmic defects” (p. 8).  
 Within the report there were plenty of benefits. Van Blerkom (above) 
criticized the panel for its “inability to spell out the specific benefits […] 
– particularly regarding treating disease”. Depending on what you would 
label as disease, the latter part of that critique may correspond to the 
HERP report. If infertility is not a disease, then there was indeed pro-
portionally less about benefits relating to cancer or tissue repair. In the 
paper Van Blerkom wrote for the panel, there seem to be similar propor-
tions. One application concerning “diseases” was mentioned, viz. trans-
plantation therapies. It was done in connection with embryonic stem 
cells.  
For example, it may be possible to establish cells lines [sic] from early em-
bryos to serve as stem cells for bone marrow transplantation, as hepatic stem 
cells for the treatment of liver dysfunction, or neuronal stem cells that can be 
used in the treatment of nerve and spinal cord injuries. Indeed, some have 
suggested that organ transplantation may be replaced as the appropriate thera-
py in cases where the tissue could be reestablished by stem cell therapy. (Van 
Blerkom 1994: 48) 
Although “spelled out” here as promising – “this approach has the po-
tential to offer a new strategy for the treatment of a wide range of 
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human diseases” (p. 49) – Van Blerkom did not in his 49 pages, say more 
than these ten lines about the specific benefits for treating diseases. 
Apart from the three pages on stem cells there were three more pages on 
the significance of embryo research for preimplantation diagnosis. More 
than treatment of disease this is a technique to avoid the development of 
embryos carrying genetic disorders. Most part of the paper concerned 
embryo research on infertility and developmental biology.  
 The HERP did not only articulate the possible benefits of embryo 
research within its report. In ensuing commentaries and debates, possible 
uses were mentioned. A lot of attention was devoted to the various re-
commended sources for research such as donated or expressly created 
embryos of various maturity, eggs and parthenotes105 (Marshall 1994b). In 
the media and in Congress the most specific benefits related to either 
preimplantation genetic diagnosis of embryos, or understanding the pro-
cess of fertilization for improved IVF techniques106, contraceptives, and 
pregnancies. More vaguely, future progress was promised in basic deve-
lopmental biology and cancer research.107 In an article in The Scientist five 
applications are mentioned: preimplantation genetic diagnosis, develop-
mental biology, cancer pathology, cancer, and transplantation therapies 
(Hoke 1994). Only the latter would qualify as being directed towards 
treating disease. Analyzing these articles, the emphasis is not on disease 
treatment, but more on basic biology:  
“We’re not going to be curing anybody of these tumors by doing research,” 
Hogan says. “On the other hand, the basic biology is extremely interesting. 
Studies in mice and in humans show that choriocarcinoma arises with a parti-
cularly high frequency when there are only paternal genes present. And, so, 
the question is why. Presumably, this is because of imprinting problems, in 
                                     
105  Eggs dividing for a limited time as if fertilized although without being so. 
106  Brigid Hogan, science co-chair at the panel explained the possible benefits for 
IVF through studies of egg maturation. 
research on human egg maturation, which requires that eggs be fertilized 
to test their viability. These studies – if they were allowed to proceed – 
would help improve the efficiency of in vitro fertilization, making the 
process safer and less expensive. (Marshall 1994a: 1635) 
107  These promises appeared in numerous accounts, e.g. Annas et al. 1996, 
Benowitz 1996, Carmen 1996: 101, Charo 1995a, Fletcher and Waldron 1996, 
Frazier O’Brien 1994, Hoke 1994, Marshall 1994a, Schwartz and Devroy 
1994.  
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the sense that certain genes are going to be either active or inactive, oncoge-
nes are going to be active, or tumor suppressors are going to be inactive in 
those cells.” (Hoke 1994) 
While the basic biology was “extremely interesting”, the therapeutic ex-
pectations were low “we are not going to be curing anybody of these tu-
mors”. When Hogan, later in the article, mentions transplantation thera-
pies through the use of ES cells the tone is again very modest:  
“So, the idea would be that maybe, down the line, you could use these for 
making blood cells for transplantation, and maybe some kinds of neuronal 
stem cells or muscle stem cells.” (Hoke 1994) 
Annas, Caplan and Elias claimed that “[e]mbryo research will not receive 
needed support unless it is linked more directly to research on fertility” 
(Annas and Elias 1989). Based on the actual lists of applications in the 
report (above), it is hard to agree with this analysis straight away. Fertility 
research had been present in the report. In July, 1996, it was a central 
theme, making one suspect that the congressmembers had read the May 
editorial by Annas et al. At least they concurred in action with the advice.  
Mr. WAXMAN. Early-stage embryo research is vital as it has the potential to 
address treatment and prevention of infertility, people who want children, want 
to bring in life into this world. 
 It could lead to cures for childhood cancer and genetic disorders such as 
cystic fibrosis, muscular dystrophy, mental retardation and Tay-Sachs. It could 
lead to the reduction, if not the elimination, of miscarriages. (House of Repre-
sentatives 1996: H7340)108 
Although all of the speakers supportive of embryo research mentioned 
these diseases and fertility research the “spelling out” failed. The opponents 
responded in concert that the promises of benefits were not scientifically 
proven, and not sufficiently urgent or relevant for federal funds. Repre-
sentative Weldon from Florida, as others, recycled Hogan’s quote to ma-
ke the points.  
Mr. WELDON. I think it is inappropriate to use taxpayers funds for this kind 
of a purpose, and it is a very dubious scientific benefit, contrary to some of 
the claims that have been made by the gentleman from California as well as 
others. I can even quote from people who were involved in studying this 
                                     
108  See also Mrs. Johnson, Mr. Fazio and Ms. Pelosi in House of Representatives 
1996. 
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issue. Dr. Brigid Hogan, a scientific expert on the NIH Human Embryo Re-
search Advisory Panel, said: “We are not going to be curing anybody of these 
tumors by doing research. On the other hand, the basic biology is extremely 
interesting.’’ That is what we are talking about funding here, a very contro-
versial, ghastly subject according to many Americans, including myself, and it 
is just going to be very, very interesting. Furthermore, we have a quote from 
Daniel Callahan, president of the Hastings Center, which is an IVF institute 
[sic].109 He said: The NIH advisory panel “report notes that four countries al-
ready allow embryo research and that it has been going on for some years in 
private laboratories in this country. Yet not a single actual benefit derived so 
far from that research is cited to back the claims of great potential benefits from 
having even more of it.’’ (House of Representatives 1996: H7342)110 
When proponents referred to the scientific needs and criticized the pro-
life opposition for setting up a “Flat Earth Society” the ball was sent 
back. 
The gentlewoman, my good friend from California, Ms. PELOSI, talks about 
the Flat Earth Society. That is interesting because the science is on our side. 
As I recall, there are two medical doctors, M.D.’s, on our side. I have not seen 
any M.D.’s or even Ph.D.’s, although there may be a hidden Ph.D. over there 
in English literature or something, but the science is from our side. (House of 
Representatives 1996: H7343) 
Mr. Hyde refers here to the number of MDs among the opposition to 
embryo research. The history of embryo research was also used to oppo-
se it. Representative Tom Coburn called out for some scientific evidence. 
I understand this is a complex issue, but after 17 years of research not one 
person in this body can stand up and tell me one positive medical outcome 
that has come from this research. There is none in the scientific literature, the-
re is none projected. We hear: could, might, may. The fact is there is no proof, 
there is no scientific study at this time of any quantifiable benefit. (House of 
Representatives 1996: H7342) 
Following the HERP some diagnosed the perceived “failure” of the pa-
nel recommendations in relation to the articulation of what embryo 
research could signify for disease treatment. Again, as to research embry-
os, it is not easy or even necessary to assess whether the diagnoses were 
                                     
109  The Hasting Center is a bioethics center – not an IVF institute – which could 
change the credibility of Callahan’s quote as used by Weldon.  
110  See also Mrs. Vucanovic, Mr. Coburn and Mr. Hyde in the House of Repre-
sentatives 1996. 
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correct or not, whether a better spelling out would have improved coor-
dination of actors.  
 Reading the report and related commentaries, the critics seem to be right 
– at least if benefits for infertility are excepted from the category of “di-
sease treatments”. Cancer and tissue replacement were marginal compa-
red to the benefits for genetic diagnosis and the improved understanding 
of developmental biology, infertility and pregnancy. In these respects 
therapeutic benefits were not made central. Scientific results were also 
lacking. The opponents called the “therapeutic cards” offered by propo-
nents and referred to the want of scientific evidence. The proponents re-
ferred to the expectations from scientists. These had been already detai-
led in the panel report. Were the benefits not sufficiently urgent, or per-
ceived as such? Why could they not induce enough support in Congress? 
These are questions for a political historian or a political scientist, and thus 
beyond the approach of this study. The issue is not to decide whether 
benefits were a crucial factor for the outcome of the negotiations, i.e. the 
validity of the proponents’ self-criticism. Quite the contrary is interesting 
here, viz. the fact that some actors did understand the situation in this way. 
Calls for more urgent benefits were their “prescription” (coherent with the 
above observed diagnoses) for how to proceed and succeed with the 
project of federally funded human embryo research.111 
 There were two comments from the proponents of embryo research 
that added an extra dimension. Again, something was lacking in the arti-
culation of possible benefits. Mark R Hughes, professor of genetics, ob-
stetrics and gynecology, and pediatrics at Georgetown University and at 
the NIH recapitulated the fetal tissue debates. Hughes 
notes that some interest groups, such as those supporting research for Par-
kinson’s disease have argued successfully for funding. “Unfortunately, those 
arguments are not as politically compelling regarding the embryo research.” 
(Benowitz 1996) 
                                     
111  Prescription is not used here as Madeleine Akrich would use it, but in a more 
commonsense, although metaphoric way, Akrich 1987, Akrich and Latour 
1992. However, an analysis drawing on her notion of script – including the 
related inscription, de-scription, pre-scriptions – is fully compatible with many 
of my observations and conclusions of how actors contributed to the shaping 
of the later reality of hESCs. In Akrich’s terms the actors’ diagnoses are close 
to de-scriptions.  
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To compel actors, applications that can bring in patient groups are need-
ed, according to Hughes. Eventually he added that he thought there would 
never be a compromise “the two sides are so diametrically opposed”. 
Another similar point came from Annas et al. They also referred to ear-
lier negotiations on fetal tissue research, but, in contrast to the resigned 
Hughes, they wrote in the hope of breaking the “gridlock”.  
Research on fetal-tissue transplantation did not garner public support and fe-
deral financing until supporters persuaded Congress that it might benefit the 
treatment of major diseases, such as Parkinson’s disease. (Annas et al. 1996) 
The authors outline a “method” for getting public support. However, Par-
kinson’s disease was not regarded as an alternative in the case of embryo 
research. Their version of the same methodology applied for embryo re-
search was to call for fertility research (see above). Both comments poin-
ted out the force of patient and interest-group mobilization. Neither of 
them at the time saw that treatments of Parkinson’s disease could be an 
option, but they called for a similar linkage between embryo research and 
“major diseases”. In relation to the panel report this suggestion may have 
been justified – depending on what a major disease is. Cancer and tissue 
repair were mentioned, but such references were usually tentative and 
marginal in relation to the other research interests. Both of the commen-
taries were right about the absence of any obvious target group “repre-
senting” the urgency of embryo research. In the panel sessions, in the sub-
sequent commentaries, and in congressional debates few, if any, patients 
or patient organizations were represented. 
The HERP and the later role of hESCs  
It is time to recapitulate the purpose and the observations of this chap-
ter. In an attempt to understand the coordination of diverse actors that 
was strong already in 1998, only a few weeks after the introduction of 
hESCs, this chapter went backwards. hESC had been articulated earlier, 
in the negotiations of federally funded embryo research in 1994. The 
crucial question is: What do the traces found there say about the pre-
existing coordination, the multiple flows and the package of hESCs?  
Prescriptions fulfilled  
By looking at the earlier articulation of hESCs, a number of things are 
found. Firstly, the 1994 negotiations resulted in a completely different co-
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ordination of actors. The only boundary-transcendence in 1994 was the 
agreement between a pro-life Congress and the Democrat President to 
not fund the creation of research embryos. Secondly, the many propo-
nents were not happy about this and voiced criticism during and after 
the panel, highlighting two elements of human embryo research. They 
made diagnoses and prescriptions to not repeat the perceived failure of – 
what can be understood as – a project of federally funded human em-
bryo research. The prescription: No creation of research embryos, and 
more salient benefits in terms of “major diseases”, e.g. Parkinson’s disease 
where there are interest groups that can persuade Congress. Coming from 
1998 and the previous chapters the actors’ diagnoses and prescriptions 
are extremely interesting, since they have a “prophetic” tinge. Put less my-
steriously: The prescriptions seem to have been followed and effective in 
the subsequent negotiations in 1998.  
 When the hESCs were announced in the two articles in November 1998 
they were made from spare embryos and one of the expected uses was 
transplantation therapy, e.g. for treating degenerative diseases such as Par-
kinson’s disease and juvenile diabetes. Creating embryos deliberately was 
not an option for either of the two major reports (NBAC and AAAS/ICS) 
or by the embryo-research proponents testifying in Senate hearings. 
 As Chapters 2 and 3 outlined the elements seem to have done the job. 
Patient organizations mobilized and presented statistics and individual 
patients telling their stories of life with diseases. Some pro-life represen-
tatives in Congress did ultimately accept the use of embryos remaining 
from IVF treatments. This changed the whole mode of coordination. From 
a no-go and strict boundaries after 1994, the hESCs provided a sort of 
common, boundary-transcendent ground. 
 Going back to 1994 thus reveals an ongoing project and actors en-
gaged in managing it to coordinate diverse – or in some cases even more 
than diverse: polarized – actors. While some resigned and claimed that it 
was “all political” and others tried to formulate an “ethical framework” 
some pursued the “project management” by re-articulating two elements 
of human embryo research. Their advice was to focus on spare embryos 
and disease treatments. This was tried in Congress 1996, but failed. It 
was not enough to (in Van Blerkom’s words) “spell it out” differently. 
Increased coordination came with the re-articulation of an object. As the 
hESCs were articulated in the laboratory, and in public debates, they 
contained or embodied (or maybe more correctly “en-celled”) the two 
elements in the prescribed configuration. The mode of coordination 
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expectedly changed from polarization to boundary-transcendence together 
with the articulation of hESCs in terms of the two elements. 
 Seen this way the role of hESCs as boundary packages is strengthened. 
It is strengthened, since some of the missing pieces outlined at the end 
of the previous chapter have come into view. hESCs were not merely 
coordinating actors in hESC research, but also in a long-standing project 
of federally funded research on human embryos. Diverse actors were not 
coordinated by direct negotiations, or by force, but through an object 
that addressed their needs. The 1994-1996 “prescriptions” from some 
actors suggest that the coordination of hESCs were due to the source 
materials and the therapeutic benefits. Spare embryos spoke to some 
pro-life actors. Transplantation therapies mobilized patient groups who 
appeared in Congress.  
Unfulfilled purposes 
Initially, this chapter moved backwards in order to unpack the reality of 
hESCs. While the OPP, the distributed coordination and multiple loops 
were interesting conceptions of hESCs, they did not constitute an 
analysis per se, but more observations in need of unpacking. Instead of 
going deeper into the actor-networks between 1998 and 2001 the early 
coordination of diverse actors suggested that events before November 
1998 played a role in the multiple flows of hESCs. These purposes gui-
ded the initial research question of the chapter about previous coordi-
nation of actors, and previous traces of the elements of the hESC pack-
age. 
 Retrospectively the actors’ diagnoses and prescriptions in terms of the 
elements of “spare embryos” and therapeutic benefits suggest that the 
hESCs were an answer to a “management problem” – the management 
of a project of federally funded human embryo research: The 1998–2001 
hESC package consisted of the two elements and it did improve coordi-
nation.  
 At the moment however, this suggestion, based on the analogy with 
the boundary object case, is premature because of several serious gaps. 
So far the analysis has conjectured two things that follow from Star and 
Griesemer’s case. Coordination was achieved by the management of hESCs 
in relation to two elements that had a potential for coordination (according to 
some actors in 1994 and after). The italicized words represent assump-
tions that are still barely more than that.  
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 First, the management aspect: Noting that the hESCs made from 
already existing embryos and useable for transplantation therapies corre-
sponded to some actors’ diagnoses of a political landscape in 1994 is 
interesting. This in itself, however, does not imply that the hESCs were 
used by actors in a way reminiscent of boundary objects. To make hESCs 
analogous to boundary objects some sort of management is needed. It 
could very well be that the scientific discovery and the biological entity 
without any relation to the HERP events accidentally happened to have 
a political significance and transform the negotiations of federally funded 
human embryo research. If so, this is still worthy of note, but also of 
another history. Such interesting and important histories are already writ-
ten by biologists and popular science writers (Lewis 2001, Smith 2001a).  
 These histories trace the origin of the hESCs to the work by Stevens 
and Pierce on teratocarcinoma, embryonal carcinoma cells and ES cells. 
The histories are based on the chain of material developments, assays, 
experiments which are described in articles that are traceable in the refe-
rences-section of review articles, and also in most research articles. hESC 
stabilization would then include the discovery of Stevens’s mouse strain 
129 (Stevens and Little 1954), the later genetic modifications of these mice 
(Stevens 1959), the collaboration with Pierce and his group (Pierce 1975), 
the embryoid body assay (Stevens 1960), proofs of multipotentiality of 
single EC cells (Kleinsmith and Pierce 1964), perhaps the disputes with 
the British tumor pathologists about the existence of embryonal carcino-
ma (Pugh 1983, Pugh and Smith 1964, Willis 1967), the move from mice 
re-transplantations to cultures in Petri-dishes, the production of chime-
ras from EC cells injected in blastocysts (Mintz and Illmensee 1975), 
Martin’s, and Evans and Kaufman’s derivation of ES and EK cells in 
1981 (Evans and Kaufman 1981, Martin 1981) which most hESC re-
searchers today go back to. Such a chain could also be described as the 
establishment of a reference, much as Latour studied the transformation 
of earth from Boa Vista to the scientific articles in Pandora’s Hope, Chap-
ter 2. 
 However, this study assumes that “scientific discovery” is articulated 
by the combination of more elements than fill up a Petri-dish, and that 
“biological entities” not only circulate in human bodies, but in Con-
gressional, corporate and other bodies too. It assumes the multiple flows 
of Pandora’s Hope Chapter 3, rather than the single circulation of refe-
rence in its Chapter 2. Most importantly, as I have formulated the thesis 
about the role of hESCs, more is intended than the accidental correspon-
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dence between a “discovery” and the diagnoses of a failed negotiation. 
To save the thesis there has to be some management of the hESCs in re-
lation to these two elements (and not only in relation to mice, teratomas, 
and British tumor pathologists in the 1960’s and 70’s). If there was a ma-
nagement, then the hESCs would to some extent, in some respects have 
changed between 1994 and 1998 to accommodate ”spare embryos” and 
transplantation therapies. If, instead, the hESCs were identical on those 
two occasions there was basically no “management” to speak of, not the 
one I have conjectured. To prove that the hESCs functioned as a sort of 
boundary object, i.e. a boundary package, traces of such modifications 
would have to be found.  
 Second, the elements’ potential for coordination: If coordination was 
achieved by the management of hESCs in relation to the two elements, 
the latter would need to have some recognized potential. Much points in 
this direction. Obviously, patient organizations and Geron hoped for 
transplantation therapies and some pro-lifers did refer to embryos that 
would be discarded anyway. According to these actors the elements had 
a coordinating potential. Also the 1994 critics claimed that the elements 
would have such a potential. But, nothing so far explains why the ele-
ments could contribute in this way. The hESCs are unpacked in terms of 
the elements, but the latter are not unpacked. Spare embryos and trans-
plantation therapies are analytic black boxes, regarded by actors as, respec-
tively, necessary, versus possible and urgent. It was informing to see that 
these elements were deliberately called for in 1994 and after, but the 
observation still opens for accusations of natural, social and techno-
logical realism. Recalling some of the articulations, “spare embryos” exis-
ted out of necessity (as it were) from IVF procedures. Even opponents 
of human embryo research accepted the possibility and urgency of trans-
plantation therapies. Nothing so far has explained why spare embryos or 
transplantation therapies were rarely questioned in 1998–2001. Where 
did this stability come from? Patients’ and corporations’ interests and 
others’ acceptance of transplantation therapies are taken for granted. Pro-
lifers’ acceptance of the existence of IVF and ”spare embryos” too. 
Some stabilization was visible already in 1994 as actors reached out for 
the elements as resources for coordination, but these resources have not 
been followed further backwards.  
 As long as these two assumptions – about coordinating effects and 
management – have not been defended, the purposes of this chapter and 
the present study remain unfulfilled. What is needed is an unpacking of 
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IVF embryos and transplantation therapies, and traces of how the hESCs 
were changed to fit those two elements. If not, this chapter amounts to 
not more than an interesting observation about the correspondence be-
tween the 1998-2001 coordination around hESCs and some commenta-
ries during 1994–1996.  
 
Summary 
To approach the configuration and the coordination of the hESCs in 
1998–2001, I went backwards in this chapter to the 1994 national panel 
about human embryo research (the HERP). I examined the HERP in 
order to find traces of the elements of hESCs and a pre-existing co-
ordination of actors. The direct result of the HERP was legal restrictions 
of human embryo research. Another result was that proponents of fede-
rally funded research criticized the negotiations. My interpretations of these 
actors were that they were involved in a distributed project, by means of 
making diagnoses and prescriptions for how to improve the outcome of 
future negotiations. Without any central entrepreneur, or any neatly 
delimited project, there was an on-going common movement (without 
being an organized “social movement”). Actors were assuming a project, 
viz. the need for federal funding of human embryo research. Interesting-
ly, attempts to improve coordination involved both the uses, and the 
material sources, that were later part of the articulations of hESCs. Like 
in 1998–2001 “spare embryos” and transplantation therapies were brought 
up, although less consistently and not primarily in relation to hESCs. 
The latter only existed as anticipated paper entities at the time. 
 These observations prompted a hypothesis about the boundary pack-
age. By being made of ”spare embryos” and being useable in transplan-
tation therapies the object fitted an already existing project. Thus hESCs 
were coordinating actors that were mobilized in a previous, failed pro-
ject. The package could coordinate actors by being a package of at least 
two elements that were somehow already stabilized. To test this hypo-
thesis, the next chapter will go further backwards to see how these ele-
ments had been stabilized and what circulations they were part of.  

 6.   Multiple and Partial Stabilizations: The Necessity of 
”Spare embryos”, and the Urgency of (Possible) 
Transplantation Therapies 
Introduction 
Earlier chapters have observed the prominent role of ”spare embryos” 
and transplantation therapies in diverse actors’ references to hESCs. Even 
before the hESCs some of the critics of the HERP referred to these two 
elements as possible meeting-points for otherwise disagreeing actors. 
What remains unanswered however is the stabilization of the elements in 
1998–2001, the reasons for the post-HERP actors and those involved in 
the hESC management to reach out for the elements. What role did the 
two elements have in the multiple flows of hESCs? 
 A lot of the articulations in 1998–2001 indicate that ”spare embryos” 
and transplantation therapies did contribute to the multiple flows of 
hESCs 1998–2001. From both proponents and opponents of hESC re-
search, the transplantation therapies were accepted as urgent and medi-
cally possible, and the production of non-implanted embryos as a neces-
sary part of IVF. Medical possibility, urgency and necessity were definitely the-
re in the actors’ articulations of hESCs. They may have contributed to 
the coordinating role of the stem cells and the changed mode of coordi-
nation. However, in line with ANT (and for that matter social worlds 
theory) urgency and necessity should not be treated as essential features 
but as constructed outcomes (Clarke and Fujimura 1992, Latour [1984] 
1988). Instead of accepting what the actors accepted, and thus treating 
the uses and sources of hESCs as analytic black boxes (i.e. unproblematic 
resources) this chapter asks how the urgency and necessity, commonly 
accepted by actors, came about.  
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 Many routes could be taken. By 2001 transplantation therapies were 
articulated as one part of a new approach to medicine, called regenerative 
medicine. Ann Parson has shown how this “bold new era in medicine” 
was prepared through the developments in various fields within brain 
and memory research, hematopoietic stem cell research, IVF and ES cell 
research (Parson 2004). It is a fascinating history of the convergence of 
several scientific investigations. However, just as the envisioned history 
about hESCs starting with Stevens’s mice (see Chapter 5), Parson’s ac-
count does not trace multiple loops of science-and-society. She follows 
scientific paths running together as a purely cognitive and technological 
development. Other paths for such an account could be organ transplan-
tation, xeno-transplantation and the emergence of banks for blood trans-
plantation. 
 This chapter does not intend to understand merely the cognitive or 
technological content of transplantation therapies or IVF, but how these 
elements were able to become resources for the coordination of diverse 
actors, i.e. not only “scientific” ones. I thus assume that the medical pos-
sibility and urgency of transplantations, or the technological necessity of 
IVF, are not categories decided only in laboratories or in conferences. 
And vice versa, their political significance and effects are decided not on-
ly in panels or in policies. The aim is to understand the multiple flows of 
hESCs among patients, pro-lifers, corporations, etc.  
 Unpacking urgency and necessity also approaches a related question 
resulting from Chapter 5. IVF embryos and transplantation therapies we-
re resources as early as 1994 since the actors at that time could suggest 
coordinating potential of the two elements in relation to the perceived 
“gridlock”. Why did actors reach out for the two elements in attempts to 
improve the coordination? It is not enough to say, in retrospect, based 
on the 1998–2001 negotiations, that “they were right”. What was en-
tailed in those references at the time? These two sets of questions con-
cerning the unpacking of urgency and necessity, and some actors’ refe-
rences to ”spare embryos” and transplantation therapies converge. They 
are answered similarly – by unpacking. 
 Urgency and necessity are not treated as givens, but as constructed 
through the inclusion of some entities and the exclusion of other entities. 
A fundamental assumption is that it could have been otherwise. This
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means that at some points entities, that were later excluded, offered alter-
natives and uncertainties to what later became necessary and urgent. The 
same process applies to the establishment of the references to the two 
elements. A reference according to Latour is what is linked to and holds 
together several other entities. This is how I use “reference” in this chap-
ter.112 Referring to something in an attempt to coordinate actors is thus 
to appeal to already existing linkages, entities held together. If some enti-
ties are held together, some entities are not held together. Thus, the flip 
side of unpacking the reference concerns candidate entities for inclusion 
which were not ultimately included in the reference. 
 In the first part of this chapter the reference to ”spare embryos” ne-
cessarily resulting from IVF treatments is unpacked. How did they be-
come an element that was possible to refer to and how inevitable was 
their necessity? And, vice versa, what possibilities were not made neces-
sary? In the second part the element of transplantation therapies is un-
packed. When, where and how could this element become a reference 
for actors, and on top of that a commonly recognized and urgent medi-
cal possibility? And, vice versa, was there a time and a place where ur-
gency and possibility were less stable? 
”Spare embryos” 
Two central differences between the hESCs of 1994 and those that were 
involved in public debates after 1998 concerned the embryo. Between 
1994 and 1998, the proponents changed the articulation of embryo re-
search in bioethical discourse and in policy proposals. The research crea-
tion of embryos was thrown out and ”spare embryos” became the sole 
source material.  
 Why did the supportive actors shift toward the already existing embry-
os and totally remove references to the research creation of embryos? 
The HERP had offered good arguments for allowing the research crea-
tion of embryos. If the preimplantation embryos are not persons or equ-
al to children, then it makes no difference for the moral status whether 
they are already created for procreation or specifically created for re-
search, the reasoning went. Clinton directly opposed the creation of em-
bryos when the recommendations were published, and in 1996 there was 
only talk of doing research on already existing, “spare”, embryos. Recapi-
                                     
112  This use of reference builds on the entanglement of signs and matter presen-
ted in Chapter 1, based on Latour and Woolgar 1979, Latour 1999b: Chapter 2. 
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tulating representative Porter’s statement in the House of Representati-
ves, July 11:  
Mr PORTER: Mr. Chairman, the creation of spare embryos is a necessary and 
inevitable part of in vitro fertilization and it seems to me, at the very bottom 
line, that given the potentials for addressing and overcoming and preventing 
human disease, their use in research gives meaning to their existence which 
would otherwise simply not exist. They would be discarded in the normal 
course of events. (House of Representatives 1996: H7340)113 
In the later hESC negotiations many actors repeat the same formula, for 
instance Senator Specter: “But the process of in vitro fertilization is to 
have a large group and then to use some but not to use others” (US Se-
nate 2001: 30). This first part of the chapter asks why there were “spare 
embryos” as a “necessary and inevitable part of IVF” to be used by (among 
others) Porter in 1996 and in the later negotiations of federally funded 
hESC research.  
  
The conception of IVF: context, conditions 
In the early 1970’s work on IVF was controversial. The Lancet rejected a 
paper by Edwards and Steptoe because of the ethical problems. Others 
critical were theologians, ethicists, scientists (such as James Watson and 
Max Perutz), politicians (such as the Labour Government Minister of 
Health in 1972) and institutions (The British Medical Research Council) 
warned of the consequences and still unknown risks for the resulting fe-
tuses and children (Edwards and Steptoe 1980: 117, 120, Kass 1971, 
Ramsey 1972a, 1972b). The US Department of Health, Education and 
Welfare (US DHEW) began considering IVF in 1973. The public response 
was mostly critical (US DHEW 1974). The resulting regulation prohibi-
ted support of IVF research “until the Ethics Advisory Board has advi-
sed the Secretary as to its ethical acceptability” (US DHEW 1979). In 
this critical landscape IVF did not only come into existence but, 15–20  
                                     
113  Also see other proponents in House of Representatives 1996. Their distinc-
tion between embryos created expressly for research and “spare” embryos was 
challenged (e.g. H7340). 
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years later, became a factor in the negotiations of hESC research. How 
did this happen? 
 The first baby born from an in vitro fertilized egg, Louise Brown, was 
born in 1978, through the efforts of embryologist Robert Edwards and 
gynecologist Patrick Steptoe. The former worked with fertilizing eggs in 
vitro. The latter handled the collecting and transferring of embryos (or 
embryo transfer, ET). The successful birth of a healthy and living baby 
was itself an argument for the IVF procedure. However, not all ethical 
uncertainty about the procedure was solved by these now actually 
existing babies. In the USA the status of IVF remained disputed in spite 
of Louise Brown.  
 A poll carried out in August 1978 asked 3.000 people in the USA about 
IVF:  
Some people oppose this type of operation because they feel it is “not 
natural”. Other people favour it because it allows a husband and wife to have 
a child they could not otherwise have. Which point of view comes closer to 
your own? (Singer and Wells 1984: 31) 114 
60% of respondents were supportive of the IVF and ET operation, while 
27% opposed it. 13% had no opinion. Among persons with enough 
knowledge to explain the procedure the degree of support was even 
higher: 75% (US DHEW 1979: 88). When the respondents were asked 
about the destruction of embryos, only 45% would allow it and 40% op-
posed it. 14% were unsure (Singer and Wells 1984: 32). In other parts of 
the world the status of IVF was also disputed.115  
 The newly appointed Ethical Advisory Board considered IVF and 
embryo transfer. One research proposal, from Dr. Pierre Soupart, was  
                                     
114  The polling question quoted by Singer and Wells was used in a joint poll by 
Harris and Gallup. This poll was also used in the 1979 report (see below), US 
DHEW 1979: 88-89. The two organizations interviewed 1500 people each – 
only women (Harris) and men and women respectively (Gallup). The figures 
among Catholics differed somewhat: 39% allow, 48% would not, 12% unsure. 
115  According to Singer and Wells there was high approval in British and 
Australian polls in the early 80’s – around 70% pro in several polls 1981–1983. 
However, the opposition in the UK was sufficiently strong to stop further 
research on embryos in the mid-80’s, Mulkay 1997. 
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recommended funding (Quigley and Andrews 1984). In a 1979 US 
DHEW report the EAB declared that IVF and ET research was 
“ethically defensible – but still legitimately controverted”: 
the Board wishes to emphasize that it is not finding that the ethical conside-
rations against such research are insubstantial. Indeed, concerns regarding the 
moral status of the embryo and the potential long-range consequences of this 
research were among the most difficult that confronted the Board. (US 
DHEW 1979: 100, emphasis by the EAB) 
The Department then received comments from around 13.000 members 
of the public and 80 member of Congress. Most of them were negative to 
federal funding of IVF research, “particularly”, explained Robert Win-
dom, assistant secretary of health, “if the procedure were to involve the 
intentional destruction of human embryos or increase the risk of 
embryos being otherwise harmed” (House of Representatives 1988: 9, 
Norman 1988). 
 After the adverse public reactions to the EAB’s recommendations of 
federally funded IVF the Reagan administration did not appoint and 
fund a new Ethical Advisory Board (see Chapter 5). Without an EAB, 
research proposals could not be federally funded. The federal policy 
during the Reagan and Bush administrations (1980–1992) was therefore 
a de facto moratorium. How did this policy – or maybe lack of policy – 
affect IVF? When the Federal administration stayed out of IVF, other 
actors became important. 
An IVF population: the infertile, clinics, researchers, materials 
While increasing numbers of babies were obvious results of IVF, other 
actors also resulted from the new technology, viz. the infertile, IVF 
clinics, researchers and embryos. In the constrained context of IVF one 
group of people was said to be especially important. The infertile population 
was a part of the IVF research in several ways. The research material, the 
expectations and the motivations came from them. In 1980 Edwards and 
Steptoe published their book, A Matter of Life, where they biographically 
recall and discuss their work on IVF and embryo transfer. The first lines 
of the first chapter read: 
She did not realize I was a medical student. Despite my youthful appearance 
she called me, “Doctor”, then briefly lost control. “What have I done wrong,” 
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 she cried, “not to have a family of my own?” Perturbed I tried to comfort 
here and in a moment she managed to continue, “I would have liked to have a 
large family but I’ve been married seven years […]” her voice trailed off. 
(Edwards and Steptoe 1980: 11) 
Infertile couples are essential in Edwards and Steptoe’s self-reconstruc-
tive narrative.116 They were also essential as donators of the raw research 
material – eggs and sperms. Couples willing to donate were not hard to 
find, although Edwards’s contacts with gynecologists were crucial, in or-
der to draw on couples’ willingness.117 The group of infertile grew in im-
portance together with the increase of IVF treatments, babies and clinics. 
Here the group is present in a 1984 anthology, Infertility: Medical, Emotio-
nal, and Social Considerations.  
As infertility is discussed more openly, the stigma and mythology associated 
with it should decline, thus minimizing the controversy and blame that have 
surrounded the issue. As the infertile population becomes more outspoken 
and visible, they will hopefully be recognized as a constituency worthy of 
social compassion and political responsiveness to their needs. (Simons 1984: 69) 
Harriet Simons hoped for increased recognition of the constituency of 
the infertile population. If “social compassion and political responsive-
ness” meant federal funding in the USA, the hope was not fulfilled. The 
Federal administration kept their money and their regulation away from 
IVF. However, the infertile constituency was recognized in terms of an 
increase in IVF clinics. The one went hand in hand with the other. The 
first provided money, eggs, and sperm. The other became the support 
for infertile couples. According to Robert Edwards at an IVF conference 
in 1984 the “alleviation of infertility is increasingly accepted as an urgent 
social and clinical need”:  
                                     
116  IVF is not a technology that presupposes couples, but in some narratives – e.g. 
in Edwards and Steptoe’s – and in some debates infertile couples are the per-
ceived benefactors of the IVF treatment. For instance, by the year 2000 more 
than 80% of reporting IVF clinics provided their services for single women, 
US DHHS 2000: 49, 2001a: 63. 
117  Robert Edwards:  
We soon discovered that patients needed to be restrained from voluntee-
ring too much. Patients would offer themselves for a second laparascopy 
or even to come into Oldham General Hospital twelve times a year if ne-
cessary! (Edwards and Steptoe 1980: 88) 
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I imagine that we all agree that many aspects of the procedure are now fully 
accepted by society as ethical. [---] This is very different from the situation 15 
years ago, when virtually everything about the procedure was questioned. We 
were accused of overpopulating the world, immorally collecting eggs and sper-
matozoa, opening a Pandora’s box of biological tricks, and jeopardizing ethi-
cal standards. The infertile couple had no supporters. Those debates are now 
well behind us, however, and the alleviation of infertility is increasingly accep-
ted as an urgent social and clinical need. (Edwards 1985: 1)118  
Whether Edwards’s characterization is completely correct or not, the in-
creasing numbers of babies and clinics pointed toward a growing circu-
lation of technology, knowledge, money, people, eggs and sperms.  
 In the USA there was no political recognition of the infertile popula-
tion in terms of federal funds, but in terms of treatments performed the 
constituency grew in importance. The first clinic in the USA was estab-
lished in 1979. In 1980 visits to infertility services were still below one mil-
lion a year. By 1985 yearly visits had risen to nearly two million per year 
(Office of Technology Assessment 1988: 5). According to Gena Corea 
IVF clinics in scientifically developed countries (Australia, Japan, Israel, 
Western Europe, and the USA) amounted to one hundred by 1984119 
(Singer and Wells 1984: 13). By the early 1990’s IVF treatments were 
practiced at 68 locations in the UK. In 1992 there were an estimated 200 
IVF clinics in the USA (Hartz et al. 1992). Approximately 20.000 babies 
had then been born through IVF-ET and related techniques (Mulkay 
1997). Twenty years after the first successful birth the number of clinics 
had grown to more than 400 (Hoffman et al. 2003). Clinics and newborn 
babies (and children, teenagers, and young adults) added to the impor-
tance of the infertile population. Another measure of the constituency’s 
strength is the perceived gravity of infertility. The National Center for Health 
Studies was motivated to comment on the popular perceptions of an 
“epidemic” of infertility (in its statistical report Fecundity and Infertility in 
the United States, 1965–88): 
In some popular descriptions of infertility, it has been suggested that there are 
9 or 10 million infertile couples, that 1 in 6 couples is infertile, that infertility is 
increasing rapidly, or that there is an ”epidemic” of infertility in the United 
States. [Mosher and Pratt refer to four works between 1980 and 1987] The 
                                     
118  The conference proceeding was published in 1985, but the conference was 
held in 1984. 
119  Corea was cited in Mulkay 1997: 1. 
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findings of this report indicate that these perceptions are inaccurate, but the 
increased use of infertility services, the increased number of childless older 
women with impaired fecundity, and other factors […] may help to account 
for the perception that infertility is increasing or that it is more common than 
it actually is. (Mosher and Pratt 1990: 1) 
The perception of an infertility epidemic coincided with the rise of IVF 
and ET as treatments for infertility. The report suggests that the percep-
tion was due to the new techniques for treating infertility, an increase in 
physicians trained to treat infertility, and increased news coverage. The 
epidemic perception and the number of clinics and doctors grew toge-
ther with research, in spite of the missing federal US dollars. Edwards’s 
earlier references to the support for infertile couples were reciprocal. The 
researchers were not only benefactors, but benefited themselves. IVF re-
search grew as a professional community after 1978. Together with the 
other editor of the proceedings, Markku Seppälä from Helsinki, Edwards 
opened the 1984 conference proceedings with a reflection on the scientific 
field. Or, maybe more appropriately, the scientific fields that had been pro-
vided with a joint interest, and a meeting-point, thanks to IVF research.  
In addition to offering new hope, this technique has brought about a vast 
increase in knowledge of early reproductive phenomena. Indeed, human in 
vitro fertilization has already opened the door to a reproduction revolution […]. 
The Helsinki Congress was third in the sequence begun in Kiel (West Ger-
many) in 1980 and followed, by the Second Congress, in Annecy (France) in 
1982. Scientific meetings on in vitro fertilization have grown progressively lar-
ger each time. In Helsinki, more than 500 scientists working on embryology, 
developmental biology, endocrinology, and andrology were brought together 
with clinicians to exchange information and to present 235 scientific papers 
on various aspects of in vitro fertilization. (Seppälä and Edwards 1985: xi) 
The vast increase in knowledge of early reproductive phenomena had a 
very material side. By connecting to and empowering the infertile popu-
lation, researchers now had access to eggs, sperms and embryos in a sca-
le never before experienced. IVF was an event, something happening to 
the infertile and to the IVF researchers. Disputed or not, politically re-
cognized as a constituency or not, the new-born babies and their parents, 
the new clinics, researchers, and scientific conferences were human and 
material links adding to the IVF and the embryos. The infertile popula-
tion grew in importance and achieved totally new ways of reaching its 
goals. Material and cognitive resources for researchers in several disci-
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plines increased. Except for the linkages mentioned here, two technolo-
gical links contributed to IVF. 
Creating “spare embryos”  
Edwards and Steptoe’s first successful IVF birth utilized an egg from 
Mrs Brown and sperm from Mr Brown. The egg was extracted through 
laparascopy as a result of Mrs Brown’s normal ovulatory cycle. After 
fertilization in vitro (i.e. in a Petri-dish) the fertilized egg was returned to 
Mrs Brown’s womb. There were alternatives to, and soon many develop-
ments of, the “protocol” of Edwards and Steptoe. There had been other 
attempts, e.g. by Landrum Shettles in New York and an Australian group 
headed by Alan Trounson. Since the IVF treatments were kept in the 
private realm in the USA different clinics could choose to adopt diffe-
rent protocols in helping couples to conceive. No uniform or centralized 
regulation guided the growing number of American IVF clinics.  
 In the beginning the success rate varied a lot and was never higher 
than the natural cycles, which are said to result in successful pregnancies 
in 20–25% of cases (Soules 1985). In 1986 some IVF centers had still not 
achieved one pregnancy (Robertson 1986: 1035). Edwards and Steptoe 
had utilized the spontaneous ovulation cycle of Mrs Brown. They had 
cautioned that the use of drugs to stimulate ovulation would hamper the 
likelihood for implantation. Since the 1960’s there had been drugs for 
stimulating the release of women’s eggs in order to facilitate pregnancies 
and to control ovulation (Schwartz and Jewelewicz 1981, Steptoe and 
Edwards 1970). The “superovulation hormones” were, by the late 
1970’s, frequently used in cattle reproduction (Seidel 1981). Soon after 
Louise Brown these hormones were used to improve the low success 
rate of IVF. By 1984 Kerin and Seamark, from a department of obste-
trics and gynecology, could write in a medical anthology of IVF and em-
bryo transfer:  
The use of ovarian stimulants to manipulate and control the human ovulatory 
cycle is now an accepted practice in the more successful groups for IVF and 
ET even though the first successes with IVF and ET were obtained in spon-
taneous ovulatory cycles. (Kerin and Seamark 1984: 99) 
The stimulants were used either to decide the timing of ovulation (and 
extraction) or to have more oocytes released. The latter usage enabled 
the implantation of several embryos, which could increase the chance for 
successful pregnancies without repeating the invasive extraction proce-
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dure. The method was adopted by several clinics. In 1986, law Professor 
and bioethical commentator John Robertson described superovulation as 
a requirement for the “standard IVF regime”.  
The standard IVF treatment regime requires that the ovaries be stimulated to 
produce several eggs, because the chance of pregnancy is very small if only 
one fertilized egg is transferred to the uterus. (Robertson 1986: 948)  
In 1978 Louise Brown was born from a normal cycle-egg. By the mid-
1980’s superovulation was “an accepted practice” or even “required” for 
the “standard IVF treatment” according to inside actors and commen-
tators.120 With this development there also came a well-known problem, 
acknowledged since earlier use of superovulation (outside of IVF). In the 
cases where several eggs were released, fertilized and implanted there 
could be multiple pregnancies causing increased abnormality in fetuses and, 
sometimes, maternal health-risks (Schenker et al. 1981). In IVF there 
were suggestions on how to solve the problem of multiple pregnancies. 
One was from Trounson’s group in Australia. Clomiphene citrate and 
gonadotrophins were common stimulants to induce ovulation: 
The widespread use of clomiphene citrate and exogenous gonadotrophins for 
in vitro fertilization (IVF) in humans, frequently results in the production of 
multiple embryos. Replacement of more than two embryos increases pregnan-
cy rate but may result in multiple pregnancies with increased pre- and post-
natal abnormality. Preservation of embryos from a limited time allows fewer 
embryos to be replaced on several different occasions and thus the problems 
of multiple pregnancy can be minimized, the effectiveness of a single IVF 
procedure increased and embryos replacement in adverse maternal conditions 
avoided. (Trounson and Mohr 1983: 707) 
If, Trounson et al. suggested, the fertilized oocytes could be preserved 
instead of implanted all at once, the risk of multiple pregnancies would 
decrease. In the paper they presented the successful implantation of an 
embryo that had been “cryopreserved”, that is, frozen. The pregnancy 
had been terminated prematurely, after 24 weeks. Trounson et al. 
claimed that the termination was not associated with the 
cryopreservation process. This theoretically opened for the possibilities 
indicated in the above quotation, although it was in no way standard 
                                     
120  Without any more exact numbers being found, the articles on superovulation 
at the time did not discuss it as possibility, but compared the efficiency and 
effects of various sorts of drugs, Kerin and Seamark 1984, Vargyas et al. 1984. 
 
 
 
208 
treatment at the time. The next year (in the medical anthology already 
visited) Kerin and Seamark spelled out not only the hoped-for 
possibilities, but also the current state of science: 
Excess embryos may be frozen and stored and hopefully with further tech-
nical developments, transferred successfully in a subsequent ovulatory cycle 
where the trauma of laparoscopy has not been involved. The stimulated and 
controlled ovulatory cycle also reduces the pressure of intense monitoring for 
timing oocyte recovery, provides a chance of obtaining a number of oocytes 
and if minor errors in timing do occur, final maturation in vitro prior to inse-
mination is possible. (Kerin and Seamark 1984: 10) 
Although the whole process from cryopreservation to pregnancies were in 
no way standardized in the mid 1980’s (House of Representatives 1987: 12, 
Robertson 1986: 949), clinics started to store embryos for later use and 
for research, not least outside of the USA (Singer and Wells 1984). One 
reason for the cryopreservation of embryos was to avoid discarding ex-
cess embryos resulting from the superovulation drugs. Bioethicists Peter 
Singer and Deane Welles (then at Monash University Centre for Human 
Bioethics, Australia) describe how “The Queen Victoria Hospital Ethics 
Committee accepted the freezing of embryos because this is less drastic 
than throwing them out” (Singer and Wells 1984: 100).  
 Superovulation and cryopreservation were thus technologies that enabled 
the storing of ”spare embryos”. The superovulation technology creates 
the spare embryo. Cryopreservation stores it. The solution chosen by The 
Queen Victoria Hospital in Australia was a way to solve the problems of 
superovulation. In so far as clinics thus chose to utilize the two techno-
logies, IVF could produce ethical dilemmas. Notice the modalities used 
in the quotations. Kerin and Seamark stated that “[e]xcess embryos may 
be frozen and stored” (my italics), and Trounson et al above discussed it 
as an option for IVF treatment. Somehow this possibility was turned into 
“necessity”. 
Creating necessity 
The “necessity” did not follow from these technological possibilities. Af-
ter 1994 IVF did in fact, by “necessity” as it was, produce scores of 
stored embryos. Just ten years earlier the “necessity” was still not there. 
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It was the result of technological possibilities, policy structures, and 
clinicians and patients in IVF.121 
 By the mid-80’s, the IVF practices had come to engage a number of 
the actors mentioned above, including the two technologies of super-
ovulation and cryopreservation. One should stress IVF practices – not 
practice in singular: The IVF technique was not one technique at the time. 
For instance, it was still not true what was said ten years later by Porter: 
“the creation of spare embryos is a necessary and inevitable part of in 
vitro fertilization” (House of Representatives 1996: H7340) – or fifteen 
years later by Specter: “But the process of in vitro fertilization is to have 
a large group and then to use some but not to use others” (US Senate 
2001: 30). There was no definite and standardized process.122 George W. 
Bush could not at this time have formulated his two fundamental ques-
tions concerning the existence of frozen embryos, as he did in his 
August 9 decision, 2001: 
As I thought through this issue, I kept returning to two fundamental ques-
tions: First, are these frozen embryos human life, and therefore, something 
precious to be protected? And second, if they’re going to be destroyed any-
way, shouldn’t they be used for a greater good, for research that has the po-
tential to save and improve other lives? (Bush 2001) 
Bush could not have asked the two questions in the mid-80’s. There we-
re not at that time hundreds of thousands of frozen embryos around.123  
 One actor still not engaged in any significant way was the Federal 
administration. Embryo research was technically possible but not fede-
rally funded. It was technically possible in the private sector. Any researcher 
could in principle – with private funds – do any research s/he wanted to 
within in vitro fertilization. The ethical and legal restrictions in the USA 
                                     
121  Considering that this is an ANT study and “necessities”, as everything else, 
are assumed to come to be through articulations, I will drop the quotation 
marks henceforth. Necessity (without inverted commas) thus refers to the 
articulated necessity. The same is obviously true for “spare embryos”, but the 
(still) politically charged role of this term justifies the keeping of the quotation 
marks, in order to keep a reification of “spare embryos” at bay. Analytic 
symmetry thus results in typographical asymmetry.  
122  In fact this was not even true in 2001, but the process Specter describes was 
one of several IVF processes. 
123  In 2002 the number of frozen embryos was around 400.000, Hoffman et al. 
2003. 
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were few and amounted to informed consent, and compliance with gene-
ral regulation, state laws and the local institutional review boards.124 This 
was for good and for bad. In 1985 Michael Soules, at an obstetrics and 
gynecology department wrote in a Fertility and Sterility editorial about how 
the competition was probably a cause for exaggerated success rates from 
clinics: 
Competition appears to be the root of the problem. In the United States, 
literally hundreds of IVF programs sprang up between 1980 and 1982. [---] 
The widespread practice of exaggerating the IVF pregnancy rate appears to be 
a marketing ploy to lure prospective infertile couples into becoming active 
IVF patients. Aware of the high cost (at $3000 to $6000 per attempt), general 
nonavailability of third-party reimbursement, and the odds of achieving a via-
ble pregnancy, many eligible infertile couples and their physicians have assu-
med a wait-and-see attitude toward IVF. [---] While inflation of the IVF preg-
nancy rate is an expedient stop-gap solution to this stalemate, this practice 
amounts to deception and exploitation of patients and is deplorable. (Soules 
1985: 513) 
Federal dollars and regulations were not a pre-condition for a new reality 
of IVF, embryos, the infertile, IVF researchers, clinics and doctors, but 
their absence had effect on how IVF was carried out. According to Soules, 
the competition between private IVF programs affected how data was 
presented to physicians and patients.  
 Private commissions and professional organizations (AMA, AFS and 
NABER)125 presented guidelines but none of these were compulsory (US 
Congress 1989, Cohen 1996, Quigley and Andrews 1984). A hundred flo-
wers could blossom, depending on the patients/clients’ and professio-
nals’ wishes. There was a space for clinical and research alternatives.  
 Superovulation and cryopreservation as possible technologies were being 
developed in the USA together with the strong desires of infertile peo-
ple, and unregulated but client-dependent IVF clinics. IVF empowered 
and was enforced by hopeful-parents-to-be, new parents and their new-
borns, clinicians, and researchers. Its shape was determined by its bene-
factors and beneficiaries and the landscape in which they all moved, i.e. 
                                     
124  In the case of fetal tissue research it was the Universal Anatomical Gift Act 
for treatment of cadaveric tissue. 
125  The full names of organizations presenting guidelines were the American Me-
dical Association (in 1983 and in 1989), the American Fertility Services (in 
1982) and the National Advisory Board on Ethics in Reproduction (in 1996). 
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an American policy-structure which meant the absence of regulation be-
cause of the non-involvement of federal dollars. In 1987–1989 there we-
re hearings in the House of Representatives to evaluate the need for, and 
appropriateness of, federal funding and regulation. No decision was ta-
ken until the formal (but quiet) lifting of the de facto moratorium in 1993.  
 By then, important decisions had already been made between clinics, 
patients, and IVF researchers. Of several ways to pursue IVF one type of 
IVF had produced stocks of frozen embryos. In the absence of federal 
interventions, a new reality had been established. Since the public sector 
would neither allow IVF in, nor definitely prohibit it by law, embryos 
had to be produced – literally and metaphorically – in the private sector. 
 In the early 1980’s Professors of Obstetrics and Gynecology at Har-
vard Medical School, Machelle Seibel and Melvin Taymor, wrote in sup-
port of IVF: 
Many opponents to IVF persist in objections that are based upon the erro-
neous information that in the process a number of embryos are formed, that 
only one is reimplanted, and that the others are discarded. This may have been 
the original approach of Steptoe and Edwards and in procedures which may 
still exist in other countries, but it is not the procedure now followed by the 
majority of centers. If one uses the natural cycle, only one egg is available for 
fertilization and implantation. Even if one utilizes fertility medications and at-
tains two or more eggs and fertilizes more than one egg, all of these fertilized 
eggs are reimplanted. The argument against IVF based upon the discarding of 
embryos is thus invalid. (Seibel and Taymor 1984: 214) 
Except for the “erroneous guess” about the original approach of Steptoe 
and Edwards it is interesting that the natural cycle and reimplantation of 
all fertilized eggs were regarded as the norm, and as an argument for 
IVF. In the Congressional debates in 1996, 1998 and later, superovula-
tion and cryopreservation were taken for granted as a part of IVF and 
used as an argument for hESC research. Seibel and Taymor renounced 
those technologies in order to argue for IVF. The technologies were thus 
in 1984 in no sense necessary for IVF to do its job as a mediator of in-
fertility and research interests. Quite the opposite. Superovulation and 
cryopreservation were a threat for the emerging IVF treatment. Many 
clinics did not adopt the new techniques and chose to implant all the 
oocytes that had been fertilized, some because of lack of resources. Small 
clinics did not have resources to test and assess innovations (because of 
insufficient statistical data) (Kerin and Seamark 1984). Other clinics did 
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not use cryopreservation because of ethical, religious, political and publi-
city interests: 
To allay opposition on ethical grounds, some centres, such as the one in Nor-
folk, Virginia, will fertilize only as many eggs as the patient is willing to have 
transferred to her womb […]. (Singer and Wells 1984: 25)126  
In spite of the lack of regulation most clinics would not store embryos. 
Right-to-life groups and collaborating hospitals demanded uterus trans-
fer of all fertilized eggs: 
Discard of unwanted embryos raises the question of embryo status and the 
substantive limits on the gamete providers’ dispositional authority. No law 
now requires that all fertilized eggs and preimplantation embryos be transfer-
red to a uterus. However, a de facto policy against discarding embryos cur-
rently exists. To avoid controversy with right-to-life groups and gain hospital 
approval, most American IVF programs claim to transfer all fertilized eggs to 
a uterus. (Robertson 1986: 977) 
In a footnote Robertson describes how this is in practice taken care of at 
IVF clinics:  
A typical IVF program will base acceptance into the program upon agreement 
that all embryos be transferred to the woman regardless of the embryos’ 
condition. [---] To avoid the dilemma described here, many programs will not 
aspirate more than five or six eggs, or will not fertilize more eggs than they 
plan to place in uterus. (Robertson 1986: 977, note 125) 
This situation lasted. Bonnie Steinbock observed, in her Life Before Birth, 
the same phenomenon in 1992.  
To avoid adverse publicity and controversy with right-to-life groups, most 
American IVF programs do not fertilize more eggs than they plan to place in 
the uterus. This avoids the problem of what to do with surplus embryos, but 
at a price. (Steinbock 1992: 198–199) 
The price, according to Steinbock, is multiple pregnancies and, if implan-
tation fails, one or several more extractions of eggs from the woman.  
 As late as 1992 the “necessary” production of ”spare embryos” was 
still optional, according to Steinbock, but the hints of necessity were al-
                                     
126  As early as in 1984 right-to-life groups were objecting to production of sur-
plus embryos. 44% approved in an Australian poll, 33% disapproved, the rest 
had no opinion or needed to know more, Singer and Wells 1984: 101. 
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ready there. Robertson (in the previous section) claimed that “The stan-
dard IVF treatment regime requires” superovulation, “because the chan-
ce of pregnancy is very small if only one fertilized egg is transferred to 
the uterus” (Robertson 1986: 948). Steinbock thought the price for avoi-
ding the surplus embryo problem too high for the women participating.  
 It is difficult to assess exactly how the saliency of cryopreservation in-
creased. An international survey based on data from 24 IVF centers in 
ten countries up to December 1986 found that almost all of them (22) 
pursued cryopreservation (Van Steirteghem and Van den Abbeel 1988). 
Unfortunately these results say little about the frequency of embryo free-
zing, and also little about the US situation. Of the 24 centers only two 
were in the USA, and circumstances can be assumed to have varied be-
tween countries such as the USA, Israel, Australia, Norway and Spain. 
Van Steirteghem and Van den Abbeel’s survey thus may say something 
about the international spread of cryopreservation techniques, but little 
about the actual use of them in the USA. 
 The situation is more clear after 1992, when the Fertility Clinic Success 
Rate and Certification Act required the Centers for Disease Control and 
Prevention to annually publish an Assisted Reproductive Technology suc-
cess rate report (US DHHS 2005). Based on such data a JAMA publica-
tion in 1999 showed that in transfers initiated in 1996 of “the most com-
mon type of ART treatment: fresh, nondonor IVF” (Schieve et al. 1999: 
1833) cryopreservation of excess embryos was done in less than half of 
the cases.127 Of the 35.554 procedures studied less than a third (29,88%) 
involved cryopreservation of excess embryos (p. 1834). Frist’s and others’ 
description of embryo storage as part of a “standard treatment proce-
dure” thus refers to a 30% usage rate. 
 “Standard” could also mean that this is a procedure that is done al-
most everywhere, which according to the annual national surveys is very 
true. As of January 2000, 90% of the clinics provided cryopreservation (US 
DHHS 2000) and according to the report for 1999 (US DHHS 2001a) 
                                     
127  These procedures did not include use of donor eggs (n = 5.162); transfers to 
surrogate mother (n = 688); transfer of already frozen embryos (n = 9.290); 
transfers into a woman’s fallopian tubes rather than uterus (n = 4.117); trans-
fers to both the uterus and the fallopian tubes (n = 619); transfers of both 
fresh and thawed embryos (n = 125); procedures that did not progress to 
embryo transfer (n = 8.890) and cycles for which patient age was either mis-
sing (n = 79), younger than 20 years (n = 6), or older than 44 years (n = 194), 
Schieve et al. 1999: 1833. 
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99% of the clinics provided cryopreservation (the latter probably con-
cerns January 2001 and not 2000). Since the 2000 report the rate of cli-
nics that have provided it has been around 97–98% (US DHHS 2005). 
 Use of superovulation drugs was clearly the predominant way to carry 
out IVF by 1998–1999. In the report summarizing the IVF clinics’ re-
sults in 1996, which was the one available for actors in the Senate hear-
ings 1998–1999 it was said that “Nationally, fewer than 1% of ART cyc-
les in 1996 were unstimulated. However, in a very few clinics, 25% or 
more of cycles were unstimulated” (US DHHS 1998: 28). 
 When procedures are investigated or studied the concern is the effi-
ciency of various procedures (Kerin and Seamark 1984), the fecundity 
and need of fertility services among the population (Mosher and Pratt 
1990) or the role of women in the treatment processes (Cussins 1996). 
Such debates could show whether the application of superovulation and 
cryopreservation was motivated by a concern for women’s health or by 
financial constraints, and who the affluent actors were.  
 There may be such traces or there may not. What is obvious from my 
observations is that the policy landscape, together with the technological 
developments enabled a “selective necessity” and an “ontological prolife-
ration” of actually existing embryos. A lot of clinics could and did 
choose to superovulate and cryopreserve, resulting in the over-
production and storage of embryos.128 There was no formal regulation 
stopping clinics from doing this. As mentioned, the Federal 
administration and Congress had neither interfered nor supported, but 
left IVF in the private sector. When the ”spare embryos” – produced by 
so-called necessity from IVF – entered the debates after HERP they 
were the result of these permissive clinics, not those that had re-
implanted all embryos. The ”spare embryos” were the result, not of the 
IVF process, but of the IVF process as pursued by certain clinics, patients 
and researchers. The selection of this process in a policy and a 
technological landscape had necessary effects. Was there a necessity in 
1994 or in 1998–2001? No, since alternative processes had been known to 
work. Yes, since the actors assumed the necessity, and few directly 
questioned it. In any case there were thousands of frozen embryos. They 
were undoubtedly there in the world. The clinics and the patients had 
                                     
128  By 1989, over 700 pregnancies resulting from the transfer of nearly 11.000 
cryopreserved embryos were reported worldwide, Gelety and Surrey 1993: 
606. 
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determined a specific “status” of embryos as an already existing, 
remaining, excess, surplus or spare status. The Federal administration 
had handed the dilemma to everybody who would participate in 
superovulation and cryopreservation as aspects of IVF.  
 A first answer to the introductory question – how ”spare embryos” 
became an element that actors could refer to and the inevitability of the 
assumed necessity – can now be offered. In spite of the pluralism implied 
in the US situation, the two IVF techniques gradually populated freezers 
with embryos that were there of necessity. The domination is mediated 
not mainly by any technological black-boxing, but through an “ontologi-
cal proliferation”. Superovulation and cryopreservation did not dominate 
in clinical use, or in the legal sense (at least not according to Steinbock’s 
comment). There was pluralism. But enough clinics’ use of the techni-
ques produced lasting entities in freezers. A literally ontological produc-
tion stabilized the existence of embryos. ”Spare embryos” became a refe-
rence-point for actors. According to this history this was due to a lack of 
regulation, technological possibilities and the choices of clinics and infer-
tility patients. It was also due to the marginalization of at least one other 
possibility that did not become necessary, in fact, was barely possible. 
Non-creation of spare oocytes 
Except for the clinical and legal option of just bypassing the new tech-
nology and pursuing the IVF process without excess embryos, alterna-
tive routes existed. One such possibility was the freezing of eggs (oocy-
tes), instead of embryos. Oocytes do not have the ethical status of em-
bryos. Few have moral problems about discarding human eggs. But there 
were other problems, according to researchers. Oocytes were relatively 
harder to handle than embryos, they claimed. 
The preservation of human gametes rather than embryos is a little more 
acceptable to some groups within the community. However, the preservation 
of human oocytes is extremely difficult. [---] We are continuing to investigate 
the possibility of freezing human oocytes but there is a scarcity of properly 
mature oocytes for these studies. (Trounson 1984: 127) 
Suddenly there is a scarcity of oocytes, in spite of the development of 
super-ovulation techniques and interested infertility patients. Trounson 
did not succeed but another Australian, Christopher Chen, in 1986, did, 
as did later two West German groups (Chen 1986, 1998, Diedrich et al. 
1986, 1988, Van Uem et al. 1987). In spite of the initial success the tech-
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nology did not come into extensive use. Others continued to develop the 
technique and showed promising results, but without establishing a rou-
tine treatment based on cryopreserved eggs instead of embryos (Gelety 
and Surrey 1993, Hesla 1993). Timothy Gelety and Eric Surrey reported 
the state of science on the cryopreservation of embryos and oocytes in 
1993. Several studies had been successful, but there were also question 
marks from other studies. Looking at the abstract of their article the need 
for further refinements dominates and the successes are merely men-
tioned. In the editorial overview John Hesla has omitted all signs of pro-
gress in the research. Only problems remain. “Finally, the authors de-
scribe the problems associated with cryopreservation of unfertilized 
oocytes” (Hesla 1993: 584). Successful studies were thus presented in 
Gelety and Surrey’s main text, but did not survive to the Editor’s Corner. 
 Oocyte cryopreservation did not manage to disturb the proliferation of 
”spare embryos”. In 1998–2001 the possibilities of using fewer oocytes 
or freezing oocytes instead of embryos, are barely visible in the debates, 
and not at all in the Senate debates.129 Could this have been otherwise? 
What would have happened to the necessary production of IVF and the 
”spare embryos” had cryopreservation of oocytes been successful? Would 
the innovation have influenced the reality of IVF? IVF mediated the 
infertile population, newborn babies, and reproductive researchers. The 
usual justification for freezing embryos was the better chance of preg-
nancies, less risk of multiple pregnancies and fewer extraction procedu-
res for the woman. This justification was based on the needs of the 
clients, especially the women. In Edwards’s introductory 1984 speech he 
talked about the research on the ”spare embryos”: 
Research on the spare embryos growing in vitro raises difficult ethical issues, 
which are still being hotly debated in my country. I have no doubt that we 
must do this research, to help improve our methods, and to introduce new 
concepts in stem cell biology, although obviously there must be limitations. 
(Edwards 1985: 1) 
In this quotation he does not bring up cryopreservation as such, but 
research on spare embryos. Neither does he address the infertile or the public. 
He addresses colleagues at the Third World Congress of in Vitro Ferti-
lization and Embryo Transfer sponsored by the International Federation 
                                     
129  Some years later (2005) the situation is again different. Federal funds are allo-
cated to “embryo adoptions” as an alternative destiny for IVF embryos, 
Nightlight Christian Adoptions 2005. 
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of Gynecology and Obstetrics. In this world of IVF and ET scientists 
Edwards displays other motives than those encountered earlier. Super-
ovulation together with cryopreservation of embryos involved scores of 
”spare embryos” that would give access to early developmental proces-
ses. Edwards mentions improvement of methods and stem cell biology. 
If IVF was not producing ”spare embryos” the possibility of such inves-
tigations would decrease significantly. The mediation performed by IVF 
would decrease, at least for the audience listening to Edwards’s speech.  
 Soon after Trounson’s successful (although terminated) pregnancy fol-
lowing embryo freezing in 1983 and before the procedure became rou-
tine, researchers expressed hope and stressed its advantages in articles and 
books. After successful pregnancies following oocyte freezing, editors 
and review authors kept emphasizing the problems – without adding ex-
pectations or hope for the procedure. The successful cryopreservation of 
eggs required extensive research from the professional group that may 
have benefited the least from it. Had the cryopreservation of oocytes be-
en successful, there might have been thousands ”spare embryos” (and 
one necessity) less, in the later negotiations of embryo research. Had the 
Federal administration been involved such research could have been 
prioritized. In the concluding chapter the paradoxical effect of the Fede-
ral administration’s non-involvement and laissez-faire – which indirectly 
resulted in the ”spare embryos” – will be elaborated more extensively. 
Before that, let us take a look at another example of how stabilization 
occurred in the constrained context of pro-life sensitivies. 
Transplantation therapies 
After the introduction of the hESCs, the appropriate path to transplan-
tation therapies is more discussed, and less the relevance of the thera-
peutic concept (see Chapter 2). Its possibility and urgency are assumed in 
both the OPP as well as the APP suggestions and were referred to and ac-
cepted as real. When the need for hESC research is questioned the thera-
peutic needs are still accepted. Here is an example from Senator Brown-
back testifying in the Senate hearings (April 2000):  
My final point is that the human embryonic stem cell research is unnecessary, 
and this is a key point because I want to see people healed, which is what the 
chairman is after, which is what the ranking member is after. We want to see 
these diseases no more hit our people or anybody else across the planet. That 
is our heart and that is our objective, and on that we all agree. That is why I 
am saying this is not necessary. We can go on the areas of legitimate research 
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into adult stem cells which do not create the moral and ethical difficulties […]. 
(US Senate 2001: 18) 
Proponents and opponents of hESC research all articulated the need “to 
see these diseases no more hit our people or anybody else across the 
planet”. It was a common “heart and […] objective”. Such a common 
heart is an issue for unpacking: Where did it come from and how was it 
stabilized? In the political debates from 1988 to 1993 a number of actors 
ultimately endorsed the possibility and urgency of research on fetal tissue 
in transplantation therapies. This was a stabilization of linkages that endured 
until the concept was again actualized in public and political debates in 
relation to hESCs. However, the response from the scientific community 
calls for a notion of stabilization that allows for different degrees of 
stabilization among various actors. While being stable in relation to some 
actors, in some circulations, the element was, and still is, unstable and 
uncertain in relation to others.  
From animals, to patients, to politicians 
The first studies articulating the concept of transplanting fetal tissue 
came in the late 1970’s (Björklund and Stenevi 1979, Markowski and Law-
ler 1977). Apart from neural studies papers on the transplantation of 
fetal islet cells also were presented in the mid-80’s (Lacy 1984). Lacy and 
other researchers (Fiandaca et al. 1988, Strömberg et al. 1988, Tuch et al. 
1988, Weiss 1988) were supported by patient organizations, but no general 
public or explicitly political attention was given to the concept. Not until 
1987–1988. 
 At this time several suggestions about the potential of cell transplan-
tations to brains surfaced, both for human patients and in animal models 
(Lindvall et al. 1987, Madrazo et al. 1987). Brain tissue from (electively or 
spontaneously) aborted fetuses was transplanted into Parkinson’s disease 
(PD) patients, allegedly resulting in improvements. These coinciding re-
ports roused public and scientific opinion (Joynt and Gash 1987, Lewin 
1987). Thus, when the Director of the NIH, Dr. James Wyngaarden, in 
1988, received an application for the transplantation of fetal tissue into 
PD patients a moratorium was issued on all such research and an advi-
sory panel was convened (The Lancet 1988b, Adams 1988, Weiss 1990).130  
                                     
130  The application was submitted by Irwin Kopin. By then 116 (non-therapeutic) 
research projects utilizing fetal tissue were already funded by the NIH 
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 A number of scientists, patient organizations, bioethicists, and pro-
lifers testified before the panel in 1988 (Adams 1988). At least seven pa-
tient organizations appeared before the panel.131 Ultimately the panel re-
commended federal funds for the research, based on a review of the scien-
tific literature. 
There is sufficient evidence from animal experimentation to justify proceeding 
with human clinical trials in Parkinson’s disease and juvenile diabetes. (Adams 
1988: 14)  
The articles, justifying the need to move to human trials, all articulated a 
therapeutic concept based on transplanting fetal tissue. In January 1988, 
Wyngaarden accepted the panel’s recommendation. In spite of, and against, 
the panel’s advice the Bush administration said no and the moratorium 
was extended.132 Privately funded research was still not illegal. A major 
reason for the moratorium was the anticipated link between fetal re-
search and an increase in abortion incidence. The former was supposed 
to encourage or justify the latter (Vawter et al. 1990: 14). 
 Patients were a crucial group in the articulation of the therapeutic con-
cept, not least for the actual surgery. According to science journalist 
Georgina Ferry they did exert pressure, at least on scientists. She asked 
why patients were so willing to risk brain surgery when the results were 
still meager and suggested an answer herself. 
Why are people queuing up to be guinea pigs in experiments that may not do 
them any good, and even do harm? For a start, they have no other hope. The 
search for an alternative drug treatment to L-dopa is going very slowly […]. 
Parkinson’s patients face the prospect of years, maybe decades of declining 
physical competence, perhaps ending in mental deterioration as well. Anything 
                                                                                                                 
amounting to $11.2 million in the fiscal year of 1987, Office of Technology 
Assessment 1990: 171–173.  
131  Juvenile Diabetes Foundation International, American Diabetes Association, 
American Paralysis Association, Huntington’s Disease Society of America, 
National Spinal Cord Injury Association, Parkinson Support Groups of Ame-
rica, United Parkinson Foundation.  
132  More precisely, Wyngaarden’s memorandum was not acted upon until Octo-
ber 1989, when the new Assistant Secretary of Health advised the new DHHS 
Secretary, Louis W. Sullivan, a continuation of the ban. In November Sullivan 
continued the temporary moratorium indefinitely, Office of Technology As-
sessment 1990: 171–173.  
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that offers the smallest chance of changing that future seems worth trying. 
(Ferry 1988: 58) 
Ferry’s Q&As concern patients lining up for the first trials. According to 
others, patients were not so visible. In late 1989, neuroscientist Fred H. 
Gage complained about the ban and the lack of patient pressure: 
“None of the reasons for the ban had anything to do with bad science or 
good science or whether or not it’s reasonable to pursue this work on scien-
tific grounds,” Gage says. “I can’t believe that patients with degenerative di-
seases are not up in arms. It doesn’t seem real. But then, I’m a scientist.” (Weiss 
1989)  
This would definitely change during the coming years. 
Patient mobilization 
During the extended moratorium advocates for and against fetal tissue 
research mobilized. Public actors called for more research, stressing the 
urgency of cures.133 Among these were 32 medical research and educa-
tional organizations that early in 1990 wrote to the Secretary of Health 
and Human Services (the DHHS), Louis W. Sullivan. Here they are repor-
ted in the The New York Times: 
“It is clear to us that the potential for good to result from this research out-
weighs the concerns about the impact on the abortion rate in this country, 
concerns that are at best speculative,” They added, “Continuing the morato-
rium ignores the suffering of millions of Americans.” (Hilts 1990: C6)  
The New York Times reporter Philip Hilts also reported that Democrat re-
presentative Ted Weiss sent the DHHS a letter. Weiss in this questioned 
the legal basis for an indefinite moratorium, which in practice served as a 
                                     
133  One such actor was professor of medicine (and a member of the fetal re-
search ethics commission of 1974) Robert J. Levine: 
Now it seems likely that transplants of human fetal cells will ameliorate such 
devastating maladies as Parkinson’s disease and juvenile diabetes. Even this 
incomplete list should serve to demonstrate the enormous value of fetal re-
search. Moreover, there is by definition no other way to secure the benefits 
of such research, since federal law allows it only when a particular benefit 
cannot be realized by other means. The opponents of fetal research are de-
manding, in other words, that society relinquish all claim to such benefits. 
(Levine 1989: 96) 
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legal ban, but without due process including public notice, solicitation of 
public comment and the establishment of a rule. A Public Health Service 
document was quoted: 
“We have chosen to make the moratorium indefinite rather than permanent” 
because “a permanent prohibition of this research would require formal rule-
making procedures and thus would require extensive formal public comment 
and would be rather easily susceptible to litigation which could reverse this 
action.” (Hilts 1990: C6)  
By yearly extending the moratorium litigation could be avoided. After “a 
legislative battle” following the next expiration of the moratorium (No-
vember 5, 1990) the pressure on the moratorium became acute (Roberts 
1993). Lobbyists had convinced some well-known pro-life senators of 
the urgency of fetal tissue research and the possibility of – institutionally 
and legally – separating the research from abortion practices.  
 One pro-life Senator, Strom Thurmond, decided to vote for lifting the 
ban on funding the research in the explicit hope that his grandchild would 
some day be helped by the research. Senator John McCain, also with a 
pro-life voting record, was convinced by Anne Udall to vote for the use 
of tissue from aborted fetuses. Udall was the daughter of Senator Mo 
Udall, a friend of McCain who had died of Parkinson’s Disease (The 
Tribune Papers 2000). A journal issued by the American Diabetes Associa-
tion, Clinical Diabetes, in the Summer of 1992 reported on its activities. 
Still, the American Diabetes Association plans to continue lending support to 
fetal tissue research even though the bill’s chances of being passed this year 
look slim. ADA is hopeful that by shoring up the support of those in Con-
gress who already support the bill and aggressively lobbying those represen-
tatives who voted against the bill, fetal tissue research may become a reality, 
and the real business of finding a cure for diabetes can begin in earnest. 
(Clinical Diabetes 1992) 
These are all traces of how patient advocates lobbied people in Congress. 
Other pro-life congressmembers followed suit, and bills that in practice 
would lift the ban were passed in the Senate and in the House of 
Representatives in April and May 1992, respectively (Vawter 1993: 82).134 
In parallel with this intermediate victory for fetal tissue research pro-life 
actors came together. Between the passing of the Senate bill and the 
                                     
134  The House had passed a bill (by vote of 274 to 144) already in July 1991 based 
on the Research Freedom Act introduced by Henry Waxman in 1990.  
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House vote, a number of pro-life organizations ran the following adver-
tisement in the congressional newspaper “Roll Call”: 
Does fetal tissue research have anything to do with abortion? 
Ask NARAL: The National Abortion Rights Action League (NARAL) intends 
to score H.R. 2507, a bill to provide taxpayer funding of abortion-dependent 
fetal research, in their annual congressional roll call scorecard.  
Ask Ted Kennedy: On April 5, 1992, Ted Kennedy told a cheering pro-
abortion rally on Capitol Hill that Senate passage of H.R. 2507 proved “your 
message is getting through, in a very important and significant way. Make no 
doubt about it.” 
Ask Laurence Tribe: Harvard Law Professor Laurence Tribe testified that 
medical demand for fetal tissue gives Congress constitutional authority to pass 
the so-called “Freedom of Choice Act” to ensure a nationwide policy of abor-
tion on demand.  
Abortion advocates agree: H.R. 2507 has everything to do with abortion. 
A congressional vote to fund abortion-dependent fetal tissue research would 
give the abortion industry something it’s never been able to achieve on its 
own: respectability. 
Such a vote will make the abortion industry look good, but make Congress 
look awfully bad. Especially when Congress can use these funds for other, 
equally promising, research methods that do not require an unprecedented 
alliance with the abortion industry.  
63 percent of Americans oppose spending tax dollars for transplant research 
that uses tissue from induced abortions (January 1992 Wirthlin poll). 
Americans want limits to abortion on demand. So why does Congress think 
now is the time to begin collaborating with the very industry that performs 
and profits from it? 
Why should Congress give the abortion industry a good name and taxpayer 
dollars? Vote No on H.R. 2507! (Charo 1995b)135 
                                     
135  Alta Charo quotes from the congressional newspaper Roll Call, May 12, 1992. 
The advertisement came from a number of organizations: The Committee on 
Research Ethics, National Rights to Life Committee, Southern Baptist Chris-
tian Life Commission, Christian Coalition, Doctors for Life, American Asso-
ciation of Pro-Life OB/Gyns, National Association of Pro-Life Nurses, Uni-
ted States Catholic Conference, American Association of Pro-Life Pediatri-
cians, American Academy of Medical Ethics, Black Americans for Life, Phar-
macists for Life, Catholic Women’s Institute, Christian Action Council, Knights 
of Columbus, American Life League, National Conference of Catholic Wo-
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The supporting organizations are visible in the footnote, and say some-
thing about the pressure exerted. The quotation exemplifies how abor-
tion and fetal tissue research were related among the pro-lifers. Ted Ken-
nedy is quoted using fetal tissue research as a way to pursue the abortion 
issue, or alternatively a way to enroll pro-choicers for the research (assu-
ming that the information provided in the ad is correct).  
Possibility assumed 
Apart from displaying the number of actors coming together the adver-
tisement bears the trace of a possibility assumed. Little or no medical and 
scientific uncertainty was attached to the concept of therapeutic trans-
plantation of fetal tissue in the ad. It can be used to “give the abortion 
industry […] respectability”. In opposing the research the advertisement 
assumes that transplantation therapies are a medically possible path. It is 
thus an implicit or “bracketed acceptance” of the concept’s perceived me-
dical potential. Otherwise transplantation therapies could not give abor-
tion respectability.  
 This articulation by opponents could have been strategic and directly 
related to the pro-life sensitivities of the expected addressees. On the 
other hand this was the strategy chosen instead of disputing the medical 
feasibility or necessity, or pointing towards viable alternatives to fetal tissue 
(Weiss 1989). It was the main strategy of pro-life opponents of the re-
search from the start, visible in relation to the panel deliberations (Adams 
1988: 39–73, Weiss 1988). It was the strategy chosen by the Federal ad-
ministration as early as 1989, after the panel report and subsequent ad-
vice. Instead of engaging in what the medical possibilities and routes to 
take might be, the therapeutic concept was rejected as such, with refe-
rence to the possible effects on abortion rates.  
 This is one answer to “when, where and how transplantation therapies 
were accepted as possible and urgent”. The concept was accepted as pos-
sible by both proponents and opponents, although through “implicit ac-
                                                                                                                 
men, Ad Hoc Committee in Defense of Life, University Faculty for Life, 
Value of Life Committee, Life Issues Institute, Concerned Women for Ame-
rica, National Association of Evangelicals, Capitol Hill Women for Life, Wo-
men Exploited by Abortion, Jewish Anti-Abortion League, Women for Faith 
and Family, Women for Women, Fortress International, Family Research 
Council, Professional Women’s Network, Traditional Values Coalition, Ame-
rican Victims of Abortion, Presbyterian for Life, Scientists for Life, Feminists 
for Life, Eagle Forum, Jews for Morality. 
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ceptance”. However, before 1992, the urgency was still not accepted. Now, 
in 1992, President Bush concurred in action with the advertisement abo-
ve, utilized his veto and sent the bills back to the Congress floor. How-
ever, unlike the earlier strategy, he did partially endorse the therapeutic 
concept. In contrast to 1989–1991, he now accepted the urgency of fetal 
tissue research claimed by patient advocates.  
Urgency established 
Bush’s proposal was that such research could be realized without re-
course to elective abortions. This had been suggested in the scientific li-
terature already (Garry et al. 1992, Thorne and Michejda 1989). If a bank 
were set up that would collect tissues resulting from spontaneous abor-
tions (miscarriages) and ectopic pregnancies there might be enough to pur-
sue the research potentials. Funds were allocated to investigate the pos-
sibilities of these sources and for setting up a fetal tissue bank.  
 A compromise bill, that would give the administration a year to pursue 
such investigations, was however blocked in Congress. Several Parkin-
son’s and diabetes patient organizations, and medical educational organi-
zations filed suit against the Bush administration asking for a court deci-
sion on the lawfulness of the federal funding ban on fetal tissue research 
(The New York Times 1992). After the election of Bill Clinton the fetal 
tissue bank and the lawsuit fell by the wayside. While still a President-
elect Clinton was approached by a number of senators:  
One must only look at the benefits fetal tissue transplantation research can 
bring to our ability to develop lifesaving therapies for diseases such as dia-
betes, Alzheimer’s disease, Parkinson’s disease, and other genetic and neuro-
logical disorders to realize the value of this research. In light of recent studies 
indicating the possibilities of fetal tissue transplantations in treating patients 
with Parkinson’s disease, it has become more urgent for the federal govern-
ment to be involved in supporting these efforts. (US Senate 1993a) 
The letter was signed by several pro-life senators, among them Bob Dole, 
Mark O Hatfield, and Strom Thurmond. Therapeutic urgency ruled. 
January 22, on his second full day in office, President Clinton lifted the 
five-year old ban on the federal funding of fetal tissue research.  
 Two months later the US Congress had passed the NIH Revitalization 
Act, issuing funds for the NIH. The new laws made it possible for pub-
licly funded scientists to pursue research on fetal tissue. However, when 
looking for the stabilization of transplantation therapies the legal change 
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is but one linkage, albeit important. Equally important for the unpacking 
was how the legal change was one more trace of how actors assumed the 
medical and scientific certainty of the therapeutic concept – even those 
actors who had opposed lifting the ban a year before. The Republican 
Senator Hatwell on the Senate bill for fetal tissue research in 1993 stated: 
Many were surprised by my support for this important research. Most ex-
pected that as a pro-life Senator I would be compelled to treat fetal tissue 
research as an abortion issue, and thus oppose it. Well, I do view this as a pro-
life issue but not as an abortion issue. I strongly believe that we must look be-
yond abortion to the research benefits fetal tissue holds, remembering to con-
sider the sanctity of all life. (US Senate 1993b: 1582) 
In the words of Hatwell the fetal tissue holds “research benefits”. The 
sanctity of life is a pro-life phrase often used to explain the value of un-
born life. Here it is turned around to explain the value of fetal tissue re-
search. When the pro-life congressmembers accepted the ethical feasibi-
lity of the research it was accepted as beneficial, and with a high degree 
of certainty. That is, no medical or scientific problems figured. Orrin 
Hatch had a well-known and consistent pro-life voting record as a Utah 
Republican and Mormon Senator, and he had earlier opposed federally 
funded fetal tissue research. His opposition did not concern the scientific 
and medical possibilities.  
Some may question how I, who led the charge against the bill last year, could 
be a strong supporter of the measure this year. In fact, earlier this month some-
one stopped me and inquired about my so-called dramatic reversal on the va-
lidity of fetal tissue research.  
 I was surprised at this question, Mr. President, because nowhere in the de-
bate did I ever criticize the scientific validity of fetal tissue research. In fact, I 
stated that some of the literature indicated it is quite promising. I also stated 
that I was a strong proponent of fetal tissue research. (US Senate 1993b: 1572) 
Hatch’s support for fetal tissue research related to alternative sources. 
These quotations are included because they display so clearly how pro-lifers 
in Congress were embracing fetal tissue research. They did so by refer-
ring to its “validity” and its relevance for “lifesaving therapies for 
diseases such as diabetes, Alzheimer’s disease, Parkinson’s disease”. 
Clinton and Congress joined hands in supporting fetal tissue research. 
Even in the face of coordinated pro-life organizations (e.g. in the “Roll 
Call” above) the concept of transplanting tissue to treat degenerative di-
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seases was politically strong because of links to pro-life politicians, pa-
tient organizations and individual patients.  
 This thus answers the initial questions about “when, where and how 
transplantation therapies became a reference for actors”. The legal change 
with the help of pro-lifers in Congress is a testimony of the strength of 
the therapeutic concept among specific actors, at the time, in 1992–1993. 
Transplanting cells to cure Parkinson’s disease and diabetes was linked to 
politicians and patients, and these actors together achieved federal fun-
ding. It is in glaring contrast with the negotiations on human embryo 
research only a year later (around the HERP). In 1994 and later critics 
and commentators complained about too few benefits. When Hughes 
and Annas et al. referred to the compelling force of serious diseases such 
as Parkinson’s disease they were referring to the coordination of actors 
in the fetal tissue negotiations. Many of the actors in 1993 were still 
around when the hESCs were announced five years later. Hatch, Thur-
mond and the patient organizations, especially for diabetes and Parkin-
son’s disease were still supportive of transplantation therapies now link-
ed to another body of contentious research material. Articulating hESCs 
in terms of transplantation therapies thus drew on an already existing sta-
bilization, linked them to a reality that was there especially among some 
crucial politicians and patients. This is probably why opponents in 1998–
2001 (see Chapter 2) mainly bring up alternative sources instead of ques-
tioning transplantation therapies as such.  
Validity questioned 
Stabilization, however, need not be global or everywhere. In the multiple 
reality Annemarie Mol describes, one reference may be involved in diffe-
rent practices with only a few points of contact without making up one 
unified or single whole. Latour claims that a reference is dependent on 
the circulations it can enable, hold together and draw on (Latour 1999b: 
99).  
 Transplanation therapies circulated as a stable element among some 
actors. Patient groups and politicians are good to draw on for public sup-
port and funding. In the practices of “garnering support” and lobbying, 
transplantation therapies were a strong element. It was as such this ele-
ment could contribute to the negotiations on hESCs. In other practices 
and circulations transplantation therapies were not a strong element. 
While the above section thus gave one answer to the stabilization of trans-
plantation therapies relating to a specific “when” and “where” and cer-
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tain “whos”, lower stabilization existed in other sites and among other 
actors and requires a different answer and ultimately a distinct theoretical 
apparatus.  
 As seen above there had been experiments supporting some sort of 
expectation from the therapeutic concept. In 1985 a review of potential 
applications of neural transplantation states: 
Mammalian neural transplantation has recently been recognized to be a valu-
able technique for studying normal development and regeneration in the cen-
tral nervous system. In addition, the ability of grafted neurons to reinnervate 
damaged regions of the host brain and to ameliorate some neuroendocrine de-
ficits, cognitive disorders and motoric dysfunctions in young adult rodents has 
suggested that transplantation therapy may be effective in treating human neuro-
degenerative diseases and neurotransmitter deficiencies related to aging. (Gash 
et al. 1985: 131, my italics) 
Notice the italicized “suggested that transplantation therapy may be ef-
fective”. Some sort of expectation, a “suggestion”, was supported by ma-
ny scientists, but there were important uncertainties about the concept 
during the whole period. The same year (1988) a state-of-the-art review 
in The Lancet attempted to slow down the rush for clinical trials: 
However, there are no confirmed accounts of definite sustained functional 
improvement in MPTP […] induced parkinsonism in primates after implan-
tation of embryonic brain tissue. [---] Surely what is needed now is not more 
operations, but careful long-term follow-up, with positron emission, tomogra-
phic scanning and neurophysiological and clinical evaluation, of patients who 
have already received grafts. (The Lancet 1988a: 1087) 
Uncertainties and the alternatives were there together with therapeutic 
expectations in many of the articles from leading scientists and in review 
articles in leading journals. Here, Science called for “patience rather than 
patients”: 
This committee, together with the apparent failure to replicate the reported 
success from Mexico City should serve to raise a public and scientific aware-
ness of the questions attendant to the use of embryonic cell grafting in PD 
patients. [---] We should not repeat the experience of the adrenal autograft 
experiments wherein far more human than nonhuman primates were operated 
upon as a result of a single unconfirmed report of two patients. (Sladek and 
Shoulson 1988: 1387) 
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The Lancet and Science are not marginal sites, but major journals and, as 
such, vessels for stabilization. Again, there is stabilization in particular 
circulations, not everywhere. In an envisioned circulation of scientific 
facts and credibility these journals, together with professional entities, 
were toning down the certainty of fetal tissue transplantation as a thera-
peutic concept ready for trials in patients. Others in agreement with this 
were the American Medical Association, which analyzed the scientific 
literature as of June 1989:  
Fetal tissue transplantation has been attempted for a limited number of clini-
cal disorders, including Parkinson’s disease, diabetes, immunodeficiency dis-
orders, and several metabolic disorders. Fetal tissue has intrinsic properties – 
ability to differentiate into multiple cell types, growth and proliferative ability, 
growth factor production, and reduced antigenicity – that make it attractive 
for transplantation research. At this time the results from fetal tissue grafts for 
Parkinson’s disease and diabetes have not demonstrated significant long-term 
clinical benefit to patients with these disorders. (American Medical Associa-
tion 1990: 565) 
“Fetal tissue has intrinsic properties” but results had “not demonstrated 
significant long-term clinical benefit”. In 1991, articles that outlined the 
therapeutic concept of fetal tissue transplantation, emphasized its experi-
mental nature:  
Although animal experimental data are very promising and clinical trials have 
given encouraging results, it must be underscored that there exists at present 
no treatment for Parkinson’s disease based on intracerebral transplantation. It 
is important that patients and relatives are informed that this research is still at 
an experimental stage and that widespread clinical trials with transplantation in 
Parkinson’s disease are not warranted at this time. (Lindvall 1991: 25) 
Lindvall was (and still is) one of the leading authorities on fetal neural 
transplantation from Sweden. Other leading figures and organizations 
concur with the characterization of Lindvall and The Lancet.136 The report 
                                     
136  Here WJ Freed, in a review for Restorative Neurology and Neuroscience: 
Only recently, a few controlled studies have obtained evidence for po-
sitive effects of SN grafts in primate models of Parkinson’s disease. In 
the few clinical studies reported thus far, there are indications that some 
clinical improvements can be produced by SN grafts, although there is 
little or no evidence that the clinical changes found so far are larger than 
the changes that have been seen after adrenal medulla grafts. The possi-
bility of a role of striatal injury in the clinical changes has not been resol-
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on Neural Grafting from the Office of Technology Assessment, largely 
devoted to the therapeutic concept of fetal transplantation, recognized 
the tentative character of the research and the need for more animal 
work (trials and models): “no definitive statement about the actual use-
fulness of neural grafting as a therapeutic procedure can be made at this 
time” (Office of Technology Assessment 1990: 84). This view had been 
voiced already in the panel by two experts, e.g. Dr. Thomas Gill, from 
the University of Pittsburgh (Adams 1988: 46). Some research groups 
were cautious, not because they didn’t believe in the therapeutic concept, 
but because they feared the adverse effects of rushing ahead with human 
experiments prematurely .137  
Separate circulations  
Not much happened with these scientific uncertainties. They were not in 
step with the political process, or vice versa. In articulations from pa-
tients and politicians or even pro-lifers the medical possibilities (although 
ethically disputed) were real.  
 The uncertainties did not to any major extent “leak” into those circu-
lations, and when they did, they weren’t soaked in. Somehow there see-
med to be a quite clear “separation” of crucial scientists and scientific in-
stitutions in one circulation from another one of patients and politicians.  
 The circulations of this chapter are thus not necessarily loops in one 
circulatory system, but can exist separately as multiple circulations. My mul-
tiple circulations may, or may not, come together and become a circula-
tory system. Unlike loops the circulations are not centered on one locus 
                                                                                                                 
ved. It is noteworthy that nearly all of the studies of SN transplantation 
in rodents, primates, and humans have employed methodologies similar 
to those developed in the course of the first few reports on SN trans-
plantation, and that the effects obtained by these methods are limited, 
even in rats. The possibility is raised that fundamental advances in SN 
transplantation techniques may be important for the development of a 
more efficacious clinical procedure. (Freed 1991: 109) 
137  Ferry mentions a British group comprising Deborah Clarke (Oxford), Steve 
Dunnett (Cambridge) and David Marsden (London). Marsden is quoted as 
saying “Before it will be justified in this country, we have to prove viability of 
transplants from human material to primates”, Ferry 1988: 58. Other exam-
ples are Bakay and Barrow 1988, Joynt and Gash 1987, Sladek and Shoulson 
1988: 1387.  
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or person (in Latour’s case, Joliot, his reactor and the work on the chain 
reaction was at the heart of the loops).  
 One possible reason for the clear division of multiple circulations 
could be the perceived stakes. The moratorium was prohibiting federal 
research, which was immediately, in 1989, perceived as a very definitive 
constriction for researchers and ultimately for patients believing in the 
new therapeutic concept.  
But while Yale has granted permission for as many as 20 such operations, lack 
of federal support may prevent Redmond’s team from ever reaching that goal. 
“People think Yale is rich,” Redmond says. “But we’re continually operating 
on the brink of not being able to proceed.” and [sic] with most scientists 
having better things to do than go scrambling for private contributions for 
their next fetal transplant, Redmond already sees researchers avoiding such 
experiments to escape the attendant hassles. (Weiss 1989: 378) 
In another report, H. Fred Voss, from a company specializing in fetal-
cell research, Hana Biologics, estimates the numbers of diabetes and Alz-
heimer’s patients that could benefit at 2 million, respectively (Weiss 1988). 
For the pro-life movement it was exactly this thought that was abhorrent 
– the thought of a cultural and economic integration of abortion into the 
treatments of millions of people. For James Bopp Jr., attorney, and one 
of the two dissenting members of the 1988 panel, it was the needs esti-
mated by, and possibly mediated through, companies as Hana Biologics 
that were the threat. 
The economic implications of this scenario are astounding says James Bopp 
Jr. […]. “Hana Biologics estimates that the potential market in treating dia-
betes and Parkinson’s disease through the use of fetal tissue from induced 
abortions exceeds $6 billion,” says Bopp. “Thus a vast, new and lucrative mar-
ket would be created for fetal issue from induced abortion” – a market whose 
gross revenue would exceed that of abortion clinics by 30 times, according to 
his controversial calculations. “The likely result is increased number of abor-
tions, changes in abortion procedures, and delayed abortions to facilitate acqui-
sition of more useful fetal tissue,” Bopp contends. (Weiss 1988: 296) 
It was this industry that was pointed out in the Roll Call advertisement 
from 1992 (above). These quotations are included to focus on the polari-
zation from both sides, which drew on radically different resources. 
Bopp Jr. does not primarily attack the uncertainties of the research, but 
the mere possibility of combining abortion with therapeutic and adjacent 
economic interests. Bopp’s emphasis was not due to ignorance about the 
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uncertainties. In his dissenting statement for the panel report 1988 he 
gave several references to the uncertainty in the professional literature. 
He used three lines and a footnote for this aspect (Adams 1988:46). The 
rest of his 26-pages statement relates to abortion. Abortion was the issue, 
not scientific uncertainty.  
 Scientific validity and ethical appropriateness were held apart, treated 
separately. This was inherent in the strategy of President Bush and his 
Secretary of Health, Sullivan, in 1989. Still, some actors did highlight the 
uncertainties, e.g. Bopp Jr. or Thomas Gill. In 1992 Bush and pro-life 
people in Congress shifted and accepted the urgency of the therapeutic 
concept, voiced by patients and others. Although Bush and some of the 
pro-life people would stick to the abortion concerns and would therefore 
propose other tissue sources, these suggestions also did not question the 
scientific and medical possibilities and the urgency of therapies. Recall 
Hatch’s and Hatwell’s articulations above. According to them, they had 
not doubted the scientific validity, but had ethical objections relating to 
abortion.  
 For Redmond and other discontented researchers the medical possibi-
lities are the issue and the scientific uncertainties are what fuels the need 
for federal funding. When discussing alternative routes, such as geneti-
cally engineered cell-lines the certainty of fetal tissue is accentuated, as 
here by Fred Gage: “It certainly is clear that fetal neuronal transplants 
are more effective than any of the other cell types at present” (Weiss 
1988: 296). Experts were approached about the scientific uncertainties as 
the 1988 panel convened. According to Bopp Jr. none of them discussed 
these (Adams 1988: 45f). 
 It was thus correct – even in the face of scientific uncertainties – to say 
in the section before the previous one that right from the beginning of 
the controversy and until the change of the funding policy the medical 
possibility and the scientific validity were (implicitly or explicitly) assumed 
and in this sense stabilized among pro-life opponents and proponents. Among 
these actors the uncertainties were either insignificant, toned down or 
neglected. Among other actors – such as some participating researchers 
and commentators in The Lancet, Science, and the OTA – the concept was 
not stabilized in the same way. During the period 1988–1993 what was 
increasingly stabilized was the urgency of the therapeutic concept. What 
finally changed with the political recognition were the economic condi-
tions for exploring it. This stabilization among specific actors endured 
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until the concept was again actualized in public and political debates in 
relation to hESCs.  
Summary 
This chapter approaches actors’ references to ”spare embryos” and 
transplantation therapies in 1998–2001 (and to some extent after 1994). 
My account thus unpacks the necessity of ”spare embryos” and the 
possibility and urgency of transplantation therapies in terms of a number 
of actors, technologies, policies, and rejection strategies. Many of these 
linkages stayed in place until the hESCs were negotiated. 
 In the first case, a necessary IVF technique was created through the in-
fluence of willing clients, i.e. hopeful parents-to-be, clinics in competi-
tion, technological possibilities and regulatory absence. While the neces-
sity seems to be questionable because of alternative IVF processes, the 
so-called necessary technology had already produced actually existing 
frozen embryos. The status of these – as frozen and as bound to be dis-
carded – could also, in principle, be questioned. Frozen embryos could 
be thawed and donated, or “adopted”. After 2001, George W. Bush to so-
me extent opened this black box of perceived necessity and the inevit-
able fate of ”spare embryos” by funding adoption programs. Without eva-
luating the success of this attempt to – metaphorically speaking – thaw 
the frozen fate of ”spare embryos”, it just proves that irreversibilities are 
hard work and are seldom definite. 
 In the second case, the medical possibility and urgency of transplan-
tation therapies were the result of negotiations of whether to federally 
fund research using tissues from elective abortion. From the start of the 
(explicitly) political disputes the major issues among politicians, patients 
and pro-lifers, opponents or proponents, was not the scientific validity of 
the expectations, but the ethical appropriateness. While many of these 
actors focused on the latter, to either support or reject federal funding, 
the many uncertainties of the medical concept among scientists did not 
significantly affect the political disputes. To understand the stabilization 
of transplantation therapies, multiple circulations have to be taken into 
account. In the circulation of political and public support the therapeutic 
element was strong. In the circulation of experimental results and col-
legial credibility it was weaker. 
 None of these histories is saying that the elements were not really real, 
or social constructions as opposed to naturally real. They were involved in 
construction, but they were also – and increasingly so – real. What this 
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chapter says is that technological necessity is the result of contingent 
processes that are not inevitable and may be reversible.  
 Furthermore, medical possibility and urgency are not always the result 
of stabilization among medical researchers or the circulation of scientific 
results and collegial support. In this case the possibility and urgency of 
transplantation therapies were more established among politicians and 
patients than among scientists. Noticing this particular circulation and the 
fact that many of the same actors re-emerged in relation to the articula-
tion of hESCs answers another question from Chapter 3 about the selec-
tion of environment. Star and Griesemer’s notion of boundary objects 
was formulated within the ecology of institutions as one way to analyze 
how an appropriate environment was selected for the project, providing 
funds, clientele and personnel.  
 The stabilizations of IVF necessity and therapeutic urgency have impli-
cations for the understanding of how the reality of hESCs in USA 1998–
2001 developed. In relation to the multiple loops of hESCs this chapter 
unpacks two of the elements and display the flows they were part of. What 
remains unanswered is how the two elements that were separate before 
1994 became a part of the multiple loops of hESCs. This will have to be 
answered in the next and final chapter. 
 

 7.   Pluripotent Articulation: Relating hESCs to Embryos and 
Transplantation Therapies 
Introduction  
A bold hypothesis ended Chapter 5. Actors were coordinated by means 
of the management of hESCs in relation to two already stabilized and 
useful elements – “spare embryos” and transplantation therapies. While 
the previous chapter displayed the stabilization of the two elements and 
the coordination of actors, nothing has been said about whether and 
how there was management of the hESCs. Management implies some 
deliberate change. This chapter therefore examines whether and how the 
configuration of hESCs were changed between 1994 and 1998–2001.  
 The first part looks at how the articulations of hESCs were changed, 
especially their “E”, that is, their embryonic character. This included a tu-
ning of the source of hESCs and a calibration of the stem cells’ capa-
cities. The second part looks at how the lin k between hESCs and trans-
plantation therapies was negotiated. Again, the stem cells’ capacities are 
an issue.  
The “embryonic” of hESCs 
The most obvious change between 1994 and 1998 in the articulation of 
hESCs was probably the shift from being a reference on paper – in the 
panel report, as vague expectations in quoted interviews, and in the dis-
cussion-sections of scientific articles – to being a reference in laborato-
ries and regarded as “existing” in scientific journals – moved from batch 
to batch, linked to markers, fetal calf serum and mouse feeder cells, being 
viewed in microscopes, photographed and transferred to prestigious scien-
tific journals.  
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 One obvious change concerns the scientific work and the political 
staging. The recognition of Thomson’s and Gearhart’s respective papers 
was tied to a change of articulation. When hESCs were articulated in 1998 
they were no longer related to the Federal administration together with other 
kinds of human embryo research. This becomes clear when comparing chap-
ters 2–3 to Chapter 5. Whereas in 1994 the stem cells were a minor part 
of a whole package of human embryo research being considered for fe-
deral funds, they were the main or only issue in 1998–2001. The HERP 
recommendations concerned the federal funding of human embryo research. 
The negotiations in 1998–2001 concerned the federal funding of hESC 
research. Chapter 2 described how the change, according to some actors, 
was prompted by the announcement of the successful cultures of hESCs:  
If there was ever a good time to reopen the congressional debate on the ban 
on federally funded research on embryos, it must surely be now. (Nature 1998: 
97) 
The announcement of the laboratory work did indeed reopen the debate. 
What this part of the chapter suggests is that hESCs were changed not 
only by virtue of appearing in Petri-dishes and becoming the main issue of 
negotiation. The change of articulation of hESCs was not merely a mat-
ter of media and political actors reacting to a sudden and remarkable 
discovery by scientists. Something happened to the hESCs as they shif-
ted from being an expectation and a reference on paper. When the stem 
cells were articulated again in 1998 as laboratory cultures – and as the 
main character of a new negotiation – their biological capacities and their 
source material were modified.  
Human spare embryonic stem cells 
From being a circulating entity in panel reports, the media and in public 
and Congressional debates, hESCs were articulated materially, first in one 
laboratory, and then others. What sort of embryo was used for the labo-
ratory production of the hESCs when they became entities in labora-
tories? To enable the work on hESCs, Thomson’s group needed embryos.  
Fresh or frozen cleavage stage human embryos, produced by in vitro fertiliza-
tion (IVF) for clinical purposes, were donated by individuals after informed 
consent and after institutional review board approval. (Thomson et al. 1998: 
1145)  
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The embryo of hESCs in the laboratory was not just any embryo, but 
“donated by individuals” and approved by the local institutional review 
board (IRB). A similar paragraph occurs in the paper from Gearhart’s 
group (but then with 5- to 9-week fetal tissue resulting from therapeutic 
termination of pregnancy). The two groups did not have to use those 
sources. Both ultimately received private funding and, in principle, no-
thing prohibited them from creating their own source embryos. Despite 
this, neither of them chose to create research embryos. 
 In practice, the disputes about embryos infringed on their freedom of 
action. Thomson mentioned IRB approval above. Since they were both 
still employed by their respective universities (University of Wisconsin 
and at Johns Hopkins) they had to comply with the local ethical review 
boards. The review processes and Thomson’s and Gearhart’s choices of 
source were affected by the opposition to embryo research (Parson 2004: 
150f, 166f).  
 In The New York Times the embryonic source was articulated as follows: 
One research team used cells from fertilized eggs that would otherwise have 
been discarded after treating infertile couples, and the other used cells from 
already aborted fetuses. They literally created a major advance from cells that 
would otherwise have been wasted. (The New York Times 1998) 
Such cells-to-be-discarded are obviously different from the research-
created embryos articulated by the HERP. Other actors also pursued this 
alternative articulation of “embryos”. Senator Harkin is a politician draw-
ing on the argument of the already existing embryos:138 
It seems to me the height of morality to say that in order to help someone’s 
life to prevent Alzheimer’s or ALS or to regenerate neurons, to help people 
with juvenile diabetes, it seems to be the moral thing to do would be to use 
what we have there in these in vitro cells that are left over, the 100,000, to 
permit the kind of ethical guidelines structure that we set up so that scientists 
can use those to help make lives better. (US Senate 1999b: 34–35)  
The same use of embryos is present in bioethicist Caplan’s argument:  
To those who say this is still permitting the use of human embryos for a pur-
pose that is disrespectful, research and the consequent destruction of the em-
bryo, it seems appropriate to ask why continued freezing is not just as disre-
spectful. It is also appropriate to ask why, even if regrettable and sad, it would 
                                     
138  See also e.g. Senator Specter, US Senate 2001: 30, 50. 
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not be worth permitting the donation of spare embryos for research that might 
lead to cures and benefits in much the same way that we allow families to 
donate their loved ones, organs and tissues under the most tragic of circum-
stances to aid others? Spare embryos would seem to be a legitimate and mo-
rally defensible source of human embryonic stem cells. (US Senate 1999b: 39)  
Again, as in 1994, Clinton asked for advice, this time, not on embryo re-
search, but on hESCs. With regard to embryos there was one difference 
between the reports of the National Bioethics Advisory Commission 
(NBAC) in 1999 and the HERP in 1994. The NBAC did not approve of any 
federal funding for the deliberate creation of embryos. 
Recommendation 3: ES Cells from Embryos Made Solely for Research Pur-
poses Using IVF 
 Federal agencies should not fund research involving the derivation or use 
of human ES cells from embryos made solely for research purposes using 
IVF. (Shapiro et al. 1999: 5) 
The NBAC then recalls the HERP recommendations to (in exceptional 
cases) federally fund the creation of embryos for research purposes and 
mentions two reasons for doing so. Ultimately the NBAC distances itself 
forcefully from HERP’s stance:139 
                                     
139  Philosopher Francois Baylis does not embrace my conclusion about a forceful 
distance between the two federal reports on the point of embryos. Instead he 
notes the big difference in “packaging”. “The NBAC’s recommendations […] 
are similar to those developed by the NIH Panel […].” Emphasizing the packa-
ging of similar recommendations misses the centrality of the distinction be-
tween the two “embryos”, the deliberately created one and the one remaining 
from infertility practices.  
This policy-making ”mistake,” such as it is (assuming that the goal is to 
secure federal funding for human embryo research), is not repeated by 
the National Bioethics Advisory Commission (NBAC) in its 1999 report 
on ”Ethical issues in human stem cell research.” The NBAC’s recom-
mendations on the use and derivation of human embryonic stem cells 
are similar to those developed by the NIH Panel 5 years earlier, but they 
are noticeably more carefully packaged to better ensure their political via-
bility. This suggests that NBAC is mindful of the political reality aptly 
described by Dan Brock […]: ”An important part of the policymaker’s 
job is to ‘sell’ a position or policy to others in the policy and political pro-
cess […], including the public. That makes the ‘packaging’ of a policy 
proposal often extremely important to its fate”. (Baylis 2000: 141) 
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Nevertheless, we have concluded that, either from a scientific or a clinical per-
spective, there is no compelling reason at this time to provide federal funds 
for the creation of embryos for research. At the current time, cadaveric fetal 
tissue and embryos remaining after infertility treatment provide an adequate 
supply of research resources for federal research projects. (Shapiro et al. 1999: 5) 
Only hESC research using embryos remaining after infertility treatments 
should be funded. In practice that meant making an exception to the ban 
on embryo research. hESCs should not, according to the NBAC, be re-
garded as embryo research in the legal sense.  
 The American Association for the Advancement of Science (AAAS) 
and the Institute for Civil Society (ICS) were even more cautious in their 
joint report. To further shield the federally funded research from contact 
with embryos, only research on already “derived” lines of hESCs was re-
commended. 
Public funding should be provided for embryonic stem cell and embryonic 
germ cell research, but not at this time for activities involved in the isolation 
of embryonic stem cells, about which there remains continuing debate. [---] 
Although the derivation of human stem cells can be done in an ethical man-
ner, there is enough objection to the process of deriving stem cells to consider 
recommending against its public funding. (Chapman et al. 1999: viii) 
The authors explained this stance a little later on in the report, where it 
outlined the controversies on the status of embryos. Could perhaps dis-
putes be bridged? 
The zone of agreement is somewhat widened, however, when we recognize 
that some who adamantly oppose the destruction of embryos or fetuses can 
accept the view that research on the cellular materials remaining from such 
acts is not always unethical. (Chapman et al. 1999: 9)140  
Thomson’s production of hESCs, Harkin’s and Caplan’s emphasis on 
“in vitro cells” and “spare embryos”, and the NBAC’s and AAAS/ICS’s 
recommendations all agree on the matter of hESCs from already existing 
                                     
140  Where did this position or zone come from? The report refers to Catholic 
thinking (p. 10). Similar justification had been put forward by Carol Tauer and 
in Catholic ideas such as Shannon and Wolter 1990, and their “ensoulment 
theory”. 
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embryos. All exclude the research creation of embryos, at least for fede-
ral funding. 141  
 Without addressing “intentions” or “strategies”, there were at least sig-
nificant differences between the two occasions. The actors were also 
aware of the HERP recommendations, the subsequent resistance and 
regulations and acted accordingly. Thomson and Gearhart started their 
work on human ES/EG cells while the Dickey-Wicker amendment was 
being put into effect. As was mentioned in the previous section, Caplan 
had criticized the HERP precisely on the issue of research creation of 
embryos. According to Caplan, this was one reason for the panel’s failure 
to produce new guidelines for embryo research (Annas et al. 1996). Con-
sidering the cautiousness of the AAAS/ICS report, and the NBAC’s 
direct reference to the 1994 panel on the creation of research embryos, 
one can assume a “learning process” from one occasion to the next. This 
was probably the case since there was an overlap between the members 
of HERP and the two later groups. One ethicist, Ronald Green, partici-
pated in the HERP and the AAAS/ICS panels. Alta Charo, Bernard Lo, 
and Thomas H. Murray were all members of the HERP and the NBAC. 
Whether it was tuning or learning, many of the 1998–1999 articulations 
on the particular point of the embryo source for hESCs differed from 
that previously put forward by the HERP. The research creation of 
embryos was no longer an option. The embryo of human embryonic 
stem cells was “spare”, frozen and already there from in vitro 
fertilization treatments. 
Degrees of “embryonic”  
Another issue concerned the subsequent regulations, viz. the status of 
the hESCs themselves – not their sources, but their embryonic potential. 
Nicholas Wade, science reporter for the The New York Times, summarized 
the legal importance of this factor, a few days after the announcement of 
the stem cells in November 1998.  
NIH officials said they believed that Congress’s intent was to ban research on 
any entity with the potential to grow into a human being, and that, as the 
human embryonic stem cells cannot do so, they would be exempt from the 
ban. (Wade 1998) 
                                     
141  Some actors did mention deliberately created embryos, in relation to cloning 
or nuclear transfer. However, until 2001 this issue was secondary to the hESCs. 
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From 1996, the Dickey-Wicker amendment had been a “legal black box” 
precluding any attempts to use embryos in federally funded research.142 
Anything that could be placed in the box was excluded from federal 
funds. However, nowhere in the paragraphs were hESCs mentioned ex-
plicitly. The debates following HERP had, as had the panel discussions, 
concerned research on embryos in general and not on hESCs in particu-
lar. According to the legal text it was a matter of whether they were “en-
tities that had the potential to grow into a human being”, and, concluded 
Wade, “as the hESCs cannot do so” they would be outside of the box. 
There was however one complication:  
“Assuming the cells are not totipotent, reservations go only to the source,” 
said Kevin T. FitzGerald, a geneticist and jesuit priest at Loyola University 
Medical School. 
 If they are totipotent, he said, he would conclude that their use could not 
be justified. But he noted the complexity of the issue, saying, “We are getting 
closer and closer to the lines of demarcation of the beginning of human life.” 
(Wade 1998) 
FitzGerald would have reservations if the cells were totipotent because 
this is the term that had been used to denote the potential of embryonic 
cells that would later develop into the whole organism. Totipotent were 
the cells that make up the embryos after a few divisions, or the cells of 
the inner cell mass of the blastocyst that form after a few days. Wade 
again:  
The cells of the inner cell mass are called “totipotent”, meaning that each can 
form any tissue of the body. Both Dr. Thomson and Dr. Gearhart proved by 
a standard test that their cells are “pluripotent,” meaning they can form many 
body tissues. The cells may also be totipotent, but the two researchers were 
                                     
142  For precise references to the Dickey-Wicker amendment, see p. 76. It 
prohibited the use of federal funds for  
research in which a human embryo or embryos are destroyed, discarded, 
or knowingly subjected to risk of injury of death greater than that allow-
ed for research on fetuses in utero under 45 CFR 46.208(a)(2) and sec-
tion 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)). (Sugar-
man et al. 1998: 159) 
  “Human embryo” was then defined as including “any organism […] that is 
derived by fertilization, parthenogenesis, cloning, or any other means from 
one or more human gametes or human diploid cells”, Sugarman et al. 1998: 
160. 
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unable for ethical reasons to perform the standard test for totipotency. – Dr. 
Gearhart, whose cells were derived from a different tissue, the embryonic 
germ cells, but are probably equivalent to Dr. Thomson’s, said he thought they 
would probably prove totipotent if the test were permissible. (Wade 1998) 
According to these definitions pluripotency means that the cells can 
form many body tissues, while totipotency is the capacity to form all of 
the tissues of the body. hESCs, said Gearhart, are probably totipotent. 
But totipotency is the capacity of the cells of the early embryo to, under 
the right conditions, develop into all the tissues of the organism and thus 
equal an embryo and “an entity with the potential to grow into a human 
being”. In case Gearhart’s assessment was confirmed by others, the hESCs 
would thus not be admissible for federally funded research.  
Terminological calibration: pluripotency and totipotency 
Wade’s article was published on November 10. In the hearings three 
weeks later, NIH director Harold Varmus explained the features of hESCs 
in relation to embryos: 
There are many issues to be raised about the cells that we’re talking about 
today, but one of those questions is whether these cells have the ability to give 
rise to a complete human being. The answer to that from a scientific perspec-
tive is no. (US Senate 1999b: 7)  
Considering the Dickey-Wicker amendment, and the opposition to fede-
rally funded research on hESCs, the affirmation and emphasis are under-
standable. Varmus’s point was repeated over and over again.143 It was im-
perative to separate the hESCs from embryos. In order to pursue this se-
paration, the concepts of pluripotency and totipotency were used as a 
“terminological calibration” of the relationship between embryos and 
hESCs.  
 On November 10 (in Wade’s article), Gearhart conjectured that hESCs 
are totipotent. On December 2 he had removed this conjecture, and his 
use instead conforms with the designation of hESCs as pluripotent. Toti-
potency is now only used to denote the early cells of the embryo that can 
                                     
143  Eg. in the next testimony by Gearhart: 
The most important point I think to be reinforced is the fact that, al-
though these cells can form many different cell types, they are unable by 
themselves to form an embryo or a human being. (US Senate 1999b: 11) 
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each become an embryo, while pluripotency is exclusively used for hESCs. 
A hierarchy of stem cells and developmental potential is presented. Var-
mus again: 
Cells from the very earliest embryo […] are totipotent stem cells. They are 
“totally potent” or totally capable of forming all cells of the body, including 
the cells required to support embryonic and fetal development. Each cell of 
this early embryo has the potential to develop into a human being. (US Senate 
1999b: 8)  
If the embryo is developed a bit further it forms a blastocyst containing 
the inner cell mass, Varmus explained: 
The cells in the inner cell mass are not totipotent. Rather, they are pluripotent. 
Pluripotent stem cells are more “committed” than totipotent stem cells. Un-
like the fertilized egg, or the early embryo, or the intact blastocyst, neither the 
disaggregated inner cell mass nor the pluripotent stem cells derived from it […] 
will produce a human being even if returned to a woman’s uterus. (US Senate 
1999b: 8) 
The distinction between hESCs and embryos is defined by the distinc-
tion between pluripotency and totipotency. The two distinctions occur 
frequently and consistently together. In one of the quotes from Varmus’s 
testimony above, one specific resource is drawn on to separate pluri- and 
totipotency. Here, totipotent cells, like embryos,  
are “totally potent” or totally capable of forming all cells of the body, including 
the cells required to support embryonic and fetal development. (US Senate 1999b: 8, my 
italics) 
Pluripotent stem cells, on the other hand, are thought not to give rise to 
the “extra-embryonic structures” that support embryonic development, 
such as the trophectoderm, trophoblasts, and, later, the placenta. What 
Varmus said out loud was more quietly confirmed by other testimonies. 
In Gearhart’s and Thomson’s testimonies, hESCs are described as giving 
rise to a number of adult tissues. None of these two pioneer hESC scien-
tists mentioned that trophectoderm and extra-embryonic tissue could be 
possible results of hESCs (US Senate 1999b: 13 and 17).144  
                                     
144  This denial later appears in other texts. In 2004, Professors D G Jones and C 
R Towns, of a New Zealand department of anatomy and structural biology, 
do not include trophectoderm as one of the cell types possibly produced by 
ES cells, Towns and Jones 2004: 412. 
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 These articulations (by withholding) stand in contrast to Gearhart’s 
earlier statement that “they would probably prove totipotent” (see quo-
tation above). They also differ from Thomson’s original Science article of 
November 6:  
After undifferentiated proliferation in vitro for 4 to 5 months, these cells still 
maintained the developmental potential to form trophoblast and derivatives of all 
three germ layers […]. (Thomson et al. 1998: 1145, my italics) 
Articulating hESCs as pluripotent and not totipotent, as developmentally 
less capable than embryos, was picked up in the legal and policy recom-
mendations. On January 15, 1999, a memorandum was issued by Harriet 
Rabb, General Counsel at the Department for Health and Human Servi-
ces (DHHS). Her interpretation and that of the DHHS was that research 
on already produced hESCs would not fall under the embryo research 
ban since “human embryonic stem cells are not a human embryo within 
the statutory definition” (NIH 2005). The DHHS definition was justified 
with reference to the fact that “the cells do not have the capacity to 
develop into a human being even if transferred to the uterus”. A few 
days later, and referring to Rabb’s memo, the NIH director Harold Var-
mus announced that the NIH was preparing guidelines for the federal 
funding of research on hESCs. These guidelines would still not allow 
“the use of such funds in the derivation of the cells” (US Senate 1999b: 
123).145  
 The New York Times reporter Gina Kolata contrasted the position of 
the DHHS and the NIH – and their dissociation of hESCs from embry-
os – by asking scientists for their opinion. Dr. Lee Silver, geneticist at 
Princeton dismissed the distinction between embryonic stem cells and 
embryos, at least based on “the capacity to develop into a human being”. 
“Metaphysically, it’s all the same”, Kolata quotes Silver: 
He thinks research with human embryo cells should be permitted but is offen-
ded, he said, by all the winking and nodding by scientists who do not want to 
admit the true potential of these cells to become a baby, if anyone wanted to 
try. (Kolata 1999) 
                                     
145  The reason: Derivation of cells would fall under the Dickey-Wicker amend-
ment as a case of “research in which a human embryo or embryos are destroy-
ed, discarded, or knowingly subjected to risk of injury of death greater than 
that allowed for research on fetuses in utero”, Sugarman et al. 1998: 159. 
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Kolata also recalled experiments pursued in 1993 that could be interpre-
ted as challenging the DHHS ruling and Varmus’s subsequent intentions. 
Andràs Nagy and Janet Rossant (and others) had, in these experiments, 
produced “live offspring which were completely ES cell-derived” (Nagy 
et al. 1993: 8424). “If”, Kolata suggested, “you can grow a mouse from a 
single embryo cell, you should in theory be able to grow a human from a 
single human embryo cell”. 
Nagy said that he saw no reason why a human embryonic stem cell could not 
become a human being. “I don’t think there’s a theoretical or practical impos-
sibility of creating a completely stem-cell derived human being, if one wanted 
to do that.” (Kolata 1999) 
In Kolata’s article Nagy and Silver are associating – not dissociating – 
hESCs and embryos by referring to the cells’ developmental potential. 
However, others questioned what this reference to developmental poten-
tial denotes. Nagy’s and Rossant’s claim that most of the resulting off-
spring were “completely ES-cell derived” did not mean that only ES cells 
had been involved in the reproductive process. The cells were not im-
planted in the uterus on their own, but were combined with “develop-
mentally compromised tetraploid embryos” (Nagy et al. 1993: 8424). In 
analyses of the the offspring’s genetic set-up, a specific version of a gene 
(GPI-BB) from the tetraploid embryos did not show up. In this sense 
the mice were indeed 100% the result of the ES cells.146 On their path to 
developmental maturity the latter had needed support from the tetra-
ploid embryo cells, which were eventually dropped, or “selected against” 
(p. 8424). Just like the embryo itself, the cells had the capacity to develop 
into a whole human being. Unlike the embryo, the cells needed some 
embryonic support, critics claimed.  
 This is also what Thomson said when approached about the issue 
(Thomson 2003). The silence on the production of extra-embryonic tissues 
was so deafening that when results were presented on trophectoderm 
differentiation of hESCs at a conference in 2003, one delegate expressed 
surprise: “Have these cells always produced trophectoderm? Since when?” 
(Informant A 2003). Before the hearings the central actors included re-
ferences to the creation of extra-embryonic cells that could support a 
                                     
146  That is, at least 98% of the individual mice did not contain any tetraploid 
genes. “A minor contribution (<2%) from tetraploid cells cannot be exclu-
ded”, Nagy et al. 1993: 8426. 
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growing embryo, such as trophoblast, and used the term totipotent, to-
gether with pluripotent, to describe the stem cells. In the hearings (De-
cember 1998 – January 1999) these articulations of the stem cells were 
changed and the hESCs were consistently described both as pluripotent 
and as a possible source of all adult tissue types.  
 This was a marked difference from the 1994 negotiations and the pre-
1998 situation. In HERP both terms occurred. The report featured pluripo-
tency, while Van Blerkom used totipotency (NIH 1994, Van Blerkom 
1994: 47). The two terms were used quite interchangeably before 1998. 
ES cells could be named toti- or pluripotent.147 Totipotency and pluri-
potency could be attributed to non-embryonic stem cells, such as hema-
topoietic or blood-forming stem cells (Diukman and Golbus 1992). This 
was also the case after 1998, but to a much lesser extent. 
 The distinction between pluri- and totipotency was increasingly adop-
ted in the scientific literature. Disciplining scientists participating in US 
Senate hearings was, however, easier than disciplining the strongly grow-
ing numbers of worldwide ES cell researchers. Scientific articles did not 
completely stop using totipotency for ES cells, but the use diminished. 
Gearhart and Thomson did their “calibration” in late 1998 and early 
1999. Having scientific articles published takes approximately 6 months 
(from the journal receiving the article to acceptance and publication).  
 In a search for articles that combine the words embryonic stem cells 
or ES cells and totipotency, totipotential, totipotent versus pluripotency, 
etc, there is a dramatic increase for the use of pluripotent terminology 
compared to the increase in use of totipotent terms (because of a general 
increase in ES cell articles there is a general increase in the use of both 
terms). 
 Even before the negotiations in 1998–1999 the number of ES cell ar-
ticles mentioning pluripotency (and related words) was approximately 4-
5 times more frequent than articles mentioning totipotency. There exis-
ted thus a preference for the pluripotency-terms. However, it is a highly 
preferred choice afterwards. The explosion of “pluripotency” in relation to 
“totipotency” comes in and after 1998. 
 
                                     
147  In several articles totipotency is used for ES cells or in discussions of prospec-
tive human ES cells, Cherny et al. 1994: 569, Harris and Mansson 1988: 9, 
Müller and Dzierzak 1994: 47, Pesce et al. 1999. Other articles use 
pluripotency for ES or EC cells, Evans 1986, Jacob 1982, Martin and Lock 
1983.  
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The three curves display the year-by-year number of Medline articles about 
ES cells (or embryonic/embryonal stem cells) using (1) exclusively the 
term pluripotency, pluripotent(ial) (i.e. “pluripoten*”), which is the high-
est curve, (2) exclusively totipotent terms (i.e. “totipoten*”), which resul-
ted in the middle curve, and (3) both terms (“duplicates”), which corre-
spond to the lowest curve. The data do not consider the context of use, 
but merely the tendency within the scientific community in its use of the 
terms in articles where also ES cells occur. 
 To put it starkly, and rather provocatively, this means that the 
pluripotent ES cells (i.e. articles) in retrospect started an exponential 
increase in relation to the totipotent ES cells at the time of the negotiations 
of federal funding of hESCs. Not all scientists were influenced by this 
terminological calibration, but there was a definite tendency that appears 
to coincide with the negotiations about the newly produced hESCs. 
However, this also shows that Gearhart’s change, from claiming 
totipotency to pluripotency, was not “mere politics”, but coherent with 
the most current practice in journals. 
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Figure 12: Distribution of “pluripoten*” and “totipoten*” in ES cell articles 
1975-2005. (Medline search conducted November 15, 2005.) 
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Year Total number 
of articles 
(3) Both 
terms 
(2) Only 
totipoten* 
(1) Only 
pluripoten* 
1975 1 0 1 0 
1976 2 0 1 1 
1977 3 0 1 2 
1978 0 0 0 0 
1979 1 0 0 1 
1980 1 0 1 0 
1981 2 0 0 2 
1982 5 0 0 5 
1983 4 0 0 4 
1984 9 0 0 9 
1985 10 0 0 10 
1986 7 0 0 7 
1987 10 0 1 9 
1988 12 0 2 10 
1989 16 0 2 14 
1990 14 0 4 10 
1991 17 0 2 15 
1992 31 1 5 25 
1993 34 1 8 25 
1994 30 3 3 24 
1995 29 0 8 21 
1996 41 4 6 31 
1997 36 3 6 27 
1998 57 3 10 44 
1999 40 1 6 33 
2000 47 0 6 41 
2001 102 5 16 81 
2002 123 7 14 102 
2003 153 6 18 129 
2004 220 12 22 186 
2005 258 2 15 241 
TOTAL 1317 48 158 1111 
 
Table 1: Distribution of “pluripoten*” and “totipoten*” in ES cell articles  
1975–2005. (Medline search conducted November 15, 2005.) 
 
 The terminological calibration, as presented here, is not a case of ex-
ternal forces invading science and causing a change. Distinguishing between 
early (8-cells and 16-cells cleavage stage) embryonic cells and (inner cell 
mass) stem cells by terminological calibration coincided with the negotia-
tion about whether or not to include hESCs in the ban on embryo re-
search. Making a clear-cut distinction between hESCs and embryos cor-
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relates with the attempts to achieve federal funding for hESC (and not 
embryo) research.148  
 Nor am I suggesting that it was a tactical deceit or a strategic move in 
order to manage the naming of hESCs. I am instead noting a historical 
conjunction of “scientific” and “political” events, in which a dissociation 
from embryos could be made and might have had significant effects. By 
dissociating hESCs from embryos, scientists and others could make a 
strong case for federal funding. Previously, the main issue had been pre-
cisely to associate the two.  
 The parallel between the development of embryonic stem cells and 
embryonic development had been one of the attractions of the stem 
cells. This was especially the case within the field of developmental bio-
logy, but also for the other envisioned uses, for instance in livestock. Such 
use built on the successful involvement of embryonic stem cells in the 
production of new individuals with genetic modifications. This point was 
made on the back cover of the 1999 special issue of Cells Tissues Organs to 
convey the importance of ES cells. 
Pluripotent mouse embryonic stem (ES) cells have been widely used to create 
mutant mice that pass genetic modifications to their offspring through germ-
line transmission. ES cells also have the capacity to differentiate in vitro into 
cells of endodermal, ectodermal and mesodermal lineages. (Wobus and Bohe-
ler 1999: back cover)  
In fact, this affiliation with embryonic development had been one of the 
recurrent motifs and aims in the elaborations of experimental models since 
                                     
148  Notice the choice of words: “Correlate” and “coincide” are not causal 
relationships. Terminological calibration did not necessarily affect the 
negotiations or vice versa. It is a sufficiently interesting observation that the 
terminological calibration occurred while the hESCs were articulated as a 
laboratory entity and possible for federally funded research. An alternative  (or 
complementary) historical separation of the two terms comes from the guest 
editors of the special issue of Cells Tissues Organs. 
The results of the nuclear transfer technology employed by Campbell 
and Wilmut [1997] led us to use the terms “totipotent” for zygotes and 
blastomeres of early cleavage stage embryos, and “pluripotent” for cells 
and cell lines derived from either the inner cell mass or primordial germ 
cells. (Wobus and Boheler 1999: 130) 
Nevertheless, in the 1999 special issue other papers had still not adopted 
the distinction. 
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the 1950’s that preceded and ultimately resulted in the production of ES 
cells. Researchers had been busy proving embryo-likeness. The linkages 
with embryonic potential or embryonic cells had played a major part 
quite early on in Leroy Stevens’s and Barry Pierce’s respective work on a 
particular tumor form, often occuring in the testis: teratoma or terato-
carcinoma. Stevens and Pierce were both active in US laboratories during 
the 1950’s, 60’s, and 70’s.  
 The specific characteristic of teratoma tumors is the development of a 
variety of tissue types, such as teeth, hair, or nerve cells. Stevens’s and 
Pierce’s research came to focus on which cells were responsible for this 
variety of tissues. One of the experimental procedures (or “assays”) that 
was developed and frequently used by Stevens and Pierce involved the 
production of “embryoid bodies” (EBs) (Kleinsmith and Pierce 1964, 
Pierce et al. 1960, Stevens 1959, 1960). After transplanting teratoma cells 
into the abdomen (the peritoneal cavity to be more precise) of mice, the 
EBs appeared. These consisted of cells from all of the three germ layers 
of the embryo (although in an inversed arrangement). Stevens and Pierce 
observed this similarity between, on the one hand the development of a 
particular teratoma cell (or cells), and on the other hand the development 
of embryos. Their hypothesis was that one very potent type of cell in the 
teratoma was responsible for all of the various tissue types. The success-
ful transplantation of single cells, resulting in EBs, settled the issue for Pierce 
and Stevens. In line with earlier teratoma terminology, they called this 
cell type “embryonal carcinoma cells”, or EC cells. According to Stevens 
and Pierce, these cells – that grew into teratomas – came from the “pri-
mordial germ cells”, i.e. the germ cells of the embryo (Pierce 1975, Ste-
vens 1967). There were thus two teratoma-related cells and both had em-
bryonic potential. Embryonal carcinoma cells were the most potent cells 
within the teratoma tumor. Those EC cells had, in turn, originated from 
embryonic (or, more correctly, primordial) germ cells.  
 British pathologists in the 1960’s and early 1970’s did not embrace the 
hypothesis that there was anything like an ”EC cell” within teratoma tu-
mors (Collins and Pugh 1964: 1, Pugh and Smith 1964: 28). In their clas-
sification systems they “discarded the term ‘embryonal carcinoma’”, sin-
ce “[i]t has led to much confusion” (Collins and Pugh 1964: 5). Earlier in 
the same article, the same authors dismissed the germ cell origin: 
It does not seem to us very realistic to trace the histogenesis of adult neo-
plasms to so primitive a past as the earliest somite embryo. (Collins and Pugh 
1964: 1) 
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The British resistance to embryonal carcinoma and to the primordial germ 
cell origin were in both cases also resistance against the association between 
these cells and the embryo. When Pierce’s and Stevens’s claims were adop-
ted and developed within a wide research community this happened pre-
cisely through a series of associations with the embryo (Sherman and Solter 
1975).  
 Several experimental models presented in this community of teratoma 
researchers established the potential participation of EC cells in normal 
embryonic development (Mintz and Illmensee 1975). The production of 
“embryonic stem cells” (ES cells – or for a while “EK cells”) at two pla-
ces in 1981 was achieved in direct relation to the EC cells (Evans and 
Kaufman 1981, Martin 1981). Both of the papers situated the produced 
cells as an extension of the embryonic relationships established in the 
earlier research on EC cells and teratoma. For these researchers, ES cells 
were articulated as the direct linkage from embryos to cell cultures in a 
dish (Evans and Kaufman 1981, Martin 1981). The cells could not only 
participate in embryonic development, but could be taken from an em-
bryo. ES cells were later compared favorably to the EC cells, precisely on 
the basis of the former’s more embryo-like character (Doetschman et al. 
1985). In spite of these developments, there were still, in the early 1980’s, 
disagreements over the classfication issues mentioned above.149  
 This demonstrates how the association with embryos had been percei-
ved as essential: first for Stevens and Pierce and their embryonal carcino-
ma cells; later for the community that developed these cells and produ-
ced the ES cells in direct relation to EC cells and the embryos. 
 There is no systematic use of totipotency and pluripotency for EC or 
ES cells in the developments outlined above. Both terms were used. One 
regularity exists. Embryos are never described as pluripotent, but always 
as totipotent. This suggests that the latter term was used to stress the 
association between the embryos and the cells in question (whether EC 
                                     
149  Two workshops were held in 1980 and 1981 to “get the leading clinicians and 
investigators in the field of testis cancer to “talk to each other”, Donohue 
1983: vii. Roger Pugh, one of the British pathologists who discarded the term 
embryonal carcinoma 1964, attended the meeting. His contribution was 
“Pathology of Testicular Tumors – A British Perspective”, Pugh 1983. He 
admitted that “there is no denying the weight of experimental evidence 
supporting the germ cell theory” (which had been related to the notion of 
embryonal carcinoma), but still “a great deal of work yet remains to be done 
to clarify the early stages of tumor induction in the human testis” (p. 2). 
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or ES cells). A terminological mixture of totipotency and pluripotency thus 
underlines the importance of embryo-association for the development of 
ES cells. To EC and ES cell researchers, a major point had been to prove 
the similarity between the stem cells and embryonic features and deve-
lopment. In a new political context the stem cells suddenly needed disso-
ciation from embryos. What was needed this time was to avoid political 
consequences from the identification of hESCs with embryos or early 
embryonic cells (with the potential to become an embryo). 
Successful calibration 
As the circulation of federal funds was at stake, the reference to the 
capacities of hESCs thus had a specific role. Making them “more pluri-
potent and less totipotent” would remove the cells from the category of 
entities that could grow into a whole organism. Was this, then, a success-
ful management of terms? There are at least two answers. One relates to 
the immediate negotiations of federal funding in 1998–2000. The other 
concerns the ultimate negotiation and decision in 2001.  
 The non-embryo status of hESCs (and also the lack of potential to de-
velop into a whole organism) had no immediate legal effect. One 
example of this was Doerflinger’s opposition to federally funded hESC 
research voiced in the first Senate hearing in December 1998 (US Senate 
1999b: 71-73), quoted above in Chapter 2. Drawing on the pluripotent 
definitions of hESCs, Senator Harkin suggested that the Dickey-Wicker 
amendment did not apply to research on hESCs, since they were not 
organisms. Therefore, Harkin claimed, the ban does not apply to hESCs. 
Doerflinger agreed about the “organism-status” of the cells, but this 
success for the taxonomic calibration did not imply any immediate legal 
success. Doerflinger still opposed Harkin’s interpretation of the Dickey-
Wicker amendment and sidestepped the issue of the exact status of 
hESCs, since the research still required the destruction of embryos. Irrespective 
of the terminological calibration that dissociated embryos and hESCs, 
Doerflinger enforced their close association in the hearing, based on the  
production/destruction process.  
 The same pattern of dissociation attempts, resistance and re-affirmed 
association is visible in the January 1999 reaction to Harriet Rabb’s legal 
interpretation of the relationship between hESCs and embryos. Rabb’s 
memo was indignantly and immediately opposed by bipartisan (Repub-
lican and Democrat) congressmembers and the Secretariat for Pro-Life 
Activities at the National Conference of Catholic Bishops (Wade 1999b). 
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They re-affirmed the close association between hESC and embryo re-
search and claimed that Rabb’s interpretation went against the spirit of 
the existing law. In these alternative interpretations of the law, toti- and 
pluripotency were of little significance. Instead, the focus was on the 
very process by which hESCs were created from ”spare embryos”. How-
ever, Rabb’s attempt (to enable NIH funding) was based not only on the 
separation of the cells from the production process, but also on the sta-
tus of hESCs as non-organisms. While the legal separation of hESC re-
search from the “spare embryonic” source failed in 1999, the new articu-
lation of the stem cells’ status – correlating with the distinction between 
toti- and pluripotency – prevailed.  
 The distinction was picked up in textbooks and among bioethicists, as 
well as in the lay press (Maienschein 2003, Parson 2004, Towns and Jo-
nes 2004). In this example from the 1999 July-August issue of the Ameri-
can Scientist, Shirley Wright re-articulates totipotency as a matter of pro-
ducing trophoblast:  
Despite their potential, isolated embryonic stem cells cannot develop into a 
mouse if returned directly to the uterus because the cells have lost their capa-
city to form trophoblast cells, which are necessary for implantation. Under 
these conditions they are considered to be pluripotent, rather than totipotent. 
(Wright 1999: 354) 
It is interesting to note how Wright continues the explanation. After clai-
ming that the stem cells are not totipotent – since they cannot form tro-
phoblast – she points to their “totipotent properties”.  
However, if the embryonic stem cells are first added to a donor tetraploid em-
bryo that is unable to develop normally and the resulting embryo is trans-
ferred to a mouse uterus, a normal mouse is born that is totally derived from 
the cultured embryonic stem cells. This indicates the incredible totipotent pro-
perties of these cells. (Wright 1999: 354) 
Wright thereby (intentionally or not) captures the ambiguity of many 
attempts to articulate the cells’ properties. The cells are not totipotent, 
but have “incredible totipotent properties”. 
 Most importantly, this was articulated in official hierarchies on stem 
cells. Varmus was at the NIH and the distinction was used in the NIH’s 
information about stem cells (NIH 1999). The AAAS/ICS report adop-
ted the distinction as it had been articulated in the hearings (Chapman et 
al. 1999: 33). On August 1, 2001, the terms and the distinction were pre-
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sented by the Congressional Research Service which serves to provide 
unbiased information for Congress:  
The earliest embryonic stem cells are referred to as totipotent, indicating that 
they can develop into an entire organism because they can produce both the 
embryo and the tissues required to support it in the uterus. Later in develop-
ment, embryonic stem cells lose the ability to form these supporting tissues, 
but are still able to develop into almost any cell type found in the body. These 
pluripotent embryonic stem cells are the current focus of intense research inte-
rest. (Johnson 2001: 1) 
August 1 was eight days before Bush’s policy decision and he adopted 
many of the definitions in the report (Bush 2001). As he concluded his 
decision the status of hESCs was crucial: 
I have concluded that we should allow federal funds to be used for research 
on these existing stem cell lines, where the life and death decision has already 
been made. (Bush 2001) 
In this respect the calibration was successful. hESCs were not identical 
to embryos in their developmental potential in Bush’s decision. Had they 
been, his statement – “the life and death decision has already been 
made” – would have made little sense. Had the hESCs been on an equal 
footing with embryos, there would still be “a life and death decision” to 
be taken.  
Pluripotent therapies  
The hESCs did change in significant ways in relation to how embryonic 
and what embryonic they were: pluripotent and spare embryonic as opposed 
to totipotent and made from deliberately created embryos. This aspect of 
the hypothesis from Chapter 5 is answered. A second aspect concerned 
the management of hESCs in relation to transplantation therapies.  
 The hESCs became important in the argument for the benefits of hu-
man embryo research. This was a major point in Clinton’s and others’ la-
ter articulations, examplified in Clinton’s letter to NBAC chair Shapiro 
that we saw in Chapter 2 (Shapiro et al. 1999). According to Clinton, the 
benefits of hESCs were the reason for a review. But was there any tuning 
of the hESCs to fit the expectations in regard to potential benefits from 
transplantation therapies? If the hESCs had been tuned, we should be 
able to find traces of change between the hESCs of 1994 and 1998. Trans-
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plantation therapies were one of the uses linked to hESCs in 1994, to-
gether with the use for developmental biology.  
 However, the very focus on hESCs resulted in a proportional increase 
in the importance of transplantation therapies. In the HERP, the hESCs 
contributed with only one application to lists of 8, 9 or 13 possible appli-
cations. Now, in 1998, transplantation therapies from hESCs were the 
predominant in the three commonly articulated uses. By enlarging the 
role of hESCs, an important re-articulation of federally funded human 
embryonic research was brought about. It was a partially successful attempt 
to separate the negotiation of federal funds for hESCs from the earlier 
negotiations of human embryo research.  
 Another re-articulation of hESCs took place, as it were, in between chap-
ters 2 and 3 of this book: Chapter 2 presented some articulations of hESCs 
as a new possibility, heralding a pluripotent transformation. In opposition 
to this attempt, some actors referred to other cells with equal potential 
and promise. In Chapter 3, Bush and some pro-lifers ultimately endorsed 
the hESCs with reference to the higher potential and promise of trans-
plantation therapies. As Orrin Hatch put it:  
It is my understanding that, at the present time, the view that adult stem cell 
research is sufficient or even scientifically preferable to embryonic stem cell 
research is not the predominant view within the biomedical research commu-
nity.  
 While I have great admiration for, confidence in, and strongly support Ame-
rica’s biomedical research enterprise, and I believe that our policy should be 
made on the best science available, I am hardly one who invariably follows the 
lead of what some may term “the science establishment.” (Hatch 2001b) 
There is, then, a time gap between the two chapters and in articulations 
of pluripotency and transplantation therapies: on the one hand, the arti-
culations of the pluripotent transformation and the opposition (in Chap-
ter 2), and on the other hand Bush’s and some other pro-lifers’ recogni-
tion of the pluripotent possibilities (in Chapter 3). Something happened 
in between. It was not just a matter of some people changing their minds, 
and not just a result of negotiations in the White House or among con-
gressmembers. The reference to hESCs was de-stabilized for a time. This 
dynamic and chronological gap is the scene for management of the link 
to transplantation therapies. While the embryonic management was star-
ted before 1998 and finished by the end of 1999, the management of 
hESCs and transplantation therapies continued until Bush’s decision in 
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2001 (and after, in fact; although this falls outside of the scope of this 
study).  
Undisputed existing linkages 
hESCs were linked to transplantation therapies in articles and in reports. 
As stated above, however, this did not constitute any major change in 
their articulation. This was the main envisioned use of hESCs even in 
1994, due to their differentiation capacities, whether they were called 
pluri- or totipotent (Van Blerkom 1994: 46ff). The graphic articulation of 
this linkage was issued by the NIH in 1999, as presented in Chapter 3, 
Figure 7. Cultured pluripotent stem cells resulted in multiple uses. 
 Few people questioned the expected benefits from hESCs. In this re-
spect, there was little difference between the supporters and opponents 
of hESC research. There were patients who challenged the therapeutic 
needs by playing down the urgency of the envisioned cures, such as Mary 
Jean Owen. Testimonies such as hers – pushing the need to recognize 
debilitating diseases and weaknesses – were, however, among the excep-
tions of the hearings (US Senate 2001: 23–34).150  
 When hESCs were announced in 1998, few actual studies had been 
conducted to prove the possibility of transplantation therapies using (non-
human) ES cells. When the NBAC explained the use of hESCs in trans-
plantation therapies, the main references were the same as Van Blerkom 
used in his commissioned paper in 1994 (Shapiro et al. 1999: Chapter 2, 
Van Blerkom 1994: 47). Those articles were merely tangential in relation 
to transplantation therapies using ES cells. Only one article expressed this 
explicitly (Hollands 1991). For one of the two most frequently mentio-
ned applications, Parkinson’s disease, two more references are used, both 
from 1999. One of these is a not-peer-reviewed paper, but a conference 
presentation of transplantations of fetal tissue cells to Parkinson patients. 
Another is a study of mouse ES cells differentiating into neurons and 
then transplanted.  
 In spite of the scarcity of scientific studies on transplantation therapies 
relating to ES cells, the possibility of transforming hESCs for transplan-
tation therapies was not questioned. One element of this certainty was 
the differentiation capacity. Its scientific name was pluripotency (or toti-
potency). It was this capacity that ensured the usefulness of hESCs for 
                                     
150  Other strategies may have dominated outside of the hearings and outside of 
public debate, but this is not covered here. 
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transplantation therapies. Articulations of hESCs and transplantation 
therapies went via pluripotency. This has in previous chapters become 
clear as a matter of textual and graphic articulations. One such example 
was Figure 1 in the Introduction. In the illustration the differentiation 
capacities are involved in flows symbolized by big orange arrows, and the 
web site explains how these are tied to the medical possibilities: 
Embryonic stem cells are of great interest to medicine and science because of 
their ability to develop into virtually any other cell made by the human body. 
In theory, if stem cells can be grown and their development directed in cultu-
re, it would be possible to grow cells of medical importance such as bone mar-
row, neural tissue or muscle. (University of Wisconsin 2005) 
The actors’ combination of pluripotency and transplantation therapies 
was already displayed in Chapter 2 and above in Bush’s decision. Below 
are two other examples from the hearings, first from Okarma (from Ge-
ron Corporation) and then the Biotechnology Industry Organization where 
they explain the applicability of the cells.  
The potential, however, is realizable and portions of it can be reduced to prac-
tice based upon prior knowledge gained from animal stem cell work and the 
convergence of available complementary technologies developed by both the 
biotech industry and the academic community. (US Senate 1999b: 51) 
It is anticipated that these cells will be differentiated into blood, skin, heart, or 
brain cells and may be able to treat cancers, spinal cord injuries, heart disease 
and potentially many other diseases. (US Senate 1999b: 104) 
Doug Melton, representing the Juvenile Diabetes Research Foundation, 
is even more assertive as he moves from the stem cells’ potential to the dif-
ferentiation of cells specific for his needs. 
These stem cells then have the potential to develop into any tissue organ in 
the body, and they could no doubt be directed to make pancreatic islet or beta 
cells. (US Senate 1999b: 99)  
All of these examples are articulations of the relationship between hESCs 
and transplantation therapies via pluripotency. Taken one by one, none 
of these linkages, between hESCs and transplantation therapies and pluri-
potency, was questioned.  
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Competing articulations 
Michel Callon has used “interessement maps” to picture how the rela-
tionships between entities can be established, intersected and restructu-
red (1986b). This section will draw on Callon’s simplified imagery of en-
tities and relationships to lay out the role of pluripotency in the complex 
landscape of possible associations involving hESCs and transplantation 
therapies. In Melton’s, Okarma’s and others’ articulations, the transplan-
tation therapies are enabled through the pluripotent capacities of hESCs:  
 
 
 
 
 
 
 
 
 
 
Some of the articulations above concerned the first arrow and some both 
arrows (e.g. Figures 7 and 8 in Chapter 3). Treated separately, none of these 
changes during the period in question. Nobody questioned the existence 
of linkages between pluripotency and hESCs. They were, if anything, too 
potent rather than lacking in potency. As was described above, there was 
work done to downplay the stem cells’ capacities, since they might take the 
hESCs uncomfortably close to the legal definition of an embryo. No-
body questioned their great potential, although they named it differently, 
as either totipotency or pluripotency.  
 To perceive a management in these relationships between hESCs and 
transplantation therapies, they cannot be treated separately, as if it were 
solely a matter of existing associations or not. The relationships were not 
questioned in an absolute sense, but in a relative actor-network sense. 
Recall the challenges to federal funding of hESCs mentioned in Chapter 
2. The opponents pointed towards findings about “adult stem cells” as 
an alternative path to transplantation therapies. Here from Republican 
Congressman Dickey (first) and from Mary Jane Owen, Executive 
Director of the National Catholic Office for Persons with Disabilities 
(second) in Senate hearings in 1999 (November) and 2000 (April):  
Figure 13: Interessement map of hESCs, 
pluripotency, and transplantation therapies. 
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numerous reports over just the last few months have shown remarkable dis-
coveries about the versatility and possible uses of stem cells found in adults. (US 
Senate 1999a: 10) 
there are many other sources of these vital human tissues which give clear 
indication of their potential for positive results. [---] Exciting possibilities lie 
ahead in making use of self-contributed stem cells […]. (US Senate 2001: 26–
27) 
Sometimes references were more specific and elaborate. In one of the 
January 1999 hearings, Doerflinger quoted an article in The New York 
Times where NIH researcher Dr. Ronald McKay explains the results of 
Dr. Vescovi’s group. 
Almost the first visible structures in animal embryos are three primary sheets 
of cells, known as the ectoderm, mesoderm, and endoderm, from which all 
the tissues of the adult body develop. [---] Dr. Vescovi’s work defies the wide-
ly held assumption that cells in the three lineages are permanently committed 
to their fate. 
 “It is that trinity that is now being challenged,” said Ronald McKay, a brain 
cell expert at the National Institutes of Health. Dr. McKay said the new result 
showed that differentiation, the commitment of a cell to a specific fate, is not 
irreversible. (US Senate 1999b: 141, Original quote from The New York Times 
Jan 22, 1999, by Nicholas Wade) 
The differentiation into the three germ layers was the main trademark of 
the pluripotency of hESCs. If Vescovi’s results were correct, these capa-
cities might not be unique to hESCs. Adult stem cell research was, in ge-
neral, not used to question the scientific quality of hESC research. None 
of the actors disagreed about the basic findings: the stem cells’ capacities 
to differentiate and self-renew. In Chapter 5, these challenges to the fe-
deral funding of hESCs were treated in terms of an alternative point of 
passage.  
 While accepting pluripotency and its significance for transplantation 
therapies, and without questioning the capacities of hESCs, the APP was 
still a challenge to the relative relationship between hESCs and transplanta-
tion therapies. The image above oversimplifies the relationship in ques-
tion. The fit between hESCs and transplantation therapies was never as 
simple as the NIH, UW, Melton or Okarma articulated it. When the 
relationship between transplantation therapies and human embryonic re-
search was first raised, it was within a “project” of achieving federal fun-
ding. The actors prescribed (see Chapter 5) that the benefits would be a 
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solution to the perceived problems. When the hESCs, and their relation-
ship to transplantation therapies, were announced, they were immediate-
ly linked to other actors too. Clinton’s letter was one example. If the ear-
lier scheme is extended with his words then the following is a possible 
result:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the figure above, the threefold relationship is extended with the en-
tities that are entailed in the “project” of the federally funded human em-
bryonic research. This funding is still uncertain throughout the whole pe-
riod, hence the shaded dotted arrow. Clinton indicated that the Federal 
administration would have an interest in transplantation therapies for 
Parkinson’s disease etc, which is visualized in the broken arrow from the 
administration to transplantation therapies. The reference to “hESCs as 
pluripotent and therefore apt for transplantation therapies” does not 
correspond to an a-historical reality, but to a sociotechnical reality of 
other elements and actors. It is articulated, and thus made real in relation 
to the Federal administration. It is not uttered in a vacuum. In fact it is 
uttered in a very particular and explicitly political site, on the Capitol. 
And the actors do it in relation to an on-going project, whether they are 
deliberately part of the project or not. Chapter 5 showed that there is 
such a project and that large number of actors were involved in it, from 
the HERP panel to the retrospective critics. It is this “reality of links” 
that the articulations of alternative stem cells enter. They are thus 
competing and competitive articulations; not only establishing associa-
tions, but linking in competing ways with already existing actors and link-
ages. The effect that the competing articulations of adult stem cells have 
Figure 14: Interessement map of the hESCs, spare embryonic research and 
the Federal administration. 
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on the relationship between hESCs and transplantation therapies is ob-
vious: The former may obliterate the need for the latter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The prescriptions after 1994 were based on the assumption that the 
benefits of federally funded human embryo research needed to be spelt 
out. The pluripotency of hESCs linked the stem cells to transplantation 
therapies for diseases such as Parkinson’s and juvenile diabetes. What 
was questioned by the adult stem cell claims was the uniqueness of the 
linkage between pluripotency and hESCs. There could be ways of 
achieving cells and subsequent therapies, opponents claimed, without ha-
ving to use embryos. The plasticity (pluripotency) claims for adult stem 
cells (ASCs) gave the Federal administration’s “funds-arrow” an alterna-
tive path if it wanted to reach the end-point – transplantation therapies. 
Paradoxically, the promise of adult stem cells built on the already stabili-
zed relationship between pluripotency and transplantation therapies. Sin-
ce this was stable, it was sufficient merely to link the ASCs to pluripotency. 
 The alternative path was the drama of the OPP and APP in Chapter 2 
and Chapter 4. In those chapters this was a way to understand how 
hESCs were associated or dissociated from the circulation of federal funds. 
As this chapter continues the story, the spotlight is set on how hESCs 
and transplantation therapies were managed in the face of obliteration, 
or at least a significant reduction. If federal funding were to be directed 
to adult stem cells, then research would be done using hESCs to a much 
Figure 15: Interessement map of hESCs and possibly pluripotent 
(highly plastic) ASCs. 
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lesser extent. There were still (by 1999; to my knowledge) no studies on 
transplanting hESCs. To many scientists American research is the engine 
of global research, and the engine of the engine is the NIH budget 
(consisting of federal funds). If adult stem cells were to be the only re-
search promoted to achieve transplantation therapies, the reality of hESCs 
and transplantation therapies would, at the very least, decrease significantly.  
 Although strongly stabilized, the hESCs’ pluripotency could be, and 
was for a period, destabilized by a comparative juxtaposition with other 
stem cells. However, the effect of this “comparative destabilization” of 
the exclusive pluripotency of hESCs was that “spelling out” benefits would 
no longer suffice. Pluripotency had to be reached solely through em-
bryonic research, or no funds would be available. Merely existing linkages 
were not enough after the competing articulation of adult stem cells. To 
make an association in this landscape required keeping competing asso-
ciations away. The association between hESCs and transplantation thera-
pies through pluripotency was already there, and was stable, but had to 
be stabilized in competition with adult stem cells.  
Mobilizing stem cells – and scientists 
In actor-network theory there are no categorical differences in terms of 
strength of elements or linkages. What is usually called an “ethical argu-
ment” may be a stronger element than a “scientific object” through its 
linkages to a number of other actors, or vice versa. There is no way of 
saying that something “ethical” is stronger than something “scientific”. 
Now, articulating adult stem cell pluripotency was a way of opposing the 
association of hESCs and the Federal administration, without appealing 
to explicitly political or explicitly ethical elements. The strength of adult 
stem cell pluripotency was dependent on which other elements and link-
ages of the network had to be moved or could be enrolled. Articulating 
alternative pluripotency suggested a network configuration without fede-
rally funded embryo research, without therefore having to depend on the mobi-
lization of actors for the embryos. Instead, scientists, laboratories and ex-
periments were enrolled through the adult stem cells. Note that the articu-
lation of adult stem cells as alternatives came not from the active scien-
tists, but from bioethical or political actors. However, the scientists’ work 
was enlisted in the articulation. A whole bunch of actors was thus acti-
vated without lobbying for a specific embryo status or the displacement 
of other elements of the network: transplantation could still be endorsed. 
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To start with there were strong allies for adult stem cell plasticity. Ron 
McKay was (is) situated at the NIH and – at least in the quotation above 
– articulated a linkage between high differentiation potential and adult 
stem cells. His articulation constituted important support because of his 
position at the NIH and his position in the field. Nicholas Wade of the 
NYT contacted him for a reason. In contrast to many of the scientists 
responsible for the articles on adult stem cell “plasticity”, i.e. high diffe-
rentiation potential, McKay appears at numerous neural stem cell confe-
rences as a keynote speaker and is well-published and frequently quoted 
in scientific articles. He was co-author to some of the earliest studies on 
neuronal differentiation and transplantation in mice (Brustle et al. 1999).  
 Although the papers on adult stem cell plasticity were published in high 
profile journals (Nature and Science) the experiments and the scientists we-
re very little entrenched in traditional stem cell disciplines or existing 
practices (Bjornson et al. 1999, Ferrari et al. 1998, Gussoni et al. 1999, 
Petersen et al. 1999). “Adult stem cells” were not a field or a discipline and 
still precariously linked to other actors, although some pro-lifers adopted 
them. Dickey referred above to stem cells in adults. The term “adult 
stem cells” was used towards the end of the period but usually in reports, 
or political, popular or media accounts. There were no departments or 
institutions explicitly doing research on “adult stem cells”. Indeed, blood 
stem cells had been used experimentally and therapeutically for more than 
Figure 16: Supportive linkages for an association between ASCs 
and pluripotent capacities (high plasticity). 
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thirty years (Thomas and Blume 1999, Till and McCulloch 1980). Neural 
stem cells were being revived after Altman’s attempts in the 60’s (Altman 
1962). These were stem cells in adult humans, but not named “adult 
stem cells”. The term appears in relation to the experiments on plasticity, 
and in relation to embryonic stem cells.  
 Vescovi, Ferrari, Bjornson and others were not recognized as “adult” 
blood- or neural stem cell scientists before the experiments indicating 
plasticity. As McKay was quoted as saying, to many scientists the phe-
nomena challenged a dogma. Neural and especially blood stem cells were 
not challenging in themselves, but their connection to an embryonic-like 
differentiation potential was. Despite this, McKay was not skeptical in 
the quotation from January 1999.151 There was however what I would 
prefer to call an inversed proportionality in progress. The opponents’ use 
increased as the scientists’ expectations decreased. In 1998 and 1999 
many scientists and journals were positive about adult stem cells. As the 
importance of adult stem cells increased in the opponents’ arguments, 
the scientists’ statements and the journals’ peer-reviewing become more 
and more cautious in relation to the capacities and promise of adult stem 
cells, in particular in relation to hESCs (Workshop on Stem Cells and the 
Future of Regenerative Medicine 2001).  
Disciplining scientists – and cells  
The attempted association to alternative stem cells eventually affected 
how differentiation capacities were articulated. Pluripotency was not only 
an element defined by ES cell research and hESC research. From being 
an interesting phenomenon in journals and among scientists it became 
relative and evaluated in relation to hESCs, and involved in a funneling, 
exclusive coordination. Dr. Goldstein is a professor in cellular and mole-
cular medicine at UCSD:  
some have argued that so-called “adult stem cells”, derived from adult tissues 
are of equivalent promise, less ethically compromised, and should therefore be 
pursued exclusively. But it is far too early to know if adult stem cells have the 
same potential as embryonic stem cells, whether they can be harvested in 
sufficient quantities to treat diseases, and whether they can grow indefinitely 
as can embryonic stem cells. In fact, it is likely to take years to find out if adult 
                                     
151  It is interesting to note that today (2005) McKay is in charge of the NIH’s 
efforts to characterize embryonic stem cells.  
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stem cells will be useful for treating many diseases that may be treatable sooner 
with embryonic stem cells. (US Senate 2001: 44)  
Goldstein distinguishes the relative certainty and potential of hESCs by 
recalling the “past 20 years using mouse embryonic stem cells” and the 
use of such cells “in a variety of ‘proof of therapeutic principle’ expe-
riments in several animal models of human disease” (US Senate 2001: 43).  
 The history of plastic adult stem cells is more brief. According to one 
researcher, it was Ian Wilmut’s successful experiments with Dolly, that 
raised expectations about adult cell versatility (Verfaillie 2002). Dolly was 
a result of two cells, one of them a somatic, adult cell that thereby dis-
played the unexpected capacity of giving rise to and participating in tis-
sue development.  
 When some of the “adult stem cell scientists” eventually appeared in 
hearings, they did associated their cells with differentiation into all three 
germ layers, or something close to it. In this respect the attempts to find 
nonhuman support for alternatives to hESCs did succeed, yet in the end 
they did not. No scientist involved in the plasticity research used it to put 
adult and embryonic stem cells on an equal footing The substitution of 
hESCs in favour of adult stem cells was eventually opposed outright by 
leading scientists responsible for the findings. The following is from Dr. 
Diane Krause in the 2001 hearing.  
This interpretation is not only stunningly premature, but potentially under-
mines the development of adult stem cell therapeutic options. In fact, the pro-
gress made in studying adult human stem cells relies on what has been learned 
from embryonic stem cell studies. – It is my testimony that these two areas of 
research together will lead to effective and safe treatments for life-threatening 
diseases. (US Senate 2002: 52)152  
There are doctors who argue against hESCs, but they were not speci-
fically working on the highly plastic adult stem cells (Do No Harm 2005, 
US Senate 2001). Between 1998 and 2001, scientists called to hearings 
and quoted in the press became increasingly unanimous on the relative 
biological advantage of hESCs. By the summer of 2001 scientific jour-
nals, such as Nature, had raised the bar for a publication of plasticity fin-
dings and similar claims about de- or transdifferentiation. (De Witt 2003, 
Verfaillie 2002). The judgments delivered by stem cell scientists at the 
National Academy of Sciences (NAS) workshop in June 2001 were un-
                                     
152  Also see Darwin Prockop’s response in US Senate 2001: 87–92.  
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equivocal (Workshop on Stem Cells and the Future of Regenerative Medicine 
2001): Adult stem cells were not equivalent to hESCs. The professional 
mobilization is marked in the figure by the bold arrow “cutting off” the 
linkage between adult stem cells and pluripotency (plasticity) and thereby 
disabling a path from the Federal administration via non-embryonic 
research to pluripotent cell transplantations. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Terminological calibration: pluripotency and multipotency 
This mobilization of stem cell professionals was paired with a terminolo-
gical calibration of the differentiation capacities of stem cells. Professio-
nals not only used their own credibility, but also the terms pluripotency 
and multipotency to distinguish between various cells.  
 Before 1998, there were two types of pluripotent stem cells, hemato-
poietic stem cells and embryonic ones. Then, at the same time as the 
hESCs went public, two things happened to the concept of pluripotency. 
The concept before and after 1998 was not exactly the same. The first 
difference has already been discussed: the distinction between pluripo-
tency and totipotency. Before 1998, both totipotency and pluripotency 
could be used to describe the developmental capacities of ES cells. This 
was less so after 1999 (see above). The second difference concerns the 
exclusivity of pluripotency in relation to the earlier usage of the term for 
another type of stem cell. Pluripotency had been developed for blood stem 
Figure 17: The association between ASCs and pluripotency is cut off. 
Pluripotency 
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cells since the 1960’s (Becker et al. 1963, McCulloch and Till 1964, Till 
1982, Till and McCulloch 1961, 1963).  
 From 1960 to the mid 1980’s, blood stem cell researchers experimen-
ted on and defined what they called “pluripotent stem cells”, in splendid 
isolation from the work on “pluripotent cells” in teratomas that later 
contributed to the ES cells. The succession and the hierarchies of stem 
cells presented were limited to the blood system. Pluripotency for blood 
stem cells could thus be used by hematopoietic researchers, without 
regard to the pluripotency defined by teratoma researchers. This double set 
of terms gradually changed in the 1980’s and 90’s as ES cells were 
applied increasingly to existing models of hematopoietic differentiation. 
As researchers of various stem cells started collaborating, the similarities 
between stem cell systems became visible and joint hierarchies were 
furnished. When the hESCs were announced and discussed in public in 
1998, such hierarchies became important. Harold Varmus stated:  
There is a hierarchy of stem cell types. Some stem cells are more committed 
than others. Some stems [sic] cells – the pluripotent stem cell we are discus-
sing today – have the ability to become many, but not all, of the cells [sic] ty-
pes in the human body. (US Senate 1999b: 8) 
In 1998 the pluripotency label was not only used to distinguish between 
embryos and hESCs, but also hESCs from other adult-derived stem cells. 
To perform this distinction, pluripotency was increasingly reserved for 
hESCs in contrast to other stem cells. One example is the AAAS/ICS 
report where adult stem cells are multipotent, and not pluripotent (Chap-
man et al. 1999: 4). Around 1998 there is a shift in blood stem cell termi-
nology in the literature. Pluripotency is still used occasionally to describe 
adult stem cell potency, but more often the term multipotency is used.  
 Hematopoietic research, especially in the 1980’s, had resulted in the 
classification of several populations of blood stem cells. These had been 
distinguished as ranging from pluripotency to more committed stem cells. 
A group of reviewers described these populations in 1997: 
Multipotent hematopoietic progenitors in mouse bone marrow can be puri-
fied in three distinct populations that differ according to self-renewal poten-
tial. Long-term, transiently, and non-self-renewing populations form a lineage 
of multipotent progenitors. Although the cells in these populations are similar 
in many ways, they undergo transitions from long-term to no self-renewal po-
tential and from pluripotency to perhaps the earliest stages of lymphoid com-
mitment. (Morrison et al. 1997: 218) 
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In 2000 and 2001, one of the authors (Weissman) again contributed to 
reviews on stem cells (Reya et al. 2001, Weissman 2000). This time pluri-
potency was not mentioned in relation to blood stem cells at all. Instead 
multipotency was used exclusively to characterize the capacity of blood 
stem cells, and other adult stem cells.153 Sometimes no specific term at all 
was used to describe the less potent adult stem cells (Edwards et al. 
2000: 3).154  
 The terminological calibration of pluripotency and multipotency is com-
bined with a hierarchization of stem cells. From the very outset, the con-
cepts of “stem cell” and “pluripotency” have been connected to the 
notion of a cell family tree, with the stem cell being part of the imagined 
stem of the tree, carrying the potential to differentiate into many of the 
branches. More differentiation capacity equals a higher rank in the 
hierarchy (or closer to the primary stem). As the unique pluripotency of 
hESCs was challenged, the hierarchization of stem cells made clear the 
relative capacities of various stem cells. The hESC is assumed to be 
higher in the stem cell hierarchy. The hESC occupies, as it were, a 
patriarchal, or even Holy Grail-like, position at the top of the stem cell 
pedigree (Whitaker 2002). This was salient in the graphic articulations (see 
above). Here is Fischbach from the NIH in the hearings: 
Now, there is a hierarchy of stem cells. I think the consensus of scientific opi-
nion is that cells proliferate and differentiate when isolated from the adult ner-
vous system, but there is a common view that cells proliferate more plenti-
                                     
153  Even in cases where pluripotent stem cells (PSCs) are found in non-embryo-
nic tissues they are separated from the allegedly non-pluripotent blood stem 
cells. The lines below, about the stem cells in the umbilical cord blood (UCB), 
would probably have been nonsensical before 1998, since hematopoietic stem 
cells (HSCs) were then pluripotent stem cells. 
It is not clear from either the preclinical or clinical models if this diffe-
rentiation into nonhematopoietic tissues represents the dedifferentiation 
of HSCs into PSCs, or if PSCs exist alongside HSCs in the marrow 
compartment. If the former proves correct, then UCB will also likely be 
a source of PSCs. If the latter is the case, then these PSCs must also exist 
alongside HSCs in UCB for the potential of UCB to be realized. (Snow 
2003: 51) 
154  The distinction between hPSCs (human pluripotent stem cells) and their adult-
derived, lineage-restricted counterparts, such as hematopoietic progenitors, lie 
mostly in their range of differentiation. 
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fully, and they have a wider range of choices, if taken from the fetal or embry-
onic tissue […]. (US Senate 2001: 53) 
Fischbach drew on the image of stem cell order, and the adult stem cells 
were subordinate to the hESC. These references set the comparison of 
hESCs and other cells outside of human decision-making or opinion. 
None of the scientists dismissed an interesting scientific potential of adult 
stem cells (just as none of the opposing actors dismissed the hESC on 
scientific grounds). Also, nobody claimed that there was total agreement 
about the state of the art (Bartelemez 2001, Weissman and Baltimore 
2001). A small degree of uncertainty was retained, but they never totally 
let go of references to “a wide consensus”, “the common view”, etc. 
Still, stem cell scientists’ testimonies were coherent: other cells lacked 
some of the differentiation capacity of the hESCs. Graphically, the ter-
minological calibration enacts a separation of “application paths” of 
adult versus embryonic stem cells: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With the separation between totipotency and pluripotency at one end of 
a developmental spectrum, and between pluripotency and multipotency 
at the other end, the hierarchy was in place and could be circulated. The 
following is from an account from 2003 in Whose View of Life?, by philo-
sopher of biology Jane Maienschein:  
Whereas a totipotent cell can become an entire organism, including all the dif-
ferent cell types, a pluripotent cell has the capacity to become any one (but not 
all) of the cell types that make up the body. Multipotent cells are a little more 
Figure 18:  The diversion of ASCs. 
Multi- 
potency 
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specialized and can become one of several, but not of any, cell types. (Maien-
schein 2003: 254)155  
New allies are good for network attempts as long as they do not betray 
you. It is impossible to say anything definite about the actions of “adult 
stem cells”. Whatever the nonhumans’ actions were, a hierarchy of stem 
cells was successfully installed that put them into neat terminological boxes. 
Seeing management 
By the summer of 2001, hESCs thus occupied a unique position in a cir-
culation of standardized terms, journal criteria, and collegial recognition. 
Although influential, the scientific circulation does not determine Presi-
dential decisions. When Bush announced his decision, August 2001, he 
referred to hESCs and acknowledged their “unique potential”. 
Based on preliminary work that has been privately funded, scientists believe 
further research using stem cells offers great promise that could help improve 
the lives of those who suffer from many terrible diseases – from juvenile dia-
betes to Alzheimer’s, from Parkinson’s to spinal cord injuries. And while scien-
tists admit they are not yet certain, they believe stem cells derived from em-
bryos have unique potential. (Bush 2001) 
After paying attention to alternative stem cells he returns to the capaci-
ties of hESCs: 
However, most scientists, at least today, believe that research on embryonic 
stem cells offer [sic] the most promise because these cells have the potential 
to develop in all of the tissues in the body. (Bush 2001) 
Although Bush mentions alternatives, the promise of hESCs is outstan-
ding. Based on this recognition, Bush did not unconditionally endorse all 
hESC research, but allowed funds for already existing cell lines. The 
reference to hESCs was managed in relation to transplantation therapies 
and embryos, but still did not achieve full federal funding. 
                                     
155  It should be mentioned that Maienschein, in contrast to the for-granted, rea-
list attitude in the above quote, in other publications takes a more analytic, 
relativist stance towards the use of the same concepts, e.g. in Maienschein 
2002.  
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Summary 
In this chapter, I have argued that hESCs were part of a longstanding 
project of federally funded human embryonic research. As prescribed by 
actors after the failed coordination of 1994, the hESCs were managed in rela-
tion to the embryonic source and the therapeutic benefits. hESCs were now mate-
rially and discursively made from ”spare embryos”. The research-crea-
tion of embryos was not a viable, although still legal, option for most of 
the actors supporting hESC research. Another adjustment was made by 
calibrating the use and meaning of pluripotency. By distinguishing the 
term from totipotency, the risk of hESCs being legally or morally classi-
fied as embryos was avoided. By distinguishing the term from multi-
potency, the uniqueness of hESCs and transplantation therapies could be 
defended in the face of alternative stem cell articulations. In both cases 
of pluripotency-calibration, scientists were the main actors. The package 
“pluripotent hESCs from spare embryos” was made uniquely apt for 
transplantation therapies by means of these circulations of criteria, credi-
bility, and collegial recognition. This composite entity played an impor-
tant role in the political circulation and negotiations of the federal fun-
ding of hESCs.  
 This chapter thus shows how hESCs as pluripotent, made from ”spare 
embryos” and suitable for transplantation therapies, were not necessary, 
or the only way to construct the package and the actor-networks of cells, 
scientists, legislation, politicians, corporations, and others. The particular 
configuration was made in relation to one project, its perceived problems 
and prescriptions. In an attempt to achieve federal funding for human 
embryonic research, the hESCs were made less totipotent, less linked to 
the research creation of embryos, and less equivalent to adult stem cells. 
In this sense, hESCs were made real in direct relation to the public and 
legal repercussions from the HERP’s recommendations. It is altogether 
an example of how laboratories, scientific evaluations and terminology 
are connected with bioethical reports, specific social groups, and political 
decision making. The reality of hESCs is not separated into biological, 
ethical and political realms, but is constituted by circulations among scien-
tists, patient organizations, IVF cycles, pro-lifers, bioethicists, politicians 
and corporations. 
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8.   Conclusions 
As promised in the Introduction, the road that this work has taken has 
not been straight. Just like an assemblage in progress, the research ques-
tions, concepts, new phenomena and issues have been added piece by 
piece to the understanding of stem cells. It is now possible to summarize 
this exercise in seeing the reality of hESCs differently.  
 I started this study with a puzzle about how to understand hESCs. So-
me things about the stem cells attracted my interest, viz. their alleged 
biological capacities and political effects. The puzzles were turned into a 
topic by using ANT, which assumes that biological capacities and politi-
cal effects are part of the same sociotechnical reality.  
 Sociotechnical reality was defined as coming to be in articulations and 
in the flows between various entities. In order to capture what was really 
making a difference, I brought up the notion of agency held by ANT as 
something appearing among heterogeneous elements. The obligatory point 
of passage and boundary objects were two models used to capture the 
distribution of agency and map the stabilization of sociotechnical reality.  
 In Chapter 2, I attempted to apply the OPP model to understand the 
negotiations of federal funding of hESC research. Even if the match was 
not total, the OPP model highlighted the funneling coordination, the as-
sumed total transformation, and an “either-or”: Either the Federal admi-
nistration gets involved or the cures for serious diseases will not be reali-
zed. Opponents accepted the need for cures, but suggested that other 
stem cells could make the cures happen. 
 In Chapter 3, I suggested that there were traits in the negotiations of 
hESC research that resembled the boundary object approach. Diverse 
actors were coordinated around the hESCs by partial connections, with-
out being totally aligned. Actors’ explanations for their support of hESCs 
refered to the multiple uses of the stem cells, within pharmacological re-
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search, developmental biology, and transplantation therapies. These uses 
were made possible through pluripotency. Another important use had to 
do with the source. Although some objected to the use of ”spare em-
bryos”, others, who were pro-life, supported federal funding of hESC re-
search which used this source. 
 Chapter 4 brought out the meta-theoretical tensions resulting from ap-
plying both of these models to the same situation. Both enabled an un-
derstanding of the sociotechnical reality (especially considering the poli-
tical and public dynamics) of hESCs in the USA, 1998–2001, in terms of 
agency and coordination.  
 Common to the two analyses was that actors articulated the hESCs 
with reference to the pluripotent capacities and the ensuing urgent and 
multiple uses of the stem cells. However, there were also striking diffe-
rences. In the OPP case the hESCs were objects of disputes and invol-
ved in total transformation and funneling. In the boundary object coor-
dination actors were partially connected to the hESCs even without a 
total federal effort behind hESC research. In the first case sociotechnical 
reality was presented as an either-or. In the second case the hESCs were 
relatively real through the flows among many actors already.  
 One solution to these apparent contradictions was to distinguish be-
tween actuality and potentiality. The OPP was a pattern in the negotia-
tions of future linkages. The boundary object coordination was there as ear-
ly as 1998. It was furthermore strengthened towards the end of the pe-
riod, in 2001, when pro-life politicians supported federally funded re-
search on hESCs.  
 A second solution was more extensive and suggested different roles of 
hESCs in relation to specific loops. I drew on Latour’s circulatory system 
and suggested that OPP and boundary objects were modes of coordi-
nation in different flows within one circulatory system of science and so-
ciety. Among non-dominating actors there was a distributed mode of 
coordination. In relation to the Federal administration, the hESCs were 
involved in an OPP funneling – in sharp competition with adult stem 
cells positioned as an alternative point of passage. The combination of 
OPP and boundary objects was thus a solution to the second meta-theo-
retical question about how to approach explicit politics in ANT: One 
way to account for dominant actors with high stakes involved is to con-
sider an OPP-like mode of coordination. Typical cases would be negotia-
tions where whole countries, states, or a Federal administration are enga-
ged. 
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 However, seeing hESCs as boundary objects in analogy with Star and 
Griesemer’s case was problematic. I pointed to the glitches between the 
two cases. Whereas the hESCs were involved in the flows typical of the 
boundary objects, they were more strongly structured than boundary ob-
jects. Spare embryos, pluripotency, and transplantation therapies were 
elements that constrained the implications and uses of the hESCs in spe-
cific ways. hESCs were involved in flows, not merely as coordinators, 
but also as objects configured in a specific way, constraining and defining 
other actors. They were boundary objects, but due to the three elements 
the hESCs had a stronger agency than in Star and Griesemer’s case. I 
suggested that these boundary-transcending composite entities were mo-
re appropriately called boundary packages.  
 In three ways, then, part one is an exercise in different seeing. First, the 
two models helped me not to separate “biological and political pluripo-
tency”. The OPP and the boundary object approach brought out the 
connections between stem cells, their capacities, multiple uses and va-
rious actors. Biological pluripotency was “seamlessly” conjoined to other 
flows. This did not question the notion of biological pluripotency, but 
insisted on the potential and actual flows in which the stem cells were 
involved. Second, I suggested an integrated model drawing on Latour’s 
circulatory system, Vissac-Charles’s combination of OPP and boundary ob-
jects, and my own focus on the public and political dynamics. My inte-
grated model is an exercise in seeing existing notions within ANT (and 
related approaches) differently. Instead of assuming that sociotechnical 
reality is coordinated homogeneously, two modes of coordination (at 
least!) can co-exist. Third, I suggested a new way of seeing the coor-
dination of diverse actors through a boundary object with stronger agen-
cy. My boundary package is both a coordinator in flows to diverse actors 
and a strongly structured combination of elements.  
 In part one the actors were taken at their word about the uses (trans-
plantation therapies), the material sources (”spare embryos”), the pluri-
potent capacities, and the environment (the flows to diverse actors of 
patients, politicians, scientists, and more). These aspects of the hESCs 
were connected to each other in part one of the study, but not unpacked.  
 Part two of this study was devoted to understanding how the socio-
technical reality of hESCs came about in 1998–2001. Unpacking the 
heterogeneous elements of hESCs would be to unpack the sociotechni-
cal reality of hESCs. I thereby assumed that neither the configuration of 
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hESCs (and the three elements) nor their flows among actors were in-
evitable but had come to be.  
 To approach these two aspects of the sociotechnical reality of hESCs, 
I went backwards to search for articulations of hESCs before the suc-
cessful cultures of hESCs were announced to the public. One such site 
for public and political debates about hESCs was the 1994 national panel 
about human embryo research (the HERP). In these debates and their 
aftermath I found a pre-existing project distributed among proponents 
of federally funded research. Such actors were making diagnoses and 
prescriptions to improve future negotiations. Interestingly, these attempts 
to improve coordination involved both the uses and the material sources 
that were later part of the articulations of hESCs. Like in 1998–2001 
”spare embryos” and transplantation therapies were brought up, although 
less consistently and not primarily in relation to hESCs. The latter only 
existed as anticipated paper entities at the time. 
 These observations prompted a hypothesis about the boundary pack-
age. Being made of ”spare embryos” and being useable in transplantation 
therapies, the object fitted an already existing project. Thus hESCs were 
coordinating actors that were mobilized in a previous, failed project. The 
package was able to coordinate actors since it was a package of at least 
two elements that were somehow already stabilized.  
 I tested this hypothesis by going further backwards to see how these 
elements had been stabilized and what circulations they were part of. I 
found that the two elements were already stabilized and, as such, were al-
ready involved in coordination among specific actors.  
 My suggestion was that multiplication, stabilization, and coordination 
were “sticking” to the IVF and frozen embryos that were part of pre-
scriptions after 1994, and, after 1998, part of articulations of hESCs.  
 The stabilization of transplantation therapies and the coordination of 
patients, scientists, and politicians during the debates in 1987–1993 hap-
pened together. Crucial for this coordination was the appearance of a 
“moderate pro-life” group. This group included many of the congress-
members that later supported federally funded hESC research. In addi-
tion, I showed that this stabilization did not include all scientists. There 
were alternative spaces, other possible paths of stabilization that were 
not pursued.  
 The uses (transplantation therapies), the sources (”spare embryos”), 
and the environment (the diverse actors of patients, politicians, scientists, 
and more) were not there inevitably, but were mutually and gradually sta-
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bilized. In the final empirical chapter, the pluripotency ascribed to the 
hESCs was also unpacked.  
 Actors’ calls for ”spare embryos” and transplantation therapies after 
the HERP indicated pre-existing anticipation and coordination attempts. 
Chapter 6 displayed the mutual stabilization and coordination related to 
the two elements. These accounts suggested that the coordination of po-
liticians, scientists, and patients around the hESCs was due to the pre-
existing flows of ”spare embryos” and transplantation therapies. How-
ever, nothing was said in Chapters 5 and 6 about how these elements 
were combined with the hESCs. 
 Chapter 7 approached the question of how the articulations of hESCs 
included the two elements. The answer to this question was that ”spare 
embryos” and transplantation therapies were “fitted” to the hESCs in se-
veral ways. Already existing frozen embryos became an element of hESCs 
by being used in the production process and in bioethical articulations of 
hESC research. By dismissing deliberate creation of embryos for re-
search, the source of hESCs became almost exclusively ”spare embryos”.  
 The hESCs’ position between legally protected embryos and the deve-
lopmental capacities needed for transplantation therapies was correlated 
to terminological definitions; the pluripotency of hESCs was situated 
between the totipotency of embryos and the multipotency of adult stem 
cells. Through the handling of ”spare embryos” and the term pluripoten-
cy, the hESCs were “hooked on” to the already existing, stabilized, and 
flowing elements of transplantation therapies and ”spare embryos”.  
 In part two of the study seeing differently was exercised by suggesting 
that the sociotechnical reality of hESCs was a result of the management 
of pre-existing elements and their flows among actors. In these pre-exis-
ting processes ”spare embryos”, transplantation therapies, pro-life sup-
porters of research using fetal materials, and pluripotency were fitted to 
each other. The articulations of hESCs were not an inevitable result of 
biological research or stable social interests, but a combination of hetero-
geneous elements that could have been otherwise.  
 A few more points need to be made concerning the analytic contributions 
that follow from this analysis. They are at least four: the strong boundary 
object, the analytic tool of multiple circulations, the ensuing modification 
of stabilization processes, and a fourth contribution that follows from 
opening up the black boxes of IVF and transplantation therapies. 
 Drawing on Star and Griesemer’s approach helped me see the coordi-
nation among diverse actors and the multiple uses. It also made me look 
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for a project and active management of the hESCs. I found something 
reminiscent of a project in the HERP debates. I also found traces of 
management in the terminological calibration of pluripotency and the 
material and discursive use of ”spare embryos”. The real work done by 
means of the notion of boundary package was tangible both above and in 
part two. By observing the three integral elements of hESCs, two things 
were assumed in the ensuing analysis; the configuration of the package 
happened together with the coordination of actors. The boundary package 
is the result of those two processes. In the stabilization of the elements 
of the package, coordinating flows across boundaries were established. Thus, 
the notion helped to keep a double view of the stabilization of each 
element, and their flows. 
 In Chapter 4 the metaphor of circulatory system of multiple loops was 
brought in to clear up the theoretical incoherence between the OPP and 
the ecological approach. In Latour’s model there are interlocking loops. 
His example was Joliot’s chain reaction, where the flows are concentric 
feedback loops managed by one person. In the case of hESCs, there were 
loops to diverse actors centered on the stem cells. I argued that agency 
was much more distributed in the hESC circulatory system than in Jo-
liot’s. These observations challenged the notion of a centered circulatory 
system. In the case of hESC research, there were interlocking flows, but 
they were not managed by one human or protecting one space.  
 During the later chapters, the circulatory system became even more 
distributed. This called for a modification of Latour’s circulatory system 
and loops to capture the distributed dynamics. When unpacking the 
”spare embryos” and the concept of transplantation therapies, I sugges-
ted that distinct and multiple circulations were found that had developed 
totally independently of hESCs. The elements in the hESC package came 
with already existing linkages. In the hESC case, ”spare embryos” were 
linked to a number of actors, but when they were combined with hESCs 
in laboratories and in the panel reports, there was no easy transfer. Some 
used IVF practices and ”spare embryos” as an argument for hESC re-
search, while others opposed the use of ”spare embryos” but did not 
oppose IVF. Something a little more fluid was needed, without giving up 
to a boundless, amorphous topology. Circulations were appropriate be-
cause of their combination of fluidity and restrictions. Circulations exist 
in vessels, veins and canals, but under the right conditions they can be 
redirected or break through. Circulations also move and exist like niches 
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in ecologies. Like niches they are not necessarily hegemonic. They can 
move separately even if joined to other circulations.  
 I have called these flows multiple circulations, not only to signify that 
there are many of them, but also to put flesh on Latour’s (and others’) 
talk of multiple reality. This was tangible when I mapped the stabilization 
of multiple circulations in the later chapters.  
 Within IVF research there were two distinct processes, or stabilities: 
one within Congressional politics, and one within IVF clinical practice. 
Since 1980 there has been insufficient political support for publicly fun-
ded IVF research. Attempts have been made to change the policy, but 
they have failed. This constituted a stability in the federal, explicitly poli-
tical arena. In another arena a different process took place. From the 
mid-1980’s, excess embryos were frozen because of the development 
and increasing use of superovulation drugs and cryopreservation. This 
was a quantitative kind of stabilization that happened in isolation from 
the political processes. The sociotechnical reality of IVF was thus not 
one circulatory system but made up of multiple quite distinct circula-
tions. In the federal circulation, IVF was a problematic technique that 
could not be publicly funded. Here ethical and political concerns were 
formulated in relation to, as it were, an already existing technology. How-
ever, the technology was not only “already existing” but was also being 
constructed and configured in a specific way. In the clinical circulation, 
the flow of newborns, “new-parents”, and frozen embryos was increa-
sing each day at a number of clinics. Ultimately, unsuccessful efforts were 
made to change the federal policy but the two circulations were kept 
separate.  
 Paradoxically, this separation was shown to be a co-productive factor 
in the stabilization processes. After the announcements of successful cul-
tures of hESCs in 1998, the clinical IVF practices contributed to the 
sociotechnical reality of hESCs because they had stabilized and multi-
plied frozen embryos away from federal regulations. The two, previously 
separated, circulations were suddenly entangled in each other. The “stan-
dard, necessary treatment” that had resulted in some hundred thousands 
of frozen embryos was a discursive and material resource in the nego-
tiations of hESC research. The clinical circulation did not change the 
political process concerning IVF, but it did contribute to the political pro-
cess concerning hESC research.  
 I showed how the stabilization of IVF only makes sense if the circu-
latory system is split up into multiple circulations that are stabilized sepa-
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rately and may or may not be combined at some point. Although trans-
plantation therapies offered a different situation, something like multiple 
circulations was needed to capture the dynamics. 
 Transplantation therapies were also stabilized differently in distinct cir-
culations. They were a scientific and medical possibility among patients, 
politicians, and corporations. The expected improvements in the original 
patients did not last, if they showed up at all. Immunosuppression was 
(and still is) a big problem. In relation to actual treatment programs, the 
degree of stabilization is to this day (2006) quite low. Transplantation 
therapies were, I suggested, just less real in these circulations of experi-
mental and clinical results among scientists.  
 The disparities between scientists, on one hand, and patients and poli-
ticians, on the other, made visible the fact that neither stabilization nor 
reality is monolithic but multiple. While stable in relation to some actors, 
the element of transplantation therapies was, and still is, unstable and 
uncertain in relation to others. The multiple measurement of stabiliza-
tion, one for each discernable circulation, is an important benefit from 
seeing the reality of multiple circulations.  
 In both cases, I have shown how it could have been different. It was 
the Federal administration’s non-involvement and laissez-faire that 
indirectly resulted in the ”spare embryos”. “Standard” IVF developed in 
a “hands-off” landscape where a hundred flowers could blossom under 
the influence of clinical competition and certain technological possibili-
ties. Had the Federal administration chosen not to “wash its hands” (like 
Pilate) but been involved, alternative procedures might have prevented 
the stores of frozen embryos. The result could have been new know-
ledge about oocyte-freezing. Without hundreds of thousands of embryos, 
the negotiation of hESCs in 1998–2001 might have been played out very 
differently. 
 The Federal administration could have adopted an involvement strate-
gy in the fetal tissue research too. With serious participation the scientific 
uncertainties and the editorial calls for more animal experiments and 
patience (rather than patients) could have prevailed. Now, there was an 
either-or articulated as the perceived consequences of abortion rates. Pre-
sident Bush (Sr.) proposed banking of tissues from spontaneous abor-
tions. If this proposal had been tried from the beginning, the patient 
mobilization might have been different. With the moratorium in place, 
the tone and intensity of mobilized organization and individuals grew. 
Scientific uncertainties were not highlighted. The medical possibility was 
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bracketed and implicitly assumed. Therefore, by 1998, and as early as 1994, 
transplantation therapies were an element already linked to a circulation 
of public and political support.  
 However, these scenarios of “it could have been otherwise” do not 
mean that “anything goes”. These alternative scenarios implicitly assume 
both cross-roads and path-dependencies. By locating cross-roads in the 
over-production of embryos and oocyte-freezing, I am assuming that 
IVF could not have been stopped as such. I am in fact assuming the de-
velopment of IVF in conferences, clinics, and among thousands of 
patients. By locating cross-roads in the banking of alternative fetal tissue, 
I am assuming the push for transplantation therapies. Unpacking can 
find alternatives and forks in the paths of stabilization, but in so doing 
many dependencies and stabilities are implicitly assumed. 
 To conclude my conclusion in a few sentences: the coordination of di-
verse actors and the articulations of hESCs in terms of ”spare embryos”, 
transplantation therapies, and pluripotency have evolved together. The 
hESCs are composite objects consisting of at least three elements invol-
ved in multiple flows to diverse actors, i.e. pluripotent circulations.  

Glossary 
Actor can be two things: An entity exercising agency as a result of its po-
sition in a network. As such, “actor-ship” is the main topic of the study; 
understanding the emergence, distribution and location of agency. More 
often, the term actor in this study refers to any human entity analyzed, for 
instance politicians, scientists, ethicists, pro-lifers. Nonhuman entities are 
usually referred to as elements, or entities. Terminologically separating 
human and nonhuman entities thus is clearly inconsistent with ANT. It is a 
consequence of taking seriously the implicit asymmetry of generalized 
symmetry (see below). The main task of this study is not to claim an 
equality between humans and nonhumans, but to display the emergence 
of reality and agency in which nonhumans are important elements.  
 Actor-networks are more than networks of associations. It is not hard to 
find networks. What makes a network an actor-network is that the ana-
lyst attends to how the agency is distributed and relocated irrespective of 
whether the network entities are human or nonhuman. This character of 
actor-networks is emphasized in the thesis of generalized symmetry (see 
below). An entity that displays potency, such as the hESCs, can be un-
derstood by tracing the network(s) packaged within the entity. In this 
sense agency is a network effect without being reducible to the network 
(thus: irreducible). Otherwise actors would be not be actors but place-
holders for other more fundamental actors. 
 Agency (see Actor and Actor-networks).  
 Articulation is the ontological movement in which the world and its 
entities or elements come to be by being associated (see association) while 
also being methodologically accessible e.g. through texts. Instead of see-
ing textual statements as representations of a reality out there, the use of 
articulation indicates that statements participate in making things real 
(which may ultimately be unsuccessful). A person can thus be articulated 
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and actively pursue articulation. An example of the former is a pro-life 
Senator who is said to have betrayed the pro-life cause. S/he risks be-
coming a little less pro-life through this articulation. S/he may also claim 
that adult stem cells are pluripotent, and be pursuing articulation. Other 
related terms for this are translation and construction. The most utilized 
alternative will be coordination (see below). Its function is however similar, 
viz. to combine and align disparate elements (usually humans) with each 
other.  
 Association, or linkage, is what is achieved by articulation (see also disso-
ciation below). Together with articulation it is the most fundamental unit 
of analysis. Potency or agency is the result of associations. An association 
can occur in texts as the combination of one entity with another. It can 
happen in practice when a scientist puts cells into the brain tissue of a 
patient, or of a mouse; when a corporation makes contact with a parti-
cular scientist to fund him/her; when a patient organization decides to 
support an umbrella organization lobbying for more funds to stem cell 
research; or when a pro-lifer claims that fetal-tissue research has effects 
on the abortion rates. There are no a priori realms that delimit which en-
tities can be associated with each other. Together, associations make up 
networks of actors (see actor-network above). 
 Boundary objects: Through the management of boundary objects and 
their flows, diverse (human) actors can collaborate in spite of diversities 
and without full alignment, i.e. the actors can remain in their respective 
worlds. Coordination without full alignment is possible because of the 
plasticity of boundary objects, together with a common identity that is 
not negated by specific uses in diverse practices. The resulting network is 
more or less stabilized depending on the number of participating actors. 
Coordination through boundary objects does not assume a central entre-
preneurial force, funneling and transforming actors as does the notion of 
obligatory point of passage (see below).  
 Circulations: see Multiple Circulations. 
 Coordination is used here as in Star and Griesemer’s case study (1989). 
Its function is similar to articulation, viz. to combine and align disparate 
elements (usually humans) with each other. Whereas articulation empha-
sizes the ontological event of combining entities, coordination does have 
such innovating, transforming and ontological effects, but the emphasis 
is on actors that remain in their worlds. Without total consistency I use 
coordination more often in relation to humans who can collaborate in 
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spite of differences. I use articulation in relation to both humans and 
nonhumans.  
 Dissociation is the noun (and dissociate the verb) that is the opposite of 
association. Articulations may dissociate elements from each other, as for 
instance when embryonic stem cells are defined as being of less develop-
mental potential than embryos, or when fetal-tissue research is regarded 
as separate from the act of abortion. 
 Generalized symmetry is the programmatic placing of humans and things 
(or “nonhumans”) on an equal footing with regard to their roles in actor-
networks. In ANT all entities in a network can be actors depending on the 
delegation of agency. Classic examples of how agency is delegated from 
humans to nonhumans is the construction of a traffic light or a speed-
bump. By constructing these in a particular way, humans are affected and 
restricted in more powerful ways than if they were only told to slow 
down. Delegated agency is thereby delegated back from nonhumans to 
affect human behavior. However, few examples of delegation in fact start 
in nonhumans delegating to humans. Although being placed on an equal 
footing theoretically, humans and nonhumans do differ in most ANT 
cases. Basically humans seem to be much more suitable for delegation 
than nonhumans because of humans’ greater capacities to delegate to 
nonhumans. The master-delegator is human. Generalized symmetry also 
denies that either nature or society are the causes of knowledge, truth, or 
reality. Instead it is the analyst’s job to follow how nature and society 
become categories, distributed as an effect of other processes.  
 Modes (or forms) of coordination, or modes of articulation. Two modes of co-
ordination are fundamental in this study: obligatory point of passage and 
boundary objects. When these concepts are applied to the case of hESC 
research the two modes are seen to be co-existent and less clearcut than 
in previous studies. Therefore I (usually) choose to talk of boundary 
object-like, or boundary-transcendent coordination, versus an OPP-like, 
funneling, or exclusive coordination. The point is to see how coordina-
tion, articulations, and associations can happen in many ways. An asso-
ciation with the Federal administration is not the same as associating the 
cells with another ethicist, one more company, or another tissue-type. 
Depending on the mode of coordination (and on what circulation), asso-
ciations come to have different implications.  
 Multiple circulations are one way to acknowledge that articulations occur 
in different places and in pre-existing activities with specific traits. The 
notion is derived from (Latour’s) Pandora’s Hope Chapter 3, and it is also 
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suggestive of Star and Griesemer’s understanding of flows of boundary 
objects between social worlds. In contrast to these other examples of flows, 
multiple circulations are not necessarily concentric, focused on one pro-
ject or on one human, but may be independent of each other. Multiple 
circulations may open for marked analytic differences between the stabi-
lization of an object in different arenas. For instance, fetal-tissue trans-
plantation is not necessarily flowing or coordinating in the same way in 
laboratories versus Senate hearings. Entities are linked to each other in a 
topography of already existing actor-networks with their own dynamics, 
structures and currencies. In this respect multiple circulations remind 
one e.g. of social worlds, but without the clear boundaries of the latter.  
 Obligatory point of passage (OPP) is one of two main models (in this stu-
dy) for how elements are articulated and coordinated, how agency is 
distributed and actor-networks are built. In the classic case studies a 
number of actors were all funneled through one definition of a situation 
in which a small group of entrepreneurs was positioned as an OPP. The 
resulting actor-network is either a total success, and subsequently of a 
dominating character, or a total failure. Many things affect the success of 
an OPP attempt. A weakening aspect is the articulation of alternative 
points of passage (APP).   
 Politics is often treated in ANT as the politics of things, i.e. the values and 
political implications congealed in stable objects, thus invested with a 
specific agency, competence or politics (see Actor and Actor-networks). I 
refer instead to explicit politics which corresponds to the commonsense 
understanding of political activity that should be considered (just as sci-
entific activity) in order to understand the reality of hESCs. While both 
activities deal with chains of humans and nonhumans (and without reinsta-
ting a total separation) explicit politics is more specialized in managing 
voices and the agency of humans (e.g. in hearings), while the decisive 
skill of scientific activities takes care of nonhumans (e.g. in laboratories). 
 Reality or sociotechnical reality is a result of articulation and stabilization. 
There is no one underlying causal reality, not a social versus a natural 
reality, neither is there a chaos of the myriad of realities of all articula-
tions. Reality is not “out there” but right here in the associations and ar-
ticulations of entities. One of Latour’s well-known examples is how the 
Amazon forest, step by step, through visits, soil samples, use of interna-
tional standards for soil quality, is ultimately transferred to the claims in a 
scientific article. Nowhere in that chain is it possible to say where reality 
stopped and became a representation. Asking for the reality of hESCs is 
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to ask for the entities associated with the cells. Two aspects of how 
reality come to be are combined in this study. One is the relative reality 
that varies relative to the number of linked elements. Rather than an 
either-or, reality is gradually stabilized. This aspect can be related to the 
notion of multiple circulations. Gradual increase of reality in one circulation 
does not necessarily imply the same degree of stability, or the same 
combination of entities, in all places. The relative reality is thus compart-
mentalized and multiple. 
 Reference: Not of a referent “out there”, but what holds together a num-
ber of flows and is held together by a number of flows. The sciences do 
not establish a reference by isolating themselves, but by establishing suc-
cessful flows, or circulations, in which the reference is used or supplied 
with money, public, collegial, or instrumental support. A reference to 
hESCs as pluripotent thus makes possible many other flows and is made 
possible through certain flows. In Chapter 7 this is salient, as the referen-
ce to pluripotency connects a circulation of fetal-tissue transplantation 
among patients and politicians to hESCs, while being defined by the cir-
culation among scientists.  
 Representation in its traditional meaning is the opposite of articulation 
since it builds on a separation of words about the world, and the world, 
in which articulations are continually creating bridges between elements 
that may be more linguistic or more material. Actors can still represent 
other actors by speaking for them, whether they are pro-life voters or 
stem cells. Representations are thus not true or false but more or less 
faithful to the ones spoken for. This notion is necessary to understand 
how a few individuals out of 300 million Americans can produce articu-
lations that significantly add to or subtract from the reality of hESCs. 
 Stabilization: Elements combined into articulations may result in chains, 
black boxes, or network nodes with a lot of invested agency. The more 
elements in the chain the more stable the object. Where a natural realist 
may talk of something existing or not, or being true or not, this study 
maps a successive stabilization. Such processes can be reversed, but it 
takes hard work to unpack them. Since the articulation of one object may 
happen in many circulations its successive stabilization may be the result 
of several chains or multiple circulations originally distinct from each other.  
 Unpacking is the crucial analytic activity of this study. It consists in 
finding out what has happened in the stabilization of an element, or an 
actor, i.e. what entities have been combined to form a new entity. One  
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example is “spare embryos”, which are the result of not only a sperm 
and egg, but of infertile clients visiting private, unregulated clinics where 
specific technologies are used in order to extract and fertilize more eggs 
than used in one treatment cycle and then to freeze the surplus embryos. 
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